Our O
data O
suggest O
that O
lipoxygenase B
metabolites I
activate O
ROI O
formation O
which O
then O
induce O
IL B
- I
2 I
expression O
via O
NF B
- I
kappa I
B I
activation O
. O

Understanding O
the O
monocyte O
- O
specific O
function O
of O
the O
peri B
- I
kappa I
B I
factor I
may O
ultimately O
provide O
insight O
into O
the O
different O
role O
monocytes O
and O
T O
cells O
play O
in O
HIV O
pathogenesis O
. O

Whereas O
different O
anti B
- I
CD4 I
mAb I
or O
HIV B
- I
1 I
gp120 I
could O
all O
trigger O
activation O
of O
the O
protein B
tyrosine I
kinases I
p56lck B
and O
p59fyn B
and O
phosphorylation O
of O
the O
Shc B
adaptor I
protein I
, O
which O
mediates O
signals O
to O
Ras B
, O
they O
differed O
significantly O
in O
their O
ability O
to O
activate O
NF B
- I
AT I
. O

ER B
- O
mediated O
repression O
of O
GATA B
- I
1 I
activity O
occurs O
on O
an O
artificial B
promoter I
containing O
a O
single O
GATA B
- I
binding I
site I
, O
as O
well O
as O
in O
the O
context O
of O
an O
intact B
promoter I
which O
is O
normally O
regulated O
by O
GATA B
- I
1 I
. O

It O
also O
primes O
cells O
to O
become O
IL B
- I
2 I
responsive O
and O
thereby O
prepares O
the O
second O
phase O
, O
in O
which O
IL B
- I
2 I
induces O
a O
100 O
- O
fold O
further O
increase O
in O
IL B
- I
2R I
alpha I
transcripts I
. O

Transient O
transfection O
experiments O
show O
that O
several O
elements O
in O
the O
promoter B
- I
proximal I
region I
of O
the O
IL B
- I
2R I
alpha I
gene I
contribute O
to O
IL B
- I
1 I
responsiveness O
, O
most O
importantly O
an O
NF B
- I
kappa I
B I
site I
conserved O
in O
the O
human B
and I
mouse I
gene I
. O

IL B
- I
2 I
responsiveness O
, O
on O
the O
other O
hand O
, O
depends O
on O
a O
78 B
- I
nucleotide I
segment I
1 O
. O
3 O
kilobases O
upstream O
of O
the O
major B
transcription I
start I
site I
. O

The O
appearance O
of O
the O
BamHI B
ZLF I
- I
1 I
gene I
product I
, O
ZEBRA B
, O
by O
RT O
- O
PCR O
, O
was O
observed O
within O
8 O
hr O
of O
infection O
. O

Transcripts O
encoding O
gp350 B
/ I
220 I
, O
the O
major B
coat I
protein I
of O
EBV O
, O
were O
identified O
, O
but O
we O
did O
not O
find O
any O
evidence O
of O
transcription O
from O
the O
LMP B
- I
2A I
or O
EBER B
- I
1 I
loci I
in O
infected O
thymocytes O
. O

Rather O
, O
EBV O
remains O
in O
a O
linear O
configuration O
from O
which O
replicative B
genes I
are O
transcribed O
. O

We O
demonstrate O
, O
through O
the O
deletion O
of O
the O
human B
UDG I
promoter I
sequences I
, O
that O
expression O
of O
E2F B
- I
1 I
activates O
the O
UDG B
promoter I
through O
several O
E2F B
sites I
. O

In O
addition O
, O
when O
used O
together O
IL B
- I
2 I
and O
IL B
- I
12 I
synergized O
in O
the O
induction O
of O
IFN B
- I
gamma I
and O
GM B
- I
CSF I
and O
this O
synergy O
was O
attributed O
to O
an O
increased O
accumulation O
and O
stability O
of O
the O
IFN B
- I
gamma I
and I
GM I
- I
CSF I
mRNAs I
. O

In O
addition O
, O
IL B
- I
2 I
but O
not O
IL B
- I
12 I
induced O
nuclear B
factors I
NF B
- I
kappa I
B I
and O
AP1 B
, O
and O
regulation O
of O
the O
nuclear O
levels O
of O
these O
two O
DNA B
binding I
protein I
complexes I
is O
correlated O
with O
IFN O
- O
gamma O
and O
GM O
- O
CSF O
gene O
expression O
. O

alpha B
B I
is O
the O
mouse B
homologue I
of O
human B
AML1 I
gene I
detected O
at O
the O
breakpoints O
of O
t O
( O
8 O
; O
21 O
) O
and O
t O
( O
3 O
; O
21 O
) O
myeloid O
leukemias O
. O

We O
examined O
alpha B
A1 I
( O
an O
alpha B
A I
- I
gene I
product I
) O
and O
alpha B
B1 I
and O
alpha B
B2 I
( O
two O
alpha B
B I
- I
encoded I
isomers I
) O
for O
their O
effects O
on O
the O
GM B
- I
CSF I
promoter I
. O

Although O
further O
studies O
are O
required O
to O
determine O
the O
precise O
role O
of O
PEBP2 B
in O
the O
GM B
- I
CSF I
promoter O
activity O
, O
the O
present O
findings O
suggested O
the O
importance O
of O
the O
relative O
ratio O
of O
different O
PEBP2 B
isoforms I
in O
regulating O
the O
levels O
of O
the O
promoter O
activity O
. O

The O
increased O
transcriptional O
rate O
correlated O
with O
a O
marked O
increase O
in O
nuclear B
factor I
- I
kappa I
B I
activity O
in O
these O
cells O
as O
determined O
by O
electrophoretic O
mobility O
shift O
assay O
using O
a O
consensus B
NF I
- I
kappa I
B I
oligonucleotide I
. O

A O
Myc B
- I
associated I
zinc I
finger I
protein I
binding I
site I
is O
one O
of O
four O
important O
functional B
regions I
in O
the O
CD4 B
promoter I
. O

Since O
the O
terminal O
events O
of O
erythropoiesis O
are O
controlled O
by O
the O
glycoprotein B
hormone I
erythropoietin I
( O
Epo B
) O
, O
we O
investigated O
whether O
the O
expression O
or O
activity O
of O
the O
TAL1 B
gene I
and O
its O
protein B
products I
were O
affected O
by O
Epo B
in O
splenic O
erythroblasts O
from O
mice O
infected O
with O
an O
anemia O
- O
inducing O
strain O
of O
Friend O
virus O
( O
FVA O
cells O
) O
. O

The O
role O
of O
shared B
receptor I
motifs I
and O
common B
Stat I
proteins I
in O
the O
generation O
of O
cytokine B
pleiotropy O
and O
redundancy O
by O
IL B
- I
2 I
, O
IL B
- I
4 I
, O
IL B
- I
7 I
, O
IL B
- I
13 I
, O
and O
IL B
- I
15 I
. O

Regulation O
of O
transcription O
of O
the O
human B
erythropoietin I
receptor I
gene I
by O
proteins O
binding O
to O
GATA B
- I
1 I
and I
Sp1 I
motifs I
. O

Erythropoietin B
( O
Epo B
) O
, O
the O
primary O
regulator O
of O
the O
production O
of O
erythroid O
cells O
, O
acts O
by O
binding O
to O
a O
cell B
surface I
receptor I
( O
EpoR B
) O
on O
erythroid O
progenitors O
. O

These O
data O
suggest O
that O
while O
GATA B
- I
1 I
can O
transactivate O
the O
EpoR B
promoter I
, O
the O
level O
of O
hEpoR B
gene I
expression O
does O
not O
depend O
on O
GATA B
- I
1 I
alone O
. O

The O
deduced O
amino O
acid O
sequence O
similarity O
to O
the O
proteins O
encoded O
by O
these O
two O
latter O
genes O
is O
approximately O
65 O
% O
and O
includes O
domains O
and O
amino O
acid O
residues O
( O
the O
leucine B
zipper I
- I
like I
and O
the O
RGD B
domain I
, O
a O
serine O
and O
a O
histidine O
residue O
in O
the O
NH2 B
- I
and O
in O
the O
COOH B
- I
terminal I
portion I
of O
the O
protein O
, O
respectively O
) O
postulated O
to O
be O
important O
for O
nm23 B
function O
. O

Double B
- I
stranded I
GIRE I
sequence I
, O
but O
not O
a O
scrambled B
sequence I
, O
was O
specifically O
bound O
by O
nuclear B
proteins I
from O
IFN O
- O
gamma O
treated O
U937 O
cells O
. O

The O
Fc B
gamma I
RIC I
GIRE I
is O
homologous O
to O
the O
IFN B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
of O
the O
guanylate B
binding I
protein I
and O
to O
X B
box I
elements I
of O
class B
II I
MHC I
genes I
. O

Murine B
macrophage I
inflammatory I
protein I
1 I
alpha I
( O
MIP B
- I
1 I
alpha I
) O
and O
its O
human B
equivalent I
( O
GOS19 B
, O
LD78 B
, O
or O
AT464 B
) O
are O
members O
of O
the O
- B
C I
- I
C I
family I
of O
low B
- I
molecular I
- I
weight I
chemokines I
. O

One O
member O
, O
ICK B
- I
1A I
, O
behaves O
as O
a O
strong B
negative I
regulator I
. O

We O
provide O
evidence O
for O
an O
additional O
binding B
site I
, O
the O
MIP B
- I
1 I
alpha I
nuclear I
protein I
( I
MNP I
) I
site I
, O
which O
overlaps O
the O
ICK B
- I
1 I
site I
. O

The O
retinoblastoma B
gene I
product I
negatively O
regulates O
transcriptional O
activation O
mediated O
by O
the O
human B
cytomegalovirus I
IE2 I
protein I
. O

We O
found O
that O
the O
retinoblastoma B
susceptibility I
gene I
product I
( O
Rb B
) O
dramatically O
suppressed O
this O
IE2 B
transactivation O
of O
various B
promoters I
. O

Retinoblastoma B
protein I
( O
RB B
) O
is O
a O
tumor O
suppressor O
and O
functions O
as O
a O
transcriptional B
repressor I
by O
binding O
and O
inactivating O
the O
transactivator B
E2F I
- I
I I
. O

RB O
- O
defective O
tumor O
lines O
are O
non O
- O
inducible O
for O
MHC B
class I
II I
by O
IFN B
- I
gamma I
, O
or O
very O
weakly O
inducible O
, O
but O
transfection O
of O
2 O
different O
lines O
with O
RB B
expression I
vectors I
re O
- O
establishes O
or O
substantially O
enhances O
class O
II O
inducibility O
. O

We O
have O
recently O
found O
a O
novel O
conserved B
motif I
in O
the O
promoters B
of O
several O
T B
- I
cell I
- I
expressed I
cytokines I
[ O
human B
interleukin I
- I
2 I
, I
- I
4 I
, I
- I
5 I
and I
- I
13 I
and O
human B
and I
mouse I
granulocyte I
/ I
macrophage I
- I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
] O
. O

In O
transfection O
assays O
, O
the O
human B
GM I
- I
CSF I
element I
has O
a O
strong O
positive O
effect O
on O
the O
expression O
of O
a O
reporter B
gene I
by O
the O
human O
T O
cell O
line O
Jurkat O
J6 O
upon O
stimulation O
. O

In O
different O
genes B
, O
the O
core B
sequences I
are O
separated O
by O
integer O
numbers O
of O
helical O
turns O
. O

Together O
, O
these O
results O
suggest O
that O
phosphorylation O
of O
I B
kappa I
B I
alpha I
, O
mediated O
through O
both O
the O
TNF B
- I
alpha I
- O
inducible O
and O
the O
PP B
- I
2A I
- I
opposing I
kinases I
, O
may O
serve O
to O
target O
I B
kappa I
B I
alpha I
for O
proteasome B
- O
mediated O
degradation O
. O

The O
5 B
' I
flanking I
region I
of O
the O
human B
alpha I
- I
globin I
gene I
is O
highly O
G O
+ O
C O
rich O
and O
contains O
multiple O
copies O
of O
the O
consensus B
sequence I
for O
the O
Sp1 B
binding I
site I
. O

In O
addition O
, O
the O
Ah B
receptor I
complex I
recognized O
a O
DNA B
binding I
site I
for O
B B
cell I
lineage I
- I
specific I
activator I
protein I
( O
BSAP B
) O
in O
the O
promoter B
region I
of O
the O
human O
CD19 B
gene I
which O
is O
similar O
to O
the O
consensus B
Ah I
receptor I
DNA I
binding I
site I
. O

We O
recently O
identified O
a O
differentiation B
inhibitory I
factor I
( O
I B
- I
factor I
) O
in O
mouse O
myeloid O
leukemia O
M1 O
cells O
as O
a O
murine B
homolog I
of O
the O
human B
nm23 I
- I
H2 I
gene I
product I
. O

Antigen O
complexed O
with O
major B
histocompatibility I
complex I
class I
I I
or I
II I
molecules I
on O
the O
surface O
of O
antigen O
presenting O
cells O
interacts O
with O
the O
T B
cell I
receptor I
( O
TCR B
) O
on O
the O
surface O
of O
T O
cells O
and O
initiates O
an O
activation O
cascade O
. O

Costimulatory O
signals O
, O
such O
as O
activation O
of O
the O
CD28 B
cell I
surface I
molecule I
on O
T O
cells O
, O
lead O
to O
activation O
through O
a O
distinct O
region O
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
promoter I
. O

From O
nuclear O
runoff O
experiments O
, O
we O
found O
that O
one O
subunit O
in O
particular O
, O
the O
B2 B
isoform I
( O
Mr O
= O
56 O
, O
000 O
) O
, O
was O
amplified O
primarily O
by O
transcriptional O
means O
. O

We O
transfected O
promoter B
- I
luciferase I
reporter I
plasmids I
into O
THP O
- O
1 O
cells O
to O
define O
sequences O
that O
mediate O
transcriptional O
control O
during O
monocyte O
differentiation O
. O

These O
results O
suggest O
that O
cell O
- O
specific O
patterns O
of O
synergy O
are O
an O
essential O
feature O
for O
c B
- I
fos I
induction O
and O
may O
be O
relevant O
for O
c B
- I
fos I
control O
through O
B B
and I
T I
cell I
antigen I
receptors I
. O

Multiple O
signals O
are O
required O
for O
function O
of O
the O
human B
granulocyte I
- I
macrophage I
colony I
- I
stimulating I
factor I
gene I
promoter I
in O
T O
cells O
. O

These O
results O
imply O
that O
at O
least O
three O
signals O
are O
required O
to O
activate O
the O
GM B
- I
CSF I
proximal I
promoter I
, O
and O
that O
the O
signals O
impinge O
on O
distinct O
transcription B
factors I
that O
bind O
to O
the O
hCLEO B
and I
NF I
- I
kappa I
B I
regions I
of O
the O
promoter B
. O

In O
this O
report O
, O
we O
show O
that O
in O
monocytes O
and O
T O
cells O
IL B
- I
10 I
stimulates O
tyrosine O
phosphorylation O
of O
the O
signal B
transducers I
and O
activators B
of I
transcription I
, O
STAT1 B
alpha I
and O
STAT3 B
, O
in O
a O
differential O
manner O
such O
that O
the O
relative O
formation O
of O
homo B
- I
and I
heterodimers I
varies O
between O
the O
two O
cell O
types O
. O

Selective O
modulation O
of O
immune O
responsiveness O
by O
IL B
- I
10 I
in O
cells O
such O
as O
monocytes O
and O
T O
cells O
may O
result O
in O
part O
from O
the O
differential O
activation O
of O
STAT B
protein I
pairs I
. O

Levels O
of O
the O
octamer O
, O
NF B
- I
kappa I
B I
( O
p50 B
- I
p65 I
heterodimer I
) O
, O
and O
AP B
- I
1 I
transcriptional I
factors I
are O
constitutively O
elevated O
in O
freshly O
isolated O
Ipr O
CD4 O
- O
8 O
- O
T O
cells O
, O
consistent O
with O
the O
activated O
phenotype O
of O
these O
cells O
. O

We O
demonstrate O
that O
cross O
- O
linking O
CD30 B
with O
an O
anti O
- O
CD30 B
- O
specific O
monoclonal O
antibody O
, O
which O
mimics O
the O
described O
biological O
activities O
of O
the O
CD30 B
ligand I
( O
CD30L B
) O
, O
results O
in O
HIV O
expression O
. O

Type B
II I
major I
histocompatibility I
complex I
combined O
immune O
deficiency O
( O
type O
II O
MHC B
CID O
or O
bare O
lymphocyte O
syndrome O
) O
is O
a O
congenital O
immunodeficiency O
disease O
characterized O
by O
absent O
MHC B
class I
II I
expression O
. O

Here O
, O
we O
demonstrate O
that O
CIITA B
is O
an O
MHC B
class I
II I
gene I
- I
specific I
transcription I
activator I
. O

The O
transcription O
activation O
function O
is O
provided O
by O
the O
N B
- I
terminal I
acidic I
domain I
( O
amino B
acids I
26 I
- I
137 I
) O
, O
which O
is O
experimentally O
exchangeable O
with O
a O
heterologous B
viral I
transcription I
- I
activating I
domain I
. O

Here O
, O
we O
report O
that O
nitric O
oxide O
( O
NO O
) O
activates O
p21ras B
in O
human O
T O
cells O
as O
evidenced O
by O
an O
increase O
in O
GTP B
- I
bound I
p21ras I
. O

In O
vitro O
studies O
using O
pure B
recombinant I
p21ras I
demonstrate O
that O
the O
activation O
is O
direct O
and O
reversible O
. O

These O
studies O
identify O
p21ras B
as O
a O
target O
of O
NO O
in O
T O
cells O
and O
suggest O
that O
NO O
activates O
p21ras B
by O
an O
action O
which O
mimics O
that O
of O
guanine B
nucleotide I
exchange I
factors I
. O

Transient O
transfections O
using O
reporter B
constructs I
with O
multiples O
of O
transcription B
factor I
binding I
sites I
from O
the O
IL B
- I
2 I
promoter I
[ O
distal B
nuclear I
factor I
( I
NF I
) I
- I
AT I
, O
proximal B
NF I
- I
AT I
, O
AP B
- I
1 I
/ I
Octamer I
( O
UPS B
) O
or O
NF B
- I
chi I
B I
( O
TCEd B
) O
sites O
] O
were O
performed O
. O

In O
EBV O
- O
transformed O
B O
clones O
, O
the O
chi B
B I
site I
exerted O
the O
strongest O
inducible O
activity O
; O
the O
NF B
- I
AT I
binding I
sites I
showed O
either O
no O
or O
only O
weak O
activity O
compared O
to O
Jurkat O
T O
cells O
. O

Here O
, O
we O
show O
that O
the O
presence O
of O
either O
wild O
- O
type O
EBV O
or O
its O
transforming B
latent I
membrane I
protein I
- I
1 I
( O
LMP B
- I
1 I
) O
results O
in O
the O
loss O
of O
TGF B
- I
beta I
1 I
- O
mediated O
growth O
inhibition O
in O
human O
B O
cells O
. O

TSHR B
antibody I
and O
microsomal B
antibody I
levels O
decreased O
after O
surgery O
, O
but O
increased O
after O
RAI O
therapy O
. O

Transfection O
experiments O
with O
c B
- I
myc I
promoter I
constructs I
in O
both O
DHL O
- O
9 O
and O
Raji O
cells O
revealed O
that O
the O
PuF B
site I
functioned O
as O
a O
positive B
regulatory I
element I
in O
B O
cells O
with O
a O
drop O
in O
activity O
with O
mutation O
of O
this O
site O
. O

Electromobility O
shift O
assays O
utilizing O
this O
sequence O
demonstrated O
binding O
of O
a O
fetal B
and I
erythroid I
- I
specific I
protein I
. O

Alanine O
substitutions O
introduced O
at O
two O
serine O
residues O
positioned O
within O
this O
N B
- I
terminal I
regulatory I
region I
of O
I B
kappa I
B I
alpha I
also O
yielded O
constitutive O
repressors O
that O
escaped O
from O
Tax B
- O
induced O
turnover O
and O
that O
potently O
inhibited O
immune O
activation O
pathways O
for O
NF B
- I
kappa I
B I
induction O
, O
including O
those O
initiated O
from O
antigen B
and I
cytokine I
receptors I
. O

These O
included O
vimentin B
, O
correlating O
to O
cell O
shape O
changes O
, O
cytokeratins B
8 I
and I
18 I
, O
associated O
with O
differentiated O
cell O
types O
of O
prostate O
epithelia O
, O
and O
neuron B
- I
specific I
enolase I
and O
serotonin O
, O
associated O
with O
neuroendocrine O
cells O
. O

Human O
peripheral O
blood O
monocytes O
responded O
to O
stimulation O
of O
platelet B
- I
activating I
factor I
( O
PAF B
) O
with O
up O
- O
regulation O
of O
the O
transcript O
for O
heparin B
- I
binding I
epidermal I
growth I
factor I
- I
like I
growth I
factor I
( O
HB B
- I
EGF I
) O
, O
a O
potent B
mitogen I
for O
vascular O
smooth O
muscle O
cells O
. O

These O
functions O
of O
PAF B
appeared O
to O
be O
mediated O
through O
the O
cell B
surface I
PAF I
receptors I
, O
as O
two O
PAF B
receptor O
antagonists O
, O
WEB O
2086 O
and O
L O
- O
659 O
, O
989 O
, O
blocked O
both O
the O
up O
- O
regulation O
of O
HB B
- I
EGF I
mRNA I
and O
kappa O
B O
binding O
activity O
induced O
by O
PAF B
. O

Several O
criteria O
indicated O
that O
the O
defect O
in O
this O
cell O
line O
influences O
the O
activity O
of O
an O
isotype B
- I
specific I
transcription I
factor I
. O

The O
DQB B
X2 I
- I
box I
was O
able O
to O
restore O
expression O
to O
the O
silent B
DRA I
reporter I
construct I
. O

Moreover O
, O
replacement O
of O
the O
DQB B
X2 I
- I
box I
with O
the O
DRA B
X2 I
- I
box I
markedly O
diminished O
the O
activity O
of O
the O
DQB B
promoter I
in O
the O
mutant O
cell O
. O

ZEBRA B
is O
a O
bZIP B
transcriptional I
activator I
which O
binds O
as O
a O
dimer O
to O
7 B
- I
bp I
response I
elements I
within O
EBV B
promoters I
and O
is O
directly O
involved O
in O
the O
stimulation O
of O
virus O
replication O
at O
the O
EBV B
lytic I
origin I
. O

Because O
these O
are O
the O
characteristics O
of O
a O
signal B
transducer I
and I
activator I
of I
transcription I
( I
Stat I
) I
protein I
, O
we O
determined O
whether O
antibodies B
to I
Stat I
proteins I
will O
interfere O
with O
gel O
mobility O
shift O
and O
found O
that O
antibodies B
to I
IL I
- I
4 I
Stat I
, O
also O
known O
as O
Stat6 B
, O
but O
not O
antibodies B
to O
other O
Stat B
proteins I
, O
interfere O
with O
the O
formation O
of O
the O
IL B
- I
4 I
NAF I
complex I
. O

In O
this O
paper O
, O
the O
expression O
of O
this O
gene O
in O
blood O
cells O
was O
first O
investigated O
in O
fractions O
of O
nucleated O
cells O
, O
revealing O
predominant O
expression O
of O
the O
Ah B
receptor I
gene I
in O
the O
monocyte O
fraction O
. O

In O
vitro O
translated O
Spi B
- I
B I
protein I
can O
bind O
to O
PU B
. I
1 I
binding I
sites I
in O
myeloid B
promoters I
and O
transactivate O
these O
promoters B
in O
nonmyeloid O
cells O
. O

The O
promoters B
were O
used O
without O
enhancers B
, O
or O
with O
enhancers B
derived O
from O
the O
beta B
- I
globin I
locus I
control I
region I
and O
the O
alpha B
- I
globin I
HS I
- I
40 I
enhancer I
. O

When O
transfected O
into O
K562 O
cells O
, O
which O
express O
zeta B
- I
globin I
, O
comparable O
amounts O
of O
activity O
were O
obtained O
from O
the O
- B
557 I
and I
- I
417 I
zeta I
- I
luciferase I
constructs I
and O
the O
alpha B
- I
luciferase I
constructs I
when O
no O
enhancers B
or O
the O
alpha B
- I
globin I
locus I
enhancers I
were O
used O
. O

This O
element O
requires O
GATA B
- I
1 I
and O
additional B
unknown I
factors I
for O
maximal O
activity O
. O

To O
address O
this O
issue O
, O
mutationally O
active O
PKC B
- I
alpha I
, I
- I
epsilon I
, I
or I
- I
zeta I
have O
been O
transfected O
into O
T O
cells O
and O
the O
consequences O
for O
T O
cell O
activation O
determined O
. O

Accordingly O
, O
the O
effects O
of O
the O
constitutively B
active I
PKCs I
were O
compared O
to O
the O
effects O
of O
mutationally O
activated O
p21ras B
. O

The O
ability O
of O
PKC B
- I
epsilon I
to O
induce O
transactivation O
of O
NF B
- I
AT I
- I
1 I
and O
AP B
- I
1 I
was O
similar O
to O
the O
stimulatory O
effect O
of O
a O
constitutively B
activated I
p21ras I
. O

Moreover O
, O
the O
data O
comparing O
the O
effects O
of O
activated B
Ras I
and O
PKC B
mutants I
suggest O
that O
PKC B
- I
alpha I
, O
p21ras B
, O
and O
PKC B
- I
epsilon I
are O
not O
positioned O
linearly O
on O
a O
single O
signal O
transduction O
pathway O
. O

Signaling O
by O
a O
wide O
variety O
of O
cytokines B
, O
including O
interferons B
, O
interleukins B
, O
and O
growth B
factors I
, O
involves O
activation O
of O
JAK B
kinases I
and O
Stat B
( I
Signal I
transducers I
and I
activators I
of I
transcription I
) I
proteins I
. O

Here O
we O
show O
that O
the O
lymphoid B
- I
specific I
transcription I
factor I
Oct I
- I
2A I
plays O
a O
critical O
role O
in O
HLA B
- I
DRA I
gene I
expression O
in O
class O
II O
- O
positive O
B O
cell O
lines O
, O
and O
that O
the O
high B
mobility I
group I
protein I
( O
HMG B
) O
I B
/ I
Y I
binds O
to O
multiple O
sites O
within O
the O
DRA B
promoter I
, O
including O
the O
Oct B
- I
2A I
binding I
site I
. O

In O
lymphoblastoid O
cell O
lines O
, O
six O
EBV B
- I
encoded I
nuclear I
antigens I
( O
EBNA1 B
, I
2 I
, I
3A I
, I
3B I
, I
3C I
, I
- I
LP I
) O
, O
three O
latent B
membrane I
proteins I
( O
LMP1 B
, O
2A B
, O
2B B
) O
, O
and O
two O
nuclear B
RNAs I
( O
EBERs B
) O
are O
expressed O
. O

In O
EBV O
- O
positive O
cases O
of O
Hodgkin O
' O
s O
disease O
, O
the O
EBERs B
, O
EBNA1 B
, O
and O
the O
LMPs B
are O
expressed O
( O
latency O
II O
) O
, O
whereas O
in O
Burkitt O
' O
s O
lymphoma O
( O
BL O
) O
only O
the O
EBERs B
and O
EBNA1 B
have O
been O
detected O
( O
latency O
I O
) O
. O

Also O
, O
the O
BZLF1 B
trans I
- I
activator I
protein I
was O
expressed O
in O
a O
few O
tumor O
cells O
in O
6 O
cases O
, O
indicating O
entry O
into O
the O
lytic O
cycle O
. O

A O
previously O
unrecognized O
element O
, O
located O
downstream O
of O
the O
start B
site I
of I
transcription I
in O
the O
first O
exon B
of O
the O
DR B
alpha I
gene I
, O
has O
been O
defined O
that O
enhances O
promoter O
activity O
up O
to O
eightfold O
in O
a O
position O
- O
dependent O
manner O
. O

The O
nuclear O
factor O
binds O
to O
the O
DR B
alpha I
and I
DP I
alpha I
element I
but O
not O
to O
the O
element O
in O
the O
DQ B
alpha I
gene I
. O

One O
of O
the O
genes O
that O
encodes O
a O
CBF B
alpha I
subunit I
is O
AML1 B
, O
also O
called O
Cbf B
alpha I
2 I
. O

In O
addition O
, O
this O
TR2RE B
- I
SV40 I
can O
function O
as O
a O
repressor O
to O
suppress O
the O
transcriptional O
activities O
of O
both O
SV40 B
early I
and I
late I
promoters I
. O

In O
HeLa O
cells O
stably O
transfected O
with O
the O
HIV B
- I
1 I
tat I
gene I
( O
HeLa O
- O
tat O
cells O
) O
, O
expression O
of O
the O
Tat B
protein I
enhanced O
both O
TNF B
- O
induced O
activation O
of O
NF B
- I
kappa I
B I
and O
TNF B
- O
mediated O
cytotoxicity O
. O

Expression O
of O
the O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
latent I
membrane I
protein I
1 I
( I
LMP I
- I
1 I
) I
oncogene I
is O
regulated O
by O
the O
EBV B
nuclear I
protein I
2 I
( I
EBNA I
- I
2 I
) I
transactivator I
. O

EBNA B
- I
2 I
is O
known O
to O
interact O
with O
the O
cellular B
DNA I
- I
binding I
protein I
J B
kappa I
and O
is O
recruited O
to O
promoters B
containing O
the O
GTGGGAA O
J B
kappa I
recognition I
sequence I
. O

The O
minimal B
EBNA I
- I
2 I
- I
responsive I
LMP I
- I
1 I
promoter I
includes O
one O
J B
kappa I
- I
binding I
site I
, O
and O
we O
now O
show O
that O
mutation O
of O
that O
site O
, O
such O
that O
J B
kappa I
can O
not O
bind O
, O
reduces O
EBNA B
- I
2 I
responsiveness O
by O
60 O
% O
. O

To O
identify O
other O
factors O
which O
interact O
with O
the O
LMP B
- I
1 I
EBNA I
- I
2 I
response I
element I
( O
E2RE B
) O
, O
a O
- B
236 I
/ I
- I
145 I
minimal I
E2RE I
was O
used O
as O
a O
probe O
in O
an O
electrophoretic O
mobility O
shift O
assay O
. O

LBF4 B
is O
B O
- O
and O
T O
- O
cell O
specific O
and O
recognizes O
the O
PU B
. I
1 I
GGAA I
core I
sequence I
as O
shown O
by O
methylation O
interference O
. O

Abnormal O
fast O
feedback O
and O
negative O
feedback O
of O
the O
hypothalamic O
- O
pituitary O
- O
adrenal O
axis O
implicates O
a O
dampened O
limbic B
- I
hippocampal I
glucocorticoid I
type I
II I
receptor I
( O
GCII B
) O
. O

We O
hypothesized O
that O
lymphocyte B
GCII I
is O
altered O
in O
adolescent O
MDD O
and O
could O
serve O
as O
a O
marker O
for O
response O
to O
SRIs O
. O

The O
role O
of O
NFATp B
in O
cyclosporin B
A I
- I
sensitive I
tumor I
necrosis I
factor I
- I
alpha I
gene I
transcription O
. O

Thus O
, O
although O
the O
kappa B
3 I
element I
has O
little O
sequence O
similarity O
to O
other O
NFATp B
- I
binding I
sites I
, O
it O
appears O
to O
function O
as O
a O
cyclosporin B
- I
sensitive I
promoter I
element I
in O
T O
cells O
by O
virtue O
of O
its O
ability O
to O
bind O
NFATp B
. O

EBNA B
- I
2 I
is O
able O
to O
trans O
- O
activate O
the O
expression O
of O
the O
LMP B
gene I
in O
several O
cell O
lines O
. O

We O
have O
previously O
shown O
that O
treatment O
of O
Jurkat O
T O
cells O
with O
phytohemaglutinin B
( O
PHA B
) O
and O
the O
phorbol O
ester O
, O
PMA O
, O
activated O
transcription O
initiation O
from O
the O
IL B
- I
3 I
gene I
. O

We O
also O
examined O
the O
function O
of O
the O
IL B
- I
3 I
CK I
- I
1 I
/ I
CK I
- I
2 I
elements I
that O
are O
present O
in O
many O
cytokine B
genes I
and O
found O
that O
they O
acted O
as O
a O
repressor O
of O
basal O
level O
expression O
when O
cloned O
upstream O
of O
a O
heterologous B
promoter I
but O
were O
also O
inducible O
by O
PMA O
/ B
PHA I
. O

Using O
a O
highly O
sensitive O
mutation O
screening O
assay O
of O
the O
DNA B
- I
and I
the I
steroid I
- I
binding I
region I
, O
none O
of O
the O
treated O
patients O
revealed O
any O
mutation O
, O
suggesting O
that O
the O
glucocorticoid B
receptor I
in O
the O
CLL O
patients O
tested O
is O
not O
altered O
in O
these O
domains O
. O

Methylation O
studies O
indicated O
that O
the O
tal B
- I
15 I
' I
GC I
- I
rich I
region I
behaves O
like O
a O
CpG B
island I
, O
hypomethylated O
in O
normal O
cells O
, O
and O
methylated O
de O
novo O
on O
transcriptionally B
inactive I
alleles I
in O
established O
cell O
lines O
. O

Transient O
chloramphenicol B
acetyltransferase I
assay O
revealed O
that O
the O
region O
containing O
E2F B
binding I
site I
had O
a O
strong O
promoter O
activity O
, O
and O
introduction O
of O
the O
mutation O
at O
the O
E2F B
binding I
site I
resulted O
in O
a O
significant O
loss O
of O
the O
activity O
. O

E2F B
- I
1 I
and I
DP I
- I
1 I
mRNAs I
were O
not O
detectable O
in O
granulocytes O
, O
monocytes O
and O
resting O
T O
- O
lymphocytes O
but O
were O
induced O
after O
the O
mitogenic O
stimulation O
of O
T O
- O
lymphocytes O
. O

Association O
of O
alterations O
in O
NF B
- I
kappa I
B I
moieties I
with O
HIV O
type O
1 O
proviral O
latency O
in O
certain O
monocytic O
cells O
. O

Human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
replication O
is O
controlled O
by O
a O
complex O
array O
of O
virally B
encoded I
and I
cellular I
proteins I
. O

The O
NFATd B
element I
, O
which O
binds O
the O
transcription B
factor I
NFAT B
- I
1 I
and O
is O
very O
active O
in O
T O
cells O
, O
is O
only O
weakly O
active O
in O
one O
B O
clone O
and O
not O
at O
all O
in O
another O
. O

Transcriptional O
activity O
of O
p105 B
is O
also O
increased O
in O
infected O
cells O
and O
is O
also O
mediated O
by O
NF B
- I
kappa I
B I
through O
a O
specific O
kappa B
B I
motif I
. O

In O
this O
study O
, O
we O
show O
that O
an O
activation B
- I
deficient I
glucocorticoid I
receptor I
mutant I
is O
as O
effective O
as O
the O
wild B
- I
type I
receptor I
in O
repression O
of O
AP B
- I
1 I
activity O
, O
inhibition O
of O
interleukin B
- I
2 I
production O
, O
inhibition O
of O
c B
- I
myc I
expression O
and O
induction O
of O
apoptosis O
. O

Insertion O
of O
this O
chimeric B
promoter I
( O
ISG15 B
LTR I
) O
upstream O
of O
the O
human B
IFNA2 I
gene I
directed O
high O
levels O
of O
IFN B
synthesis O
in O
Tat O
- O
expressing O
cells O
, O
while O
this O
promoter O
was O
not O
responsive O
to O
tumor B
necrosis I
factor I
alpha I
- O
mediated O
activation O
. O

Selected O
transfected O
clones O
produced O
low O
levels O
of O
IFN B
A I
( O
IFNA B
) O
constitutively O
, O
and O
their O
abilities O
to O
express O
interleukin B
- I
2 I
and O
interleukin B
- I
2 I
receptor I
upon O
stimulation O
with O
phytohemagglutinin B
and O
phorbol O
myristate O
acetate O
were O
retained O
. O

The O
second O
abnormality O
in O
kappa O
B O
- O
binding O
activity O
in O
T O
cells O
from O
these O
patients O
is O
that O
RelA B
, O
a O
member O
of O
the O
Rel B
homology I
family I
which O
is O
part O
of O
the O
normal O
NF B
- I
kappa I
B I
complex I
, O
was O
not O
induced O
in O
the O
nucleus O
following O
activation O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
two O
interactive O
mechanisms O
regulate O
monocytic B
I I
kappa I
B I
alpha I
/ I
MAD I
- I
3 I
mRNA I
levels O
. O

In O
extracts O
from O
nonstimulated O
cells O
the O
receptor O
is O
recovered O
in O
an O
inducible O
cytoplasmic O
form O
associated O
with O
the O
90 B
- I
kDa I
heat I
shock I
protein I
( O
hsp90 B
) O
, O
a O
molecular B
chaperone I
. O

Here O
, O
we O
report O
that O
stimulation O
through O
the O
IL B
- I
2R I
induced O
tyrosine O
phosphorylation O
and O
subsequent O
nuclear O
translocation O
of O
stat3 B
, O
a O
newly O
identified O
member O
of O
the O
signal B
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
family I
of O
proteins O
. O

This O
protein O
had O
an O
apparent O
molecular O
mass O
of O
84 O
kDa O
and O
was O
not O
recognized O
by O
stat3 B
or O
stat1 B
mAb I
or O
antisera O
. O

Taken O
together O
, O
we O
report O
that O
IL B
- I
2 I
induces O
tyrosine O
phosphorylation O
and O
subsequent O
nuclear O
translocation O
of O
stat3 B
and O
an O
as O
yet O
undefined O
84 B
- I
kDa I
protein I
in O
antigen O
- O
specific O
human O
T O
cell O
lines O
. O

Therefore O
we O
investigated O
the O
modifications O
imposed O
on O
NF B
- I
kappa I
B I
/ I
I I
kappa I
B I
components I
following O
stimulation O
and O
show O
that O
the O
final O
step O
of O
NF B
- I
kappa I
B I
induction O
in O
vivo O
involves O
phosphorylation O
of O
several O
members O
of O
the O
NF B
- I
kappa I
B I
/ I
I I
kappa I
B I
protein I
families I
. O

GIG10 B
is O
a O
novel O
sequence O
and O
GIG18 B
is O
the O
mouse O
homologue O
of O
a O
human B
expressed I
sequence I
tag I
isolated O
from O
activated O
B O
lymphocytes O
. O

This O
function O
was O
a O
result O
of O
the O
interaction O
of O
EBV O
with O
its O
receptor O
, O
CD21 B
, O
but O
was O
caused O
by O
infection O
rather O
than O
surface O
signaling O
, O
because O
neither O
specific B
mAb I
nor O
the O
P3HR O
- O
1 O
strain O
of O
virus O
mimicked O
the O
effect O
of O
B95 O
- O
8 O
. O

Consistent O
with O
the O
activity O
of O
B95 B
- I
8 I
, O
EBNA B
- I
2 I
transcripts I
were O
identified O
within O
infected O
thymocyte O
populations O
. O

The O
regulation O
of O
nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
activation O
by O
the O
T B
cell I
receptor I
( I
TcR I
) I
/ I
CD3 I
complex I
in O
primary O
human O
T O
cells O
has O
been O
studied O
at O
various O
times O
after O
activation O
. O

p50 B
. I
c I
- I
rel I
heterodimers I
were O
also O
detected O
bound O
to O
this O
sequence O
at O
early O
time O
points O
( O
7 O
- O
16 O
h O
; O
early O
) O
, O
and O
both O
remained O
active O
at O
later O
time O
points O
( O
40 O
h O
; O
late O
) O
after O
activation O
. O

The O
cis B
- I
acting I
region I
, O
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
( O
positions B
- I
95 I
and O
- B
73 I
) O
, O
within O
the O
murine B
GM I
- I
CSF I
gene I
promoter I
is O
required O
for O
maximal O
induction O
by O
stimulation O
with O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
calcium O
ionophore O
( O
A23187 O
) O
in O
T O
cells O
. O

We O
report O
here O
that O
three O
copies O
of O
the O
GC B
- I
box I
can O
functionally O
compensate O
for O
the O
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
region I
, O
suggesting O
that O
the O
GC O
- O
motif O
can O
function O
independently O
of O
the O
GM B
- I
kappa I
B I
motif I
. O

A O
factor O
that O
regulates O
the O
class B
II I
major I
histocompatibility I
complex I
gene I
DPA B
is O
a O
member O
of O
a O
subfamily O
of O
zinc B
finger I
proteins I
that O
includes O
a O
Drosophila B
developmental I
control I
protein I
. O

It O
encodes O
a O
protein O
predicted O
to O
contain O
688 O
amino O
acid O
residues O
, O
including O
11 O
zinc B
finger I
motifs I
of O
the O
C2H2 B
type I
in O
the O
C B
- I
terminal I
region I
, O
that O
are O
Kruppel O
- O
like O
in O
the O
conservation O
of O
the O
H B
/ I
C I
link I
sequence I
connecting O
them O
. O

One O
of O
the O
Drosophila B
sequences I
, O
ttk B
, O
is O
a O
developmental B
control I
gene I
, O
while O
a O
second O
does O
not O
contain O
a O
zinc B
finger I
region I
but O
encodes O
a O
structure O
important O
in O
oocyte O
development O
. O

This O
protein O
appears O
to O
require O
both O
the O
S B
and I
J I
elements I
, O
which O
are O
separated O
by O
10 O
bp O
for O
optimal O
binding O
. O

We O
also O
show O
that O
both O
Fos B
and O
Jun B
components O
of O
the O
AP B
- I
1 I
factors O
participate O
in O
the O
OAP40 B
complex I
. O

OAP B
confers O
to O
Oct B
- I
2 I
responsivity O
to O
both O
TPA O
/ O
Ca2 O
+ O
and O
RA O
, O
since O
specific O
mutations O
of O
the O
AP B
- I
1 I
/ I
OAP I
- I
binding I
site I
significantly O
reduce O
the O
transactivation O
by O
Oct B
- I
2 I
in O
response O
to O
TPA O
and O
Ca2 O
+ O
and O
abolish O
the O
inhibition O
by O
RA O
. O

PMA B
- I
but I
not I
TG I
- I
induced I
IL I
- I
2R I
alpha I
is O
inhibited O
by O
the O
PKC B
inhibitor O
H7 O
, O
whereas O
TG B
- I
but I
not I
PMA I
- I
induced I
IL I
- I
2R I
alpha I
was O
inhibited O
by O
cholera O
toxin O
, O
forskolin O
and O
1 O
, O
9 O
- O
dideoxy O
forskolin O
. O

Two O
gel B
shift I
complexes I
( O
Mono B
A I
and O
Mono B
B I
) O
were O
formed O
with O
separate O
sequence O
elements O
within O
this O
region O
. O

Furthermore O
, O
multimerized B
region I
II I
sequence I
elements I
enhanced O
the O
activity O
of O
a O
heterologous O
thymidine O
kinase O
promoter O
in O
monocytic O
cells O
but O
not O
other O
cell O
types O
tested O
. O

OBF B
- I
1 I
, O
a O
novel B
B I
cell I
- I
specific I
coactivator I
that O
stimulates O
immunoglobulin B
promoter I
activity O
through O
association O
with O
octamer B
- I
binding I
proteins I
. O

The O
OBF B
- I
1 I
mRNA I
is O
expressed O
in O
a O
highly O
cell O
- O
specific O
manner O
, O
being O
most O
abundant O
in O
B O
cells O
and O
essentially O
absent O
in O
most O
of O
the O
other O
cells O
or O
tissues O
tested O
. O

The O
T B
cell I
surface I
molecule I
CD28 B
binds O
to O
ligands O
on O
accessory O
cells O
and O
APCs O
, O
playing O
an O
important O
costimulatory O
role O
in O
the O
response O
of O
T O
cells O
to O
Ags B
. O

Mutagenesis O
studies O
, O
and O
the O
use O
of O
a O
reporter O
construct O
containing O
an O
enhancerless O
promoter O
, O
indicate O
that O
these O
transcriptional O
effects O
are O
due O
principally O
to O
the O
22 B
- I
bp I
sequence I
duplication I
and O
the O
NF B
kappa I
B I
site I
contained O
within O
it O
. O

The O
constitutive O
NF B
- I
kappa I
B I
appears O
to O
be O
functionally O
active O
, O
since O
a O
low O
level O
of O
tumour B
necrosis I
factor I
( I
TNF I
) I
transcript I
is O
detectable O
in O
monocytes O
, O
and O
this O
level O
can O
be O
increased O
by O
blocking O
transcript O
degradation O
using O
cycloheximide O
. O

Activated O
macrophages O
contribute O
to O
chronic O
inflammation O
by O
the O
secretion O
of O
cytokines B
and O
proteinases B
. O

Calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
II I
downregulates O
both O
calcineurin O
and O
protein O
kinase O
C O
- O
mediated O
pathways O
for O
cytokine B
gene I
transcription O
in O
human O
T O
cells O
. O

Induction O
of O
TaxI B
in O
a O
human O
T O
- O
cell O
line O
Jurkat O
carrying O
the O
TaxI B
gene I
under O
the O
metallothionein B
promoter I
led O
to O
increases O
in O
mRNA B
and O
surface O
expression O
of O
ICAM B
- I
I I
. O

Three O
other O
ATL O
cell O
lines O
( O
TL O
- O
OmI O
, O
H582 O
, O
HuT102 O
) O
were O
found O
to O
have O
little O
mRNA B
for O
the O
LFA B
- I
I I
beta I
chain I
( O
CD18 B
) O
. O

H582 O
and O
HuT102 O
were O
also O
negative O
for O
the O
LFA B
- I
I I
alpha I
chain I
( I
CDIIa I
) I
mRNA I
. O

We O
generated O
conditional O
EBV O
mutants O
by O
expressing O
EBNA2 B
as O
chimeric B
fusion I
protein I
with O
the O
hormone O
binding O
domain O
of O
the O
estrogen B
receptor I
on O
the O
genetic O
background O
of O
the O
virus O
. O

A O
synthetic O
oligodeoxyribonucleo O
containing O
an O
SP1 B
- I
box I
( O
5 O
' O
- O
GGGCGG O
) O
could O
compete O
with O
factors O
binding O
to O
the O
12 B
- I
bp I
insert I
. O

Functional O
Myc B
- I
Max I
heterodimer I
is O
required O
for O
activation O
- O
induced O
apoptosis O
in O
T O
cell O
hybridomas O
. O

Computer O
analysis O
of O
the O
SM B
protein I
sequence O
showed O
a O
C B
terminal I
section I
of O
SM B
to O
be O
related O
to O
genome B
positional I
homologues I
of O
four O
other O
herpesviruses O
and O
revealed O
consensus B
CKII I
sites I
near O
the O
N B
termini I
of O
the O
EBV B
SM I
protein I
, O
the O
herpes B
simplex I
virus I
( I
HSV I
) I
ICP27 I
protein I
and O
the O
herpesvirus B
saimiri I
( I
HVS I
) I
open I
reading I
frame I
57 I
protein I
. O

The O
serum B
response I
element I
( O
SRE B
) O
in O
the O
c B
- I
fos I
regulatory I
region I
participates O
in O
induction O
of O
transcription O
by O
various O
growth B
factors I
and O
by O
phorbol O
esters O
and O
subsequent O
squelching O
of O
transcription O
. O

Thus O
, O
the O
use O
of O
DNase B
I I
allowed O
us O
, O
for O
the O
first O
time O
, O
to O
correlate O
the O
AIR B
- I
1 I
locus I
defect I
with O
class B
II I
promoter I
occupancy O
alterations O
and O
distinguish O
these O
alterations O
from O
the O
ones O
observed O
in O
phenotypically O
similar O
but O
genetically O
distinct O
MHC O
class O
II O
- O
negative O
cells O
. O

Elf B
- I
1 I
physically O
associated O
with O
HMG B
- I
I I
and O
with O
NF B
- I
kappa I
B I
p50 B
and O
c B
- I
Rel I
in O
vitro O
, O
suggesting O
that O
protein O
- O
protein O
interactions O
might O
functionally O
coordinate O
the O
actions O
of O
the O
upstream B
and I
downstream I
positive I
regulatory I
elements I
. O

Among O
258 O
X O
chromosome O
- O
containing O
sperm O
, O
19 O
% O
had O
a O
repeat O
number O
equal O
to O
the O
donor B
' I
s I
somatic I
DNA I
( O
47 O
repeats O
) O
, O
66 O
% O
were O
expansions O
and O
15 O
% O
were O
contractions O
. O

The O
expression O
of O
the O
QR B
gene I
is O
regulated O
by O
the O
transcription B
factor I
AP B
- I
1 I
. O

These O
findings O
suggest O
a O
molecular O
mechanism O
of O
positive O
regulation O
of O
PAFR B
gene O
expression O
by O
PAF B
through O
NF B
- I
kappa I
B I
, O
possibly O
by O
a O
phosphorylation O
reaction O
involving O
protein B
kinase I
C I
by O
PAF B
. O

One O
gene O
, O
two O
transcripts B
: O
isolation O
of O
an O
alternative O
transcript O
encoding O
for O
the O
autoantigen B
La I
/ I
SS I
- I
B I
from O
a O
cDNA B
library I
of O
a O
patient O
with O
primary O
Sjogrens O
' O
syndrome O
. O

The O
B B
cell I
- I
associated I
surface I
molecule I
CD40 I
functions O
to O
regulate O
B O
cell O
responses O
. O

Changes O
of O
calcitriol B
receptors I
in O
primary O
and O
secondary O
hyperparathyroidism O
could O
magnify O
the O
consequences O
of O
disturbances O
in O
serum O
concentration O
of O
calcitriol O
itself O
and O
might O
play O
an O
important O
role O
in O
the O
development O
of O
secondary O
hyperparathyroidism O
in O
uremia O
. O

Studies O
of O
these O
females O
show O
that O
the O
XIST B
locus I
on O
their O
tiny B
ring I
X I
chromosomes I
is O
either O
not O
present O
or O
not O
expressed O
. O

As O
XIST B
transcription O
is O
well O
correlated O
with O
inactivation O
of O
the O
X B
chromosome I
in O
female O
somatic O
cells O
and O
spermatogonia O
, O
nonexpression O
of O
the O
locus O
even O
when O
it O
is O
present O
suggests O
that O
these O
chromosomes B
are O
transcriptionally O
active O
. O

We O
examined O
the O
transcriptional O
activity O
of O
ring O
X B
chromosomes I
lacking O
XIST B
expression O
( O
XISTE O
- O
) O
, O
from O
three O
females O
with O
severe O
phenotypes O
. O

The O
increase O
in O
IL B
- I
2 I
gene O
expression O
triggered O
by O
CD28 B
involves O
a O
kappa B
B I
- I
like I
sequence I
in O
the O
5 B
' I
- I
regulatory I
region I
of O
the O
IL B
- I
2 I
promoter I
, O
called O
CD28 B
- I
responsive I
element I
. O

The O
activity O
of O
constructs O
containing O
5 B
' I
deletion I
mutants I
of O
the O
alpha B
4 I
gene I
promoter I
was O
compared O
in O
transfection O
assays O
into O
cell O
lines O
that O
express O
alpha B
4 I
and O
cell O
lines O
that O
do O
not O
. O

The O
sequence O
between O
position O
- B
42 I
and I
- I
76 I
base I
pairs I
( O
bp O
) O
was O
required O
for O
efficient O
transcription O
in O
cells O
that O
express O
alpha B
4 I
, O
but O
it O
showed O
no O
activity O
in O
HeLa O
cells O
, O
which O
do O
not O
express O
alpha B
4 I
. O

This O
arrangement O
of O
Ets B
sites I
, O
coupled O
with O
the O
tissue O
- O
and O
developmental O
- O
specific O
expression O
of O
Ets B
members I
, O
likely O
play O
a O
key O
role O
in O
defining O
the O
pattern O
of O
alpha B
4 I
integrin I
. O

Antiandrogens O
result O
in O
protection O
of O
both O
the O
hinge B
region I
and O
C B
- I
terminus I
of O
the O
androgen B
receptor I
agonist O
proteolytic O
attack O
, O
whereas O
other O
studies O
showed O
that O
antiestrogens O
and O
antiprogestagens O
expose O
the O
C B
- I
terminal I
end I
of O
the O
ligand B
binding I
domain I
of O
their O
respective O
receptors O
to O
protease B
. O

To O
identify O
ets B
- I
related I
transcriptional I
regulators I
expressed O
in O
pre O
- O
B O
lymphocytes O
that O
may O
interact O
with O
either O
the O
pi B
or O
the O
microB B
site I
, O
we O
have O
used O
a O
PCR O
approach O
with O
degenerate O
oligonucleotides O
encoding O
conserved O
sequences O
in O
all O
members O
of O
the O
ets B
family I
. O

Nonpituitary B
human I
prolactin I
gene I
transcription O
is O
independent O
of O
Pit B
- I
1 I
and O
differentially O
controlled O
in O
lymphocytes O
and O
in O
endometrial O
stroma O
. O

One O
of O
the O
nuclear B
factors I
( O
NFs B
) O
that O
regulates O
the O
response O
of O
the O
IL B
- I
5 I
promoter I
to O
cAMP O
and O
PMA O
has O
properties O
similar O
to O
NF B
for O
activated O
t O
cell O
. O

T O
lymphocyte O
activation O
and O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
production O
require O
at O
least O
two O
signals O
, O
generated O
by O
phorbol O
ester O
( O
TPA O
) O
and O
Ca2 O
+ O
ionophore O
or O
costimulation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
and O
the O
CD28 B
auxiliary I
receptor I
. O

Full O
activation O
of O
the O
MAP B
kinases I
that O
phosphorylate O
the O
Jun B
activation I
domain I
, O
JNK1 B
and O
JNK2 B
, O
required O
costimulation O
of O
T O
cells O
with O
either O
TPA O
and O
Ca2 O
+ O
ionophore O
or O
antibodies O
to O
TCR B
and O
CD28 B
. O

In O
vivo O
protein O
- O
DNA O
contacts O
are O
detectable O
at O
Ii B
kappa I
B I
- I
1 I
in O
cell O
lines O
in O
which O
this O
site O
is O
functional O
as O
either O
a O
positive B
or I
negative I
regulator I
. O

OBJECTIVE O
: O
To O
determine O
whether O
activation O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
replication O
in O
tumour O
cells O
of O
AIDS O
- O
related O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
ARNHL O
) O
is O
correlated O
with O
CD4 B
+ I
cell O
counts O
and O
influences O
antibody O
response O
to O
EBV O
[ O
anti B
- I
Z I
Epstein I
- I
Barr I
replicative I
activator I
( O
ZEBRA B
) O
, O
anti B
- I
early I
antigen I
( O
EA B
) O
, O
anti B
- I
viral I
capsid I
antigen I
( O
VCA B
) O
] O
. O

Addition O
of O
rIL B
- I
2 I
fully O
restored O
the O
proliferative O
response O
and O
partially O
restored O
the O
production O
of O
IL B
- I
4 I
and O
IL B
- I
5 I
, O
but O
not O
that O
of O
other O
cytokines B
. O

It O
seems O
therefore O
that O
PGE2 B
, O
by O
elevating O
cAMP O
levels O
, O
interferes O
with O
the O
activation O
pathway O
for O
NF B
- I
kappa I
B I
but O
not O
for O
NF B
- I
AT I
, O
AP B
- I
1 I
or O
CLE0 B
binding I
protein I
. O

In O
contrast O
, O
analysis O
of O
pp90rsk B
activity O
by O
phosphorylation O
of O
a O
peptide O
derived O
from O
S6 B
protein I
demonstrated O
stimulation O
of O
this O
kinase B
in O
TPA O
- O
treated O
U O
- O
937 O
, O
and O
not O
TUR O
, O
cells O
. O

PDTC O
or O
N O
- O
acetylcysteine O
dose O
dependently O
reduced O
TNF B
- I
induced I
VCAM I
- I
1 I
but O
not O
ICAM B
- I
1 I
surface I
protein I
( O
also O
in O
human O
umbilical O
arterial O
endothelial O
cells O
) O
and O
mRNA O
expression O
( O
by O
70 O
% O
at O
100 O
mumol O
/ O
L O
PDTC O
) O
in O
HUVECs O
as O
assessed O
by O
flow O
cytometry O
and O
polymerase O
chain O
reaction O
. O

We O
have O
identified O
a O
` B
` I
two I
- I
handed I
' I
' I
zinc I
finger I
protein I
, O
denoted O
ZEB B
, O
the O
DNA O
- O
binding O
specificity O
of O
which O
mimics O
that O
of O
the O
cellular B
repressor I
. O

In O
order O
to O
elucidate O
the O
role O
of O
c B
- I
myb I
gene I
in O
erythroid O
differentiation O
of O
K562 O
cell O
induced O
by O
hemin B
( O
Hm B
) O
and O
erythropoietin B
( O
Epo B
) O
, O
we O
constructed O
recombinant B
plasmid I
that O
could O
produce O
antisense B
myb I
RNA I
after O
induction O
with O
dexamethasone O
. O

HRBC O
and O
LPS O
indeed O
stimulated O
the O
maternal O
immune O
system O
as O
revealed O
by O
specific O
anti B
- I
HRBC I
antibody I
production O
and O
enhanced O
IL O
- O
1 O
beta O
mRNA O
expression O
in O
splenocytes O
, O
respectively O
. O

The O
transmission O
of O
signals O
from O
the O
membrane O
to O
the O
nucleus O
is O
mediated O
principally O
through O
the O
action O
of O
protein B
tyrosine I
and I
serine I
/ I
threonine I
kinases I
. O

The O
RAR B
alpha I
rearranged O
band O
in O
the O
Southern O
blot O
analysis O
and O
a O
chimaeric B
product I
of O
PML B
- I
RAR I
alpha I
by O
polymerase O
chain O
reaction O
were O
strongly O
visible O
before O
ATRA O
treatment O
, O
but O
at O
the O
time O
of O
maximal O
basophilia O
both O
of O
them O
were O
markedly O
diminished O
. O

Activation O
of O
the O
interleukin B
6 I
gene I
by O
Mycobacterium O
tuberculosis O
or O
lipopolysaccharide O
is O
mediated O
by O
nuclear B
factors I
NF I
- I
IL6 I
and O
NF B
- I
kappa I
B I
[ O
published O
erratum O
appears O
in O
Proc O
Natl O
Acad O
Sci O
U O
S O
A O
1995 O
Apr O
11 O
; O
92 O
( O
8 O
) O
: O
3632 O
] O

Two O
nuclear B
factor I
NF I
- I
IL6 I
( O
positions O
- B
153 I
to I
- I
145 I
and O
- O
83 O
to O
- O
75 O
) O
and O
one O
nuclear B
factor I
NF I
- I
kappa I
B I
( I
positions I
- I
72 I
to I
- I
63 I
) I
motifs I
are O
present O
within O
this O
fragment O
. O

We O
conclude O
that O
the O
NF B
- I
IL6 I
and I
NF I
- I
kappa I
B I
sites I
mediate O
IL B
- I
6 I
induction O
in O
response O
to O
both O
LPS O
and O
LAM B
, O
acting O
as O
bacterial B
or I
mycobacterial I
response I
elements I
. O

The O
glutathione O
- O
depleting O
agent O
diethyl O
maleate O
( O
DEM O
) O
prevented O
the O
development O
of O
differentiated O
features O
in O
response O
to O
phorbol O
esters O
, O
including O
adherence O
of O
the O
cells O
to O
plastic O
surfaces O
and O
repression O
of O
the O
myeloperoxidase B
and I
CD34 I
genes I
. O

Furthermore O
, O
we O
found O
that O
20 O
% O
to O
25 O
% O
of O
both O
the O
adhesion B
protein I
Mac I
- I
1 I
and O
the O
NADPH B
- I
oxidase I
component I
cytochrome I
b558 B
is O
localized O
in O
gelatinase B
granules O
. O

Retinoid B
- I
like I
receptors I
play O
a O
central O
role O
in O
hormonal O
responses O
by O
forming O
heterodimers B
with O
other O
nuclear B
hormone I
receptors I
. O

Hence O
, O
PPAR B
can O
positively O
or O
negatively O
influence O
TH O
action O
depending O
on O
TRE B
structure O
and O
THR B
isotype I
. O

To O
test O
this O
hypothesis O
, O
light B
- I
chain I
gene I
structure I
was O
examined O
in O
pre O
- O
B O
cells O
transformed O
by O
temperature O
- O
sensitive O
mutants O
of O
the O
Abelson O
virus O
and O
in O
derivatives O
that O
survive O
at O
the O
nonpermissive O
temperature O
because O
they O
express O
a O
human B
BCL I
- I
2 I
gene I
. O

Our O
studies O
reveal O
that O
inactivation O
of O
the O
v B
- I
abl I
protein I
tyrosine I
kinase I
triggers O
high O
- O
frequency O
rearrangement O
of O
kappa B
and I
lambda I
light I
- I
chain I
genes I
. O

Expression O
and O
genomic O
configuration O
of O
GM B
- I
CSF I
, O
IL B
- I
3 I
, O
M B
- I
CSF I
receptor I
( O
C B
- I
FMS I
) O
, O
early B
growth I
response I
gene I
- I
1 I
( O
EGR B
- I
1 I
) O
and O
M B
- I
CSF I
genes I
in O
primary O
myelodysplastic O
syndromes O
. O

The O
expression O
of O
the O
M B
- I
CSF I
gene I
, O
that O
has O
been O
recently O
reassigned O
to O
the O
short B
arm I
of I
chromosome I
1 I
( O
lp B
) O
, O
was O
also O
investigated O
. O

The O
expression O
of O
the O
p50 B
and I
p65 I
NF I
- I
kappa I
B I
subunits I
was O
also O
shown O
to O
be O
regulated O
differentially O
after O
exposures O
to O
1 O
. O
0 O
and O
2 O
. O
0 O
Gy O
. O

The O
two O
human B
GATA3 I
zinc I
fingers I
are O
encoded O
by O
two O
separate O
exons B
highly O
conserved O
with O
those O
of O
GATA1 B
, O
but O
no O
other O
structural O
homologies O
between O
these O
two O
genes O
can O
be O
found O
. O

The O
human B
and I
mouse I
GATA3 I
transcription I
units I
start O
at O
a O
major B
initiation I
site I
. O

Retinoic O
acid O
- O
induced O
expression O
of O
CD38 B
antigen I
in O
myeloid O
cells O
is O
mediated O
through O
retinoic B
acid I
receptor I
- I
alpha I
. O

CD38 B
is O
a O
leukocyte B
differentiation I
antigen I
that O
has O
been O
thought O
to O
be O
a O
phenotypic O
marker O
of O
different O
subpopulations O
of O
T O
- O
and O
B O
- O
lymphocytes O
. O

Some O
antioxidants O
inhibit O
, O
in O
a O
co O
- O
ordinate O
fashion O
, O
the O
production O
of O
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
beta I
, O
and O
IL B
- I
6 I
by O
human O
peripheral O
blood O
mononuclear O
cells O
. O

Examination O
of O
the O
primary O
amino O
acid O
sequence O
of O
this O
protein O
indicates O
that O
it O
is O
a O
member O
of O
the O
signal B
transducers I
and I
activators I
of I
transcription I
( I
Stat I
) I
family I
of O
DNA B
binding I
proteins I
, O
hereby O
designated O
IL B
- I
4 I
Stat I
. O

Such O
observations O
indicate O
that O
IL B
- I
4 I
Stat I
has O
the O
same O
functional B
domain I
for O
both O
receptor O
coupling O
and O
dimerization O
. O

Lung O
disease O
associated O
with O
disorders O
such O
as O
cystic O
fibrosis O
( O
CF O
) O
may O
be O
amenable O
to O
somatic O
gene O
therapy O
in O
which O
there O
is O
delivery O
of O
the O
normal B
gene I
directly O
to O
the O
respiratory O
epithelium O
using O
E1a O
- O
adenovirus O
( O
Ad O
) O
type O
2 O
- O
or O
5 O
- O
based O
vectors O
. O

To O
characterize O
mechanisms O
responsible O
for O
these O
LIF B
effects O
, O
levels O
of O
HIV B
mRNA I
, O
activation O
of O
the O
DNA B
binding I
protein I
nuclear I
factor I
( B
NF I
) I
- I
kB I
, O
signal O
transduction O
pathways O
, O
and O
potential O
interactions O
with O
other O
cytokines B
were O
analyzed O
. O

The O
mechanisms O
involved O
in O
the O
inhibition O
of O
growth O
of O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
by O
anti B
- I
MHC I
class I
II I
antibodies I
( O
Ab B
) O
were O
compared O
with O
those O
in O
anti B
- I
IgM I
Ab I
- O
induced O
B104 O
growth O
inhibition O
. O

In O
order O
to O
study O
CD14 B
gene I
regulation O
, O
the O
human B
CD14 I
gene I
was O
cloned O
from O
a O
partial O
EcoRI B
digested I
chromosome I
5 I
library I
. O

The O
Sp1 B
transcription B
factor I
bound O
to O
three O
different O
regions O
in O
the O
CD14 B
promoter I
. O

Stimulation O
of O
the O
CD28 B
cell I
surface I
molecule I
delivers O
costimulatory O
signals O
essential O
for O
lymphokine B
production O
in O
activated O
T O
cells O
via O
a O
conserved B
sequence I
element I
found O
in O
the O
promoter B
of O
several O
lymphokine B
genes I
. O

Furthermore O
, O
the O
present O
results O
demonstrate O
clearly O
that O
mycoplasma B
products I
can O
have O
a O
profound O
impact O
on O
the O
activation O
status O
of O
eukaryotic O
cells O
. O

Novel B
membrane I
receptors I
for O
aldosterone O
in O
human O
lymphocytes O
: O
a O
50 B
kDa I
protein I
on O
SDS O
- O
PAGE O
. O

Analysis O
of O
the O
chromatin O
organization O
of O
the O
integrated O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
genome I
has O
previously O
revealed O
a O
major B
constitutive I
DNase I
I I
- I
hypersensitive I
site I
associated O
with O
the O
pol B
gene I
( O
E O
. O
Verdin O
, O
J O
. O
Virol O
. O
65 O
: O
6790 O
- O
6799 O
, O
1991 O
) O
. O

Site B
D I
( O
nt B
4816 I
to I
4851 I
) O
specifically O
bound O
a O
ubiquitously B
expressed I
factor I
. O

Sequence O
analyses O
show O
that O
this O
protein O
has O
significant O
homology O
with O
the O
human B
cytomegalovirus I
UL44 I
gene I
coding O
for O
the O
ICP36 B
family I
of O
early B
- I
late I
- I
class I
phosphoprotein I
. O

Analysis O
of O
Oct2 B
- I
isoform I
expression O
in O
lipopolysaccharide O
- O
stimulated O
B O
lymphocytes O
. O

Oct2 B
- I
isoform I
expression O
in O
splenic O
B O
cells O
stimulated O
with O
lipopolysaccharide O
or O
lipopolysaccharide O
plus O
phorbol O
- O
di O
- O
butyrate O
was O
analysed O
by O
cDNA O
cloning O
. O

A O
new O
exon B
containing O
a O
highly O
basic O
region O
( O
4c O
) O
was O
characterized O
, O
between B
exons I
4 I
and I
5 I
. O

In O
addition O
, O
a O
new O
combination O
isoform O
containing O
Oct2a B
' I
s I
amino I
terminal I
insert I
( O
exon B
7a I
) O
and O
Oct2b B
' I
s I
carboxy I
terminal I
insert I
( O
exon B
13 I
) O
was O
found O
that O
created O
a O
novel O
large O
isoform O
, O
Oct2ab B
. O

The O
role O
of O
the O
human B
immunodeficiency I
virus I
( I
HIV I
- I
1 I
) I
Nef I
protein I
in O
T O
cell O
activation O
pathways O
was O
investigated O
using O
a O
Jurkat O
CD4 O
+ O
cell O
line O
stably O
transfected O
with O
a O
Nef O
expression O
vector O
. O

We O
have O
previously O
shown O
that O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
expressed O
surface B
IgM I
( O
sIgM B
) O
and O
surface B
IgD I
( O
sIgD B
) O
, O
and O
that O
crosslinking O
of O
sIgM B
and O
sIgD B
by O
anti B
- I
IgM I
antibody I
( I
Ab I
) I
and O
anti B
- I
IgD I
Ab I
, O
respectively O
, O
induced O
Ca2 O
+ O
influx O
to O
almost O
the O
same O
degree O
, O
whereas O
only O
sIgM B
- O
crosslinking O
caused O
B104 O
cell O
death O
. O

Treatment O
of O
human O
erythrocytes O
with O
10 O
microM O
sodium O
orthovanadate O
( O
NaOV O
) O
, O
an O
inhibitor O
of O
plasma B
membrane I
Ca I
- I
ATPase I
and O
phosphotyrosine B
phosphatase I
, O
decreased O
parasitemia O
by O
30 O
% O
. O

Acetylsalicylic O
acid O
and O
sodium O
salicylate O
inhibit O
LPS O
- O
induced O
NF B
- I
kappa I
B I
/ I
c I
- I
Rel I
nuclear O
translocation O
, O
and O
synthesis O
of O
tissue B
factor I
( O
TF B
) O
and O
tumor B
necrosis I
factor I
alfa I
( O
TNF B
- I
alpha I
) O
in O
human O
monocytes O
. O

PMA O
acted O
synergistically O
with O
ionomycin O
to O
activate O
JNK B
MAPKs I
in O
Jurkat O
and O
EL4 O
within O
10 O
minutes O
. O

The O
transmembrane O
domains O
are O
well O
conserved O
, O
but O
there O
is O
striking O
sequence O
divergence O
of O
the O
carboxy B
- I
terminal I
cytoplasmic I
domain I
essential O
for O
B O
- O
cell O
immortalization O
and O
interaction O
with O
the O
tumor B
necrosis I
factor I
receptor I
signaling O
pathway O
. O

In O
this O
study O
, O
we O
have O
investigated O
the O
mechanisms O
by O
which O
the O
R24 B
mAb I
affects O
T O
cell O
functions O
. O

We O
have O
observed O
that O
the O
R24 B
mAb I
stimulates O
GD3 O
+ O
T O
cell O
proliferation O
, O
cytotoxicity O
, O
and O
surface O
marker O
expression O
of O
IL B
- I
2R I
alpha I
- I
chain I
, O
IL B
- I
2R I
beta I
- I
chain I
, O
HLA B
- I
DR I
, O
CD11a B
, O
and O
CD11c B
. O

R24 B
- O
stimulated O
increases O
in O
proliferation O
, O
cytotoxicity O
, O
and O
cell O
surface O
protein O
expression O
could O
be O
blocked O
by O
cyclosporin O
and O
staurosporin O
, O
indicating O
that O
cyclophilin B
/ I
calcineurin I
and O
protein B
kinase I
C I
may O
be O
involved O
in O
the O
R24 B
signaling O
pathway O
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB B
, O
TFIIE B
alpha I
, O
TFIIE B
beta I
, O
RAP30 B
, O
RAP74 B
and O
the O
62 B
kDa I
subunit I
, O
of O
TFIIH B
are O
located O
at O
the O
human B
chromosomal I
bands I
6q26 I
- I
27 I
, I
1p21 I
- I
22 I
, I
3q21 I
- I
24 I
, I
8p12 I
, I
13q14 I
, I
19p13 I
. I
3 I
and I
11p14 I
- I
15 I
. I
1 I
, O
respectively O
. O

Octamer O
independent O
activation O
of O
transcription O
from O
the O
kappa B
immunoglobulin I
germline I
promoter I
. O

Flow O
cytometry O
analyses O
on O
cultured O
cells O
that O
were O
treated O
with O
tepoxalin O
or O
antisense O
oligonucleotides O
to O
the O
P65 B
/ I
p50 I
subunit I
of O
NF B
- I
kappa I
B I
, O
and O
then O
stimulated O
with O
PMA O
, O
revealed O
a O
reduced O
expression O
of O
CD11b B
/ I
CD18 I
on O
monocytic O
HL60 O
cells O
, O
and O
endothelial B
adhesion I
molecule I
- I
1 I
( O
CD62E B
) O
and O
vascular B
adhesion I
molecule I
- I
1 I
( O
CD106 B
) O
on O
human O
umbilical O
vein O
endothelial O
cells O
. O

Tepoxalin O
also O
inhibited O
the O
secretion O
of O
a O
NF B
- I
kappa I
B I
regulated I
chemokine I
, O
IL B
- I
8 I
, O
a O
known O
inducer O
of O
CD11b B
/ I
CD18 I
expression O
. O

Characterization O
of O
a O
CD43 B
/ I
leukosialin I
- O
mediated O
pathway O
for O
inducing O
apoptosis O
in O
human O
T O
- O
lymphoblastoid O
cells O
. O

The O
monoclonal B
antibody I
( O
mAb B
) O
J393 B
induces O
apoptosis O
in O
Jurkat O
T O
- O
cells O
. O

NH2 B
- O
terminal O
amino O
acid O
sequence O
analysis O
identified O
the O
140 B
- I
kDa I
surface I
antigen I
for O
mAb B
J393 I
as O
CD43 B
/ I
leukosialin I
, O
the O
major O
sialoglycoprotein B
of O
leukocytes O
. O

While O
Jurkat O
cells O
co O
- O
expressed O
two O
discrete O
cell B
- I
surface I
isoforms I
of O
CD43 B
, O
recognized O
by O
mAb B
J393 I
and O
mAb B
G10 I
- I
2 I
, O
respectively O
, O
only O
J393 B
/ I
CD43 I
signaled O
apoptosis O
. O

Tyrosine B
kinase I
inhibition O
by O
herbimycin O
A O
diminished O
J393 B
/ I
CD43 I
- O
mediated O
apoptosis O
, O
whereas O
inhibition O
of O
phosphotyrosine B
phosphatase I
activity O
by O
bis O
( O
maltolato O
) O
oxovanadium O
- O
IV O
enhanced O
cell O
death O
. O

Consequently O
, O
the O
present O
study O
was O
addressed O
to O
understand O
this O
phenomenon O
and O
revealed O
the O
existence O
of O
a O
unique B
47 I
kDa I
protein I
factor I
having O
affinity O
for O
this O
SRE B
sequence I
in O
lymphocytes O
from O
normal O
subjects O
as O
well O
as O
its O
absence O
in O
lymphocytes O
from O
untreated O
CML O
patients O
. O

To O
understand O
the O
mechanism O
by O
which O
PRL B
regulates O
the O
biphasic O
expression O
of O
IRF B
- I
1 I
, O
we O
cloned O
the O
rat B
IRF I
- I
1 I
gene I
and O
functionally O
characterized O
the O
IRF B
- I
1 I
promoter I
. O

Hence O
, O
the O
PRL B
- O
induced O
biphasic O
expression O
of O
the O
IRF B
- I
1 I
gene I
appears O
to O
be O
controlled O
by O
separate O
PRL B
- I
responsive I
elements I
: O
elements O
in O
the O
first O
0 O
. O
2 O
kb O
of O
the O
IRF B
- I
1 I
promoter I
region I
act O
during O
early O
activation O
, O
and O
elements O
between O
0 O
. O
2 O
and O
1 O
. O
7 O
kb O
act O
in O
concert O
with O
the O
proximal O
0 O
. O
2 O
- O
kb O
region O
during O
S O
phase O
progression O
. O

In O
most O
cell O
lines O
, O
proteins O
of O
molecular O
weight O
49 O
and O
44 O
kDa O
were O
found O
, O
however O
two O
myeloid O
cell O
lines O
expressed O
only O
lower O
molecular B
weight I
species I
of I
24 I
and I
22 I
kDa I
. O

This O
effect O
required O
surface O
expression O
of O
the O
CD45 B
PTPase I
and O
was O
not O
observed O
in O
CD45 O
- O
deficient O
variants O
of O
Jurkat O
cells O
. O

Pervanadate B
activated I
NF I
- I
kappa I
B I
, O
as O
shown O
by O
an O
increase O
in O
DNA O
- O
binding O
activity O
of O
this O
transcription B
factor I
. O

We O
have O
shown O
elsewhere O
that O
both O
the O
major B
immediate I
- I
early I
gene I
( O
MIE B
) O
and O
lytic O
cycle O
infectious O
progeny O
virus O
expression O
can O
be O
induced O
in O
otherwise O
nonpermissive O
monocyte O
- O
like O
U O
- O
937 O
cell O
cultures O
infected O
with O
either O
human O
CMV O
( O
HCMV O
) O
or O
simian O
CMV O
( O
SCMV O
) O
by O
treatment O
with O
the O
phorbol O
ester O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
. O

Therefore O
, O
to O
evaluate O
the O
mechanism O
of O
TPA O
responsiveness O
of O
the O
SNE B
motifs I
and O
of O
a O
related O
16 O
- O
bp O
SEE B
( O
SRF B
/ I
ETS I
element I
) O
motif O
found O
in O
the O
HCMV B
and I
chimpanzee I
CMV I
MIE I
enhancers I
, O
we O
have O
examined O
the O
functional O
responses O
and O
protein O
binding O
properties O
of O
multimerized B
wild I
- I
type I
and I
mutant I
elements I
added O
upstream O
to O
the O
SCMV B
MIE I
or O
simian B
virus I
40 I
minimal I
promoter I
regions I
in O
the O
U O
- O
937 O
, O
K O
- O
562 O
, O
HL O
- O
60 O
, O
THP O
- O
1 O
, O
and O
Jurkat O
cell O
lines O
. O

TSC2 B
messenger I
RNA I
was O
widely O
expressed O
in O
various O
cell O
types O
throughout O
the O
body O
, O
including O
epithelia O
, O
lymphocytes O
, O
and O
cells O
with O
endocrine O
functions O
, O
e O
. O
g O
. O
, O
adrenal O
cortex O
and O
anterior O
pituitary O
. O

Cipro O
did O
not O
affect O
the O
nuclear B
transcription I
factors I
AP B
- I
1 I
or O
NFIL B
- I
2A I
. O

Furthermore O
, O
the O
physical O
interaction O
of O
Tax B
with O
p100 B
leads O
to O
the O
inhibition O
of O
Tax B
- O
induced O
activation O
of O
the O
HTLV O
- O
I O
and O
human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeats I
, O
reflecting O
p100 B
- O
mediated O
cytoplasmic O
sequestration O
of O
the O
normally O
nuclearly O
expressed O
Tax B
protein I
. O

Selection O
against O
such O
mutations O
may O
be O
the O
result O
of O
functional O
redundancy O
of O
these O
myogenic B
transcription I
factors I
. O

In O
previous O
studies O
, O
it O
was O
shown O
that O
the O
fusion O
region O
of O
the O
pml B
/ I
RAR I
- I
alpha I
protein I
, O
expressed O
by O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
cells O
, O
can O
be O
specifically O
recognized O
in O
vitro O
by O
donor O
( O
D O
. O
E O
. O
) O
CD4 O
T O
cells O
in O
a O
HLA B
class I
II I
DR11 O
- O
restricted O
fashion O
. O

We O
present O
here O
the O
results O
on O
the O
recognition O
of O
several O
pml O
/ O
RAR O
- O
alpha O
peptides O
by O
APL O
patients O
expressing O
HLA B
DR11 I
. O

The O
proximal O
element O
is O
a O
composite O
site O
that O
binds O
members O
of O
the O
CREB B
/ I
ATF I
, O
AP B
- I
1 I
, O
and O
octamer B
families I
of O
transcription B
factors I
. O

S107 O
plasmacytoma O
cells O
, O
which O
express O
CD40 B
but O
are O
defective O
for O
the O
nuclear O
appearance O
of O
p50 B
/ I
p65 I
- I
NF I
- I
kappaB I
, O
do O
not O
express O
RelB B
after O
CD40 B
stimulation O
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
amino B
- I
terminal I
portion I
of O
Sp140 B
was O
similar O
to O
Sp100 B
, O
a O
previously O
identified O
NB B
protein I
. O

B O
lymphocyte O
stimulation O
via O
both O
CD40 B
and O
surface B
Ig I
( I
sIg I
) I
receptors I
substantially O
induced O
fra B
- I
1 I
expression O
, O
and O
for O
both O
receptors O
, O
induction O
was O
protein B
kinase I
C I
( O
PKC B
) O
dependent O
. O

Association O
of O
TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
with O
an O
Epstein B
- I
Barr I
virus I
LMP1 I
domain I
important O
for O
B O
- O
lymphocyte O
transformation O
: O
role O
in O
NF B
- I
kappaB I
activation O
. O

The O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
transforming I
protein I
LMP1 I
appears O
to O
be O
a O
constitutively B
activated I
tumor I
necrosis I
factor I
receptor I
( O
TNFR B
) O
on O
the O
basis O
of O
an O
intrinsic O
ability O
to O
aggregate O
in O
the O
plasma O
membrane O
and O
an O
association O
of O
its O
cytoplasmic B
carboxyl I
terminus I
( O
CT B
) O
with O
TNFR B
- I
associated I
factors I
( O
TRAFs B
) O
. O

TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
bind O
to O
a O
single O
site O
in O
the O
LMP1 B
CT I
corresponding O
to O
amino O
acids O
( O
aa O
) O
199 O
to O
214 O
, O
within O
a O
domain O
which O
is O
important O
for O
B O
- O
lymphocyte O
growth O
transformation O
( O
aa O
187 O
to O
231 O
) O
. O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

The O
gene O
encoding O
the O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
- I
specific I
dUTPase I
was O
amplified O
from O
virus B
DNA I
by O
PCR O
. O

Two O
pp56 B
( I
lck I
) I
mutants I
lacking O
either O
the O
entire O
catalytic B
domain I
or O
the O
entire O
NH2 B
regulatory B
domain I
were O
generated O
, O
and O
their O
abilities O
to O
trigger O
transactivation O
of O
the O
TCR B
- I
regulated I
nuclear I
factor I
of I
activated I
T I
cells I
( I
NF I
- I
AT I
) I
region I
of O
the O
IL B
- I
2 I
promoter I
were O
compared O
. O

We O
identified O
an O
86 O
- O
nucleotide O
fragment O
that O
is O
90 O
% O
identical O
to O
the O
recently O
characterized O
murine B
IL I
- I
2 I
- I
responsive I
element I
( O
mIL B
- I
2rE I
) O
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

The O
IRF B
- I
2 I
promoter B
region I
contains O
a O
CpG O
island O
, O
with O
several O
GC B
boxes I
, O
a O
putative O
NF B
- I
kappa I
B I
- I
binding I
site I
, O
and O
a O
CAAT B
box I
, O
but O
no O
TATA B
box I
. O

When O
the O
promoter B
region I
was O
linked O
with O
a O
heterologous B
reporter I
gene I
, O
we O
found O
that O
the O
promoter B
region I
is O
inducible O
by O
both O
interferons B
( O
interferon B
- I
alpha I
and I
- I
gamma I
) O
and O
interferon B
regulatory I
factor I
1 I
. O

Binding O
of O
the O
cDNA B
fusion I
protein I
, O
similarly O
to O
the O
results O
obtained O
with O
purified O
Jurkat O
protein O
, O
was O
decreased O
by O
introduction O
of O
site O
- O
specific O
mutations O
in O
the O
DRE B
1 I
regulatory I
sequence I
. O

Cotransfection O
of O
a O
YB B
- I
1 I
expression I
plasmid I
increases O
HTLV O
- O
I O
basal O
transcription O
approximately O
14 O
- O
fold O
in O
Jurkat O
T O
lymphocytes O
. O

In O
these O
cells O
, O
nuclear B
factors I
involved O
in O
activation O
of O
the O
HIV B
- I
1 I
LTR I
, O
which O
contains O
the O
transcriptional B
control I
elements I
of O
the O
virus O
, O
are O
unknown O
. O

Cell O
specific O
expression O
of O
human B
Bruton I
' I
s I
agammaglobulinemia I
tyrosine I
kinase I
gene I
( O
Btk B
) O
is O
regulated O
by O
Sp1 B
- I
and O
Spi B
- I
1 I
/ I
PU I
. I
1 I
- I
family I
members I
. O

They O
also O
demonstrate O
for O
the O
first O
time O
the O
occurrence O
of O
T O
cell O
responses O
against O
EBV B
transactivating I
factors I
, O
which O
might O
be O
central O
in O
the O
control O
of O
virus O
reactivation O
. O

Thus O
, O
the O
tyrosine B
kinase I
activated O
by O
G B
- I
CSF I
appears O
to O
directly O
transduce O
a O
signal O
to O
a O
protein O
which O
functions O
as O
a O
transcriptional B
regulator I
. O

This O
effect O
is O
blocked O
by O
anti B
- I
VCAM I
antibodies I
. O

Moreover O
, O
ZK161422 O
, O
but O
not O
ZK157202 O
, O
showed O
preference O
for O
gene O
activation O
from O
a O
promoter B
carrying O
a O
VD B
response I
element I
with O
a O
palindromic O
arrangement O
of O
two O
hexameric B
receptor I
binding I
sites I
spaced O
by O
9 O
nucleotides O
( O
IP9 O
) O
rather O
than O
for O
activation O
from O
a O
response B
element I
formed O
by O
a O
direct O
repeat O
spaced O
by O
3 O
nucleotides O
( O
DR3 O
) O
. O

Calcineurin B
acts O
in O
synergy O
with O
PMA O
to O
inactivate O
I B
kappa I
B I
/ I
MAD3 I
, O
an O
inhibitor O
of O
NF B
- I
kappa I
B I
. O

Calcineurin B
stimulates O
the O
NF B
- I
kappa I
B I
element I
by O
enhancing O
inactivation O
of O
I B
kappa I
B I
/ I
MAD3 I
, O
an O
inhibitor O
of O
NF B
- I
kappa I
B I
, O
thereby O
increasing O
the O
amount O
of O
nuclear O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
. O

Inhibition O
of O
membrane O
IL B
- I
2R I
alpha I
and O
IL B
- I
2R I
beta I
expression O
by O
10 O
( O
- O
6 O
) O
M O
DM O
was O
partially O
reversible O
by O
recombinant B
human I
IL I
- I
2 I
( O
rhIL B
- I
2 I
) O
. O

Characterization O
of O
the O
murine B
cyclin I
- I
dependent I
kinase I
inhibitor I
gene I
p27Kip1 B
. O

The O
gene O
consists O
of O
at O
least O
three O
exons O
and O
spans O
more O
than O
5 B
. I
6 I
kb I
of I
DNA I
. O

The O
- B
326 I
to I
- I
615 I
region I
contained O
positive B
regulatory I
elements I
. O

Furthermore O
, O
overexpression O
and O
constitutive O
nuclear O
localization O
of O
NF B
- I
AT I
, O
but O
not O
Jun B
, I
Fos I
, I
NF I
- I
kappaB I
, I
Oct I
or I
Ets I
family I
members I
, O
renders O
the O
interleukin B
- I
2 I
enhancer I
in O
Jurkat O
T O
lymphocytes O
resistant O
to O
FK506 O
and O
cyclosporin O
A O
. O

First O
, O
anti B
- I
CD45 I
antibodies I
did O
not O
affect O
basal O
but O
decreased O
activated O
levels O
of O
expression O
from O
the O
HIV B
- I
1 I
LTR I
. O

The O
constitutively O
active O
type O
of O
the O
CN B
A I
subunit I
, O
which O
lacks O
the O
auto B
- I
inhibitory I
and O
calmodulin B
- I
binding I
domains I
, O
acts O
in O
synergy O
with O
PMA O
to O
activate O
transcription O
from O
the O
GM B
- I
CSF I
promoter I
. O

ORF1 B
consists O
of O
240 O
bp O
that O
would O
encode O
80 O
amino O
acids O
, O
while O
the O
major B
ORF2 I
consists O
of O
648 O
bp O
capable O
of O
coding O
for O
216 O
amino O
acids O
. O

Several O
forms O
of O
EGR B
- I
1 I
protein I
are O
found O
within O
the O
different O
groups O
of O
cell O
lines O
, O
and O
the O
binding O
activity O
to O
DNA B
consensus I
sequences I
was O
investigated O
. O

In O
all O
cells O
tested O
, O
IL B
- I
10 I
activated O
Stat1 B
and O
Stat3 B
and O
induced O
the O
formation O
of O
three O
distinct O
DNA B
binding I
complexes I
that O
contained O
different O
combinations O
of O
these O
two O
transcription B
factors I
. O

This O
study O
thus O
supports O
the O
concept O
that O
utilization O
of O
distinct O
STAT B
proteins I
by O
different O
cytokine B
receptors I
is O
dependent O
on O
the O
expression O
of O
particular O
ligand O
- O
activatable O
, O
tyrosine B
- I
containing I
STAT I
docking I
sites I
in O
receptor B
intracellular I
domains I
. O

Silencing O
of O
human O
fetal O
globin B
expression O
is O
impaired O
in O
the O
absence O
of O
the O
adult B
beta I
- I
globin I
gene I
activator I
protein I
EKLF B
. O

E3 B
, O
a O
hematopoietic B
- I
specific I
transcript I
directly O
regulated O
by O
the O
retinoic B
acid I
receptor I
alpha I
. O

These O
results O
indicate O
that O
E3 B
is O
a O
hematopoietic B
- I
specific I
gene I
that O
is O
an O
immediate O
target O
for O
the O
activated O
RAR B
alpha I
during O
myelopoiesis O
. O

To O
examine O
whether O
an O
active O
negative O
regulatory O
process O
occurs O
, O
we O
created O
a O
reporter B
construct I
containing O
as O
an O
enhancer B
four O
copies O
of O
the O
NF B
- I
AT I
site I
and O
one O
copy O
of O
the O
octamer B
site I
( O
4X B
NF I
- I
AT I
- I
Oct I
) O
. O

In O
contrast O
, O
expression O
of O
the O
activation B
- I
dependent I
cell I
surface I
markers I
CD25 B
and O
CD69 B
was O
within O
normal O
limits O
. O

During O
Epstein O
- O
Barr O
virus O
latent O
infection O
of O
B O
lymphocytes O
in O
vitro O
, O
six O
viral B
nuclear I
antigens I
( O
EBNAs B
) O
are O
expressed O
from O
one O
of O
two O
promoters B
, O
Cp B
or O
Wp B
, O
whose O
activities O
are O
mutually O
exclusive O
. O

Deletion O
of O
the O
glucocorticoid O
response O
elements O
located O
at O
ca B
. I
bp I
- I
850 I
upstream O
of O
Cp B
did O
not O
result O
in O
a O
significant O
loss O
in O
activity O
. O

The O
identification O
of O
oriP B
and O
the O
EBNA2 B
- I
dependent I
enhancer I
as O
the O
major O
positive O
cis B
elements I
involved O
in O
regulating O
Cp B
activity O
in O
LCL O
suggests O
that O
EBNA B
gene I
transcription O
is O
largely O
autoregulated O
by O
EBNA B
1 I
and O
EBNA B
2 I
. O

HIV O
- O
1 O
infection O
resulted O
in O
constitutive O
, O
low O
- O
level O
expression O
of O
type B
1 I
interferon I
( O
IFN B
) O
at O
the O
mRNA O
level O
. O

Nuclear O
translocation O
of O
NF B
- I
kappaB I
subunits I
may O
ultimately O
increase O
the O
intracellular O
pool O
of O
NF B
- I
kappaB I
/ I
IkappaBalpha I
by O
an O
autoregulatory O
mechanism O
. O

The O
transcription O
and O
transformation O
activity O
of O
c B
- I
Jun I
is O
governed O
by O
a O
27 B
- I
amino I
acid I
regulatory I
motif I
, O
labeled O
the O
delta B
- I
domain I
, O
which O
is O
deleted O
in O
v B
- I
Jun I
. O

All O
cells O
tested O
express O
TAFII105 B
mRNA I
, O
but O
only O
B O
cells O
contain O
significant O
levels O
of O
protein O
associated O
with O
TFIID B
. O

Seventeen O
microsatellite B
markers I
that O
span O
the O
common O
deleted O
region O
were O
used O
to O
search O
for O
loss O
of O
heterozygosity O
in O
granulocyte B
DNA I
. O

Therefore O
, O
the O
human B
androgen I
receptor I
assay O
( O
HUMARA O
) O
was O
used O
to O
determine O
granulocyte O
clonality O
. O

Soluble B
factors I
secreted O
by O
activated O
T O
- O
lymphocytes O
modulate O
the O
transcription O
of O
the O
immunosuppressive B
cytokine I
TGF B
- I
beta I
2 I
in O
glial O
cells O
. O

The O
transcriptionally B
regulatory I
regions I
of O
the O
lymphomagenic O
Akv O
and O
SL3 O
- O
3 O
murine O
leukemia O
retroviruses O
( O
MLVs O
) O
contain O
two O
types O
of O
E B
- I
box I
consensus I
motifs I
, O
CAGATG O
. O

We O
have O
examined O
the O
requirements O
of O
the O
individual O
E B
- I
boxes I
in O
MLV O
transcriptional O
regulation O
. O

In O
lymphoid O
cell O
lines O
only O
, O
the O
E B
( I
gre I
) I
- I
binding I
protein I
complexes I
included O
ALF1 B
or O
HEB B
and O
E2A B
basic I
helix I
- I
loop I
- I
helix I
proteins I
. O

Moreover O
, O
ectopic B
Id1 I
repressed O
E B
( I
gre I
) I
- O
directed O
but O
not O
EA B
/ I
S I
- O
directed O
MLV O
transcription O
in O
lymphoid O
cell O
lines O
. O

Reversal O
of O
apoptosis O
by O
the O
leukaemia O
- O
associated O
E2A B
- I
HLF I
chimaeric I
transcription I
factor I
. O

We O
cloned O
human O
nur77 B
beta I
cDNA I
, O
called O
TINUR B
. O

Although O
NGFI B
- I
B I
/ I
nur77 I
is O
essential O
for O
TCR O
- O
mediated O
apoptosis O
in O
T B
- I
cell I
hybridomas I
, O
the O
reports O
on O
nur77 O
knock O
- O
out O
mice O
and O
nur77 O
dominant O
negative O
transgenic O
mice O
suggest O
that O
there O
is O
a O
functional O
redundancy O
among O
NGFI B
- I
B I
/ I
nur77 I
family I
. O

Correlations O
were O
found O
between O
plasma B
IFN I
alpha I
and O
receptor O
Kd O
on O
monocytes O
of O
AIDS O
- O
GR O
( O
r O
= O
0 O
. O
77 O
) O
and O
between O
IFN B
alpha I
and O
plasma O
cortisol O
in O
the O
same O
group O
( O
r O
= O
0 O
. O
74 O
) O
. O

MNDA B
( O
myeloid B
cell I
nuclear I
differentiation I
antigen I
) O
is O
an O
interferon B
alpha I
regulated I
nuclear I
protein I
expressed O
only O
in O
cells O
of O
the O
human O
myelomonocytic O
lineage O
. O

Transient O
expression O
of O
NFATc B
. I
beta I
was O
capable O
of O
activating O
an O
interleukin B
- I
2 I
NFAT I
- I
driven I
reporter I
gene I
in O
stimulated O
Jurkat O
cells O
in O
a O
CsA O
- O
sensitive O
manner O
. O

However O
, O
NFATc B
. I
beta I
neither O
bound O
to O
the O
kappa3 B
element I
( O
an O
NFAT B
- I
binding I
site I
) O
in O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
nor O
activated O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
in O
cotransfection O
assays O
. O

Both O
are O
located O
in O
the O
particulate O
fraction O
following O
platelet O
activation O
and O
are O
also O
able O
to O
bind O
to O
a O
GST B
- I
construct I
containing O
the O
SH2 B
and I
SH3 I
domains I
of O
phospholipase B
C I
gamma I
1 I
. O

Constitutive O
expression O
of O
specific O
interferon B
isotypes I
in O
peripheral O
blood O
leukocytes O
from O
normal O
individuals O
and O
in O
promonocytic O
U937 O
cells O
. O

Constitutive O
expression O
of O
IFN B
- I
alpha5 I
and O
IFN B
- I
beta I
was O
detected O
in O
different O
lymphoid O
cells O
including O
peripheral O
blood O
mononuclear O
cells O
from O
normal O
individuals O
following O
amplification O
of O
IFN B
mRNA I
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
and O
direct O
sequencing O
of O
the O
amplified B
product I
. O

These O
results O
suggest O
that O
IFN B
- I
alpha5 I
and O
IFN B
- I
beta I
are O
produced O
at O
low O
levels O
in O
normal O
tissues O
and O
play O
an O
important O
role O
in O
the O
regulation O
of O
cell O
function O
and O
in O
the O
maintenance O
of O
homeostasis O
. O

Thus O
, O
IL B
- I
2 I
- O
induced O
IL B
- I
2R I
alpha I
promoter I
activity O
requires O
a O
complex B
upstream I
element I
, O
which O
appears O
to O
contain O
binding B
sites I
for O
both O
positive B
and I
negative I
regulatory I
factors I
. O

Lymphocytes O
from O
CML O
patients O
lack O
a O
47 B
kDa I
factor I
having O
affinity O
for O
a O
genomic B
sterol I
regulatory I
sequence I
. O

The O
proximal B
sequence I
element I
( I
PSE I
) I
- I
binding I
transcription I
factor I
( O
PTF B
) O
, O
which O
binds O
the O
PSE B
of O
both O
RNA B
polymerase I
II I
- I
and I
RNA I
polymerase I
III I
- I
transcribed I
mammalian I
small I
nuclear I
RNA I
( I
snRNA I
) I
genes I
, O
is O
essential O
for O
their O
transcription O
. O

Here O
we O
describe O
the O
isolation O
and O
expression O
of O
a O
cDNA B
encoding O
PTF B
beta I
, O
as O
well O
as O
functional O
studies O
using O
anti B
- I
PTF I
beta I
antibodies I
. O

We O
report O
here O
on O
the O
identification O
of O
a O
17 B
kDa I
variant I
of O
the O
14 B
kDa I
Id I
- I
3 I
protein O
termed O
Id B
- I
3L I
( O
long O
version O
) O
which O
possesses O
a O
unique O
60 B
amino I
acid I
carboxy I
- I
terminus I
generated O
by O
read O
through O
of O
a O
' O
coding B
intron I
' O
and O
alternative O
splicing O
. O

Tyloxapol O
inhibits O
NF B
- I
kappa I
B I
and O
cytokine B
release O
, O
scavenges O
HOCI B
, O
and O
reduces O
viscosity O
of O
cystic O
fibrosis O
sputum O
. O

In O
this O
study O
, O
we O
examined O
the O
molecular O
mechanism O
by O
which O
agents O
that O
elevate O
intracellular O
cAMP O
inhibit O
the O
expression O
of O
the O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
) O
, O
tissue B
factor I
, O
endothelial B
leukocyte I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
genes I
. O

We O
propose O
that O
direct O
interaction O
between O
the O
glucocorticoid B
receptor I
and O
nuclear B
factor I
- I
kappa I
B I
factors I
is O
at O
least O
a O
partial O
explanation O
for O
the O
effects O
of O
this O
hormone O
in O
inflammatory O
diseases O
. O

The O
primary O
and O
recurrent O
tumors O
in O
Group O
A O
did O
not O
show O
structural O
alterations O
in O
the O
p16 B
, I
p15 I
or I
CDK4 I
genes I
, O
whereas O
homozygous O
codeletion O
of O
p16 B
and O
p15 B
was O
observed O
in O
both O
primary O
and O
recurrent O
tumors O
in O
Group O
B O
. O

Approximately O
40 O
% O
of O
diffuse O
large O
cell O
lymphoma O
are O
associated O
with O
chromosomal O
translocations O
that O
deregulate O
the O
expression O
of O
the O
BCL6 B
gene I
by O
juxtaposing O
heterologous B
promoters I
to O
the O
BCL B
- I
6 I
coding I
domain I
. O

In O
transient O
transfectin O
experiments O
, O
BCL6 B
can O
repress O
transcription O
from O
promoters B
linked O
to O
its O
DNA B
target I
sequence I
and O
this O
activity O
is O
dependent O
upon O
specific O
DNA O
- O
binding O
and O
the O
presence O
of O
an O
intact O
N B
- I
terminal I
half I
of O
the O
protein O
. O

Altogether O
, O
these O
results O
suggest O
that O
ATRA O
/ O
9 O
- O
cis O
RA O
may O
play O
a O
key O
role O
in O
FL O
hematopoiesis O
via O
a O
dual O
effect O
hypothetically O
mediated O
by O
interaction O
with O
the O
RAR B
/ I
RXR I
heterodimer I
, O
ie O
, O
inhibition O
of O
HSC O
/ O
primitive O
HPC O
proliferation O
and O
induction O
of O
CFU O
- O
GEMM O
/ O
BFU O
- O
E O
/ O
CFU O
- O
M O
shift O
from O
the O
multipotent O
/ O
erythroid O
/ O
monocytic O
to O
the O
granulocytic O
- O
neutrophilic O
differentiation O
program O
. O

Analysis O
of O
the O
ligand B
- I
binding I
domain I
of O
human B
retinoic I
acid I
receptor I
alpha I
by O
site O
- O
directed O
mutagenesis O
. O

From O
these O
results O
, O
we O
can O
conclude O
that O
electrostatic O
interactions O
of O
retinoids O
with O
the O
RAR B
alpha I
- I
LBD I
play O
a O
significant O
role O
in O
ligand O
binding O
. O

Our O
findings O
support O
the O
recently O
determined O
calcineurin B
X O
- O
ray O
crystal O
structure O
, O
provide O
evidence O
that O
calcineurin B
is O
the O
only O
CsA B
- I
sensitive I
component I
limiting O
signaling O
from O
the O
T B
cell I
receptor I
to O
the O
nucleus O
, O
and O
suggest O
a O
means O
to O
render O
cells O
and O
tissues O
resistant O
to O
the O
toxic O
side O
effects O
of O
CsA O
and O
FK506 O
. O

Epstein O
- O
Barr O
viral O
latency O
is O
disrupted O
by O
the O
immediate B
- I
early I
BRLF1 I
protein I
through O
a O
cell O
- O
specific O
mechanism O
. O

The O
extent O
to O
which O
peptides O
containing O
chemically O
and O
post O
- O
translationally O
modified O
amino B
acid I
side I
chains I
are O
recognized O
by O
primed O
CTL O
has O
not O
been O
clearly O
defined O
. O

A O
3 O
' O
- O
- O
> O
5 O
' O
XPB B
helicase I
defect O
in O
repair B
/ I
transcription I
factor I
TFIIH B
of O
xeroderma O
pigmentosum O
group O
B O
affects O
both O
DNA O
repair O
and O
transcription O
. O

DNase B
I I
hypersensitive I
site I
( O
DHS B
) O
mapping O
revealed O
that O
the O
perforin B
locus I
contained O
six O
DHS B
within O
7 O
. O
0 O
kb O
of O
the O
5 B
' I
upstream I
sequence I
( O
- O
7 O
. O
0 O
kb O
) O
and O
two O
DHS B
in O
intron B
2 I
. O

Chloramphenicol B
acetyltransferase I
( O
CAT B
) O
activities O
directed O
by O
5 B
' I
upstream I
promoter I
were O
detected O
preferentially O
in O
perforin O
- O
expressing O
cell O
lines O
. O

Instead O
, O
ATF B
- I
2 I
and O
Jun B
proteins I
bind O
to O
the O
composite B
kappa I
3 I
/ I
CRE I
site I
and O
NFATp B
binds O
to O
a O
newly O
identified O
second O
NFAT B
site I
centered O
at O
- B
76 I
nucleotides I
relative O
to O
the O
TNF B
- I
alpha I
transcription I
start I
site I
. O

Consistent O
with O
these O
results O
, O
quantitative O
DNase B
footprinting O
of O
the O
TNF B
- I
alpha I
promoter I
using O
increasing O
amounts O
of O
recombinant O
NFATp B
demonstrated O
that O
the O
- B
76 I
site I
binds O
to O
NFATp B
with O
a O
higher O
affinity O
than O
the O
kappa B
3 I
site I
. O

Thus O
, O
through O
the O
differential O
use O
of O
the O
same O
promoter B
element I
, O
the O
composite B
kappa I
3 I
/ I
CRE I
site I
, O
the O
TNF B
- I
alpha I
gene I
is O
regulated O
in O
a O
cell O
- O
type O
- O
specific O
manner O
in O
response O
to O
the O
same O
extracellular O
signal O
. O

To O
address O
possible O
mechanisms O
that O
could O
explain O
this O
selective O
activity O
of O
c B
- I
ErbB I
, O
we O
analyzed O
the O
ability O
of O
these O
receptors O
to O
activate O
the O
different O
members O
of O
the O
Stat B
transcription I
factor I
family I
. O

Precise O
alignment B
of I
sites I
required O
for O
mu B
enhancer I
activation O
in O
B O
cells O
. O

The O
lymphocyte B
- I
specific I
immunoglobulin I
mu I
heavy I
- I
chain I
gene I
intronic I
enhancer I
is O
regulated O
by O
multiple O
nuclear B
factors I
. O

The O
previously O
defined O
minimal B
enhancer I
containing O
the O
muA B
, I
muE3 I
, I
and I
muB I
sites I
is O
transactivated O
by O
a O
combination O
of O
the O
ETS B
- I
domain I
proteins I
PU B
. I
1 I
and O
Ets B
- I
1 I
in O
nonlymphoid O
cells O
. O

The O
core O
GGAAs O
of O
the O
muA B
and I
muB I
sites I
are O
separated O
by O
30 O
nucleotides O
, O
suggesting O
that O
ETS B
proteins I
bind O
to O
these O
sites O
from O
these O
same O
side O
of O
the O
DNA O
helix O
. O

Mechanisms O
of O
transactivation O
by O
nuclear B
factor I
of I
activated I
T I
cells I
- I
1 I
. O

Nuclear B
factor I
of I
activated I
T I
cells I
- I
family I
proteins I
( O
NFAT1 B
/ I
NFATp I
, O
NFATc B
, O
NFAT3 B
, O
and O
NFAT4 B
/ I
NFATx I
/ I
NFATc3 I
) O
play O
a O
key O
role O
in O
the O
transcription O
of O
cytokine B
genes I
and O
other O
genes O
during O
the O
immune O
response O
. O

The O
results O
suggest O
a O
new O
option O
for O
HIV O
gene O
therapy O
; O
bcl B
- I
2 I
muteins I
that O
have O
noncleavable B
alterations I
surrounding O
the O
HIV B
protease I
cleavage I
site I
. O

The O
induction O
of O
T O
cell O
proliferation O
requires O
signals O
from O
the O
TCR B
and O
a O
co B
- I
receptor I
molecule I
, O
such O
as O
CD28 B
, O
that O
activate O
parallel O
and O
partially O
cross O
- O
reactive O
signaling O
pathways O
. O

Our O
results O
suggest O
that O
PKA B
inhibits O
T O
cell O
activation O
by O
interfering O
with O
multiple O
events O
along O
the O
two O
signaling O
pathways O
operating O
downstream O
of O
the O
TCR B
and O
the O
CD28 B
co I
- I
receptor I
molecules I
. O

To O
determine O
the O
contribution O
of O
the O
cytoplasmic B
domain I
of O
the O
IL B
- I
7 I
receptor I
alpha I
chain I
( O
IL B
- I
7R I
alpha I
) O
to O
activation O
of O
STAT B
proteins I
, O
transfectants O
of O
the O
murine O
pro O
- O
B O
cell O
line O
BAF3 O
were O
made O
that O
express O
chimeric B
receptors I
consisting O
of O
the O
extracellular B
domain I
of O
human B
granulocyte I
colony I
- I
stimulating I
factor I
receptor I
( O
G B
- I
CSF I
- I
R I
) O
and O
the O
transmembrane B
and I
intracellular I
domains I
of O
human B
IL I
- I
7R I
alpha I
. O

We O
demonstrate O
that O
CaMKIV B
/ I
Gr I
reconstitutes O
the O
capacity O
of O
the O
cytosolic O
component O
of O
NFAT B
to O
direct O
transcription O
from O
NFAT B
sites I
in O
non O
- O
T O
cells O
. O

Increasing O
the O
levels O
of O
BCL B
- I
2 I
retarded O
the O
G0 O
- O
- O
> O
S O
transition O
, O
sustained O
the O
levels O
of O
cyclin B
- I
dependent I
kinase I
inhibitor O
p27Kip1 O
, O
and O
repressed O
postactivation O
death O
. O

A O
2 B
- I
bp I
mutation I
within O
the O
CBF B
site O
resulted O
in O
a O
2 O
- O
3 O
- O
fold O
decrease O
in O
the O
activities O
of O
both O
a O
69 B
- I
bp I
proximal I
promoter I
fragment I
and O
a O
627 B
- I
bp I
full I
- I
length I
promoter I
fragment I
. O

The O
AML1 B
and I
CBF I
beta I
genes I
that O
encode O
CBF B
each O
have O
the O
ability O
to O
influence O
cell O
growth O
and O
differentiation O
and O
have O
been O
implicated O
as O
proto B
- I
oncogenes I
in O
acute O
myeloid O
leukemia O
. O

The O
GM B
- I
CSF I
locus I
may O
represent O
one O
of O
several O
target O
genes B
that O
are O
dysregulated O
in O
acute O
myeloid O
leukemia O
. O

The O
preferential O
induction O
of O
c B
- I
jun I
by O
H2O2 O
did O
not O
represent O
redox O
stabilization O
of O
mRNA B
transcripts I
, O
and O
oxidative O
signals O
closely O
resembled O
PHA O
/ O
PMA O
stimulation O
by O
effectively O
transactivating O
the O
full O
length O
c B
- I
jun I
promoter O
via O
the O
proximal B
jun1 I
tumor I
promoter I
- I
responsive I
element I
( I
TRE I
) I
- I
like I
promoter I
element I
. O

Furthermore O
, O
sublethal O
levels O
of O
H2O2 O
actively O
suppressed O
the O
transcriptional O
activation O
of O
NF B
- I
AT I
and O
IL B
- I
2 I
reporters I
as O
well O
as O
the O
expression O
of O
IL B
- I
2 I
mRNA I
in O
cells O
stimulated O
with O
PHA O
/ O
PMA O
. O

The O
effects O
of O
either O
catecholamine O
on O
IL B
- I
12 I
or O
IL B
- I
10 I
secretion O
were O
blocked O
completely O
by O
propranolol O
, O
a O
beta O
- O
adrenoreceptor O
antagonist O
, O
indicating O
that O
they O
were O
mediated O
by O
the O
beta B
- I
adrenergic I
receptor I
. O

There O
is O
increasing O
evidence O
that O
lipoproteins B
of O
Treponema O
pallidum O
and O
Borrelia O
burgdorferi O
are O
key O
inflammatory O
mediators O
during O
syphilis O
and O
Lyme O
disease O
. O

The O
present O
study O
describes O
the O
cloning O
of O
a O
lymphoid B
- I
restricted I
gene I
, O
LYSP100 B
, O
that O
is O
homologous O
to O
another O
protein O
that O
localizes O
to O
PML O
NBs O
, O
SP100 B
. O

Early O
studies O
in O
murine O
T O
cell O
lines O
indicated O
that O
transcriptional O
transactivation O
functions O
encoded O
in O
the O
glucocorticoid B
receptor I
( I
GR I
) I
N I
- I
terminal I
domain I
are O
required O
for O
glucocorticoid O
- O
mediated O
apoptosis O
. O

To O
better O
understand O
the O
contribution O
of O
the O
GR B
N I
- I
terminal I
transactivation I
domain I
in O
mediating O
murine O
thymocyte O
apoptosis O
, O
we O
stably O
transfected O
GR B
, O
GR B
variants I
, O
and O
the O
androgen B
receptor I
( O
AR B
) O
into O
receptor O
- O
negative O
S49 O
murine O
thymoma O
cells O
. O

Gel O
mobility O
shift O
and O
immunoprecipitation O
analyses O
revealed O
that O
in O
addition O
to O
activating O
STAT3 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
) O
and O
STAT5 B
, O
IL B
- I
2 I
induced O
tyrosine O
and O
serine O
phosphorylation O
of O
STAT1 B
alpha I
, O
which O
formed O
IFN B
- I
gamma I
- I
activated I
sequence I
- I
binding I
complexes I
by O
itself O
and O
with O
STAT3 B
. O

Our O
data O
support O
the O
notion O
that O
NF B
( I
kappa I
) I
B I
and O
I B
( I
kappa I
) I
B I
proteases I
play O
obligate O
roles O
in O
T O
cell O
activation O
and O
mitogenesis O
, O
roles O
that O
are O
enhanced O
significantly O
by O
NAC O
. O

Recently O
it O
has O
become O
clear O
that O
these O
cytokines B
activate O
a O
number O
of O
important O
intracellular B
signaling I
molecules I
, O
including O
the O
Janus B
kinases I
JAK1 B
and O
JAK3 B
and O
members O
of O
the O
transcription B
factor I
family I
of O
signal B
transducers I
and O
activators B
of I
transcription I
( O
STATs B
) O
. O

Yet O
, O
little O
is O
known O
as O
to O
how O
the O
RA B
and I
VitD3 I
receptor I
network I
operates O
in O
hematopoietic O
cells O
, O
and O
whether O
receptor O
interactions O
can O
explain O
the O
interplay O
between O
the O
RA O
- O
and O
VitD3 O
- O
signaling O
pathways O
during O
differentiation O
. O

Therefore O
, O
we O
analyzed O
the O
expression O
, O
DNA O
binding O
, O
and O
transcriptional O
activity O
of O
the O
endogenous B
RA I
and I
VitD3 I
receptors I
[ O
retinoic B
acid I
receptors I
( O
RARs B
) O
, O
retinoid B
X I
receptors I
( O
RXRs B
) O
, O
and O
VitD3 B
receptor I
( O
VDR B
) O
] O
in O
the O
U O
- O
937 O
cell O
line O
, O
in O
which O
RA O
and O
VitD3 O
induce O
distinct O
monocytic O
differentiation O
pathways O
. O

However O
, O
transcriptional O
activation O
was O
only O
observed O
from O
a O
VitD3 B
response I
element I
- I
driven I
reporter I
construct I
. O

Also O
, O
VitD3 O
inhibited O
the O
expression O
of O
CD23 B
and O
CD49f B
, O
characteristic O
markers O
of O
retinoid O
- O
induced O
U O
- O
937 O
cell O
differentiation O
. O

Freshly O
isolated O
monocytes O
expressed O
94 B
- I
kD I
STAT5A I
, O
92 O
- O
kD O
STAT5B B
, O
and O
an O
80 B
- I
kD I
STAT5A I
molecule I
. O

STAT5A B
- I
STAT5A I
homodimers I
and O
STAT5A B
- I
STAT5B I
heterodimers I
formed O
in O
response O
to O
GM B
- I
CSF I
. O

Translocation B
( I
3 I
; I
14 I
) I
( I
q27 I
; I
q11 I
) I
: O
a O
new O
variant O
translocation O
in O
a O
patient O
with O
non O
- O
Hodgkin O
' O
s O
lymphoma O
of O
B O
- O
cell O
type O
with O
BCL6 B
rearrangement O
. O

Southern O
blot O
analysis O
showed O
rearrangement O
of O
BCL6 B
, O
JH B
, O
and O
TCR B
beta I
but O
not O
of O
TCR B
delta I
. O

Latent B
membrane I
protein I
1 I
and O
, O
to O
a O
lesser O
extent O
, O
EBV B
nuclear I
antigen I
2 I
mediated O
the O
increase O
in O
p53 B
levels O
via O
activation O
of O
the O
NF B
- I
kappaB I
transcription B
factor I
. O

Tissue O
- O
specific O
expression O
of O
interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
is O
mediated O
via O
cis B
- I
acting I
elements I
located O
within O
315 O
base O
pairs O
of O
the O
transcription B
start I
. O

In O
addition O
to O
the O
already O
identified O
NIP B
repressor I
site I
, O
evidence O
is O
presented O
for O
a O
second B
repressor I
region I
that O
restricts O
promoter O
activity O
in O
fibroblasts O
. O

IL B
- I
13 I
caused O
rapid O
phosphorylation O
of O
the O
three O
out O
of O
four O
members O
of O
the O
known O
Janus B
family I
of I
kinases I
( O
JAKs B
) O
. O

In O
chloramphenicol B
acetyltransferase I
assays O
, O
utilizing O
the O
transient O
transfection O
of O
a O
chloramphenicol B
acetyltransferase I
reporter I
plasmid I
containing O
the O
IL B
- I
6 I
gene I
promoter I
, O
IL B
- I
4 I
, O
but O
not O
IL B
- I
10 I
, O
suppressed O
the O
transcriptional O
activity O
of O
the O
IL O
- O
6 O
gene O
promoter O
stimulated O
by O
PMA O
and O
LPS O
. O

Electrophoretic O
mobility O
shift O
assay O
showed O
the O
induction O
of O
a O
CsA B
- I
resistant I
NFAT I
complex I
in O
the O
nuclear O
extracts O
of O
peripheral O
blood O
T O
cells O
stimulated O
with O
PMA O
plus O
alphaCD28 B
. O

We O
compared O
the O
effects O
of O
the O
deactivating B
cytokine I
interleukin B
10 I
( O
IL B
- I
10 I
) O
on O
human O
peripheral O
blood O
mononuclear O
cell O
( O
PBMC O
) O
responses O
to O
lipopolysaccharide O
( O
LPS O
) O
, O
Cryptococcus O
neoformans O
, O
and O
Candida O
albicans O
. O

The O
IL B
- I
10R I
, O
together O
with O
reporter O
gene O
constructs O
containing O
different O
IL B
- I
6 I
- I
responsive I
gene I
elements I
, O
reconstituted O
in O
hepatoma O
cells O
an O
induction O
of O
transcription O
by O
IL B
- I
10 I
that O
was O
comparable O
to O
that O
by O
IL B
- I
6 I
. O

These O
receptor O
functions O
required O
the O
presence O
of O
the O
box B
3 I
motifs I
, O
as O
shown O
by O
the O
analysis O
of O
the O
mouse O
IL B
- I
10R I
constructs O
containing O
progressively B
truncated I
cytoplasmic I
domains I
. O

There O
are O
four O
putative O
NF B
- I
kappa I
B I
binding I
sites I
( O
kappa B
B I
- I
1 I
, O
kappa B
B I
- I
2 I
, O
kappa B
B I
- I
3 I
, O
kappa B
B I
- I
4 I
) O
in O
human B
TNF I
- I
alpha I
promoter I
. O

We O
have O
demonstrated O
that O
the O
level O
of O
CRE B
binding I
protein I
( O
CREB B
) O
was O
the O
same O
in O
all O
cell O
lines O
and O
that O
the O
putative O
AR B
- I
CRE I
forms O
specific O
and O
compatible O
protein O
interactions O
with O
CREB B
. O

Structural O
and O
functional O
characterization O
of O
the O
human B
CD36 I
gene I
promoter I
: O
identification O
of O
a O
proximal O
PEBP2 B
/ I
CBF I
site I
. O

In O
these O
cells O
, O
CD36 B
is O
involved O
in O
phagocytosis O
of O
apoptotic O
cells O
, O
and O
foam O
cell O
formation O
by O
uptake O
of O
oxidized B
low I
density I
lipoprotein I
. O

Biochemical O
analysis O
of O
the O
region O
- B
158 I
/ I
- I
90 I
revealed O
a O
binding O
site O
for O
transcription B
factors I
of O
the O
polyomavirus B
enhancer I
- I
binding I
protein I
2 I
/ I
core I
- I
binding I
factor I
( I
PEBP2 I
/ I
CBF I
) I
family I
at O
position B
- I
103 I
. O

Disruption O
of O
the O
PEBP2 B
/ I
CBF I
site I
markedly O
diminished O
the O
role O
of O
the O
PEBP2 B
/ I
CBF I
factors I
in O
the O
constitutive O
transcription O
of O
the O
CD36 B
gene I
. O

The O
association O
of O
specific O
HLA B
- I
DQ I
alleles I
with O
autoimmunity O
is O
correlated O
with O
discrete O
polymorphisms O
in O
the O
HLA B
- I
DQ I
sequence I
that O
are O
localized O
within O
sites O
suitable O
for O
peptide O
recognition O
. O

Based O
on O
the O
presence O
of O
T B
cell I
receptor I
- I
beta I
( I
TcR I
- I
beta I
) I
gene I
rearrangements I
in O
L428 O
and O
HDLM O
- O
1 O
cells O
, O
the O
expression O
of O
CD2 B
in O
HDLM O
- O
1 O
cells O
, O
and O
the O
presence O
of O
immunoglobulin B
heavy I
- I
chain I
( I
IgH I
) I
gene I
rearrangement I
in O
KM O
- O
H2 O
cells O
, O
some O
researchers O
have O
concluded O
that O
these O
long O
- O
term O
cell O
lines O
derived O
from O
patients O
with O
Hodgkin O
' O
s O
disease O
are O
lymphoid O
in O
nature O
. O

Expression O
of O
the O
MAP B
kinase I
- I
specific I
phosphatase I
, O
MKP B
- I
1 I
, O
which O
blocks O
ERK B
activation O
, O
inhibited O
IL B
- I
2 I
promoter I
and O
NF B
- I
AT I
- O
driven O
transcription O
stimulated O
by O
a O
calcium O
ionophore O
and O
PMA O
, O
and O
in O
addition O
, O
MKP B
- I
1 I
neutralized O
the O
transcriptional O
enhancement O
caused O
by O
active O
Raf O
- O
1 O
and O
MEK1 O
expression O
. O

We O
investigated O
oligonucleotide O
- O
directed O
triple O
helix O
formation O
across O
this O
regulatory B
sequence I
as O
a O
potential O
tool O
to O
inhibit O
GM B
- I
CSF I
gene O
transcription O
. O

Triplex O
formation O
by O
GM3 O
blocked O
recombinant B
and I
nuclear I
NF I
- I
kappaB I
proteins I
binding O
to O
the O
GM B
- I
CSF I
element I
. O

Finally O
, O
GM3 O
greatly O
reduced O
the O
concentration O
of O
endogenous O
GM B
- I
CSF I
mRNA I
induced O
by O
different O
stimuli O
in O
Jurkat O
T O
cells O
but O
did O
not O
affect O
interleukin B
3 I
mRNA I
levels O
in O
the O
same O
cells O
. O

Using O
these O
T O
cells O
as O
a O
model O
of O
IL B
- I
12 I
signal O
transduction O
, O
we O
confirmed O
that O
these O
events O
involve O
members O
of O
the O
Janus B
kinase I
family I
of O
nonreceptor B
tyrosine I
kinases I
JAK2 B
, O
TYK2 B
, O
and O
signal B
transducer I
and I
activator I
of I
transcription I
4 I
. O

These O
mechanisms O
include O
the O
assembly O
of O
higher B
order I
nucleoprotein I
complexes I
and O
other O
protein O
- O
protein O
interactions O
that O
enhance O
the O
functional O
specificity O
of O
transcriptional B
regulators I
in O
lymphocytes O
. O

However O
, O
no O
cytoplasmic B
p62c I
- I
fos I
was O
detected O
in O
unstimulated O
PBL O
, O
although O
in O
some O
cases O
cytoplasmic B
p39c I
- I
jun I
was O
detected O
, O
suggesting O
that O
subcellular O
compartmentalization O
of O
these O
proteins B
may O
occur O
under O
certain O
circumstances O
. O

However O
, O
synthesis O
of O
the O
26 B
- I
kDa I
membrane I
form I
of O
TNF B
was O
effectively O
blocked O
by O
CNI O
- O
1493 O
. O

r B
- I
hTBP I
- I
1 I
and O
rhu B
TNFR I
: I
Fc I
also O
decreased O
p24 B
antigen I
synthesized O
by O
U1 O
cells O
in O
response O
to O
other O
stimuli O
, O
including O
phytohemagglutinin B
( I
PHA I
) I
- I
induced I
supernatant I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
interleukin B
- I
6 I
, O
and O
TNF B
. O

Transcriptional O
activation O
of O
RNA B
polymerase I
III I
- I
dependent I
genes I
by O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
tax I
protein I
. O

The O
viral B
protein I
Tax I
was O
likely O
responsible O
for O
this O
higher O
level O
of O
class B
II I
gene I
transcription O
, O
as O
purified B
Tax I
was O
found O
to O
stimulate O
both O
genes O
when O
added O
to O
the O
uninfected O
cell O
extract O
or O
in O
reconstituted O
systems O
. O

We O
have O
generated O
rabbit O
antisera O
against O
this O
putative O
p13MTCP1 B
protein I
and O
screened O
for O
expression O
of O
p13MTCP1 B
normal O
lymphoid O
tissues O
and O
33 O
cases O
of O
immature O
and O
mature O
lymphoid O
T O
- O
cell O
proliferations O
using O
a O
sensitive O
Western O
blot O
assay O
. O

The O
p13MTCP1 B
protein I
was O
detected O
in O
the O
three O
T O
- O
cell O
proliferations O
with O
MTCP1 B
rearrangements I
because O
of O
t O
( O
X O
; O
14 O
) O
translocations O
, O
but O
neither O
in O
normal O
resting O
and O
activated O
lymphocytes O
nor O
in O
the O
other O
T O
- O
cell O
leukemias O
. O

A O
variety O
of O
cytokines B
and O
growth B
factors I
act O
through O
an O
induction O
of O
gene O
expression O
mediated O
by O
a O
family O
of O
latent B
transcription I
factors I
called O
STAT B
( I
signal I
transducers I
and I
activators I
of I
transcription I
) I
proteins I
. O

We O
have O
previously O
identified O
a O
new O
transcription B
factor I
family I
( O
the O
MNP B
family I
) O
whose O
expression O
is O
crucial O
for O
the O
induction O
of O
MIP B
- I
1 I
alpha I
transcription O
during O
cellular O
activation O
and O
in O
transformed O
B O
cells O
. O

Here O
we O
identify O
the O
gene O
encoding O
the O
lymphocyte B
homing I
and I
migration I
protein I
CD44 B
as O
a O
target O
of O
EGR1 B
regulation O
in O
B O
cells O
. O

The O
EGR1 B
binding I
motif I
was O
shown O
to O
be O
necessary O
for O
stimulus O
- O
induced O
expression O
of O
a O
CD44 B
promoter B
- I
chloramphenicol I
acetyltransferase I
reporter I
construct I
in O
nontransformed O
B O
lymphocytes O
and O
was O
required O
for O
transactivation O
by O
an O
EGR1 B
expression I
vector I
in O
a O
B O
- O
cell O
line O
. O

A O
mutant O
Tax B
protein I
deficient O
in O
transactivation O
of O
genes O
by O
the O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
pathway O
was O
unable O
to O
induce O
transcriptional O
activity O
of O
IL B
- I
1alpha I
promoter I
- I
CAT I
constructs I
, O
but O
was O
rescued O
by O
exogenous O
provision O
of O
p65 B
/ I
p50 I
NF B
- I
kappaB I
. O

Although O
a O
13 B
- I
kilobase I
- I
pair I
( I
kb I
) I
human I
c I
- I
fes I
transgene I
exhibits O
high O
levels O
of O
expression O
in O
mice O
, O
the O
sequences O
that O
confer O
myeloid O
- O
cell O
- O
specific O
expression O
of O
the O
human B
c I
- I
fes I
gene I
have O
not O
been O
defined O
. O

Electrophoretic O
mobility O
shift O
analyses O
demonstrated O
that O
the O
151 B
- I
bp I
region I
contains O
nuclear B
protein I
binding I
sites I
for O
Sp1 B
, O
PU B
. I
1 I
, O
and O
/ O
or O
Elf B
- I
1 I
, O
and O
a O
novel B
factor I
. O

IL B
- I
10 I
markedly O
reduces O
nuclear O
factor O
( B
NF I
) I
- I
kappa I
B I
/ I
Rel I
nuclear O
activity O
induced O
in O
PBMC O
by O
stimulation O
with O
the O
anti B
- I
CD3 I
mAb I
OKT3 B
. O

As O
judged O
by O
supershifting O
the O
DNA B
- I
protein I
complexes I
with O
Abs B
recognizing O
specific O
components O
of O
the O
NF B
- I
kappa I
B I
/ I
Rel I
protein I
family I
, O
the O
p50 B
/ I
p65 I
( O
Rel B
A I
) O
heterodimeric O
form O
of O
NF B
- I
kappa I
B I
is O
primarily O
affected O
. O

Here O
we O
provide O
evidence O
that O
this O
transformation O
is O
the O
result O
of O
double O
infection O
of O
a O
cell O
with O
two O
virions O
, O
the O
P3HR1 B
virus I
genome I
and O
a O
mini B
- I
EBV I
plasmid I
carrying O
the O
chimeric O
EBNA2 B
gene I
. O

It O
remains O
open O
whether O
the O
growth O
retarding O
property O
of O
the O
EBNA2 B
- I
oestrogen I
receptor I
fusion I
protein I
in O
B O
cell O
lymphoma O
lines O
is O
due O
to O
unphysiologically O
high O
expression O
of O
the O
chimeric B
protein I
or O
to O
interference O
with O
a O
cellular O
programme O
driving O
proliferation O
in O
these O
cell O
lines O
. O

These O
results O
indicate O
that O
, O
as O
already O
reported O
for O
the O
IL2Rbeta B
promoter I
, O
GA B
- I
binding I
protein I
is O
an O
essential O
component O
of O
gammac O
basal O
promoter O
activity O
. O

Detection O
of O
intracellular B
signal I
transduction I
molecules I
in O
PBMC O
from O
rhesus O
macaques O
and O
sooty O
mangabeys O
. O

This O
shows O
that O
in O
a O
eukaryotic O
nucleus O
, O
Tax B
specifically O
interacts O
with O
the O
basic B
domain I
- I
leucine I
zipper I
region I
of O
ATF B
- I
1 I
, O
CREB B
, O
and O
CREM B
. O

Interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
- B
reporter I
gene I
behavior O
closely O
parallels O
the O
endogenous B
gene I
in O
response O
to O
T B
cell I
receptor I
and O
costimulatory O
signals O
. O

After O
treatment O
of O
APL O
cells O
with O
AM580 O
either O
alone O
or O
in O
combination O
with O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
, O
the O
compound O
induces O
granulocytic O
maturation O
, O
as O
assessed O
by O
determination O
of O
the O
levels O
of O
leukocyte B
alkaline I
phosphatase I
, I
CD11b I
, I
CD33 I
, I
and I
G I
- I
CSF I
receptor I
mRNA I
, O
at O
concentrations O
that O
are O
10 O
- O
to O
100 O
- O
fold O
lower O
than O
those O
of O
ATRA O
necessary O
to O
produce O
similar O
effects O
. O

Inhibition O
of O
vitamin B
D I
receptor I
- I
retinoid I
X I
receptor I
- I
vitamin I
D I
response I
element I
complex I
formation O
by O
nuclear O
extracts O
of O
vitamin O
D O
- O
resistant O
New O
World O
primate O
cells O
. O

In O
addition O
, O
vitamin O
D O
- O
resistant O
cell O
nuclear O
extract O
contained O
a O
protein O
( O
s O
) O
which O
was O
bound O
specifically O
to O
the O
VDRE B
and O
was O
capable O
of O
completely O
inhibiting O
VDR B
- I
RXR I
- I
VDRE I
complex I
formation O
; O
these O
effects O
were O
not O
demonstrated O
with O
nuclear O
extract O
from O
the O
wild O
type O
cell O
line O
or O
with O
the O
post O
- O
nuclear O
extract O
of O
the O
vitamin O
D O
- O
resistant O
cell O
line O
. O

We O
conclude O
that O
a O
VDRE B
- I
binding I
protein I
( O
s O
) O
, O
distinct O
from O
IDBP B
and O
present O
in O
nuclear O
extract O
of O
cells O
from O
a O
prototypical O
vitamin O
D O
- O
resistant O
NWP O
, O
is O
capable O
of O
inhibiting O
normal O
VDR B
- I
RXR I
heterodimer O
binding O
to O
the O
VDRE B
. O

We O
have O
isolated O
a O
novel B
cDNA I
clone I
encoding O
interferon B
( I
IFN I
) I
consensus I
sequence I
- I
binding I
protein I
in O
adult O
T O
- O
cell O
leukemia O
cell O
line O
or O
activated O
T O
cells O
( O
ICSAT B
) O
; O
this O
protein O
is O
the O
human O
homolog O
of O
the O
recently O
cloned O
Pip B
/ I
LSIRF I
. O

Here O
, O
we O
describe O
the O
effect O
of O
383 B
- I
bp I
( I
delta383 I
) I
and I
99 I
- I
bp I
( I
delta99 I
) I
sequences I
containing O
the O
PYBF B
- I
binding I
site I
on O
transcription O
from O
various O
globin O
and O
non O
- O
globin O
promoters O
, O
using O
a O
transient O
assay O
with O
the O
cat B
reporter I
gene I
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
, O
a O
cell O
line O
with O
abundant O
PYBF B
activity O
. O

Translocation B
breakpoints I
in O
three O
patients O
with O
campomelic O
dysplasia O
and O
autosomal O
sex O
reversal O
map O
more O
than O
130 O
kb O
from O
SOX9 B
. O

Campomelic O
dysplasia O
( O
CMPD1 O
) O
and O
autosomal O
XY O
sex O
reversal O
( O
SRA1 O
) O
are O
caused O
by O
mutations O
in O
the O
SRY B
- I
related I
gene I
SOX9 B
on O
17q B
. O

Unexpectedly O
, O
the O
17q B
breakpoints I
in O
four O
CMPD1 O
translocation O
cases O
previously O
analyzed O
by O
us O
and O
others O
map O
50 O
kb O
or O
more O
from O
SOX9 B
. O

Both O
CIITA B
and O
Bob1 B
increase O
the O
expression O
from O
the O
DRA B
promoter I
, O
which O
is O
a O
prototypic O
class B
II I
promoter I
. O

However O
, O
the O
growth O
of O
most O
mutated O
viruses O
was O
suppressed O
in O
primary O
rhesus O
monkey O
alveolar O
macrophages O
( O
SIVmacMER O
approximately O
2xNFkappaB B
approximately O
substNFkappaB B
> O
deltaNFkappaB B
> O
deltaNFkappaB B
deltaSpl234 B
approximately O
deltaNFkappaBdeltaSp B
> O
deltaSpl234 B
approximately O
substSpl2 B
> O
substSp23 B
approximately O
substSp34 B
approximately O
substSpl234 B
> O
or O
= O
SIVmac239 O
) O
. O

A O
hydrophobic O
domain O
of O
Ca2 B
+ I
- I
modulating I
cyclophilin I
ligand I
modulates O
calcium O
influx O
signaling O
in O
T O
lymphocytes O
. O

Ca2 B
+ I
- I
modulating I
cyclophilin I
ligand I
( O
CAML B
) O
was O
originally O
described O
as O
a O
cyclophilin B
B I
- I
binding I
protein I
whose O
overexpression O
in O
T O
cells O
causes O
a O
rise O
in O
intracellular O
calcium O
, O
thus O
activating O
transcription B
factors I
responsible O
for O
the O
early O
immune O
response O
. O

The O
Epstein B
- I
Barr I
virus I
- I
encoded I
nuclear I
antigen I
EBNA I
- I
5 I
accumulates O
in O
PML O
- O
containing O
bodies O
. O

The O
chromosome B
17 I
breakpoint I
was O
localized O
to O
intron B
2 I
of O
RARA B
by O
Southern O
blotting O
, O
and O
there O
was O
no O
evidence O
at O
the O
molecular O
level O
for O
rearrangement O
at O
PML B
locus I
. O

Cyclic O
AMP O
- B
responsive I
element I
- O
dependent O
activation O
of O
Epstein O
- O
Barr O
virus O
zebra B
promoter I
by O
human O
herpesvirus O
6 O
. O

Mutation O
of O
the O
consensus B
AP I
- I
1 I
/ I
CRE I
site I
within O
ZII B
abolished O
the O
inducibility O
of O
Zp B
by O
HHV O
- O
6 O
, O
whereas O
positioning O
of O
the O
ZII B
domain I
upstream O
of O
the O
beta B
- I
globin I
minimal I
promoter I
conferred O
responsiveness O
following O
HHV O
- O
6 O
infection O
. O

Antibodies O
against O
CRE B
- I
binding I
( I
CREB I
) I
protein I
but O
not O
against O
c B
- I
Fos I
or O
c B
- I
Jun I
were O
able O
to O
supershift O
the O
DNA B
- I
protein I
complex I
, O
identifying O
the O
nature O
of O
the O
transcription B
factor I
which O
binds O
to O
ZII B
as O
a O
member O
of O
the O
CREB B
family I
of I
proteins I
. O

Structure O
/ O
function O
analysis O
of O
various O
Oct B
- I
2a I
effector I
regions I
in O
the O
context O
of O
the O
GAL4 B
DNA I
- I
binding I
domain I
revealed O
that O
Oct B
- I
2a I
contains O
two O
functionally O
different O
activation B
domains I
at O
the O
N B
and I
the I
C I
termini I
. O

In O
this O
study O
we O
present O
a O
deletion O
analysis O
of O
the O
N B
- I
terminal I
region I
of O
Oct B
- I
2a I
to O
determine O
the O
minimal B
repression I
domain I
. O

The O
first O
was O
to O
abruptly O
terminate O
tumor O
necrosis O
factor O
- O
induced O
NF B
- I
kappaB I
binding O
to O
the O
enhancer O
sequences O
in O
U1 O
monocytic O
cells O
, O
using O
a O
short O
pulse O
of O
exogenous B
tumor I
necrosis I
factor I
. O

Together O
, O
our O
results O
indicate O
that O
occupancy O
of O
the O
viral B
enhancer I
by O
NF B
- I
kappaB I
( I
p50 I
/ I
p65 I
) I
heterodimers I
is O
required O
for O
ongoing O
transcription O
of O
integrated O
HIV O
provirus O
in O
monocytes O
, O
even O
in O
cells O
chronically O
infected O
and O
permanently O
producing O
functional O
HIV B
Tat I
protein I
. O

Transcriptional O
basis O
for O
hyporesponsiveness O
of O
the O
human B
inducible I
nitric I
oxide I
synthase I
gene I
to O
lipopolysaccharide O
/ O
interferon O
- O
gamma O
. O

Two O
explanations O
for O
hyporesponsiveness O
of O
the O
human B
iNOS I
promoter I
to O
LPS O
+ O
/ O
- O
IFN B
- I
gamma I
were O
found O
: O
( O
1 O
) O
multiple O
inactivating O
nucleotide O
substitutions O
in O
the O
human O
counterpart O
of O
the O
enhancer B
element I
that O
has O
been O
shown O
to O
regulate O
LPS O
/ O
IFN B
- I
gamma I
induced O
expression O
of O
the O
mouse B
iNOS I
gene I
; O
and O
( O
2 O
) O
and O
absence O
of O
one O
or O
more O
nuclear B
factors I
in O
human O
macrophages O
( O
e O
. O
g O
. O
, O
an O
LPS B
- I
inducible I
nuclear I
factor I
- I
kappa I
B I
/ I
Rel I
complex I
) O
, O
that O
is O
( O
are O
) O
required O
for O

Severe O
skewing O
of O
X O
inactivation O
resulting O
in O
inactivity O
of O
the O
intact O
X B
was O
found O
in O
blood O
and O
cultures O
of O
both O
types O
of O
skin O
, O
but O
analysis O
of O
DNA O
prepared O
directly O
from O
hypopigmented O
skin O
showed O
significant O
inactivation O
of O
the O
translocated O
X B
, O
inconsistent O
with O
the O
usual O
mechanism O
of O
phenotypic O
expression O
in O
X B
; I
autosome I
translocations I
. O

While O
partial O
variable O
monosomy O
of O
loci O
on O
chromosome B
17p I
can O
not O
be O
excluded O
as O
contributing O
to O
the O
phenotype O
in O
this O
patient O
, O
it O
is O
argued O
that O
the O
major O
likely O
factor O
is O
partial O
functional O
disomy O
of O
sequences O
on O
Xp B
in O
cell O
lineages O
that O
have O
failed O
to O
inactivate O
the O
intact O
X B
chromosome I
. O

In O
contrast O
, O
in O
vivo O
footprints O
on O
GT B
( I
CACCC I
) I
motifs I
differed O
between O
the O
cells O
expressing O
the O
fetal O
or O
the O
adult O
globin O
program O
. O

Activation O
of O
macrophages O
by O
bacterial O
lipopolysaccharide O
( O
LPS O
) O
induces O
transcription O
of O
genes O
that O
encode O
for O
proinflammatory B
regulators I
of O
the O
immune O
response O
. O

LPS O
treatment O
of O
RAW O
264 O
. O
7 O
cells O
, O
murine O
bone O
marrow O
- O
derived O
macrophages O
, O
and O
the O
human O
monocyte O
cell O
line O
THP O
- O
1 O
resulted O
in O
rapid O
activation O
of O
the O
p46 B
and I
p54 I
isoforms I
of O
JNK B
. O

A O
cell B
type I
- I
specific I
enhancer I
in O
the O
human B
B7 I
. I
1 I
gene I
regulated O
by O
NF B
- I
kappaB I
. O

This O
183 B
- I
bp I
region I
was O
both O
cell O
type O
specific O
and O
responsive O
to O
two O
distinct O
stimuli O
, O
lipopolysaccharide O
and O
dibutyryl O
cAMP O
, O
known O
to O
regulate O
B7 B
. I
1 I
expression O
. O

Deletional O
and O
site O
- O
directed O
mutagenesis O
revealed O
the O
presence O
of O
multiple O
functionally O
critical O
cis B
elements I
within O
this O
region O
, O
one O
of O
which O
was O
a O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
consensus I
sequence I
. O

This O
is O
the O
first O
description O
, O
to O
our O
knowledge O
, O
of O
regulatory B
elements I
that O
control O
expression O
of O
a O
gene O
encoding O
a O
B7 B
costimulatory I
molecule I
. O

Recombinant O
c B
- I
Jun I
and O
c B
- I
Fos I
were O
ubiquitinylated O
by O
the O
ubiquitin B
carrier I
enzymes I
E214K B
, O
E220K B
, O
or O
E232K B
in O
the O
presence O
of O
the O
ubiquitin B
- I
activating I
enzyme I
, O
E1 B
. O

We O
have O
also O
characterized O
the O
genomic B
mBob1 I
clone I
. O

Analysis O
of O
its O
intron O
- O
exon O
structure O
has O
allowed O
identification O
of O
a O
C B
- I
terminal I
splice I
variant I
. O

Moreover O
, O
gp120 B
induces O
tyrosine O
phosphorylation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
( O
STAT B
- I
1 I
alpha I
) O
as O
well O
as O
the O
Janus B
kinase I
( O
JAK2 B
) O
in O
glial O
cells O
. O

Northern O
blot O
analysis O
as O
well O
as O
Ab O
blocking O
and O
cytokine B
secretion O
studies O
indicated O
that O
the O
induction O
of O
either O
endogenous B
TNF I
- I
alpha I
or O
IL B
- I
10 I
was O
not O
involved O
in O
the O
cooperativity O
, O
nor O
was O
an O
up O
- O
regulation O
of O
TNF B
- I
alpha I
receptors I
. O

Interaction O
of O
HTLV B
- I
I I
Tax I
with O
the O
human B
proteasome I
: O
implications O
for O
NF B
- I
kappa I
B I
induction O
. O

We O
identified O
a O
physical O
interaction O
between O
Tax B
and O
the O
HsN3 B
subunit I
of O
the O
human B
proteasome I
. O

This O
raises O
the O
intriguing O
possibility O
that O
physical O
association O
of O
the O
HsN3 B
proteasome I
subunit I
with O
HTLV B
- I
I I
Tax I
coupled O
with O
the O
independent O
interaction O
of O
Tax B
with O
either O
p100 O
or O
p65 O
- O
I B
kappa I
B I
alpha I
targets O
these O
cytoplasmic B
NF I
- I
kappa I
B I
/ I
Rel I
complexes I
to O
the O
proteasome B
for O
processing O
. O

IL B
- I
11 I
mRNA I
and O
protein O
were O
both O
up O
- O
regulated O
during O
the O
course O
of O
this O
inflammatory O
response O
. O

Recently O
, O
we O
and O
others O
have O
shown O
that O
thrombopoietin B
induces O
rapid O
tyrosine O
phosphorylation O
of O
Jak2 B
and O
other O
proteins O
in O
human O
platelets O
and O
BaF3 O
cells O
, O
genetically O
engineered O
to O
express O
c B
- I
Mpl I
, O
a O
receptor O
for O
thrombopoietin B
. O

Thus O
, O
our O
data O
indicate O
that O
Stat3 B
and O
Stat5 B
may O
be O
involved O
in O
signal O
transduction O
after O
ligand O
binding O
to O
c B
- I
Mpl I
and O
that O
this O
event O
may O
have O
a O
role O
in O
megakaryopoiesis O
/ O
thrombopoiesis O
or O
possibly O
a O
mature O
platelet O
function O
such O
as O
aggregation O
. O

One O
such O
example O
is O
the O
excessive O
expression O
of O
` B
` I
normal I
' I
' I
lymphokines I
of O
cytokines B
which O
accompanies O
many O
lymphoproliferative O
diseases O
. O

IL B
- I
4 I
activates O
gene O
expression O
by O
inducing O
tyrosine O
phosphorylation O
, O
homodimerization O
, O
and O
nuclear O
translocation O
of O
the O
latent B
transcription I
factor I
, O
STAT6 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
6 I
) O
. O

One O
- O
hybrid O
assays O
in O
yeast B
isolated I
NF I
- I
ATp I
as O
an O
E1 B
binding I
protein I
, O
and O
transfection O
of O
NF B
- I
ATp I
into O
T O
and O
B O
cell O
lines O
strongly O
enhanced O
the O
activation B
- I
dependent I
SCM I
- I
1 I
promoter O
activity O
. O

The O
importance O
of O
NF B
- I
kappaB I
sites I
was O
confirmed O
by O
using O
vectors O
containing O
wild B
- I
type I
or I
mutant I
kappaB I
sites I
in O
a O
heterologous B
promoter I
. O

In O
this O
study O
, O
we O
analyzed O
the O
binding O
activity O
of O
IL B
- I
10 I
- I
and I
IFN I
- I
gamma I
- I
activated I
STAT I
molecules I
to O
two O
kinds O
of O
GAS B
- O
motif O
sequences O
. O

Peptides O
derived O
from O
the O
HSV B
- I
2 I
VP16 I
protein I
were O
utilized O
for O
studies O
of O
peptide O
binding O
to O
DQ0302 O
molecules O
and O
T O
cell O
activation O
at O
both O
neutral O
and O
acidic O
pH O
. O

A O
recent O
sib O
- O
pair O
analysis O
revealed O
a O
tight O
linkage O
between O
markers O
on O
5q31 B
. I
1 I
and O
a O
major B
susceptibility I
gene I
controlling O
total O
serum O
IgE B
levels O
. O

Inhibition O
of O
lipopolysaccharide O
- O
induced O
monocyte B
interleukin I
- I
1 I
receptor I
antagonist O
synthesis O
by O
cortisol O
: O
involvement O
of O
the O
mineralocorticoid B
receptor I
. O

Here O
, O
we O
have O
readdressed O
the O
issue O
of O
CD8 O
( O
+ O
) O
T O
cells O
specific O
for O
the O
72 B
- I
kDa I
major I
immediate I
- I
early I
protein I
( O
IE B
- I
1 I
) O
, O
which O
is O
nonstructural O
but O
is O
found O
very O
early O
and O
throughout O
the O
replicative O
cycle O
. O

Here O
, O
we O
report O
a O
model O
of O
CD28 B
costimulation O
using O
PMA O
plus O
the O
natural B
ligand I
CD80 I
that O
resulted O
in O
very O
limited O
stimulation O
of O
IL B
- I
2 I
, O
as O
evidenced O
by O
both O
cytokine B
production O
and O
IL B
- I
2 I
promoter I
stimulation O
. O

In O
transient O
- O
transfection O
assays O
, O
a O
Qp B
- I
CAT I
reporter I
was O
activated O
by O
cotransfected O
JAK B
- I
1 I
and O
by O
treatment O
of O
cells O
with O
the O
cytokine B
IL B
- I
6 I
. O

Reactive O
oxygen O
intermediate O
- O
release O
of O
fibre O
- O
exposed O
monocytes O
increases O
inflammatory O
cytokine B
- I
mRNA I
level O
, O
protein B
tyrosine I
kinase I
and O
NF B
- I
kappaB I
activity O
in O
co O
- O
cultured O
bronchial O
epithelial O
cells O
( O
BEAS O
- O
2B O
) O
. O

Mutagenesis O
of O
NF B
kappa I
B I
or I
Sp I
- I
1 I
elements I
within O
the O
LTR B
resulted O
in O
no O
change O
in O
the O
ability O
of O
CD8 O
+ O
T O
cell O
supernatants O
to O
inhibit O
Tat O
- O
or O
mitogen O
- O
mediated O
LTR O
transcription O
. O

Taken O
together O
, O
these O
observations O
suggest O
that O
mitogenic O
activation O
, O
mediated O
primarily O
through O
the O
NF B
kappa I
B I
enhancer I
, O
is O
susceptible O
to O
CD8 B
- O
mediated O
inhibition O
, O
however O
, O
inhibition O
of O
Tat B
- O
mediated O
activation O
may O
rely O
upon O
a O
different O
pathway O
that O
is O
NFAT B
- I
1 I
dependent O
. O

Nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
is O
a O
redox B
sensitive I
cytosolic I
transcription I
factor I
. O

In O
this O
study O
, O
we O
demonstrate O
that O
constitutive O
expression O
of O
bcl B
- I
xl I
but O
not O
bcl B
- I
2 I
, O
bcl B
- I
xs I
, O
bak B
, O
bad B
, O
or O
bax B
was O
associated O
with O
apoptosis O
resistance O
after O
IL B
- I
2 I
deprivation O
in O
CTLL O
- O
2 O
cells O
that O
expressed O
Tax B
. O

Transient O
- O
transfection O
assays O
showed O
that O
bcl B
- I
x I
promoter I
was O
transactivated O
by O
wild B
- I
type I
Tax I
. O

We O
find O
that O
recruitment O
of O
EKLF B
to O
5 B
' I
HS2 I
requires O
the O
TATA B
box I
, O
but O
recruitment O
to O
5 B
' I
HS3 I
depends O
on O
the O
CACCC O
and O
TATA B
boxes I
of O
the O
beta B
- I
globin I
promoter I
. O

We O
also O
report O
that O
in O
RAW O
264 O
. O
7 O
cells O
, O
an O
E O
( O
2 O
) O
receptor O
- O
positive O
murine O
monocytic O
line O
, O
E O
( O
2 O
) O
downregulates O
cytokine O
- O
induced O
TNF B
gene O
expression O
by O
decreasing O
the O
activity O
of O
the O
Jun B
NH I
( I
2 I
) I
- I
terminal I
kinase I
( O
JNK B
) O
. O

The O
resulting O
diminished O
phosphorylation O
of O
c B
- I
Jun I
and O
JunD B
at O
their O
NH B
( I
2 I
) I
- I
termini I
decreases O
the O
ability O
of O
these O
nuclear O
proteins O
to O
autostimulate O
the O
expression O
of O
the O
c B
- I
Jun I
and I
JunD I
genes I
, O
thus O
leading O
to O
lower O
production O
of O
c B
- I
Jun I
and O
JunD B
. O

The O
B B
cell I
- I
associated I
surface I
molecule I
CD40 B
plays O
a O
key O
role O
in O
T O
cell O
- O
dependent O
B O
cell O
maturation O
, O
as O
individuals O
with O
defects O
in O
either O
CD40 B
or O
its O
ligand O
are O
impaired O
in O
immunoglobulin B
isotype O
class O
switching O
and O
germinal O
center O
formation O
. O

CD40 B
signaling O
activates O
downstream B
effectors I
, O
including O
the O
tyrosine B
protein I
kinase I
, O
Lyn B
, O
the O
phosphatidylinositol B
- I
3 I
- I
kinase I
( O
PI B
- I
3 I
kinase I
) O
, O
and O
the O
transcription O
factor O
, O
NF B
- I
kappa I
B I
. O

Previously O
, O
the O
action O
of O
MC903 O
and O
KH1060 O
was O
presumed O
to O
be O
mediated O
by O
the O
nuclear B
vitamin I
D I
receptor I
( O
VDRnuc B
) O
. O

These O
data O
suggest O
that O
although O
MC903 O
and O
KH1060 O
may O
bind O
the O
VDRnuc B
, O
that O
the O
differentiative O
activities O
of O
these O
agents O
requires O
nongenomic O
signaling O
pathways O
. O

Here O
we O
show O
that O
1alpha O
, O
25 O
( O
OH O
) O
2 O
- O
d5 O
- O
previtamin O
D3 O
( O
HF O
) O
, O
JN O
, O
KH1060 O
, O
and O
MC903 O
induce O
expression O
of O
PKC B
alpha I
and O
PKC B
delta I
and O
translocation O
of O
both O
isoforms O
to O
the O
particulate O
fraction O
, O
and O
PKC B
alpha I
to O
the O
nuclear O
fraction O
. O

Induced O
MIP B
- I
1alpha I
expression O
and O
secretion O
in O
PMA O
/ O
PHA O
stimulated O
tax O
transfected O
cells O
correlate O
with O
the O
noninduction O
of O
MNP B
- I
1 I
transcription B
factor I
, O
which O
is O
intimately O
involved O
in O
downmodulating O
the O
MIP B
- I
1alpha I
gene I
. O

MBP B
also O
induced O
transient O
increases O
in O
mRNA B
for O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
- I
1alpha I
and O
MIP B
- I
1beta I
, O
but O
did O
not O
stimulate O
the O
release O
of O
either O
chemokine B
. O

Patients O
with O
the O
recessively O
inherited O
disorder O
ataxia O
telangiectasia O
( O
A O
- O
T O
) O
have O
a O
high O
level O
of O
specific O
chromosome B
translocations I
which O
can O
be O
easily O
observed O
in O
peripheral O
T O
cells O
and O
show O
a O
greatly O
increased O
predisposition O
to O
leukaemia O
/ O
lymphoma O
, O
mainly O
of O
T O
cell O
origin O
. O

A O
high O
- O
affinity O
calcineurin B
- O
binding O
peptide O
was O
selected O
from O
combinatorial O
peptide O
libraries O
based O
on O
the O
calcineurin B
docking I
motif I
of O
NFAT B
. O

Substitution O
of O
the O
optimized O
peptide O
sequence O
into O
the O
natural O
calcineurin B
docking I
site I
increased O
the O
calcineurin B
responsiveness O
of O
NFAT B
. O

We O
have O
investigated O
mechanisms O
and O
consequences O
of O
STAT5 B
activation O
through O
the O
human B
IL I
- I
4 I
receptor I
( O
IL B
- I
4R I
) O
. O

By O
functionally O
expressing O
receptor B
mutants I
in O
the O
murine O
pro O
- O
B O
cell O
line O
Ba O
/ O
F3 O
, O
we O
could O
show O
that O
phosphorylated O
tyrosine O
residues O
within O
the O
IL B
- I
4R I
alpha I
chain I
are O
dispensable O
for O
IL B
- I
4 I
- O
induced O
STAT5 B
activity O
. O

An O
inhibitory O
, O
` O
` O
dominant O
- O
negative O
, O
' O
' O
form O
of O
the O
calcineurin B
catalytic I
( I
A I
) I
subunit I
was O
prepared O
, O
which O
lacks O
the O
calmodulin B
- I
binding I
domain I
, O
autoinhibitory B
domain I
and O
most O
of O
its O
catalytic O
core O
but O
possesses O
the O
regulatory B
( I
B I
) I
subunit I
binding O
domain O
. O

Immunoprecipitation O
of O
epitope B
- I
labeled I
BKO I
demonstrated O
for O
the O
formation O
of O
a O
tight O
complex O
with O
endogenous B
B I
subunit I
in O
Jurkat O
cells O
, O
consistent O
with O
an O
inhibitory O
mechanism O
that O
involves O
the O
sequestration O
of O
the O
B B
subunit I
. O

Monoclonal B
anti I
- I
D I
antibodies I
submitted O
to O
the O
Third O
Monoclonal O
International O
Workshop O
were O
evaluated O
against O
a O
number O
of O
D O
variant O
cells O
using O
standard O
serological O
techniques O
. O

B O
cells O
were O
purified O
from O
buffy O
coat O
preparations O
of O
healthy O
blood O
donors O
by O
positive O
selection O
using O
an O
anti B
CD20 I
monoclonal I
antibody I
and O
a O
MiniMACS O
separation O
unit O
. O

Expression O
of O
wild B
- I
type I
SHP1 I
had O
a O
very O
small O
effect O
on O
the O
TCR O
- O
induced O
tyrosine O
phosphorylation O
of O
ZAP B
- I
70 I
and O
Syk B
, O
even O
when O
SHP1 B
was O
overexpressed O
20 O
- O
100 O
- O
fold O
over O
endogenous B
SHP1 I
. O

In O
the O
cell O
line O
HT93A O
, O
which O
is O
capable O
of O
differentiating O
towards O
both O
the O
eosinophil O
and O
neutrophil O
lineages O
in O
response O
to O
retinoic O
acid O
( O
RA O
) O
, O
C B
/ I
EBPalpha I
mRNA I
expression O
decreased O
significantly O
concomitant O
with O
eosinophilic O
and O
neutrophilic O
differentiation O
, O
whereas O
C B
/ I
EBPbeta I
expression O
was O
markedly O
increased O
. O

Role O
of O
the O
camp B
response I
element I
site I
in O
mediating O
repression O
by O
the O
upstream B
regulatory I
region I
. O

DNase B
I I
footprinting O
identified O
several O
protected O
areas O
including O
Sp1 B
, I
Sp1 I
/ I
AP I
- I
2 I
, I
and I
cAMP I
response I
element I
( I
CRE I
) I
binding I
sites I
within O
the O
201 O
- O
bp O
core O
promoter O
region O
and O
Sp1 B
, I
NRE I
- I
2a I
, I
TCF I
- I
1 I
/ I
LEF I
- I
1 I
, I
and I
Sp1 I
/ I
NF I
- I
AT I
binding I
sites I
in O
the O
upstream B
regulatory I
region I
. O

In O
summary O
, O
we O
have O
identified O
a O
tissue B
- I
specific I
regulatory I
region I
5 O
' O
of O
the O
ecto B
- I
5 I
' I
- I
NT I
core I
promoter I
that O
requires O
the O
presence O
of O
a O
functional O
CRE B
site I
within O
the O
basal B
promoter I
for O
its O
suppressive O
activity O
. O

( O
2 O
- O
Amino O
- O
3 O
' O
- O
methoxyphenyl O
) O
oxanaphthalen O
- O
4 O
- O
one O
( O
PD O
98059 O
) O
, O
an O
inhibitor O
of O
extracellular O
signal B
- I
regulated I
protein I
kinase I
( O
ERK B
) O
activation O
, O
blocked O
the O
serine O
phosphorylation O
of O
STAT3 B
induced O
by O
chemotactic B
factors I
or O
PMA O
. O

These O
foci O
, O
which O
were O
preferentially O
found O
adjacent O
to O
nucleoli O
or O
at O
the O
nuclear O
periphery O
, O
did O
not O
represent O
sites O
of O
active O
transcription O
or O
binding O
of O
GATA B
- I
1 I
to O
consensus B
sites I
in O
the O
beta B
- I
globin I
loci I
. O

After O
exercise O
following O
placebo O
administration O
we O
observed O
increases O
in O
concentrations O
of O
blood O
substrates O
, O
plasma B
adrenocorticotropin I
( O
ACTH B
) O
, O
growth O
hormone O
and O
cortisol O
and O
in O
the O
number O
of O
glucocorticoid B
receptors I
in O
lymphocytes O
without O
changes O
in O
the O
dissociation O
constant O
. O

Intravenous O
PCr O
injection O
led O
to O
smaller O
changes O
in O
ACTH B
and O
cortisol O
concentrations O
as O
well O
as O
to O
a O
lower O
activation O
of O
glucocorticoid O
binding O
in O
lymphocytes O
. O

Putative B
steroid I
binding I
domain I
of O
the O
human B
mineralocorticoid I
receptor I
, O
expressed O
in O
E O
. O
coli O
in O
the O
presence O
of O
heat B
shock I
proteins I
shows O
typical O
native O
receptor O
characteristics O
. O

These O
bacterially B
- I
produced I
MR I
constructs I
had O
no O
steroid O
binding O
activity O
per O
se O
. O

A O
novel O
immunosuppressive B
factor I
in O
bovine O
colostrum O
blocks O
activation O
of O
the O
interleukin B
2 I
gene I
enhancer I
at O
the O
NFAT B
site I
. O

A O
factor O
in O
bovine O
colostrum O
( O
colostrum B
inhibitory I
factor I
, O
CIF B
) O
inhibits O
interleukin B
2 I
( O
IL2 B
) O
production O
in O
activated O
T O
helper O
cells O
by O
blocking O
the O
accumulation O
of O
IL2 B
mRNA I
. O

The O
NFAT B
- I
controlled I
luciferase I
gene I
system I
distinguishes O
CIF B
from O
other O
T O
cell O
inhibitory O
activities O
present O
in O
colostrum O
, O
in O
particular O
, O
TGF B
beta I
1 I
and O
TGF B
beta I
2 I
and O
the O
glucocorticoids O
. O

Using O
a O
combination O
of O
bacterial O
motility O
assays O
in O
platelet O
extracts O
with O
Escherichia O
coli O
expressing O
the O
Shigella B
IcsA I
protein I
and O
in O
vitro O
analysis O
of O
reconstituted O
systems O
from O
purified B
proteins I
, O
we O
show O
here O
that O
the O
bacterial B
protein I
IcsA I
binds O
N B
- I
WASP I
and O
activates O
it O
in O
a O
Cdc42 B
- O
like O
fashion O
. O

VASP O
is O
not O
involved O
in O
Shigella O
movement O
, O
and O
the O
function O
of O
profilin B
does O
not O
require O
its O
binding O
to O
proline B
- I
rich I
regions I
. O

We O
have O
shown O
that O
the O
c B
- I
Maf I
and O
c B
- I
Myb I
transcription I
factors I
physically O
interact O
in O
myeloid O
cells O
to O
form O
inhibitory O
complexes O
that O
hinder O
transactivation O
of O
c B
- I
Myb I
target I
genes I
through O
direct O
binding O
to O
Myb B
consensus I
sites I
. O

Elevated O
levels O
of O
c B
- I
Maf I
protein I
led O
to O
marked O
increases O
in O
Myb B
: I
Maf I
complexes I
and O
the O
accumulation O
of O
monocyte O
/ O
macrophage O
cells O
, O
followed O
by O
eventual O
programmed O
cell O
death O
. O

Analysis O
of O
targets O
that O
could O
mediate O
these O
phenotypic O
changes O
indicated O
that O
c B
- I
Maf I
likely O
plays O
a O
key O
role O
in O
myeloid O
cell O
development O
through O
dual O
mechanisms O
; O
inhibition O
of O
a O
select O
set O
of O
c B
- I
Myb I
regulated O
targets O
, O
such O
as O
Bcl B
- I
2 I
and O
CD13 B
/ I
APN I
, O
coupled O
with O
the O
activation O
of O
as O
yet O
undefined O
differentiation B
- I
promoting I
genes I
. O

We O
have O
examined O
the O
effect O
of O
Rb B
expression O
on O
the O
activation O
of O
the O
promoter O
for O
HLA B
- I
DRA I
, O
the O
prototype B
class I
II I
gene I
. O

To O
better O
understand O
the O
assembly O
mechanism O
for O
the O
progesterone B
receptor I
( O
PR B
) O
, O
we O
have O
developed O
cell O
- O
free O
systems O
for O
studying O
interactions O
of O
PR B
, O
hsp90 B
, O
and O
other O
associated B
proteins I
. O

Furthermore O
, O
our O
studies O
showed O
association O
of O
the O
IKK B
- I
alpha I
/ I
beta I
heterodimer I
with O
NIK B
, O
IkappaB B
- I
alpha I
and O
- B
epsilon I
in O
unstimulated O
cells O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
ability O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
, O
a O
proinflammatory B
cytokine I
) O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
an O
anti B
- I
inflammatory I
cytokine I
) O
to O
differentially O
regulate O
the O
sensitivity O
of O
human O
monocytes O
/ O
macrophages O
to O
glucocorticoids O
. O

Because O
NF B
- I
kappa I
B I
contributes O
to O
the O
transcription O
of O
numerous O
inflammatory B
genes I
and O
has O
been O
shown O
to O
be O
a O
molecular O
target O
of O
antiinflammatory O
drugs O
, O
we O
sought O
to O
characterize O
the O
functional O
role O
of O
the O
NF B
- I
kappa I
B I
protein I
complex I
in O
lupus O
T O
cells O
. O

As O
p65 B
complexes I
are O
transcriptionally O
active O
in O
comparison O
to O
the O
p50 O
homodimer O
, O
this O
novel O
finding O
may O
provide O
insight O
on O
the O
origin O
of O
abnormal B
cytokine I
or O
other O
gene O
transcription O
in O
SLE O
patients O
. O

Here O
we O
provide O
novel O
evidence O
that O
AG O
- O
490 O
potently O
inhibits O
the O
autokinase O
activity O
of O
JAK3 B
and O
tyrosine O
phosphorylation O
and O
DNA O
binding O
of O
signal B
transducer I
and I
activator I
of I
transcription I
5a I
and I
5b I
( I
STAT5a I
/ I
b I
) I
. O

PU B
. I
1 I
is O
a O
hematopoietic B
- I
specific I
Ets I
family I
transcription I
factor I
that O
is O
required O
for O
development O
of O
some O
lymphoid O
and O
myeloid O
lineages O
. O

Both O
the O
DNA B
binding I
and O
transactivation B
domains I
of O
PU B
. I
1 I
are O
required O
for O
repression O
and O
both O
domains O
are O
also O
needed O
to O
block O
terminal O
differentiation O
in O
MEL O
cells O
. O

To O
better O
clarify O
the O
molecular O
basis O
of O
IL B
- I
12 I
action O
, O
we O
set O
out O
to O
characterize O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
first O
by O
contrasting O
IL B
- I
12 I
- O
and O
IFN B
- I
alpha I
- I
inducible I
genes I
. O

We O
identified O
several O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
namely O
, O
MIP B
- I
1alpha I
, O
MIP B
- I
1beta I
, O
IL B
- I
1RA I
, O
and O
IFN B
regulatory I
factor I
- I
1 I
( I
IRF I
- I
1 I
) I
. O

To O
determine O
whether O
it O
is O
possible O
to O
artificially O
enhance O
the O
opening O
of O
the O
chromatin O
structure O
of O
a O
minimal B
beta I
- I
globin I
promoter I
, O
we O
placed O
a O
101bp O
, O
erythroid B
- I
specific I
DNase I
1 I
hypersensitive I
site I
- I
forming I
element I
( O
HSFE B
) O
immediately O
upstream O
of O
the O
beta B
- I
globin I
promoter I
and I
gene I
. O

Nuclear B
factor I
- I
90 I
of O
activated O
T O
- O
cells O
: O
A O
double B
- I
stranded I
RNA I
- O
binding O
protein O
and O
substrate O
for O
the O
double B
- I
stranded I
RNA I
- I
dependent I
protein I
kinase I
, O
PKR B
. O

C5a O
- O
induced O
reporter B
gene I
expression O
was O
abolished O
by O
introducing O
mutations O
into O
the O
kappaB B
sites I
and O
by O
coexpression O
of O
a O
dominant B
negative I
IkappaBalpha I
construct I
resistant O
to O
agonist O
- O
induced O
phosphorylation O
. O

Pertussis O
toxin O
, O
which O
ADP O
- O
ribosylates O
the O
Gi B
proteins I
known O
to O
couple O
to O
the O
C5a B
receptor I
, O
produced O
minimal O
inhibition O
of O
C5a O
- O
induced O
IL B
- I
8 I
expression O
and O
had O
little O
effect O
on O
C5a O
- O
induced O
calcium O
mobilization O
in O
RAW264 O
. O
7 O
cells O
. O

CD40 B
/ B
CD40 I
ligand O
interactions O
play O
a O
key O
role O
in O
the O
immune O
responses O
of O
B O
lymphocytes O
, O
monocytes O
, O
and O
dendritic O
cells O
. O

However O
, O
the O
components O
of O
the O
NF B
- I
kappaB I
complexes I
were O
different O
in O
monocytes O
and O
B O
cells O
, O
because O
p50 B
is O
part O
of O
the O
NF B
- I
kappaB I
complex I
induced O
by O
CD40 B
triggering O
in O
both O
monocytes O
and O
B O
cells O
, O
whereas O
p65 B
was O
only O
induced O
in O
B O
cells O
. O
In O
contrast O
, O
although O
the O
Janus B
kinase I
3 I
tyrosine I
kinase I
was O
associated O
with O
CD40 B
molecules O
in O
both O
monocytes O
and O
resting O
B O
cells O
, O
Janus B
kinase I
3 I
phosphorylation O
induction O
was O
observed O
only O
in O
CD40 O
- O
activated O
monocytes O
, O
with O
subsequent O
induction O
of O
STAT5a B
DNA O
binding O
activity O
in O
the O
nucleus O
. O

Potent O
and O
stable O
attenuation O
of O
live O
- O
HIV O
- O
1 O
by O
gain O
of O
a O
proteolysis B
- I
resistant I
inhibitor I
of O
NF B
- I
kappaB I
( O
IkappaB B
- I
alphaS32 I
/ I
36A I
) O
and O
the O
implications O
for O
vaccine O
development O
. O

Nuclear O
localization O
and O
formation O
of O
beta B
- I
catenin I
- I
lymphoid I
enhancer I
factor I
1 I
complexes I
are O
not O
sufficient O
for O
activation O
of O
gene O
expression O
. O

Enhancer O
replacement O
is O
therefore O
an O
effective O
strategy O
to O
target O
expression O
of O
a O
retroviral B
transgene I
to O
a O
specific O
progeny O
of O
transduced O
hematopoietic O
stem O
cells O
. O

Regulation O
of O
Fas B
ligand I
expression O
and O
cell O
death O
by O
apoptosis B
- I
linked I
gene I
4 I
. O

These O
results O
indicate O
that O
ALG B
- I
4 I
is O
necessary O
and O
sufficient O
for O
FasL B
expression O
. O

Among O
upstream B
signaling I
molecules I
of O
ERK B
, O
Shc B
was O
constitutively O
associated O
with O
Grb2 O
and O
was O
not O
tyrosine O
- O
phosphorylated O
by O
GM B
- I
CSF I
and O
FMLP O
, O
and O
Sos1 B
and O
c B
- I
Raf I
- I
1 I
were O
not O
phosphorylated O
by O
GM B
- I
CSF I
, O
IL O
- O
3 O
, O
TNF O
, O
and O
FMLP O
in O
monocytes O
, O
whereas O
all O
these O
signaling O
molecules O
were O
affected O
and O
/ O
or O
utilized O
by O
GM B
- I
CSF I
in O
MO7e O
cells O
. O

RESULTS O
: O
A O
human O
IL B
- I
5 I
promoter I
/ I
enhancer I
- I
luciferase I
gene I
construct I
, O
pIL B
- I
5 I
( I
- I
511 I
) I
Luc I
, O
was O
transcribed O
on O
activation O
of O
IL O
- O
5 O
- O
producing O
T O
- O
cell O
clones O
, O
but O
not O
IL O
- O
5 O
- O
nonproducing O
clones O
. O

pIL B
- I
5 I
( I
- I
511 I
) I
Luc I
was O
transcribed O
by O
T O
- O
cell O
hybridomas O
derived O
from O
fusion O
between O
IL O
- O
5 O
- O
producing O
T O
- O
cell O
clones O
and O
an O
IL O
- O
5 O
gene O
- O
nonexpressing O
T O
- O
cell O
line O
, O
but O
not O
by O
hybridomas O
derived O
from O
IL O
- O
5 O
- O
nonproducing O
T O
- O
cell O
clones O
. O

Of O
even O
more O
interest O
, O
IkappaBalpha B
overexpression O
inhibited O
the O
production O
of O
matrix B
metalloproteinases I
1 I
and I
3 I
while O
not O
affecting O
their O
tissue O
inhibitor O
. O

Messenger B
RNA I
production O
coding O
for O
IL B
- I
8 I
, O
RANTES B
, O
and O
MCP B
- I
1 I
showed O
parallel O
variations O
to O
the O
production O
of O
the O
correspondent B
proteins I
. O

Furthermore O
, O
SLP B
- I
76 I
and O
Vav B
have O
a O
synergistic O
effect O
on O
interleukin B
( I
IL I
) I
- I
2 I
promoter I
activity O
in O
T O
cells O
. O

Here O
, O
we O
show O
that O
Jagged1 B
is O
a O
Rel B
/ I
NF I
- I
kappaB I
- I
responsive I
gene I
. O

This O
correlated O
with O
the O
initiation O
of O
signaling O
downstream O
of O
Notch O
, O
as O
evidenced O
by O
increased O
levels O
of O
HES B
- I
1 I
transcripts I
in O
co O
- O
cultivated O
T O
cells O
and O
of O
CD23 B
transcripts I
in O
co O
- O
cultivated O
B O
cells O
. O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

A O
cell O
culture O
system O
was O
then O
employed O
that O
permitted O
the O
differentiation O
of O
Th B
effectors I
from O
resting O
memory O
T O
cells O
by O
short O
term O
priming O
. O

A O
polymorphism O
that O
affects O
OCT B
- I
1 I
binding O
to O
the O
TNF B
promoter I
region I
is O
associated O
with O
severe O
malaria O
[ O
see O
comments O
] O

Enforced O
expression O
of O
Id3 B
, O
which O
has O
the O
capacity O
to O
inhibit O
many O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
transcription I
factors I
, O
in O
human O
CD34 O
( O
+ O
) O
hematopoietic O
progenitor O
cells O
that O
have O
not O
undergone O
T B
cell I
receptor I
( I
TCR I
) I
gene I
rearrangements I
inhibits O
development O
of O
the O
transduced O
cells O
into O
TCRalpha O
beta O
and O
gamma O
delta O
cells O
in O
a O
fetal O
thymic O
organ O
culture O
( O
FTOC O
) O
. O

HIV O
- O
1 O
reactivation O
in O
resting O
peripheral O
blood O
mononuclear O
cells O
of O
infected O
adults O
upon O
in O
vitro O
CD4 B
cross O
- O
linking O
by O
ligands O
of O
the O
CDR2 B
- I
loop I
in O
extracellular B
domain I
1 I
. O

Additionally O
, O
virus O
reactivation O
in O
resting O
PBMCs O
infected O
in O
vitro O
with O
HIV O
- O
1 O
was O
found O
to O
be O
specifically O
induced O
by O
ligands O
of O
the O
CDR2 B
- I
loop I
in O
domain B
1 I
( O
D1 B
) O
of O
CD4 B
( O
virus B
envelope I
and I
anti I
- I
CD4 I
monoclonal I
antibodies I
) O
. O

In O
contrast O
, O
virus O
reactivation O
was O
not O
observed O
following O
CD4 B
oligomerization O
by O
antibodies B
that O
bind O
other O
epitopes O
in O
D1 B
, O
including O
the O
D1 B
/ I
CDR3 I
- I
loop I
. O

Our O
results O
indicate O
that O
the O
signaling O
events O
initiated O
in O
PBMCs O
by O
oligomerization O
of O
CD4 B
at O
the O
D1 B
/ I
CDR2 I
- I
loop I
can O
trigger O
HIV O
- O
1 O
upregulation O
in O
infected O
individuals O
. O

Signaling O
through O
the O
lymphotoxin B
- I
beta I
receptor I
stimulates O
HIV O
- O
1 O
replication O
alone O
and O
in O
cooperation O
with O
soluble O
or O
membrane B
- I
bound I
TNF I
- I
alpha I
. O

The O
mAECA B
, O
but O
not O
normal B
human I
IgG I
, O
had O
anti O
- O
human O
aortic O
EC O
activity O
. O

However O
NF B
- I
ATs I
appear O
in O
the O
nuclei O
of O
IL O
- O
4 O
- O
, O
IL O
- O
5 O
- O
, O
or O
ionomycin O
- O
stimulated O
eosinophils O
. O

All O
tissues O
and O
cells O
studied O
were O
homozygous O
for O
the O
wild B
- I
type I
gene I
, O
and O
were O
heterozygous O
as O
well O
as O
homozygous O
for O
the O
codon B
- I
10 I
- I
variant I
type I
. O

These O
results O
indicate O
that O
the O
presence O
of O
the O
codon B
- I
10 I
- I
variant I
type I
is O
not O
a O
characteristic O
of O
breast O
cancer O
. O

USF B
/ I
c I
- I
Myc I
enhances O
, O
while O
Yin B
- I
Yang I
1 I
suppresses O
, O
the O
promoter O
activity O
of O
CXCR4 B
, O
a O
coreceptor B
for O
HIV O
- O
1 O
entry O
. O

We O
have O
identified O
an O
E B
box I
around O
- B
260 I
and O
a O
YY1 B
binding I
site I
around O
- B
300 I
relative O
to O
the O
transcription B
start I
site I
. O

RCC O
- O
S O
did O
not O
alter O
the O
cytoplasmic O
levels O
of O
RelA B
and O
NF B
- I
kappaB1 I
but O
did O
suppress O
their O
nuclear O
localization O
and O
inhibited O
the O
activation O
of O
RelA B
/ I
NF I
- I
kappaB1 I
binding I
complexes I
. O

STAT1 B
activity O
was O
evident O
on O
the O
STAT B
binding I
sequences I
( O
SBE B
) O
present O
in O
the O
promoters B
of O
genes O
which O
are O
up O
- O
regulated O
during O
monocyte O
to O
macrophage O
maturation O
such O
as O
FcgammaRI B
and O
ICAM B
- I
1 I
, O
and O
in O
the O
promoter O
of O
the O
transcription B
factor I
IFN I
regulatory I
factor I
- I
1 I
. O

We O
have O
localized O
a O
317 O
base O
pair O
cis B
- I
acting I
regulatory I
element I
, O
HS B
I I
, O
associated O
with O
a O
hematopoietic B
- I
specific I
DNase I
I I
hypersensitive I
site I
, O
which O
lies O
approx O
. O

In O
addition O
, O
sodium O
salicylate O
and O
additional O
NSAIDs O
used O
at O
concentrations O
that O
activate O
HSF1 B
also O
inhibited O
the O
expression O
of O
other O
monocytic B
genes I
( O
TNF B
- I
alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
IL B
- I
10 I
, O
ICAM B
- I
1 I
) O
activated O
by O
exposure O
to O
a O
pro O
- O
inflammatory O
stimulus O
( O
lipopolysaccharide O
, O
LPS O
) O
. O

Fibroblast B
growth I
factors I
( O
FGFs B
) O
are O
heparin B
- I
binding I
proteins I
crucial O
to O
embryogenesis O
, O
angiogenesis O
, O
and O
wound O
healing O
. O

C3 O
transferase O
and O
cytochalasin O
D O
did O
not O
alter O
the O
expression O
levels O
of O
monocyte B
- I
binding I
receptors I
on O
endothelial O
cells O
, O
but O
did O
inhibit O
clustering O
of O
E B
- I
selectin I
, O
ICAM B
- I
1 I
, O
and O
VCAM B
- I
1 I
on O
the O
cell O
surface O
induced O
by O
monocyte O
adhesion O
or O
cross B
- I
linking I
antibodies I
. O

Finally O
, O
receptor O
clusters O
colocalized O
with O
ezrin B
/ I
moesin I
/ I
radixin I
proteins I
. O

In O
conclusion O
, O
production O
of O
a O
Th1 B
cytokine I
, O
IFN B
- I
gamma I
, O
by O
HBsAg B
- O
reactive O
cells O
was O
associated O
with O
hepatocyte O
damage O
in O
chronic O
hepatitis O
B O
, O
while O
no O
counteracting O
effect O
of O
Th2 B
cytokines I
produced O
by O
those O
cells O
was O
observed O
. O

As2O3 O
induced O
PML O
( O
promyelocytic O
leukemia O
) O
protein O
degradation O
but O
did O
not O
modulate O
expression O
of O
cell B
cycle I
- I
related I
proteins I
, O
including O
c B
- I
myc I
, O
retinoblastoma B
protein I
, O
cyclin B
- I
dependent I
kinase I
4 I
, O
cyclin B
D1 I
, O
and O
p53 B
, O
or O
expression O
of O
differentiation B
- I
related I
antigens I
. O

A20 O
can O
be O
regulated O
by O
the O
NF B
- I
kappaB I
transcription B
factor I
, O
which O
is O
known O
to O
be O
activated O
by O
the O
EBV B
LMP I
- I
1 I
protein I
. O

Further O
, O
CTLA B
- I
4 I
engagement O
inhibited O
progression O
through O
the O
cell O
cycle O
by O
inhibiting O
the O
production O
of O
cyclin B
D3 I
, O
cyclin B
- I
dependent I
kinase I
( B
cdk I
) I
4 I
, O
and O
cdk6 B
when O
the O
T O
cells O
were O
stimulated O
with O
anti B
- I
CD3 I
/ I
CD28 I
and O
with O
anti B
- I
CD3 I
alone O
. O

In O
the O
culture O
system O
reported O
here O
, O
( O
1 O
) O
the O
growth B
factor I
( O
GF B
) O
stimulus O
induces O
cord O
blood O
( O
CB O
) O
progenitor O
cells O
to O
proliferate O
and O
differentiate O
/ O
mature O
exclusively O
along O
the O
erythroid O
lineage O
; O
( O
2 O
) O
this O
erythropoietic O
wave O
is O
characterized O
by O
less O
than O
4 O
% O
apoptotic O
cells O
; O
( O
3 O
) O
asymmetric O
divisions O
are O
virtually O
absent O
, O
ie O
, O
nonresponsive O
hematopoietic O
progenitors O
with O
no O
erythropoietic O
potential O
are O
forced O
into O
apoptosis O
; O
( O
4 O
) O
the O
system O
is O
cell O
division O
controlled O
( O
cdc O

Single O
- O
cell O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
was O
applied O
to O
this O
culture O
system O
to O
investigate O
gene O
expression O
of O
diverse O
receptors B
, O
markers B
of I
differentiation I
, O
and O
transcription B
factors I
( O
EKLF B
, O
GATA B
- I
1 I
, O
GATA B
- I
2 I
, O
p45 B
NF I
- I
E2 I
, O
PU B
. I
1 I
, O
and O
SCL B
/ I
Tal1 I
) O
at O
discrete O
stages O
of O
erythropoietic O
development O
. O

Here O
we O
report O
that O
in O
erythroid O
cells O
, O
GATA B
- I
1 I
strongly O
induces O
the O
expression O
of O
the O
anti B
- I
apoptotic I
protein I
bcl B
- I
xL I
, O
but O
not O
the O
related O
proteins O
bcl B
- I
2 I
and O
mcl B
- I
1 I
. O

In O
T O
lymphocytes O
, O
the O
hematopoietic B
cytokine I
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
uses O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
- O
induced O
signaling O
pathways O
to O
regulate O
E2F B
transcriptional O
activity O
, O
a O
critical O
cell O
cycle O
checkpoint O
. O

PI B
3 I
- I
kinase I
also O
regulates O
the O
activity O
of O
p70 B
( I
s6k I
) I
, O
the O
40S B
ribosomal I
protein I
S6 I
kinase I
, O
a O
response O
that O
is O
abrogated O
by O
the O
macrolide O
rapamycin O
. O

Moreover O
, O
the O
effects O
of O
rapamycin O
on O
, O
and O
the O
role O
of O
p70 B
( I
s6k I
) I
in O
, O
IL B
- I
2 I
and O
PI B
3 I
- I
kinase I
activation O
of O
E2Fs B
have O
not O
been O
characterized O
. O

Since O
1988 O
, O
several O
families O
of O
functionally O
important O
T B
cell I
transcription I
factors I
have O
been O
identified O
. O

These O
include O
the O
Ikaros B
, O
LKLF B
, O
and O
GATA3 B
zinc I
- I
finger I
proteins I
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF B
- I
kappa I
B I
/ I
Rel I
/ I
NFAT I
transcription I
factors I
; O
the O
Stat B
proteins I
; O
and O
HMG B
box I
transcription I
factors I
such O
as O
LEF1 B
, O
TCF1 B
, O
and O
Sox4 B
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- B
319 I
and I
- I
219 I
bp I
upstream I
of O
the O
initiation O
codon O
and O
co O
- O
transfections O
with O
transcription B
factor I
expression I
plasmids I
for O
AP B
- I
2 I
and O
Sp1 B
resulted O
in O
augmented O
ASM O
promoter O
activity O
, O
which O
was O
abolished O
when O
the O
binding B
sites I
for O
these O
two O
factors O
were O
deleted O
. O

The O
effects O
of O
GDSP O
on O
pancreatic O
weight O
, O
serum B
amylase I
and I
lipase I
, O
morphologic O
changes O
in O
the O
pancreas O
, O
neutrophil O
infiltration O
, O
and O
nuclear B
factor I
KB I
( O
NF B
- I
KB I
) O
activation O
were O
measured O
in O
rats O
infused O
with O
supramaximal O
dose O
of O
cerulein O
( O
5 O
( O
g O
/ O
kg O
/ O
h O
) O
for O
6 O
h O
. O

Our O
previous O
studies O
pertaining O
to O
macrophage O
response O
to O
LPS O
identified O
a O
novel O
DNA B
- I
binding I
domain I
located O
from O
- O
550 O
to O
- O
487 O
in O
the O
human B
TNF I
- I
alpha I
promoter I
that O
contains O
transcriptional O
activity O
, O
but O
lacks O
any O
known O
NF B
- I
kappaB I
- B
binding I
sites I
. O

Inhibition O
of O
LITAF B
mRNA I
expression O
in O
THP O
- O
1 O
cells O
resulted O
in O
a O
reduction O
of O
TNF B
- I
alpha I
transcripts O
. O

In O
addition O
, O
high O
level O
of O
expression O
of O
LITAF B
mRNA I
was O
observed O
predominantly O
in O
the O
placenta O
, O
peripheral O
blood O
leukocytes O
, O
lymph O
nodes O
, O
and O
the O
spleen O
. O

A O
human B
IFNGR1 I
small I
deletion I
hotspot I
associated O
with O
dominant O
susceptibility O
to O
mycobacterial O
infection O
[ O
see O
comments O
] O

Characterization O
of O
expression O
of O
the O
gene O
for O
human B
pterin I
carbinolamine I
dehydratase I
/ I
dimerization I
cofactor I
of O
HNF1 B
. O

In O
the O
nucleus O
, O
it O
functions O
as O
a O
dimerization B
cofactor I
of O
HNF1 B
and O
increases O
the O
transcriptional O
activity O
of O
HNF1 B
. O

Capacitance O
would O
simply O
involve O
expression O
of O
IL B
- I
12R I
beta I
1 I
and I
beta I
2 I
subunits I
, O
regulated O
by O
TCR O
, O
IL B
- I
4 I
and O
IFNs B
. O

The O
activation O
of O
STAT3 B
was O
not O
found O
in O
human O
eosinophils O
, O
monocytes O
, O
and O
HL O
- O
60 O
cells O
, O
although O
the O
STAT3 B
protein I
was O
expressed O
in O
these O
cells O
. O

Inhibition O
of O
T O
cell O
signaling O
by O
mitogen B
- I
activated I
protein I
kinase I
- I
targeted I
hematopoietic I
tyrosine I
phosphatase I
( O
HePTP B
) O
. O

In O
contrast O
, O
HePTP B
had O
no O
effects O
on O
N B
- I
terminal I
c I
- I
Jun I
kinase I
or O
on O
events O
upstream O
of O
the O
MAP O
kinases O
. O

Epo B
caused O
an O
increase O
in O
the O
proportion O
of O
cells O
expressing O
cell O
surface O
glycophorin B
A I
( O
GPA B
) O
and O
up O
- O
regulated O
beta B
- I
and I
gamma I
- I
globin I
by O
several O
fold O
. O

Interferon B
- I
beta I
mediates O
stromal O
cell O
rescue O
of O
T O
cells O
from O
apoptosis O
. O

Interferon B
- I
alpha I
and I
- I
beta I
promote O
the O
reversion O
of O
blast O
Tcells O
to O
a O
resting O
G0 O
/ O
G1 O
configuration O
with O
all O
the O
characteristic O
features O
of O
stromal O
cell O
rescue O
; O
such O
as O
high O
Bcl B
- I
XL I
expression O
and O
low O
Bcl B
- I
2 I
. O

In O
this O
study O
, O
the O
influence O
of O
the O
sequences O
located O
between B
- I
3134 I
and I
- I
2987 I
on O
the O
transcriptional O
activity O
of O
the O
proIL B
- I
1beta I
gene I
in O
LPS O
- O
stimulated O
Raw O
264 O
. O
7 O
cells O
was O
examined O
in O
detail O
. O

These O
data O
indicated O
that O
two O
NF B
- I
kappaB I
- I
binding I
sites I
, O
which O
are O
located O
between O
- B
3134 I
and I
- I
3059 I
, O
are O
critical O
for O
the O
activation O
of O
proIL B
- I
1beta I
gene I
transcription O
. O

Gel O
supershift O
assays O
demonstrated O
that O
thrombin B
induced O
binding O
of O
NF B
- I
kappa I
Bp65 I
( O
Rel B
A I
) O
to O
downstream O
NF B
- I
kappa I
B I
site I
of O
the O
ICAM B
- I
1 I
promoter I
. O

Thrombin B
receptor O
activation O
peptide O
, O
a O
14 O
- O
amino O
- O
acid O
peptide O
representing O
the O
new O
NH2 B
terminus I
of O
proteolytically O
activated O
receptor B
- I
1 I
, O
mimicked O
thrombin B
' O
s O
action O
in O
inducing O
ICAM B
- I
1 I
expression O
. O

These O
data O
indicate O
that O
thrombin B
activates O
endothelial O
ICAM B
- I
1 I
expression O
and O
polymorphonuclear O
leukocyte O
adhesion O
by O
NF B
- I
kappa I
Bp65 I
binding O
to O
the O
downstream O
NF B
- I
kappa I
B I
site I
of O
ICAM B
- I
1 I
promoter I
after O
proteolytically O
activated O
receptor O
- O
1 O
activation O
. O

Here O
we O
demonstrate O
that O
both O
Smad6 B
and O
Smad7 B
are O
human B
bone I
morphogenetic I
protein I
- I
2 I
( O
hBMP B
- I
2 I
) O
- O
inducible O
antagonists O
of O
hBMP B
- I
2 I
- O
induced O
growth O
arrest O
and O
apoptosis O
in O
mouse O
B O
cell O
hybridoma O
HS O
- O
72 O
cells O
. O

50 O
% O
HCS O
downregulates O
the O
alpha B
- I
chain I
and O
slightly O
upregulates O
the O
beta B
- I
chain I
. O

HLA B
class I
I I
Ags I
have O
been O
implicated O
to O
play O
a O
major O
role O
in O
this O
process O
, O
since O
signaling O
via O
HLA B
class I
I I
molecules I
can O
induce O
the O
proliferation O
of O
aortic O
endothelial O
as O
well O
as O
smooth O
muscle O
cells O
. O

A O
cdk2 O
inhibitor O
, O
Olomoucine O
, O
as O
well O
as O
a O
dominant B
- I
negative I
cdk2 I
construct I
prevented O
HLA B
class I
I I
- O
mediated O
inactivation O
of O
Rb B
; O
in O
contrast O
, O
dominant B
- I
negative I
cdk4 I
and I
cdk6 I
constructs I
had O
no O
effect O
. O

PG490 O
can O
completely O
inhibit O
transcriptional O
activation O
at O
the O
purine B
- I
box I
/ I
ARRE I
/ I
NF I
- I
AT I
and I
NF I
- I
kappaB I
target I
DNA I
sequences I
triggered O
by O
all O
stimuli O
examined O
( O
PMA O
, O
PMA O
/ O
Iono O
, O
tumor B
necrosis I
factor I
- I
alpha I
) O
. O

PG490 O
also O
inhibits O
PMA O
- O
stimulated O
activation O
of O
a O
chimeric B
transcription I
factor I
in O
which O
the O
C B
- I
terminal I
TA1 I
transactivation I
domain I
of O
NF B
- I
kappaB I
p65 I
is O
fused O
to O
the O
DNA B
binding I
domain I
of O
GAL4 B
. O

Most O
erythroleukemic O
cell O
lines O
established O
in O
vitro O
coexpress O
erythrocytic B
and I
megakaryocytic I
markers I
that O
often O
are O
associated O
with O
expression O
of O
Spi B
- I
1 I
and O
/ O
or O
Fli B
- I
1 I
transcription I
factors I
known O
as O
transactivators B
of I
megakaryocyte I
- I
specific I
promoters I
. O

However O
, O
like O
normal O
Ter O
119 O
erythroid O
cells O
, O
these O
Ter O
119 O
positive O
cells O
from O
transgenic O
mice O
still O
expressed O
high O
levels O
of O
beta B
- I
globin I
and O
very O
low O
or O
undetectable O
glycoprotein B
IIb I
and O
platelet B
factor I
4 I
megakaryocytic I
transcripts I
. O

Taken O
together O
, O
these O
data O
indicate O
that O
the O
unexpected O
expression O
of O
megakaryocytic B
genes I
is O
a O
specific O
property O
of O
immortalized O
cells O
that O
can O
not O
be O
explained O
only O
by O
enhanced O
expression O
of O
Spi B
- I
1 I
and I
/ I
or I
Fli I
- I
1 I
genes I
. O

STAT1 B
, O
which O
is O
activated O
in O
response O
to O
many O
lymphocyte B
- I
activating I
cytokines I
including O
the O
interferons B
, O
is O
essential O
for O
cell O
- O
mediated O
immunity O
, O
as O
the O
absence O
of O
this O
protein O
is O
associated O
with O
prominent O
defects O
in O
the O
ability O
to O
control O
viral O
infections O
. O

Fludarabine O
caused O
a O
specific O
depletion O
of O
STAT1 B
protein I
( O
and O
mRNA O
) O
but O
not O
of O
other O
STATs B
. O

Spi B
- I
C I
interacted O
with O
DNA O
similarly O
to O
PU B
. I
1 I
as O
judged O
by O
methylation O
interference O
, O
band O
- O
shift O
and O
site O
selection O
analysis O
, O
and O
activated O
transcription O
of O
a O
kappaY B
element I
reporter I
gene I
upon O
co O
- O
transfection O
of O
HeLa O
cells O
. O

Spi B
- I
C I
RNA I
was O
expressed O
in O
mature O
B O
lymphocytes O
and O
at O
lower O
levels O
in O
macrophages O
. O

However O
, O
the O
HTLV B
- I
I I
genes I
including O
Tax B
are O
not O
expressed O
significantly O
in O
primary O
leukemic O
cells O
from O
ATL O
patients O
. O

Although O
MKK3 B
, O
MKK4 B
, O
and O
MKK6 B
all O
activated O
p38 B
MAPk I
in O
experimental O
models O
, O
only O
MKK3 B
was O
found O
to O
activate O
recombinant O
p38 B
MAPk I
in O
LPS O
- O
treated O
neutrophils O
. O

The O
I B
gamma I
3 I
ECS B
lies O
upstream O
of O
the O
major B
I I
gamma I
3 I
transcription I
initiation I
site I
and O
displays O
more O
than O
90 O
% O
identity O
with O
the O
corresponding O
human B
I I
gamma I
1 I
, O
I B
gamma I
2 I
, O
and O
I B
gamma I
4 I
regions O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
p50 B
/ I
p65 I
/ I
c I
- I
Rel I
and O
STAT B
- I
6 I
are O
effectively O
induced O
by O
CD40L B
and O
IL B
- I
4 I
, O
respectively O
, O
and O
bind O
to O
specific O
DNA B
motifs I
within O
the O
ECS B
. O

CIITA B
- O
induced O
occupation O
of O
MHC B
class I
II I
promoters I
is O
independent O
of O
the O
cooperative O
stabilization O
of O
the O
promoter B
- I
bound I
multi I
- I
protein I
complexes I
. O

Activation O
of O
MHC B
class I
II I
promoters I
requires O
binding O
of O
at O
least O
three O
distinct O
multi B
- I
protein I
complexes I
( O
RFX B
, O
X2BP B
and O
NF B
- I
Y I
) O
. O

We O
show O
, O
however O
, O
that O
the O
presence O
of O
CIITA B
does O
not O
affect O
the O
stability O
of O
the O
higher O
- O
order O
protein O
complex O
formed O
on O
DNA O
by O
RFX B
, O
X2BP B
and O
NF B
- I
Y I
. O

SH2 B
domain I
- I
containing I
protein I
76 I
( O
SLP B
- I
76 I
) O
interacts O
with O
the O
guanine B
nucleotide I
exchange I
factor I
Vav B
to O
activate O
the O
nuclear B
factor I
of I
activated I
cells I
( O
NF B
- I
AT I
) O
, O
and O
its O
expression O
is O
required O
for O
normal O
T O
cell O
development O
. O

In O
contrast O
, O
another O
inducible O
gene O
expression O
of O
monocyte B
chemotactic I
protein I
- I
1 I
( O
a O
CC B
chemokine I
) O
and O
the O
activation O
of O
the O
transcriptional B
factor I
( O
FcRFgamma B
) O
bound O
to O
the O
gamma B
response I
region I
were O
similarly O
or O
less O
abundantly O
induced O
by O
IFNgamma B
treatment O
in O
PMA O
- O
or O
RA O
- O
differentiated O
U937 O
cells O
, O
indicating O
that O
increased O
IP B
- I
10 I
mRNA I
induction O
was O
not O
due O
to O
the O
augmented O
ability O
of O
the O
cells O
to O
respond O
to O
the O
presence O
of O
IFNgamma B
. O

Role O
of O
cellular B
tumor I
necrosis I
factor I
receptor I
- I
associated I
factors I
in O
NF B
- I
kappaB I
activation O
and O
lymphocyte O
transformation O
by O
herpesvirus O
Saimiri O
STP B
. O

MDS1 B
/ I
EVI1 I
is O
inappropriately O
activated O
in O
myeloid O
leukemias O
following O
chromosomal O
rearrangements O
involving O
band B
3q26 I
. O

In O
this O
report O
, O
we O
have O
analyzed O
the O
response O
of O
the O
hematopoietic O
precursor O
cell O
line O
32Dcl3 O
, O
expressing O
either O
the O
normal B
protein I
MDS1 I
/ I
EVI1 I
or O
the O
fusion B
protein I
AML1 I
/ I
MDS1 I
/ I
EVI1 I
, O
to O
factors O
that O
control O
cell O
differentiation O
or O
cell O
replication O
. O

This O
effect O
is O
similar O
to O
that O
previously O
described O
by O
others O
for O
32Dcl3 O
cells O
that O
express O
transgenic B
Evil I
. O

By O
using O
the O
yeast O
two O
- O
hybrid O
system O
, O
we O
also O
show O
that O
EVI1 B
( O
contained O
in O
its O
entirety O
in O
MDS1 B
/ I
EVI1 I
and O
AML1 B
/ I
MDS1 I
/ I
EVI1 I
) O
physically O
interacts O
with O
SMAD3 B
, O
which O
is O
an O
intracellular O
mediator O
of O
TGF B
- I
beta1 I
signaling O
. O

Tcf B
- I
1 I
- O
mediated O
transcription O
in O
T O
lymphocytes O
: O
differential O
role O
for O
glycogen B
synthase I
kinase I
- I
3 I
in O
fibroblasts O
and O
T O
cells O
. O

Beta O
- O
catenin O
is O
the O
vertebrate O
homolog O
of O
the O
Drosophila B
segment I
polarity I
gene I
Armadillo B
and O
plays O
roles O
in O
both O
cell O
- O
cell O
adhesion O
and O
transduction O
of O
the O
Wnt O
signaling O
cascade O
. O

Recently O
, O
members O
of O
the O
Lef B
/ I
Tcf I
transcription I
factor I
family I
have O
been O
identified O
as O
protein O
partners O
of O
beta B
- I
catenin I
, O
explaining O
how O
beta B
- I
catenin I
alters O
gene O
expression O
. O

Expression O
of O
EBNA2 B
led O
to O
the O
transcriptional O
activation O
of O
both O
endogenous O
or O
transfected O
IFN B
- I
stimulated I
genes I
( O
ISGs B
) O
, O
genes O
which O
contain O
within O
their O
promoters B
either O
the O
interferon B
- I
stimulated I
response I
element I
( O
ISRE B
) O
or O
the O
gamma B
interferon I
activation I
site I
( O
GAS B
) O
. O

Angiotensin B
II I
activates O
the O
proinflammatory B
transcription I
factor I
nuclear B
factor I
- I
kappaB I
in O
human O
monocytes O
. O

Detection O
of O
intracellular B
phosphorylated I
STAT I
- I
1 I
by O
flow O
cytometry O
. O

Because O
these O
induced O
gene O
products O
have O
NF B
- I
kappaB I
sites I
in O
their O
promoter B
regions I
, O
we O
next O
examined O
whether O
there O
was O
an O
up O
- O
regulation O
of O
nuclear O
NF B
- I
kappaB I
levels O
. O

Glycoprotein B
( I
GP I
) I
IX I
is O
a O
subunit O
of O
the O
von B
Willebrand I
receptor I
, O
GPIb B
- I
V I
- I
IX I
, O
which O
mediates O
adhesion O
of O
platelets O
to O
the O
subendothelium O
of O
damaged O
blood O
vessels O
. O

These O
results O
suggest O
that O
Fli B
- I
1 I
is O
likely O
to O
regulate O
lineage B
- I
specific I
genes I
during O
megakaryocytopoiesis O
. O

Additionally O
, O
CoCl2 O
caused O
a O
two O
- O
to O
threefold O
increase O
in O
the O
rate O
of O
transendothelial O
migration O
of O
monocyte O
- O
like O
HL O
- O
60 O
cells O
and O
a O
twentyfold O
increase O
in O
phosphorylation O
of O
platelet B
endothelial I
cell I
adhesion I
molecules I
( O
PECAM B
- I
1 I
) O
. O

This O
RXR B
agonist O
activity O
is O
blocked O
by O
RAR B
- O
specific O
antagonists O
, O
suggesting O
extensive O
cross O
- O
talk O
between O
the O
partners O
of O
the O
RXR B
- I
RARalpha403 I
heterodimer I
. O

Expression O
of O
the O
alpha B
- I
chain I
of O
IL B
- I
2Ralpha I
on O
peripheral O
blood O
monocytes O
( O
PBM O
) O
was O
induced O
by O
M O
. O
tuberculosis O
by O
flow O
cytometry O
evaluation O
. O

Furthermore O
, O
the O
two O
VDR B
3 I
' I
- I
UTR I
haplotypes O
conferred O
an O
identical O
half O
- O
life O
on O
a O
heterologous B
beta I
- I
globin I
reporter I
gene I
, O
in O
an O
in O
vitro O
assay O
. O

Similarly O
, O
IL B
- I
2 I
neither O
activates O
JNK B
nor O
increases O
AP B
- I
1 I
binding O
activity O
to O
a O
consensus O
o B
- I
tetradecanoylphorbol I
13 I
- I
acetate I
( I
TPA I
) I
response I
element I
. O

The O
phosphorylation O
appears O
to O
be O
related O
to O
the O
signaling O
events O
that O
are O
activated O
by O
TRAF2 B
under O
these O
circumstances O
, O
since O
two O
nonfunctional O
mutants O
were O
found O
to O
be O
phosphorylated O
significantly O
less O
than O
the O
wild B
- I
type I
protein I
. O

We O
conclude O
from O
these O
studies O
that O
the O
phosphorylation O
of O
TRAF2 B
is O
likely O
to O
play O
an O
important O
role O
in O
regulating O
signaling O
by O
virtue O
of O
its O
ability O
to O
influence O
the O
CD40 B
- B
TRAF2 I
interaction O
. O

Though O
the O
levels O
of O
DP1 B
and I
- I
2 I
increase O
when O
cells O
progress O
from O
G0 O
to O
S O
, O
the O
proportion O
of O
DP1 B
to O
DP2 B
remains O
relatively O
constant O
during O
the O
cell O
cycle O
. O

We O
also O
observed O
an O
increase O
in O
electrophoretic O
mobility O
of O
the O
predominant O
E2F B
components I
, O
DP1 B
and O
E2F4 B
, O
as O
B O
- O
lymphocytes O
progressed O
from O
G0 O
into O
early O
G1 O
. O

In O
addition O
, O
DNA O
- O
binding O
activities O
of O
Jun B
- I
Fos I
heterodimers I
were O
observed O
by O
electrophoretic O
mobility O
shift O
assays O
during O
the O
course O
of O
natural O
cytotoxicity O
. O

Despite O
minimal O
discrepancies O
in O
the O
coding B
region I
, O
there O
are O
striking O
tissue O
- O
and O
cell O
type O
- O
specific O
differences O
in O
isoform O
expression O
patterns O
. O

Furthermore O
, O
these O
oxidative O
stresses O
inhibited O
activity O
of O
calcineurin O
, O
a O
serine O
/ O
threonine B
phosphatase I
that O
regulates O
NFAT B
activation O
. O

Several O
intracellular O
signaling B
proteins I
, O
such O
as O
CBL B
and O
VAV B
, O
were O
phosphorylated O
on O
tyrosine O
in O
response O
to O
CD80 B
, O
CD86 B
, O
and O
anti B
- I
CD28 I
mAb I
. O

In O
order O
to O
elucidate O
the O
role O
of O
NF B
- I
ATp I
, O
one O
of O
the O
most O
prominent O
members O
of O
family O
of O
NF B
- I
AT I
transcription I
factors I
in O
peripheral O
T O
lymphocytes O
, O
in O
T O
cell O
activation O
and O
differentiation O
we O
created O
NF B
- I
ATp I
- O
deficient O
mice O
by O
gene O
targeting O
. O

Apart O
from O
clear O
- O
cut O
defects O
in O
the O
synthesis O
of O
mRNAs B
for O
Th2 B
- I
type I
lymphokines I
, O
such O
as O
IL B
- I
4 I
, O
IL B
- I
5 I
, O
IL B
- I
10 I
and O
IL B
- I
13 I
, O
in O
primary O
and O
secondary O
stimulations O
of O
spleen O
cells O
in O
vitro O
, O
of O
a O
distinct O
impaired O
deletion O
of O
V O
beta O
11 O
+ O
/ O
CD4 O
+ O
T O
lymphocytes O
from O
these O
mice O
was O
detected O
after O
superantigen O
injection O
. O

We O
previously O
identified O
a O
Fas B
ligand I
regulatory I
element I
( O
FLRE B
) O
in O
the O
Fas B
ligand I
( I
fasL I
) I
promoter I
that O
binds O
Egr B
family I
proteins I
and O
demonstrated O
that O
Egr B
- I
3 I
( O
PILOT B
) O
but O
not O
Egr B
- I
1 I
( O
NGFI B
- I
A I
, O
Krox B
- I
24 I
, O
Tis B
- I
8 I
, O
and O
Zif B
- I
268 I
) O
induces O
transcription O
of O
fasL B
. O

The O
aberrant O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
T O
cells O
from O
lpr O
/ O
lpr O
and O
gld O
/ O
gld O
mice O
, O
which O
have O
mutations O
in O
the O
genes O
encoding O
Fas B
and O
FasL B
, O
respectively O
, O
have O
an O
activated O
phenotype O
and O
constitutively O
express O
high O
levels O
of O
fasL B
mRNA I
, O
prompting O
us O
to O
ask O
what O
role O
if O
any O
the O
FLRE B
and O
Egr B
family I
proteins I
have O
in O
this O
aberrant O
expression O
of O
fasL B
. O

Although O
overexpressed O
Egr B
- I
1 I
was O
ineffective O
, O
overexpressed O
Egr B
- I
2 I
was O
as O
potent O
as O
Egr B
- I
3 I
in O
inducing O
fasL B
promoter I
- I
dependent I
reporter I
constructs I
in O
T O
cell O
hybridomas O
and O
HeLa O
cells O
, O
and O
both O
up O
- O
regulated O
endogenous O
fasL B
mRNA I
in O
HeLa O
cells O
. O

FasL B
- I
dependent I
reporter I
constructs I
in O
MRL O
- O
lpr O
/ O
lpr O
and O
C3H O
- O
gld O
/ O
gld O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
T O
cells O
were O
constitutively O
active O
, O
and O
this O
activity O
was O
largely O
prevented O
by O
mutation O
of O
the O
critical O
Egr B
family I
binding I
element I
. O

The O
activity O
of O
the O
CCAAT B
- I
box I
binding I
factor I
NF I
- I
Y I
is O
modulated O
through O
the O
regulated O
expression O
of O
its O
A B
subunit I
during O
monocyte O
to O
macrophage O
differentiation O
: O
regulation O
of O
tissue B
- I
specific I
genes I
through O
a O
ubiquitous O
transcription B
factor I
. O

Differential O
induction O
of O
DNA B
- I
binding I
activities I
following O
CD19 B
cross O
- O
linking O
in O
human O
B O
lineage O
cells O
. O

The O
B B
cell I
- I
specific I
cell I
surface I
molecule I
CD19 B
is O
expressed O
at O
all O
stages O
of O
B O
cell O
development O
, O
including O
normal O
plasma O
cells O
, O
and O
mediates O
signal O
transduction O
via O
interaction O
with O
cytoplasmic B
effector I
proteins I
. O

Finally O
, O
oxidants O
are O
believed O
to O
promote O
intestinal O
epithelial O
cell O
apoptosis O
, O
and O
the O
B B
- I
cell I
lymphoma I
/ I
leukemia I
- I
2 I
gene I
product I
is O
believed O
to O
inhibit O
this O
phenomenon O
in O
an O
antioxidant O
- O
dependent O
manner O
. O

The O
regulatory B
regions I
of O
several O
genes O
specifically O
expressed O
in O
B O
cells O
contain O
functional B
binding I
sites I
for O
Oct2 B
. O

Binding O
of O
c B
- I
Rel I
to O
STAT5 B
target I
sequences I
in O
HTLV O
- O
I O
- O
transformed O
T O
cells O
. O

Although O
resting O
Jurkat O
cells O
express O
Fas B
, O
Fas B
mRNA I
was O
induced O
approximately O
10 O
- O
fold O
in O
2 O
h O
upon O
P O
/ O
I O
stimulation O
. O

The O
functional O
contribution O
of O
the O
kappaB B
- I
Sp1 I
composite I
site I
in O
P B
/ I
I I
- I
inducible I
fas I
promoter I
activation O
was O
verified O
by O
using O
kappaB O
- O
Sp1 B
concatamers O
( O
- B
295 I
to I
- I
286 I
) O
in O
a O
thymidine B
kinase I
promoter I
- I
driven I
reporter I
construct I
and O
native B
promoter I
constructs I
in O
Jurkat O
cells O
overexpressing O
IkappaB B
- I
alpha I
. O

Members O
of O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
binding I
( I
CREB I
) I
/ I
activating I
transcription I
factor I
1 I
( I
ATF I
- I
1 I
) I
family I
of O
transcription B
factors I
bind O
three O
21 B
- I
bp I
repeats I
( O
Tax B
- I
responsive I
element I
- I
1 I
, O
or O
TRE B
- I
1 I
) O
within O
the O
viral B
promoter I
and O
are O
important O
for O
basal O
and O
Tax O
- O
mediated O
transcription O
. O

However O
, O
while O
HUVECs O
contained O
endothelial O
NOS B
protein I
, O
no O
inducible O
NOS B
was O
detected O
in O
either O
tolerant O
or O
nontolerant O
cells O
. O

Delta O
- O
opioid O
receptors O
expressed O
by O
Jurkat O
T O
cells O
enhance O
IL B
- I
2 I
secretion O
by O
increasing O
AP B
- I
1 I
complexes I
and O
activity O
of O
the O
NF B
- I
AT I
/ I
AP I
- I
1 I
- I
binding I
promoter I
element I
. O

Reporter O
gene O
constructs O
were O
used O
to O
map O
this O
effect O
of O
deltorphin O
to O
the O
AP B
- I
1 I
- I
and I
NF I
- I
AT I
/ I
AP I
- I
1 I
- I
binding I
sites I
of O
the O
IL B
- I
2 I
promoter I
. O

These O
cells O
, O
stimulated O
by O
an O
agonistic O
monoclonal O
antibody O
against O
CD40 B
or O
by O
transfection O
with O
a O
CD40L B
expression I
vector I
, O
secreted O
p40 B
and O
showed O
enhanced O
p40 B
mRNA I
expression O
. O

We O
have O
mapped O
the O
DNase B
- I
I I
- I
hypersensitive I
( I
HS I
) I
regions I
of O
the O
human B
GATA I
- I
3 I
gene I
in O
T O
- O
cells O
and O
non O
- O
T O
- O
cells O
and O
studied O
their O
transcriptional O
activities O
. O

HS B
I I
- I
III I
, O
located O
5 O
' O
from O
the O
transcriptional B
initiation I
site I
, O
were O
found O
in O
hematopoietic O
and O
non O
- O
hematopoietic O
cells O
, O
whereas O
HS B
IV I
- I
VII I
, O
located O
3 O
' O
from O
the O
transcriptional B
start I
site I
, O
were O
exclusively O
observed O
in O
T O
- O
cells O
. O

Among O
these O
hypersensitive B
sites I
, O
two O
transcriptional B
control I
elements I
were O
found O
, O
one O
in O
the O
first B
intron I
of O
the O
GATA B
- I
3 I
gene I
and O
the O
other O
between B
8 I
. I
3 I
and I
5 I
. I
9 I
kilobases I
5 O
' O
from O
the O
GATA B
- I
3 I
transcriptional I
initiation I
site I
. O

Two O
CAGGTG O
E O
- O
boxes O
, O
located O
at O
the O
5 B
' I
- I
and I
3 I
' I
- I
ends I
of O
the O
silencer O
, O
were O
necessary O
for O
this O
silencer O
activity O
. O

The O
3 B
' I
- I
CAGGTG I
E I
- I
box I
could O
bind O
USF B
proteins I
, O
the O
ubiquitous B
repressor I
ZEB B
, O
or O
the O
basic B
helix I
- I
loop I
- I
helix I
proteins I
E2A B
and O
HEB B
, O
and O
we O
showed O
that O
a O
competition O
between O
ZEB B
and O
E2A B
/ I
HEB I
proteins I
is O
involved O
in O
the O
silencer O
activity O
. O

Cutting O
edge O
: O
dominant O
effect O
of O
Ile50Val B
variant I
of O
the O
human B
IL I
- I
4 I
receptor I
alpha I
- I
chain I
in O
IgE B
synthesis O
. O

Constitutive O
expression O
of O
human B
colony I
- I
stimulating I
factor I
- I
1 I
receptor I
( O
CSF B
- I
1R I
) O
confers O
long O
- O
lasting O
CSF B
- I
1 I
- O
dependent O
proliferation O
to O
mouse O
myeloid O
cell O
lines O
. O

Here O
we O
show O
that O
JunB B
, O
but O
not O
the O
other O
Jun B
family I
members I
, O
was O
selectively O
induced O
in O
Th2 O
cells O
and O
not O
in O
Th1 O
cells O
during O
differentiation O
. O

However O
, O
both O
pathways O
were O
necessary O
for O
another O
transformation O
- O
related O
activity O
( O
colony O
formation O
in O
soft O
agar O
) O
of O
CTLL B
- I
2 I
/ I
Tax I
. O

First O
, O
it O
gives O
no O
information O
on O
memory O
to O
lytic B
cycle I
antigens I
; O
second O
, O
it O
preferentially O
amplifies O
the O
dominant O
components O
of O
latent O
antigen O
- O
specific O
memory O
at O
the O
expense O
of O
key O
subdominant O
reactivities O
. O

Surprisingly O
, O
overexpression O
of O
GRbeta B
in O
Jurkat O
cells O
did O
not O
cause O
significant O
inhibition O
of O
GRalpha B
- O
induced O
transactivation O
of O
a O
GRE B
- I
dependent I
luciferase I
reporter I
gene I
either O
. O

Extinction O
of O
immunoglobulin B
gene I
expression O
in O
B O
cells O
upon O
fusion O
with O
HeLa O
cells O
is O
preceded O
by O
rapid O
nuclear O
depletion O
of O
essential B
transcription I
factors I
and O
is O
accompanied O
by O
widespread O
inactivation O
of O
genes O
expressed O
in O
a O
B O
cell O
- O
specific O
manner O
. O

Evidence O
for O
suppressed O
activity O
of O
the O
transcription B
factor I
NFAT1 B
at O
its O
proximal B
binding I
element I
P0 B
in O
the O
IL B
- I
4 I
promoter I
associated O
with O
enhanced O
IL B
- I
4 I
gene I
transcription O
in O
T O
cells O
of O
atopic O
patients O
. O

These O
findings O
suggest O
that O
high O
- O
level O
IL B
- I
4 I
production O
in O
atopic O
Th2 O
cells O
is O
associated O
with O
selective O
reduction O
of O
suppressive O
NFAT1 B
activity O
at O
the O
IL B
- I
4 I
P0 I
element I
and O
that O
some O
patients O
with O
this O
multifactorial O
disease O
may O
have O
a O
putative O
systemic O
disorder O
at O
this O
level O
. O

A O
role O
for O
changes O
in O
immunophilins B
, O
causing O
glucocorticoid O
resistance O
in O
neotropical O
primates O
, O
is O
supported O
by O
the O
following O
: O
the O
changes O
in O
FKBP51 B
and O
FKBP52 B
were O
observed O
in O
cells O
from O
other O
neotropical O
primates O
with O
glucocorticoid O
resistance O
; O
the O
elevated O
level O
of O
FKBP51 B
was O
reflected O
in O
an O
abundance O
of O
FKBP51 B
in O
heat B
shock I
protein I
90 I
complexes I
in O
SML O
; O
when O
cytosols O
of O
SML O
and O
L929 O
cells O
were O
mixed O
, O
the O
decrease O
in O
GR O
binding O
was O
associated O
with O
incorporation O
of O
FKBP51 B
into O

GR B
heterocomplexes I
; O
the O
effect O
of O
SML O
cytosol O
on O
GR O
binding O
was O
reproduced O
with O
cytosol O
from O
COS O
cells O
expressing O
squirrel O
monkey O
FKBP51 B
; O
and O
both O
the O
effect O
of O
SML O
cytosol O
on O
GR O
binding O
and O
the O
incorporation O
of O
FKBP51 B
into O
GR B
heterocomplexes I
were O
blocked O
by O
FK506 O
. O

Serial O
sectioning O
of O
6 O
micrometer O
was O
performed O
using O
a O
cryostat O
, O
and O
samples O
were O
immunohistochemicall O
stained O
using O
the O
streptoavidin B
- B
biotin I
peroxidase I
method O
and O
a O
monoclonal O
antibody O
against O
c O
- O
fos O
. O

The O
allele O
- O
specific O
expression O
profiles O
of O
other O
imprinted B
genes I
, O
IGF2 B
and O
H19 B
, O
on O
human B
chromosome I
11 I
were O
constant O
and O
consistent O
with O
those O
in O
other O
tissues O
. O

T O
cell O
responses O
to O
some O
nuclear O
antigens O
, O
particularly O
U1RNP B
, O
have O
been O
detected O
in O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
and O
in O
healthy O
subjects O
. O

Tumor B
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
- O
induced O
HIV O
- O
1 O
replication O
in O
OM10 O
. O
1 O
or O
Ach2 O
cells O
was O
significantly O
inhibited O
by O
non O
- O
cytotoxic O
doses O
of O
AuTG O
( O
> O
10 O
microM O
in O
OM10 O
. O
1 O
cells O
and O
> O
25 O
F O
. O
M O
in O
Ach2 O
cells O
) O
, O
while O
25 O
microM O
of O
the O
counter B
- I
anion I
thioglucose I
( O
TG B
) O
or O
gold O
compound O
containing O
divalent O
gold O
ion O
, O
HAuCl3 O
, O
had O
no O
effect O
. O

This O
pro B
- I
IL I
- I
16 I
is O
subsequently O
processed O
to O
the O
mature O
cytokine O
of O
13 B
kDa I
. O

The O
5 B
' I
sequences I
up O
to O
nucleotide O
- O
120 O
of O
the O
human O
and O
murine O
IL B
- I
16 I
genes O
share O
> O
84 O
% O
sequence O
homology O
and O
harbor B
promoter I
elements I
for O
constitutive O
and O
inducible O
transcription O
in O
T O
cells O
. O

A O
Taq B
I I
polymorphism I
was O
identified O
which O
enabled O
chicken O
IL2 B
to O
be O
mapped O
to O
chromosome B
4 I
, O
linked O
to O
ANX5 B
, O
with O
synteny O
with O
mouse B
chromosome I
3 I
and O
human B
chromosome I
4 I
. O

The O
Megakaryocyte B
/ I
Platelet I
- I
specific I
enhancer I
of O
the O
alpha2beta1 B
integrin I
gene I
: O
two O
tandem O
AP1 B
sites I
and O
the O
mitogen B
- I
activated I
protein I
kinase I
signaling O
cascade O
. O

Transcriptional O
regulation O
of O
the O
alpha2 B
integrin I
gene I
in O
cells O
undergoing O
megakaryocytic O
differentiation O
requires O
a O
core B
promoter I
between O
bp O
- O
30 O
and O
- O
92 O
, O
a O
silencer B
between O
bp O
- O
92 O
and O
- O
351 O
, O
and O
megakaryocytic B
enhancers I
in O
the O
distal B
5 I
' I
flank I
. O

These O
agents O
also O
significantly O
decreased O
TNF B
- O
and O
LPS O
- O
stimulated O
increases O
in O
HUVEC B
surface I
VCAM I
- I
1 I
. O

Functional O
testosterone B
receptors I
in O
plasma O
membranes O
of O
T O
cells O
. O

Cytoplasmic B
AR I
do O
not O
translocate O
to O
the O
nucleus O
of O
T O
cells O
in O
the O
presence O
of O
testosterone O
, O
in O
contrast O
to O
cytoplasmic B
AR I
in O
human O
cancer O
LNCaP O
cells O
. O

Using O
the O
wild B
- I
type I
or I
mutated I
human I
retinoic I
acid I
receptor I
alpha I
as O
a O
model O
, O
kDa O
values O
determined O
by O
classical O
competition O
binding O
assays O
using O
tritiated O
ligands O
are O
in O
agreement O
with O
those O
measured O
by O
the O
proteolytic O
assay O
. O

B O
lymphocytes O
from O
patients O
with O
chronic O
lymphocytic O
leukemia O
contain O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
1 I
and O
STAT3 B
constitutively O
phosphorylated O
on O
serine O
residues O
. O

IL B
- I
10 I
preincubation O
resulted O
in O
the O
inhibition O
of O
gene O
expression O
for O
several O
IFN B
- I
induced I
genes I
, O
such O
as O
IP B
- I
10 I
, O
ISG54 B
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
. O

IL B
- I
10 I
treatment O
prevented O
the O
downregulation O
of O
p27 B
( I
Kip1 I
) O
, O
an O
inhibitory B
protein I
that O
controls O
progression O
out O
of O
the O
G0 O
phase O
of O
the O
cell O
cycle O
. O

In O
conclusion O
, O
the O
long O
- O
term O
regulation O
of O
transcription B
factor I
gene O
expression O
in O
non O
- O
proliferating O
cells O
seems O
to O
be O
of O
minor O
importance O
after O
influenza O
infection O
since O
in O
apoptosisprone O
cells O
an O
immediate O
availability O
of O
transcription B
factor I
proteins I
is O
required O
. O

Patients O
with O
diabetic O
nephropathy O
showed O
higher O
NF B
- I
kappaB I
binding O
activity O
in O
Electrophoretic O
Mobility O
Shift O
Assays O
and O
stronger O
immunohistological O
staining O
for O
activated O
NF B
- I
kappaBp65 I
than O
patients O
without O
renal O
complications O
. O

We O
incubated O
sodium O
oleate O
with O
human O
umbilical O
vein O
endothelial O
cells O
for O
0 O
to O
72 O
hours O
, O
followed O
by O
coincubation O
of O
oleate O
with O
human B
recombinant I
tumor I
necrosis I
factor I
, O
interleukin B
( I
IL I
) I
- I
1alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
4 I
, O
Escherichia O
coli O
lipopolysaccharide O
( O
LPS O
) O
, O
or O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
for O
a O
further O
6 O
to O
24 O
hours O
. O

The O
importance O
of O
BCL2 B
and O
Stat3 B
on O
IL B
- I
6 I
- O
induced O
macrophage O
- O
differentiation O
and O
apoptosis O
was O
studied O
with O
1A9 O
- O
M O
cells O
expressing O
human B
BCL2 I
or O
a O
dominant O
- O
negative O
form O
of O
Stat3 B
, O
respectively O
. O

Interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
is O
a O
chemokine B
that O
belongs O
to O
the O
alpha B
- I
chemokine I
or O
CXC B
subfamily I
and O
is O
produced O
by O
a O
wide O
variety O
of O
human O
cells O
, O
including O
monocytes O
and O
polymorphonuclear O
cells O
( O
PMN O
) O
. O

In O
this O
report O
, O
we O
show O
that O
Mycoplasma B
fermentans I
lipid I
- I
associated I
membrane I
proteins I
( O
LAMPf B
) O
induce O
the O
production O
of O
high O
levels O
of O
IL B
- I
8 I
by O
THP O
- O
1 O
( O
human O
monocyte O
) O
cells O
and O
PMN O
at O
the O
same O
extent O
as O
LPS O
. O

These O
results O
demonstrate O
the O
capacity O
of O
intact O
C3a B
and O
its O
circulating O
des B
- I
Arg I
form I
to O
exert O
immunmodulatory O
effects O
in O
vitro O
. O

The O
suggested O
roles O
of O
the O
downstream B
3 I
' I
regions I
acting O
as O
a O
Locus B
Control I
Region I
( O
LCR B
) O
, O
have O
allowed O
comparisons O
to O
be O
made O
between O
the O
regulation O
of O
the O
IgH B
locus I
with O
other O
model O
systems O
whose O
gene O
expression O
is O
governed O
by O
LCR B
activity O
. O

T O
lymphocytes O
recognize O
antigens O
in O
the O
form O
of O
peptides O
bound O
to O
HLA B
- I
molecules I
. O

MATERIALS O
AND O
METHODS O
: O
Peptides O
derived O
from O
oncogenic B
proteins I
were O
screened O
for O
the O
presence O
of O
HLA B
binding I
motifs I
; O
actual O
binding O
were O
evaluated O
by O
HLA O
stabilization O
experiments O
using O
transfectants O
and O
specific O
anti B
- I
HLA I
antibodies I
. O

RESULTS O
: O
We O
identified O
peptides O
derived O
from O
EWS B
/ I
FLI I
- I
1 I
fusion I
protein I
and O
from O
mutated B
K I
- I
RAS I
protein I
( O
encompassing O
respectively O
the O
fusion B
point I
and O
the O
mutation O
at O
position B
12 I
) O
that O
showed O
binding B
motif I
for O
HLA B
- I
Cw I
* I
0702 I
and O
HLA B
- I
A3 I
respectively O
. O

We O
eliminate O
both O
Stat5 B
and O
Raf B
/ B
MEK I
pathways O
from O
E2F B
regulation O
. O

TRADD B
was O
the O
only O
protein O
that O
interacted O
with O
wild B
- I
type I
TES2 I
and O
not O
with O
isoleucine B
- I
mutated I
TES2 I
. O

Thus O
, O
replication O
of O
the O
transcriptional B
template I
is O
not O
a O
prerequisite O
for O
expression O
with O
late O
kinetics O
, O
a O
finding O
inconsistent O
with O
the O
current O
models O
which O
posit O
a O
cis O
- O
active O
relationship O
between O
lytic O
EBV O
DNA O
replication O
and O
late O
gene O
expression O
. O

We O
suspect O
that O
the O
C B
/ I
EBP I
epsilon I
promoter I
/ I
enhancer I
contains O
a O
retinoic B
acid I
- I
response I
element I
that O
is O
directly O
stimulated O
by O
retinoids O
. O

Core B
- I
specific I
mAb I
inhibited O
mCD14 B
- O
mediated O
uptake O
of O
homologous O
and O
heterologous O
LPS O
, O
while O
producing O
less O
concurrent O
enhancement O
of O
non O
- O
mCD14 B
- O
mediated O
LPS O
uptake O
. O

Transfection O
of O
EL O
- O
4 O
cells O
with O
the O
IL B
- I
4 I
promoter I
- I
reporter I
constructs I
carrying O
mutated B
P I
- I
like I
elements I
showed O
that O
four O
P B
- I
like I
elements I
, O
CLE0 B
, O
P B
, O
P2 B
and O
P4 B
, O
but O
not O
P3 B
, O
were O
required O
for O
optimal O
activation O
of O
the O
IL B
- I
4 I
promoter I
. O

The O
initiating O
event O
is O
still O
uncertain O
, O
but O
activation O
of O
a O
recently O
described O
receptor B
- I
associated I
protein I
kinase I
is O
one O
of O
the O
earliest O
events O
detectable O
( O
Martin O
et O
al O
. O
, O
Eur O
. O
J O
. O
Immunol O
. O
1994 O
. O
24 O
: O
1566 O
) O
. O

From O
these O
observations O
we O
conclude O
that O
free O
thiols O
in O
the O
IL B
- I
1RI I
complex I
are O
essential O
for O
the O
activation O
of O
the O
IL B
- I
1RI I
- I
associated I
protein I
kinase I
and O
that O
this O
process O
is O
mandatory O
for O
IL B
- I
1 I
signaling O
leading O
to O
NF B
- I
kappa I
B I
activation O
. O

The O
A B
- I
myb I
transcription I
factor I
in O
neoplastic O
and O
normal O
B O
cells O
. O

These O
bHLH B
antagonists I
are O
induced O
during O
a O
mitogenic O
signalling O
response O
, O
and O
they O
function O
by O
sequestering O
their O
bHLH B
targets I
in O
inactive B
heterodimers I
that O
are O
unable O
to O
bind O
to O
specific O
gene B
regulatory I
( I
E I
box I
) I
sequences I
. O

Furthermore O
, O
compared O
with O
wild B
- I
type I
Id3 I
, O
an O
Id3 B
Asp5 I
mutant I
( O
mimicking O
phosphorylation O
) O
is O
unable O
to O
promote O
cell O
cycle O
S O
phase O
entry O
in O
transfected O
fibroblasts O
, O
whereas O
an O
Id3 B
Ala5 I
mutant I
( O
ablating O
phosphorylation O
) O
displays O
an O
activity O
significantly O
greater O
than O
that O
of O
wild B
- I
type I
Id3 I
protein I
. O

Here O
we O
describe O
cloning O
and O
characterization O
of O
full O
- O
length O
cDNA B
encoding I
murine I
( I
m I
) I
NFATc I
which O
predicts O
that O
the O
protein O
has O
all O
the O
conserved B
structural I
motifs I
of O
NFAT B
family I
members I
, O
including O
the O
rel O
homology O
domain O
, O
the O
NFAT B
homology I
domain I
and O
the O
nuclear O
translocation O
signals O
. O

These O
data O
indicate O
that O
the O
TRE B
- I
like I
cAMP I
- I
responsive I
DSE I
sites I
within O
the O
5 B
' I
- I
untranslated I
leader I
can O
mediate O
the O
transcriptional O
cooperativity O
between O
TNFalpha B
and O
the O
cAMP O
/ B
PKA I
pathway O
. O

Cooperation O
of O
binding B
sites I
for O
STAT6 B
and O
NF B
kappa I
B I
/ I
rel I
in O
the O
IL B
- I
4 I
- O
induced O
up O
- O
regulation O
of O
the O
human B
IgE I
germline I
promoter I
. O

Cyclosporin O
A O
inhibits O
early O
mRNA O
expression O
of O
G0 B
/ I
G1 I
switch I
gene I
2 I
( O
G0S2 B
) O
in O
cultured O
human O
blood O
mononuclear O
cells O
. O

LSF B
( O
also O
known O
as O
LBP B
- I
1 I
, O
UBP B
, O
and O
CP B
- I
2 I
) O
has O
been O
shown O
to O
repress O
LTR O
transcription O
in O
vitro O
, O
but O
transient O
expression O
of O
LSF B
has O
no O
effect O
on O
LTR B
activity O
in O
vivo O
. O

Here O
we O
report O
a O
real O
- O
time O
study O
of O
factor O
/ O
DNA O
interactions O
using O
a O
surface O
plasmon O
resonance O
approach O
and O
further O
characterization O
of O
recovered B
proteins I
involved O
in O
this O
interaction O
. O

Stable O
transfection O
of O
U937 O
cells O
with O
sense O
or O
antisense B
RXR I
- I
alpha I
cDNA I
suggests O
a O
role O
for O
RXR B
- I
alpha I
in O
the O
control O
of O
monoblastic O
differentiation O
induced O
by O
retinoic O
acid O
and O
vitamin O
D O
. O

The O
role O
of O
the O
viral B
trans I
- I
activator I
Tax I
protein I
in O
the O
induction O
of O
VCAM B
- I
1 I
was O
first O
indicated O
by O
the O
detection O
of O
this O
adhesion B
molecule I
on O
Jurkat O
T O
- O
cell O
clones O
stably O
expressing O
the O
tax O
gene O
. O

The O
effect O
of O
Tax B
on O
VCAM B
- I
1 I
gene O
transcription O
was O
next O
confirmed O
in O
JPX O
- O
9 O
cells O
, O
a O
subclone O
of O
Jurkat O
cells O
, O
carrying O
the O
tax B
sequences I
under O
the O
control O
of O
an O
inducible B
promoter I
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B
- I
1 I
promoter I
performed O
with O
chloramphenicol B
acetyltransferase I
constructs I
revealed O
that O
Tax B
was O
trans O
activating O
the O
VCAM B
- I
1 I
promoter I
via O
two O
NF B
- I
kappaB I
sites I
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM B
- I
1 I
gene I
promoter I
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B
- O
induced O
expression O
of O
this O
adhesion B
molecule I
. O

Interleukin B
2 I
( O
IL B
- I
2 I
) O
induces O
tyrosine O
phosphorylation O
of O
STATs B
3 I
and I
5 I
( O
signal O
transducer O
and O
activator O
of O
transcription O
) O
. O

IL B
- I
2 I
and O
T B
cell I
antigen I
receptor I
complex I
induction O
of O
STAT3alpha B
serine O
727 O
phosphorylation O
is O
dependent O
on O
the O
activity O
of O
the O
MEK B
/ B
ERK I
pathway O
. O

These O
results O
thus O
show O
that O
STAT3 B
proteins I
are O
targets O
for O
multiple O
kinase O
pathways O
in O
T O
cells O
and O
can O
integrate O
signals O
from O
both O
cytokine B
receptors I
and O
antigen B
receptors I
. O

In O
addition O
, O
both O
RelA B
and O
c B
- I
Rel I
, O
but O
not O
NF B
- I
kappa I
B1 I
, O
were O
shown O
to O
transactivate O
an O
ICAM B
- I
1 I
kappa I
B I
- I
reporter I
construct I
. O

The O
composite B
PU I
. I
1 I
and I
Pip I
site I
likely O
accounts O
for O
both O
lineage O
and O
stage O
- O
specific O
expression O
of O
CD20 B
whereas O
the O
CD20 B
E I
box I
binding I
proteins I
enhance O
overall O
promoter O
activity O
and O
may O
link O
the O
promoter O
to O
a O
distant B
enhancer I
. O

Control O
of O
NF B
- I
kappa I
B I
activity O
by O
the O
I B
kappa I
B I
beta I
inhibitor I
. O

The O
transcription B
factor I
NF B
- I
kappa I
B I
is O
maintained O
in O
an O
inactive O
cytoplasmic O
state O
by O
I B
kappa I
B I
inhibitors I
. O

Increased O
CRH B
promoter O
activity O
following O
phorbol O
ester O
treatment O
was O
inhibited O
by O
a O
dominant O
negative O
NF B
- I
IL6 I
mutant I
, O
showing O
that O
the O
effects O
of O
phorbol O
ester O
were O
principally O
mediated O
by O
C B
/ I
EBP I
. O

A O
similar O
spectrum O
of O
transcript O
deletions O
has O
previously O
been O
described O
in O
the O
putative B
tumour I
suppressor I
gene I
FHIT B
. O

Interleukin B
- I
7 I
upregulates O
the O
interleukin B
- I
2 I
- I
gene I
expression O
in O
activated O
human O
T O
lymphocytes O
at O
the O
transcriptional O
level O
by O
enhancing O
the O
DNA O
binding O
activities O
of O
both O
nuclear O
factor O
of O
activated O
T O
cells O
and O
activator B
protein I
- I
1 I
. O

The O
three O
- O
dimensional O
positioning O
of O
immunoglobulin B
( I
Ig I
) I
genes I
within O
the O
nucleus O
of O
human O
cells O
was O
investigated O
using O
in O
situ O
hybridization O
and O
confocal O
microscopy O
. O

The O
visualization O
of O
heavy B
and I
light I
chain I
genes I
in O
B O
- O
lymphoid O
cells O
showed O
that O
the O
three O
Ig B
genes I
are O
differentially O
and O
nonrandomly O
distributed O
in O
different O
nuclear O
subvolumes O
: O
the O
kappa B
genes I
were O
found O
to O
be O
preferentially O
confined O
to O
an O
outer O
nuclear O
volume O
, O
whereas O
the O
gamma B
and I
lambda I
genes I
consistently O
occupied O
more O
central O
positions O
within O
the O
nucleus O
, O
the O
lambda B
genes I
being O
more O
interior O
when O
compared O
with O
the O
gamma B
genes I
. O

Transcription B
factor I
NF B
- I
kappa I
B I
must O
be O
released O
from O
cytoplasmic B
inhibitory I
molecules I
( O
I B
kappa I
Bs I
) O
in O
order O
to O
move O
to O
the O
nucleus O
and O
to O
activate O
its O
target B
genes I
. O

TCR B
beta I
analysis O
showed O
that O
while O
there O
was O
loop O
length O
restriction O
in O
the O
putative O
peptide O
contact O
site O
of O
all O
responding O
beta B
chains I
, O
diverse O
and O
unique O
( O
non O
- O
recurrent O
) O
TCR O
beta O
clonotypes O
were O
selected O
in O
individuals O
during O
primary O
infection O
and O
continued O
to O
emerge O
after O
long O
- O
term O
virus O
exposure O
. O

To O
define O
the O
CD40 B
signaling O
components O
upstream O
of O
NF B
- I
kappa I
B I
activation O
and O
the O
functional O
consequences O
downstream O
of O
NF B
- I
kappa I
B I
activation O
, O
we O
examined O
mouse O
B O
cell O
transfectants O
expressing O
wild B
- I
type I
or I
mutant I
human I
CD40 I
. O

A O
threonine O
residue O
at O
position B
234 I
, O
previously O
shown O
to O
be O
important O
for O
CD40 B
association O
with O
TNF B
receptor I
- I
associated I
factor I
2 I
( O
TRAF2 B
) O
, O
TRAF3 B
, O
and O
TRAF5 B
, O
was O
not O
required O
for O
NF B
- I
kappa I
B I
activation O
. O

Induction O
of O
endothelial B
cell I
surface I
adhesion I
molecules I
by O
tumor B
necrosis I
factor I
is O
blocked O
by O
protein O
tyrosine O
phosphatase O
inhibitors O
: O
role O
of O
the O
nuclear B
transcription I
factor I
NF I
- I
kappa I
B I
. O

Further O
, O
M O
. O
tuberculosis O
and O
its O
tuberculin B
, O
purified B
protein I
derivative I
, O
induced O
the O
degradation O
of O
I B
kappa I
B I
- I
alpha I
and O
the O
expression O
of O
I B
kappa I
B I
- I
alpha I
mRNA I
, O
and O
purified O
protein O
derivative O
induced O
the O
activation O
of O
NF B
- I
kappa I
B I
in O
monocytes O
. O

Spi B
- I
1 I
/ I
PU I
. I
1 I
is O
a O
myeloid B
- I
and I
B I
- I
cell I
specific I
transcription I
factor I
which O
is O
also O
involved O
in O
Friend O
virus O
- O
induced O
murine O
erythroleukemia O
. O

They O
also O
suggest O
that O
the O
function O
of O
Spi B
- I
1 I
/ I
PU I
. I
1 I
in O
the O
late O
phase O
of O
Friend O
leukemia O
requires O
specific O
signaling O
from O
the O
gp55 B
- I
modified I
EpoR I
generated O
during O
the O
early O
phase O
of O
the O
disease O
. O

As O
shown O
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
and O
electrophoretic O
mobility O
shift O
assay O
, O
respectively O
, O
treatment O
with O
CsA O
leads O
to O
decreased O
TF B
mRNA I
expression O
and O
reduced O
activation O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
, O
which O
is O
known O
to O
contribute O
to O
the O
induction O
of O
the O
TF B
promotor I
in O
human O
monocytes O
. O

IL B
- I
2 I
and O
IL B
- I
7 I
were O
equivalent O
in O
their O
ability O
to O
induce O
tyrosine O
phosphorylation O
of O
STAT5A B
and O
STAT5B B
and O
to O
facilitate O
binding O
of O
these O
STATs B
to O
an O
immobilized B
GAS I
element I
. O

These O
data O
suggest O
that O
IL B
- I
2 I
and O
IL B
- I
7 I
induce O
assembly O
of O
STAT B
heterodimers I
in O
a O
similar O
manner O
and O
that O
subsequent O
cellular O
responses O
may O
be O
driven O
by O
induction O
of O
similar O
sets O
of O
genes B
. O

The O
POU B
transcription I
factors I
Oct B
- I
1 I
and O
Oct B
- I
2 I
regulate O
the O
activity O
of O
octamer B
- I
dependent I
promoters I
, O
including O
those O
that O
direct O
transcription O
from O
rearranged O
immunoglobulin B
genes I
. O

The O
class B
II I
trans I
- I
activator I
( O
CIITA B
) O
is O
a O
bi B
- I
or I
multi I
- I
functional I
domain I
protein I
which O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

Rather O
, O
helenalin O
modifies O
the O
NF B
- I
kappaB I
/ I
IkappaB I
complex I
, O
preventing O
the O
release O
of O
IkappaB B
. O

The O
tax B
protein I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
mediates O
the O
transactivation O
of O
the O
c B
- I
sis I
/ I
platelet I
- I
derived I
growth I
factor I
- I
B I
promoter I
through O
interactions O
with O
the O
zinc B
finger I
transcription I
factors I
Sp1 B
and O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

In O
the O
present O
work O
, O
we O
have O
investigated O
the O
mechanism O
( O
s O
) O
whereby O
Tax B
transactivates O
the O
c B
- I
sis I
/ I
PDGF I
- I
B I
proto I
- I
oncogene I
. O

The O
CAML B
( I
calcium I
- I
modulator I
and I
cyclophilin I
ligand I
) I
protein I
is O
a O
coinducer O
of O
NF B
- I
AT I
activation O
when O
overexpressed O
in O
Jurkat O
T O
cells O
. O

Proteins O
of O
the O
ATF O
/ O
CREB B
class O
of O
transcription B
factors I
stimulate O
gene O
expression O
of O
several O
cell B
growth I
- I
related I
genes I
through O
protein B
kinase I
A I
- I
related I
cAMP I
response I
elements I
. O

One O
ATF B
/ I
CRE I
motif I
is O
located O
in O
the O
distal B
promoter I
at O
the O
nuclear B
matrix I
- I
associated I
Site I
IV I
, O
and O
the O
second O
motif O
is O
present O
in O
the O
proximal B
promoter I
at O
Site B
I I
. O

Site O
- O
directed O
mutational O
studies O
demonstrate O
that O
Site B
I I
and O
Site B
IV I
together O
support O
ATF1 O
- O
and O
CREB O
- O
induced O
trans O
- O
activation O
of O
the O
H4 B
promoter I
. O

Thus O
, O
our O
data O
establish O
that O
ATF B
/ I
CREB I
factors I
functionally O
modulate O
histone B
H4 I
gene I
transcription O
at O
distal B
and I
proximal I
promoter I
elements I
. O

Purification O
and O
characterization O
of O
the O
human B
SR I
31747A I
- I
binding I
protein I
. O

A O
nuclear B
membrane I
protein I
related O
to O
yeast B
sterol I
isomerase I
. O

Using O
a O
radiolabeled O
chemical O
probe O
, O
we O
here O
purified O
a O
target O
of O
SR O
31747A O
and O
called O
it O
SR B
31747A I
- I
binding I
protein I
( O
SR B
- I
BP I
) O
. O

Purified B
SR I
- I
BP I
retained O
its O
binding O
properties O
and O
migrated O
on O
SDS O
- O
polyacrylamide O
gel O
as O
a O
Mr B
28 I
, I
000 I
protein I
. O

Northern O
blot O
analysis O
of O
SR B
- I
BP I
gene O
expression O
revealed O
a O
single O
transcript O
of O
2 B
kilobases I
which O
was O
widely O
expressed O
among O
organs O
, O
with O
the O
highest O
abundance O
in O
liver O
and O
the O
lowest O
abundance O
in O
brain O
. O

In O
this O
study O
, O
we O
used O
a O
RT O
- O
PCR O
based O
approach O
to O
compare O
the O
stability O
of O
the O
big B
T I
and I
small I
t I
allele I
in O
normal O
heterozygous O
lymphocytes O
and O
the O
heterozygous O
cell O
lines O
NB4 O
( O
myeloid O
leukemia O
) O
and O
PC O
- O
3 O
and O
DU O
145 O
( O
prostate O
cancers O
) O
. O

Interestingly O
, O
we O
consistently O
observed O
30 O
% O
less O
RT B
- I
PCR I
product I
derived O
from O
the O
small B
t I
allele I
mRNA I
in O
steady O
state O
, O
a O
finding O
which O
also O
speaks O
against O
a O
higher O
stability O
of O
the O
small B
t I
allele I
mRNA I
. O

Nuclear B
factor I
- I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
/ I
Rel I
transcription I
factors I
may O
be O
involved O
in O
atherosclerosis O
, O
as O
is O
suggested O
by O
the O
presence O
of O
activated O
NF B
- I
kappa I
B I
in O
human O
atherosclerotic O
lesions O
. O

Our O
results O
demonstrate O
that O
short O
- O
term O
incubation O
of O
these O
cells O
with O
oxLDL B
activated I
p50 I
/ I
p65 I
containing O
NF B
- I
kappa I
B I
dimers I
and O
induced O
the O
expression O
of O
the O
target B
gene I
IL I
- I
8 I
. O

PURPOSE O
: O
To O
demonstrate O
that O
leukocyte O
adhesion O
to O
cultured O
corneal O
endothelial O
cells O
is O
mediated O
by O
the O
CD18 B
antigen I
, O
and O
to O
determine O
whether O
dexamethasone O
directly O
suppresses O
adhesion O
by O
inhibiting O
activation O
of O
nuclear B
factor I
kappa I
B I
( O
NFkappaB B
) O
. O

The O
transcriptional B
start I
sites I
were O
identified O
by O
an O
RNase B
protection O
assay O
. O

Restriction O
analysis O
revealed O
that O
neutrophils O
express O
the O
GH B
- I
N I
gene I
but O
not O
the O
GH B
- I
V I
gene I
. O

Eotaxin B
is O
an O
eosinophil B
specific I
beta I
- I
chemokine I
assumed O
to O
be O
involved O
in O
eosinophilic O
inflammatory O
diseases O
such O
as O
atopic O
dermatitis O
, O
allergic O
rhinitis O
, O
asthma O
and O
parasitic O
infections O
. O

The O
pp52 B
promoter I
contains O
an O
initiator O
specifying O
the O
unique O
5 B
' I
terminus I
of O
pp52 B
mRNA I
, O
tandem O
pairs O
of O
Ets B
and I
SP1 I
motifs I
, O
and O
a O
lone B
C I
/ I
EBP I
motif I
. O

BACKGROUND O
: O
Recent O
studies O
have O
raised O
the O
hypothesis O
that O
glucocorticoids O
could O
diminish O
the O
ability O
of O
endothelial O
cells O
to O
direct O
leukocyte O
traffic O
into O
inflamed O
tissues O
by O
inhibiting O
expression O
of O
the O
adhesion B
molecules I
endothelial B
- I
leukocyte I
adhesion I
molecule I
- I
1 I
and O
intercellular B
adhesion I
molecule I
- I
1 I
. O

The O
immediate O
- O
early O
gene O
product O
Egr B
- I
1 I
regulates O
the O
human B
interleukin I
- I
2 I
receptor I
beta I
- I
chain I
promoter I
through O
noncanonical B
Egr I
and I
Sp1 I
binding I
sites I
. O

Like O
the O
class B
II I
genes I
, O
the O
HLA B
- I
DM I
genes I
contain O
upstream O
regulatory O
sequences O
similar O
to O
the O
S B
- I
X I
- I
Y I
regulatory I
region I
as O
well O
as O
additional O
putative O
regulatory O
sites O
. O

The O
class B
II I
- I
specific I
transcription I
factors I
RFX B
and O
CIITA B
are O
also O
required O
for O
expression O
, O
as O
cell O
lines O
deficient O
in O
these O
factors O
failed O
to O
allow O
transcription O
from O
the O
DM B
promoters I
. O

Critical O
cytoplasmic B
domains I
of O
human B
interleukin I
- I
9 I
receptor I
alpha I
chain I
in O
interleukin B
- O
9 O
- O
mediated O
cell O
proliferation O
and O
signal O
transduction O
. O

The O
genes O
encoding O
the O
functionally O
related O
hepatocyte B
nuclear I
factors I
HNF B
- I
1alpha I
and O
HNF B
- I
4alpha I
play O
a O
critical O
role O
in O
normal O
pancreatic O
beta O
- O
cell O
function O
. O

In O
this O
study O
, O
we O
show O
that O
HNF B
- I
3alpha I
, I
- I
3beta I
, I
- I
3gamma I
, I
- I
4gamma I
, I
and I
- I
6 I
are O
expressed O
in O
pancreatic O
beta O
- O
cells O
. O

We O
report O
the O
identification O
and O
characterization O
of O
simple B
tandem I
repeat I
DNA I
polymorphisms I
in O
the O
genes O
encoding O
HNF B
- I
3alpha I
, O
- B
3beta I
, O
- B
3gamma I
, O
- B
4gamma I
, O
and O
- B
6 I
and O
the O
mapping O
of O
HNF B
- I
6 I
to O
chromosome B
bands I
15q21 B
. I
1 I
- I
21 I
. I
2 I
by O
fluorescence O
in O
situ O
hybridization O
. O

Decreased O
transcriptional O
activation O
by O
N B
- I
terminal I
deletions I
of O
CIITA B
is O
correlated O
directly O
with O
their O
reduced O
binding O
to O
TAFII32 B
. O

Molecular O
cloning O
of O
SLAP B
- I
130 I
, O
an O
SLP B
- I
76 I
- I
associated I
substrate I
of O
the O
T B
cell I
antigen I
receptor I
- I
stimulated I
protein I
tyrosine I
kinases I
. O

From O
analyses O
of O
mice O
deficient O
in O
transcription B
factor I
genes I
and O
from O
the O
characterizations O
of O
chromosome B
breakpoints I
in O
human O
leukemias O
, O
it O
has O
become O
evident O
that O
transcription B
factors I
are O
important O
regulators O
of O
hematopoiesis O
. O

In O
THP O
- O
1 O
cells O
transfected O
with O
HIV B
plasmid I
constructs I
, O
both O
organisms O
induced O
transcription O
from O
the O
HIV B
long I
terminal I
repeat I
that O
was O
dependent O
on O
intact O
NF B
- I
kappaB I
binding I
sequences I
. O

In O
this O
report O
we O
present O
the O
characterisation O
of O
NF B
- I
kappaB I
subunits I
engaged O
in O
complexes O
binding O
to O
the O
HIV B
- I
1 I
NF I
- I
kappaB I
site I
in O
human O
8e51 O
T O
- O
cells O
, O
that O
harbour O
a O
defective O
HIV O
- O
1 O
. O

In O
these O
cells O
, O
Stat6 B
activation O
led O
to O
the O
induction O
of O
the O
beta B
- I
casein I
gene I
promoter I
. O

In O
fact O
, O
mAb B
L243 I
but O
not O
the O
staphylococcal B
superantigens I
, O
staphylococcal B
exotoxin I
toxic I
shock I
syndrome I
toxin I
- I
I I
or O
staphylococcal B
enterotoxin I
B I
, O
regulate O
the O
NF B
- I
kappa I
B I
binding O
activity O
. O

Regulation O
of O
inosine B
- I
5 I
' I
- I
monophosphate I
dehydrogenase I
type I
II I
gene O
expression O
in O
human O
T O
cells O
. O

Additional O
major O
protein O
- O
DNA O
interactions O
do O
not O
occur O
within O
the O
promoter O
region O
after O
T O
lymphocyte O
activation O
, O
indicating O
a O
requirement O
for O
additional O
protein O
- O
protein O
interactions O
and O
/ O
or O
post O
- O
translational O
modifications O
of O
pre B
- I
bound I
transcription I
factors I
to O
account O
for O
the O
observed O
increase O
in O
IMPDH O
type O
II O
gene O
expression O
. O

NAC O
had O
no O
effect O
on O
the O
half O
- O
life O
of O
E B
- I
selectin I
or I
VCAM I
- I
1 I
mRNA I
. O

Fusion O
proteins O
involving O
the O
retinoic O
acid O
receptor B
alpha I
( O
RAR B
alpha I
) O
and O
the O
PML B
or O
PLZF B
nuclear I
protein I
are O
the O
genetic O
markers O
of O
acute O
promyelocytic O
leukemias O
( O
APLs O
) O
. O

This O
presents O
several O
problems O
in O
vectors O
, O
particularly O
those O
in O
which O
additional O
genes O
, O
either O
a O
co B
- I
stimulatory I
gene I
or O
a O
selectable O
marker O
, O
are O
inserted O
. O

There O
was O
, O
however O
, O
a O
significant O
decrease O
in O
the O
plasma B
sialyltransferase I
: I
cortisol O
ratio O
in O
the O
depressed O
group O
suggesting O
an O
inability O
of O
the O
raised O
cortisol O
levels O
to O
induce O
enzyme O
expression O
and O
this O
ratio O
may O
provide O
a O
useful O
biochemical O
marker O
of O
cortisol O
receptor O
function O
. O

Therefore O
, O
while O
the O
total O
plasma B
sialyltransferase I
: O
cortisol O
ratio O
reflects O
HPA O
axis O
function O
, O
alterations O
in O
specific O
isozyme O
activity O
may O
also O
be O
associated O
with O
other O
CNS O
disease O
states O
. O

Using O
a O
previously O
described O
mutant O
of O
the O
Jurkat O
T O
cell O
line O
, O
we O
show O
that O
proximal O
signaling O
events O
dependent O
on O
the O
presence O
of O
the O
CD45 B
tyrosine I
phosphatase I
are O
required O
for O
TCR B
- O
stimulated O
CD95 B
ligand I
expression O
. O

TCP O
succinate O
( O
200 O
microM O
, O
24 O
h O
) O
reduced O
TNF B
- I
induced I
VCAM I
- I
1 I
and O
E B
- I
selectin I
expression O
from O
a O
specific O
mean O
fluorescence O
intensity O
of O
151 O
+ O
/ O
- O
28 O
to O
12 O
+ O
/ O
- O
4 O
channels O
and O
from O
225 O
+ O
/ O
- O
38 O
to O
79 O
+ O
/ O
- O
21 O
channels O
, O
respectively O
. O

Liberated O
NF B
- I
kappa I
B I
migrates O
to O
the O
nucleus O
, O
where O
it O
binds O
to O
specific B
promoter I
sites I
and O
activates O
gene O
transcription O
. O

The O
human B
C I
/ I
EBPepsilon I
gene I
is O
transcribed O
by O
two O
alternative O
promoters B
, O
Palpha B
and O
Pbeta B
. O

A O
combination O
of O
differential O
splicing O
and O
alternative O
use O
of O
promoters B
generates O
four O
mRNA B
isoforms I
, O
of O
2 O
. O
6 O
kb O
and O
1 O
. O
3 O
- O
1 O
. O
5 O
kb O
in O
size O
. O

Thus O
, O
C B
/ I
EBPepsilon I
is O
regulated O
in O
a O
complex O
fashion O
and O
may O
play O
a O
role O
in O
the O
regulation O
of O
genes O
involved O
in O
myeloid O
differentiation O
. O

One O
of O
them O
, O
hT86 O
, O
encoding O
a O
putative B
zinc I
finger I
protein I
was O
found O
to O
derepress O
beta B
- I
galactosidase I
activity O
in O
the O
Oct B
- I
2 I
- O
harboring O
tester O
strain O
at O
the O
transcriptional O
level O
. O

Functional O
analysis O
of O
monocytic O
THP O
- O
1 O
cells O
transfected O
with O
plasmids B
containing O
various O
lengths O
of O
TNF B
- I
alpha I
promoter I
localized O
enhancer B
elements I
in O
a O
region O
( O
- B
182 I
to I
- I
37 I
base I
pairs I
( O
bp O
) O
) O
that O
were O
required O
for O
optimal O
transcription O
of O
the O
TNF B
- I
alpha I
gene I
in O
response O
to O
LPS O
. O

In O
unstimulated O
THP O
- O
1 O
, O
CRE B
- I
binding I
protein I
and O
, O
to O
a O
lesser O
extent O
, O
c B
- I
Jun I
complexes I
were O
found O
to O
bind O
to O
the O
CRE B
site I
. O

The O
CRE B
and I
kappaB3 I
sites I
in O
region B
II I
together O
conferred O
strong O
LPS O
responsiveness O
to O
a O
heterologous B
promoter I
, O
whereas O
individually O
they O
failed O
to O
provide O
transcriptional O
activation O
. O

Furthermore O
, O
increasing O
the O
spacing O
between O
the O
CRE B
and I
the I
kappaB3 I
sites I
completely O
abolished O
LPS O
induction O
, O
suggesting O
a O
cooperative O
interaction O
between O
c B
- I
Jun I
complexes I
and O
p50 B
/ I
p65 I
. O

IFN B
- I
alpha I
/ I
beta I
specifically O
induced O
tyrosine O
phosphorylation O
and O
translocation O
into O
nucleus O
of O
signal B
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
2 I
protein I
in O
the O
T O
cell O
clones O
. O

IL B
- I
10 I
inhibition O
of O
IFN B
- I
gamma I
- O
induced O
ICAM B
- I
1 I
expression O
was O
apparent O
as O
early O
as O
3 O
hours O
and O
was O
blocked O
by O
an O
anti B
- I
IL I
- I
10 I
antibody I
but O
not O
by O
an O
isotype B
- I
matched I
control I
antibody I
. O

The O
other O
, O
CIITA B
, O
encodes O
a O
large O
protein O
with O
a O
defined O
acidic B
transcriptional I
activation I
domain I
; O
this O
protein O
does O
not O
interact O
with O
DNA O
. O

However O
, O
these O
plasmids B
produced O
transcriptional O
activity O
in O
HeLa O
cells O
only O
in O
conjunction O
with O
interferon B
gamma I
stimulation O
, O
a O
condition O
in O
which O
expression O
of O
both O
CIITA B
and O
class B
II I
major I
histocompatibility I
complex I
surface I
proteins I
are O
induced O
. O

Acute O
promyelocytic O
leukemia O
( O
APL O
) O
is O
associated O
with O
reciprocal O
chromosomal O
translocations O
involving O
the O
retinoic B
acid I
receptor I
alpha I
( I
RARalpha I
) I
locus I
on O
chromosome B
17 I
. O

The O
resulting O
fusion B
genes I
encode O
the O
two O
structurally O
unique O
PML B
/ I
RARalpha I
and O
RARalpha B
/ I
PML I
fusion I
proteins I
as O
well O
as O
aberrant B
PML I
gene I
products I
, O
the O
respective O
pathogenetic O
roles O
of O
which O
have O
not O
been O
elucidated O
. O

This O
novel B
target I
site I
, O
denoted O
the O
C B
- I
site I
, O
was O
shown O
by O
several O
criteria O
, O
including O
cell O
distribution O
studies O
, O
stimulation O
experiments O
, O
supershift O
assays O
, O
and O
cross O
- O
competition O
electrophoretic O
mobility O
shift O
assays O
to O
bind O
the O
transcription B
factor I
AP I
- I
1 I
. O

Latent O
infection O
of O
B O
lymphocytes O
by O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
can O
be O
disrupted O
by O
expression O
of O
the O
EBV B
ZEBRA I
protein I
. O

To O
better O
understand O
the O
AP B
- I
1 I
- O
dependent O
luciferase B
expression O
in O
Jurkat O
T O
cells O
, O
we O
tested O
two O
specific O
inhibitors O
of O
serine B
/ I
threonine I
phosphatases I
- I
1 I
and I
- I
2A I
: O
okadaic O
acid O
and O
calyculin O
A O
. O

Our O
results O
indicate O
that O
CCK O
- O
8 O
exerts O
a O
trophic O
effect O
in O
Jurkat O
T O
cells O
through O
stimulation O
of O
CCK B
( I
B I
) I
receptors I
by O
modulation O
of O
expression O
of O
AP B
- I
1 I
- I
regulated I
genes I
. O

Binding B
sites I
at O
the O
core O
region O
show O
little O
conservation O
with O
consensus B
sites I
. O

Molecular O
cloning O
and O
characterization O
of O
a O
cDNA B
, O
CHEMR1 B
, O
encoding O
a O
chemokine B
receptor I
with O
a O
homology O
to O
the O
human B
C I
- I
C I
chemokine I
receptor I
, O
CCR B
- I
4 I
. O

These O
are O
known O
to O
bind O
to O
seven B
- I
transmembrane I
- I
domain I
containing I
receptors I
. O

This O
suggests O
that O
CHEMR1 B
may O
be O
a O
receptor O
for O
unidentified O
C B
- I
C I
chemokine I
or O
a O
low O
- O
affinity O
receptor O
for O
MIP B
- I
1alpha I
. O

Human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Tat I
, O
an O
early O
regulatory B
protein I
that O
is O
critical O
for O
viral O
gene O
expression O
and O
replication O
, O
transactivates O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
via O
its O
binding O
to O
the O
transactivation B
response I
element I
( O
TAR B
) O
and O
, O
along O
with O
other O
cellular O
factors O
, O
increases O
viral O
transcription O
initiation O
and O
elongation O
. O

In O
this O
study O
, O
a O
combined O
pharmacologic O
and O
genetic O
strategy O
using O
two O
PKC B
( O
NF B
- I
kappa I
B I
) O
inhibitors O
, O
pentoxifylline O
( O
PTX O
) O
and O
Go O
- O
6976 O
, O
and O
a O
stably O
expressed O
anti B
- I
Tat I
single I
- I
chain I
intracellular I
antibody I
( O
sFv B
intrabody I
) O
was O
employed O
to O
obtain O
cooperative O
inhibition O
of O
both O
HIV O
- O
1 O
LTR B
- O
driven O
gene O
expression O
and O
HIV O
- O
1 O
replication O
. O

The O
combined O
treatment O
resulted O
in O
more O
durable O
inhibition O
of O
HIV O
- O
1 O
replication O
than O
was O
seen O
with O
the O
NF B
- I
kappa I
B I
inhibitors O
alone O
or O
the O
anti O
- O
Tat B
sFv I
intrabodies I
alone O
. O

Also O
in O
the O
current O
study O
, O
binding O
activity O
to O
the O
CD28RE B
/ I
AP I
- I
1 I
sequence I
of O
the O
IL B
- I
2 I
promoter I
is O
evaluated O
. O

These O
data O
indicate O
that O
functional O
complexes O
encompassing O
both O
the O
CD28RE B
and O
the O
AP B
- I
1 I
- I
binding I
sites I
influence O
IL B
- I
2 I
promoter I
activity O
in O
CD28 B
- O
costimulated O
T O
cells O
. O

Inducible O
expression O
and O
phosphorylation O
of O
coactivator B
BOB I
. I
1 I
/ I
OBF I
. I
1 I
in O
T O
cells O
[ O
see O
comments O
] O

The O
methodology O
employed O
transient O
transfection O
of O
HEK O
293 O
cells O
with O
a O
cDNA O
for O
the O
52 O
- O
kDa O
form O
of O
G B
( I
S I
) I
alpha I
under O
regulation O
by O
inducible B
metallothionein I
promoters I
. O

Patients O
with O
one O
type O
of O
major B
histocompatibility I
complex I
class I
II I
combined O
immunodeficiency O
have O
mutations O
in O
a O
gene O
termed O
class B
II I
transactivator I
( O
CIITA B
) O
, O
which O
coordinately O
controls O
the O
transcription O
of O
the O
three O
major O
human B
class I
II I
genes I
, O
HLA B
- I
DR I
, I
- I
DQ I
, I
and I
- I
DP I
. O

We O
report O
here O
that O
ectopic O
expression O
of O
CIITA B
cDNAs I
derived O
by O
reverse O
transcriptase O
polymerase O
chain O
reaction O
from O
clone O
13 O
do O
not O
restore O
expression O
of O
HLA B
- I
DQ I
in O
another O
CIITA O
- O
deficient O
cell O
line O
, O
RJ2 O
. O
2 O
. O
5 O
. O

In O
contrast O
, O
somatic O
cell O
fusion O
between O
clone O
13 O
and O
RJ2 O
. O
2 O
. O
5 O
restored O
expression O
of O
the O
HLA B
- I
DQ I
haplotype O
encoded O
by O
the O
RJ2 B
. I
2 I
. I
5 I
DQB I
gene I
. O

We O
show O
that O
ligand O
- O
induced O
homodimerization O
of O
chimeric B
surface I
receptors I
consisting O
of O
the O
extracellular B
and I
transmembrane I
domains I
of O
the O
erythropoietin B
receptor I
and O
of O
the O
intracellular B
domain I
of O
IL B
- I
4Ralpha I
induces O
Janus B
kinase I
1 I
( O
Jak1 B
) O
activation O
, O
STAT6 B
activation O
, O
and O
Cepsilon B
germline I
transcripts I
in O
human O
B O
cell O
line O
BJAB O
. O

Characterization O
of O
peripheral O
blood O
T O
- O
lymphocytes O
transduced O
with O
HTLV B
- I
I I
Tax I
mutants I
with O
different O
trans O
- O
activating O
phenotypes O
. O

Treatment O
of O
cells O
expressing O
the O
chimeric B
receptor I
kit B
/ I
IL I
- I
4R I
alpha I
with O
SCF B
induces O
activation O
of O
the O
IL B
- I
4R I
alpha I
- I
associated I
kinase I
JAK B
- I
1 I
and O
the O
transcription B
factor I
STAT6 B
. O

The O
present O
work O
shows O
that O
the O
primary O
CD8 O
+ O
CTL O
response O
to O
EBV O
in O
infectious O
mononucleosis O
patients O
contains O
multiple O
lytic O
antigen O
- O
specific O
reactivities O
at O
levels O
at O
least O
as O
high O
as O
those O
seen O
against O
latent B
antigens I
; O
similar O
reactivities O
are O
also O
detectable O
in O
CTL O
memory O
. O

Clonal O
analysis O
revealed O
individual O
responses O
to O
the O
two O
immediate B
early I
proteins I
BZLF1 B
and O
BRLF1 B
, O
and O
to O
three O
( O
BMLF1 B
, O
BMRF1 B
, O
and O
BALF2 B
) O
of O
the O
six O
early B
proteins I
tested O
. O

Triggering O
of O
HLA B
class I
II I
antigens I
by O
the O
anti B
- I
HLA I
- I
DR I
monoclonal I
antibody I
( I
mAb I
) I
L243 I
significantly O
( O
P O
< O
0 O
. O
05 O
) O
and O
differentially O
enhanced O
the O
release O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
by O
the O
non O
- O
Hodgkin O
' O
s O
lymphoma O
cells O
Ri O
- O
I O
, O
Ci O
- O
I O
, O
and O
Sc O
- O
I O
, O
which O
are O
at O
a O
distinct O
stage O
of O
B O
- O
cell O
differentiation O
, O
and O
by O
the O
more O
mature O
Burkitt O
lymphoma O
cell O
Raji O
; O
in O
contrast O
, O
it O
did O
not O
induce O
TNF B
- I

Altogether O
, O
our O
data O
demonstrate O
that O
: O
( O
a O
) O
the O
ability O
of O
B O
cells O
to O
release O
TNF B
- I
alpha I
after O
triggering O
of O
HLA B
- I
DR I
antigens I
depends O
on O
their O
stage O
of O
differentiation O
; O
( O
b O
) O
levels O
of O
released O
TNF B
- I
alpha I
seem O
to O
correlate O
with O
the O
stage O
of O
B O
- O
cell O
maturation O
but O
do O
not O
correlate O
with O
the O
amounts O
of O
cell B
surface I
HLA I
- I
DR I
antigens I
; O
( O
c O
) O
secreted O
TNF B
- I
alpha I
regulates O
the O
levels O
of O
expression O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
by O
an O
autocrine O
loop O
; O
and O
( O
d O
) O
intracellular O
signals O
mediating O

The O
predictive B
protein I
- I
coding I
region I
of O
RP1 B
had O
a O
significant O
homology O
to O
members O
of O
the O
recently O
found O
adenomatous B
polyposis I
coli I
( I
APC I
) I
protein I
- I
binding I
EB1 I
gene I
family I
, O
which O
codes O
for O
yet O
unknown O
protein O
( O
s O
) O
. O

Bacterially O
expressed O
RP1 B
protein I
revealed O
specific O
binding O
to O
wild B
- I
type I
but O
not O
to O
mutated B
APC I
protein I
. O

We O
show O
for O
human O
Jurkat O
T O
leukemia O
cells O
, O
as O
well O
as O
human O
and O
mouse O
primary O
T O
lymphocytes O
, O
that O
this O
inhibitory O
effect O
is O
accompanied O
by O
an O
impaired O
nuclear O
translocation O
of O
the O
Rel B
proteins I
c B
- I
Rel I
, O
RelA B
/ I
p65 I
and O
NF B
- I
kappa I
B1 I
/ I
p50 I
, O
whereas O
the O
nuclear O
appearance O
of O
RelB B
remains O
unaffected O
. O

Accordingly O
, O
immunoblot O
experiments O
showed O
that O
amongst O
NF B
- I
kappa I
B I
/ B
Rel I
proteins I
, O
RelA B
and O
p50 B
are O
mobilized O
to O
the O
nucleus O
following O
microglial O
cell O
stimulation O
with O
A O
beta O
( O
25 O
- O
35 O
) O
plus O
IFN B
gamma I
. O

As O
expected O
, O
LPS O
strongly O
induced O
the O
formation O
of O
two O
NF B
- I
kappa I
B I
DNA O
- O
binding O
activities O
, O
one O
of O
which O
was O
identified O
as O
RelA B
/ I
p50 I
. O

Collectively O
, O
these O
findings O
indicate O
that O
NF B
- I
kappa I
B I
activation O
might O
constitute O
one O
of O
the O
mechanisms O
underlying O
the O
inducible O
expression O
of O
kappa B
B I
- I
dependent I
genes I
in O
microglia O
stimulated O
by O
A O
beta O
peptides O
and O
IFN B
gamma I
, O
or O
by O
LPS O
. O

The O
serum O
also O
detected O
a O
170 B
- I
kD I
protein I
that O
seems O
to O
be O
a O
mouse O
homologue O
of O
human B
BAF170 I
. O

Transcriptional O
induction O
of O
collagenase B
- I
1 I
in O
differentiated O
monocyte O
- O
like O
( O
U937 O
) O
cells O
is O
regulated O
by O
AP B
- I
1 I
and O
an O
upstream B
C I
/ I
EBP I
- I
beta I
site I
. O

Chloramphenicol B
acetyltransferase I
expression I
constructs I
containing O
regions O
of O
the O
human B
collagenase I
- I
1 I
promoter I
were O
stably O
or O
transiently O
transfected O
into O
U937 O
cells O
, O
and O
reporter O
activity O
was O
assessed O
at O
various O
times O
after O
the O
onset O
of O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
- O
mediated O
differentiation O
. O

In O
particular O
, O
Western O
, O
supershift O
, O
and O
promoter O
deletion O
analyses O
suggested O
a O
role O
for O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
- I
beta I
( I
C I
/ I
EBP I
- I
beta I
) I
binding I
site I
between O
- B
2010 I
and I
- I
1954 I
in O
regulating O
transcription O
of O
collagenase B
- I
1 I
in O
monocytic O
cells O
. O

To O
evaluate O
the O
physiologic O
plausibility O
of O
these O
claims O
, O
we O
compared O
the O
abundance O
of O
the O
VDR B
mRNA I
in O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
between O
different O
VDR B
genotypes I
using O
a O
quantitative O
reverse O
transcribed O
polymerase O
chain O
reaction O
- O
based O
method O
. O

The O
concentration O
of O
the O
VDR B
mRNA I
, O
corrected O
for O
the O
number O
of O
monocytes O
, O
was O
similar O
among O
the O
three O
genotype O
groups O
, O
as O
were O
the O
other O
variables O
examined O
: O
serum B
calcitriol I
, O
serum B
osteocalcin I
, O
and O
vertebral O
and O
hip O
bone O
density O
. O

Both O
truncated O
forms O
also O
bound O
to O
the O
transcription B
factor I
RBP I
- I
Jkappa I
in O
extracts O
prepared O
from O
human O
and O
murine O
T O
- O
ALL O
cell O
lines O
. O

EMS O
analyses O
utilizing O
a O
series O
of O
mutated B
pp I
repeat I
elements I
demonstrate O
that O
the O
nucleotide O
sequence O
requirements O
for O
U1 B
( O
U1A B
/ I
U1B I
) O
and O
U2 B
formation O
are O
separable O
from O
those O
required O
for O
C1 B
- I
C3 I
formation O
. O

Signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
( O
STAT3 B
) O
is O
constitutively O
activated O
in O
normal O
, O
self O
- O
renewing O
B O
- O
1 O
cells O
but O
only O
inducibly O
expressed O
in O
conventional O
B O
lymphocytes O
[ O
see O
comments O
] O

Cytokine B
and O
growth B
factor I
receptor I
engagement O
leads O
to O
the O
rapid O
phosphorylation O
and O
activation O
of O
latent O
, O
cytosolic B
signal I
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
proteins I
, O
which O
then O
translocate O
to O
the O
nucleus O
where O
they O
regulate O
transcriptional O
events O
from O
specific B
promoter I
sequences I
. O

This O
effect O
was O
specifically O
due O
to O
Tat B
, O
since O
Jurkat O
and O
U937 O
cells O
cotransfected O
either O
with O
tat B
cDNA I
in O
antisense O
orientation O
( O
tat B
/ I
AS I
) O
, O
tat B
carrying O
a O
mutation O
in O
the O
aminoacid B
cys22 I
- I
gly22 I
( O
tat B
22 I
/ I
S I
) O
or O
with O
the O
backbone B
vector I
alone I
( O
pRPneo B
- I
SL3 I
) O
did O
not O
show O
any O
significant O
difference O
in O
c B
- I
fos I
promoter I
activity O
as O
compared O
to O
cells O
transfected O
with O
FC3 B
plasmid I
alone O
. O

c B
- I
Fos I
protein O
was O
shown O
essential O
for O
an O
optimal O
transactivation O
of O
the O
HIV O
- O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
by O
Tat B
: O
incubation O
of O
Jurkat O
cells O
with O
antisense O
, O
but O
not O
sense O
, O
c O
- O
fos O
oligonucleotides O
significantly O
reduced O
either O
the O
Tat B
- O
enhanced O
expression O
of O
an O
LTR B
- I
CAT I
reporter I
construct I
or O
the O
levels O
of O
gag B
p24 I
in O
the O
culture O
supernatants O
of O
Jurkat O
cells O
and O
PBMC O
acutely O
infected O
with O
HIV O
- O
1 O
. O

The O
human B
TF I
promoter I
contains O
binding O
sites O
for O
the O
transcription O
factors O
AP B
- I
1 I
, O
c B
- I
Rel I
/ I
p65 I
, O
Egr B
- I
1 I
, O
and O
Sp1 B
. O

Two O
main O
pieces O
of O
data O
prompted O
us O
to O
focus O
on O
the O
activation O
of O
the O
platelet B
fibrinogen I
receptor I
, O
the O
alphaIIbbeta3 B
integrin I
. O

Immunoblot O
and O
flow O
cytometry O
analysis O
revealed O
a O
limited O
proteolysis O
of O
the O
carboxyl B
terminus I
of O
the O
alphaIIb B
subunit I
heavy I
chain I
( O
alphaIIbH B
) O
, O
as O
judged O
by O
the O
disappearance O
of O
the O
epitope O
for O
the O
monoclonal B
antibody I
PMI I
- I
1 I
. O

Treatment O
by O
NE B
of O
ATP O
- O
depleted O
platelets O
or O
Chinese O
hamster O
ovary O
cells O
expressing O
human B
recombinant I
alphaIIbbeta3 I
clearly O
established O
that O
activation O
of O
the O
integrin B
was O
independent O
of O
signal O
transduction O
events O
and O
was O
concomitant O
with O
the O
proteolysis O
of O
alphaIIbH B
. O

These O
studies O
were O
conducted O
with O
highly O
purified O
( O
FACS O
- O
isolated O
) O
subsets O
of O
CD4 O
T O
cells O
identified O
by O
expression O
of O
both O
CD45RA B
and O
CD62L B
. O

The O
suppression O
of O
productive O
LAI O
replication O
in O
naive O
T O
cells O
is O
not O
due O
to O
differential O
expression O
of O
viral B
coreceptors I
, O
nor O
is O
it O
due O
to O
inhibition O
of O
activation O
of O
the O
important O
HIV O
transcription B
factors I
, O
nuclear B
factor I
- I
kappaB I
and O
activator B
protein I
- I
1 I
. O

To O
test O
the O
hypothesis O
that O
the O
chimera B
PMLRAR I
alpha I
plays O
a O
role O
in O
leukemogenesis O
, O
we O
expressed O
a O
PMLRAR B
alpha I
cDNA I
in O
myeloid O
cells O
of O
transgenic O
mice O
. O

Our O
results O
demonstrate O
that O
PMLRAR B
alpha I
impairs O
neutrophil O
differentiation O
and O
initiates O
the O
development O
of O
APL O
. O

Such O
hypermethylation O
- O
associated O
silencing O
of O
gene O
expression O
has O
been O
shown O
for O
several O
genes O
regulating O
the O
growth O
and O
differentiation O
of O
hematopoietic O
cells O
, O
including O
the O
estrogen B
receptor I
( I
ER I
) I
gene I
, O
P15 O
, O
P16 O
and O
others O
. O

Finally O
, O
reactivation O
of O
tumor O
- O
suppressor O
gene O
expression O
through O
pharmacologic O
inhibition O
of O
DNA B
methyltransferase I
and O
resultant O
DNA O
demethylation O
appears O
to O
be O
a O
promising O
new O
avenue O
of O
therapy O
in O
acute O
leukemia O
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
to O
screen O
for O
proteins O
which O
interact O
with O
Tax1 B
, O
we O
isolated O
the O
B B
subunit I
of O
the O
CCAAT B
binding I
protein I
NF B
- I
Y I
from O
a O
HeLa B
cDNA I
library I
. O

The O
interaction O
of O
Tax1 B
with O
NF B
- I
YB I
was O
specific O
in O
that O
NF B
- I
YB I
did O
not O
interact O
with O
a O
variety O
of O
other O
transcription B
factors I
, O
including O
human B
immunodeficiency I
virus I
Tat I
, O
human B
papillomavirus I
E6 I
, O
and O
Bicoid B
, O
or O
with O
the O
M7 B
( I
amino I
acids I
29CP I
- I
AS I
) I
Tax1 I
mutant I
. O

However O
, O
NF B
- I
YB I
did O
interact O
with O
the O
C B
- I
terminal I
Tax1 I
mutants I
M22 B
( O
130TL B
- I
AS I
) O
and O
M47 B
( O
319LL B
- I
RS I
) O
. O

Through O
activation O
of O
this O
and O
other O
NF B
- I
Y I
driven O
promoters B
, O
the O
Tax1 B
- B
NF I
- I
Y I
interaction O
may O
play O
a O
critical O
role O
in O
causing O
cellular O
transformation O
and O
HTLV O
- O
1 O
pathogenesis O
. O

In O
murine O
Ba O
/ O
F3 O
cells O
transfected O
with O
the O
human B
G I
- I
CSFR I
and O
NFS O
- O
60 O
cells O
constitutively O
expressing O
the O
murine B
G I
- I
CSFR I
, O
G B
- I
CSF I
induced O
tyrosine O
phosphorylation O
and O
activation O
of O
Jak1 B
, O
Jak2 B
, O
and O
Tyk2 B
. O

Using O
a O
mitogenically B
incompetent I
human I
G I
- I
CSFR I
mutant I
in O
which O
Pro639 O
and O
Pro641 O
were O
substituted O
by O
alanine O
, O
the O
box B
1 I
PDP I
motif I
was O
found O
to O
be O
required O
for O
activation O
of O
Jak B
kinases I
, O
tyrosine O
phosphorylation O
of O
the O
G B
- I
CSFR I
, O
and O
recruitment O
of O
Stat B
proteins I
. O

Activation O
of O
the O
Jak B
- B
Stat I
pathway O
correlates O
with O
proliferative O
signaling O
by O
the O
G B
- I
CSFR I
and O
requires O
the O
membrane B
- I
proximal I
box I
1 I
PXP I
motif I
, O
which O
is O
conserved O
in O
members O
of O
the O
cytokine B
receptor I
superfamily I
. O

Impaired O
induction O
of O
c B
- I
fos I
/ I
c I
- I
jun I
genes I
and O
of O
transcriptional B
regulatory I
proteins I
binding O
distinct O
c B
- I
fos I
/ I
c I
- I
jun I
promoter I
elements I
in O
activated O
human O
T O
cells O
during O
aging O
. O

In O
addition O
, O
RNase B
protection O
assays O
revealed O
that O
anti O
- O
CD3 O
/ O
PMA O
- O
stimulated O
T O
cells O
from O
a O
substantial O
proportion O
of O
elderly O
subjects O
exhibited O
decreased O
levels O
of O
c B
- I
fos I
and I
/ I
or I
c I
- I
jun I
mRNA I
compared O
to O
T O
cells O
from O
young O
subjects O
. O

CONCLUSION O
: O
These O
studies O
suggest O
that O
RA O
can O
augment O
IL B
- I
2 I
mRNA I
production O
by O
T O
cells O
with O
a O
possible O
paracrine O
effect O
on O
IL B
- I
2R I
- I
alpha I
expression O
. O

These O
observations O
suggest O
that O
p65 B
and I
c I
- I
Rel I
complexes I
play O
distinct O
roles O
in O
gene O
expression O
and O
that O
both O
forms O
of O
NF B
- I
kappa I
B I
play O
critical O
roles O
during O
late O
stages O
of O
the O
intrathymic O
maturation O
of O
T O
cells O
. O

We O
overexpressed O
AML1a B
( O
without O
the O
transcription B
- I
activating I
domain I
) O
and O
AML1b B
( O
with O
the O
domain O
) O
proteins O
in O
K562 O
leukemia O
cells O
, O
which O
can O
be O
induced O
to O
differentiate O
into O
hemoglobin O
- O
producing O
cells O
and O
megakaryocytes O
. O

Using O
anti B
- I
C I
/ I
EBPbeta I
( O
NF B
- I
IL6 I
) O
, O
anti B
- I
C I
/ I
EBPdelta I
( O
NF B
- I
IL6beta I
) O
, O
anti B
- I
NF I
- I
ATc I
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti B
- I
Jun I
Abs I
we O
demonstrate O
that O
the O
previously O
identified O
PRE B
- I
I I
binding I
factor I
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

Experimental O
expression O
in O
mice O
and O
spontaneous O
expression O
in O
human O
SLE O
of O
polyomavirus B
T I
- I
antigen I
. O

We O
have O
previously O
demonstrated O
that O
experimental O
expression O
of O
the O
polyomavirus B
transcription I
factor I
T I
- I
antigen I
has O
the O
potential O
to O
induce O
anti B
- I
DNA I
antibodies I
in O
mice O
. O

The O
results O
described O
here O
indicate O
that O
cognate O
interaction O
of O
B O
cells O
recognizing O
DNA O
or O
DNA B
- I
associated I
proteins I
and O
T O
cells O
recognizing O
T B
antigen I
had O
taken O
place O
as O
a O
consequence O
of O
complex O
formation O
between O
T B
ag I
and O
DNA O
in O
vivo O
in O
the O
context O
of O
polyomavirus O
reactivations O
. O

Cell O
- O
to O
- O
cell O
contact O
activates O
the O
long B
terminal I
repeat I
of O
human O
immunodeficiency O
virus O
1 O
through O
its O
kappaB B
motif I
. O

HIV B
- I
1 I
LTR I
transcription O
is O
controlled O
by O
a O
complex O
array O
of O
virus B
- I
encoded I
and I
cellular I
proteins I
. O

By O
contrast O
, O
the O
binding O
activity O
of O
the O
NF B
- I
kappa I
( I
B I
) I
and O
EGR B
- I
1 I
transcription B
factors I
was O
little O
affected O
. O

The O
LAZ3 B
/ I
BCL6 I
transcript I
was O
found O
in O
a O
variety O
of O
tissues O
, O
including O
skeletal O
muscle O
, O
peripheral O
blood O
leukocytes O
, O
and O
weakly O
in O
normal O
lymph O
nodes O
. O

IL O
- O
4 O
treatment O
rapidly O
induced O
tyrosine O
phosphorylation O
of O
insulin B
receptor I
substrate I
( I
IRS I
) I
- I
1 I
and O
IRS B
- I
2 I
in O
1D4 O
but O
not O
in O
E1C3 O
cells O
. O

Nuclear B
transcription I
factor I
kB I
( O
NF B
- I
kappa I
B I
) O
is O
a O
ubiquitous B
transcription I
factor I
and O
pleiotropic B
regulator I
of O
numerous O
genes O
involved O
in O
the O
immune O
and O
inflammatory O
responses O
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

Based O
upon O
work O
from O
our O
laboratory O
, O
we O
propose O
that O
inhibition O
of O
NF B
- I
kappa I
B I
activation O
produces O
significant O
anti O
inflammatory O
activity O
which O
may O
be O
mediated O
by O
the O
inhibition O
of O
transcription O
of O
certain O
pro B
- I
inflammatory I
mediators I
and O
adhesion B
molecules I
. O

Understanding O
the O
cis B
- I
and I
transacting I
factors I
that O
regulate O
the O
tissue O
- O
specific O
expression O
of O
PECAM B
- I
1 I
should O
increase O
our O
understanding O
of O
the O
mechanisms O
by O
which O
vascular O
- O
specific O
gene O
expression O
is O
achieved O
. O

Interaction O
of O
transcription B
factors I
RFX1 B
and O
MIBP1 B
with O
the O
gamma B
motif I
of O
the O
negative B
regulatory I
element I
of O
the O
hepatitis B
B I
virus I
core I
promoter I
. O

The O
negative B
regulatory I
element I
( O
NRE B
) O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
core I
promoter I
contains O
three O
subregions O
which O
act O
synergistically O
to O
suppress O
core O
promoter O
activity O
. O

The O
additional O
function O
that O
is O
required O
for O
initiation O
of O
the O
lytic O
viral O
life O
cycle O
is O
likely O
to O
require O
phosphorylation O
of O
serine O
186 O
of O
the O
ZEBRA B
protein I
, O
which O
may O
influence O
either O
DNA O
recognition O
or O
transcriptional O
activation O
of O
lytic B
viral I
promoters I
in O
a O
chromatinized B
viral I
episome I
. O

A O
T B
cell I
- I
specific I
enhancer I
in O
the O
interleukin B
- I
3 I
locus I
is O
activated O
cooperatively O
by O
Oct B
and I
NFAT I
elements I
within O
a O
DNase B
I I
- I
hypersensitive I
site I
. O

We O
suggest O
that O
the O
T O
cell O
- O
specific O
expression O
of O
the O
IL B
- I
3 I
gene I
is O
partly O
controlled O
through O
the O
enhancer O
by O
cooperation O
between O
Oct B
and I
NFAT I
family I
proteins I
. O

The O
adenovirus B
E1B I
19K I
gene I
plays O
an O
essential O
role O
in O
transformation O
of O
primary O
rodent O
cells O
in O
cooperation O
with O
E1A B
and O
in O
the O
inhibition O
of O
apoptosis O
during O
lytic O
infection O
. O

It O
has O
been O
shown O
that O
this O
E1B B
19K I
protein I
is O
not O
necessary O
for O
viral O
DNA O
replication O
in O
human O
cell O
lines O
, O
such O
as O
HeLa O
and O
KB O
. O

Mutants O
of O
type O
5 O
adenovirus O
( O
Ad5 O
) O
with O
reiterated B
DNA I
sequences I
in O
the O
E1a B
region I
appeared O
in O
a O
human O
T O
- O
lymphocyte O
cell O
line O
, O
Molt O
- O
4 O
, O
persistently O
infected O
with O
H5sub304 O
, O
a O
deletion O
/ O
substitution O
mutant O
that O
has O
a O
wild O
- O
type O
phenotype O
in O
viral O
replication O
. O

There O
was O
not O
any O
DNA O
homology O
between O
the O
breakpoints O
in O
the O
second O
exon B
and O
the O
inserting B
sequences I
( O
starting O
at O
nt O
532 O
, O
710 O
, O
or O
792 O
) O
. O

The O
observed O
E1a B
reiterations I
provide O
a O
model O
to O
gain O
insight O
into O
understanding O
the O
evolutionary O
events O
of O
some O
, O
if O
not O
all O
, O
adenovirus O
types O
during O
many O
years O
of O
symbiotic O
, O
persistent O
relationship O
in O
human O
tonsils O
and O
adenoids O
and O
possibly O
other O
lymphoid O
organs O
. O

Residues O
432 O
, O
435 O
, O
437 O
, O
438 O
, O
and O
440 O
( O
position B
P1 I
, I
P4 I
, I
P6 I
, I
P7 I
, I
and I
P9 I
) O
contributed O
to O
DQ2 B
binding O
, O
whereas O
residues O
431 O
, O
433 O
, O
434 O
, O
and O
436 O
( O
positions B
P I
1 I
, I
P2 I
, I
P3 I
, I
and I
P5 I
) O
contributed O
to O
TCR B
contact O
. O

V3 B
- I
BH10 I
neither O
blocked O
radiolabeled O
IL B
- I
2 I
binding O
to O
IL B
- I
2 I
receptors I
nor O
affected O
tyrosyl O
phosphorylation O
of O
several O
cellular B
proteins I
( O
p120 B
, O
p98 B
, O
p96 B
, O
p54 B
, O
and O
p38 B
) O
, O
which O
is O
immediately O
induced O
by O
IL B
- I
2 I
stimulation O
. O

The O
predominant O
E2F B
complex I
in O
human O
primary O
haemopoietic O
cells O
and O
in O
AML O
blasts O
contains O
E2F B
- I
4 I
, O
DP B
- I
1 I
and O
p130 B
. O

An O
E2F B
- I
4 I
/ I
p130 I
complex I
was O
detected O
in O
representative O
samples O
of O
all O
FAB B
types O
analysed O
. O

Our O
results O
demonstrate O
that O
1 O
. O
3E2 O
is O
a O
cellular B
transduction I
mutant I
exhibiting O
a O
defect O
in O
a O
step O
that O
is O
required O
by O
several O
different O
stimuli O
to O
activate O
NF B
- I
kappaB I
. O

In O
order O
to O
evaluate O
the O
conditions O
for O
optimal O
expression O
and O
immunogenicity O
of O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
proteins I
in O
a O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
) O
vector O
, O
we O
selected O
the O
VZV B
glycoprotein I
E I
( O
gE B
) O
, O
encoded O
by O
ORF B
68 I
and O
the O
VZV B
product I
of O
ORF B
62 I
, O
an O
immediate B
- I
early I
major I
tegument I
protein I
( O
IE62 B
) O
. O

Higher B
- I
molecular I
- I
weight I
species I
of O
NFATc B
( O
of O
110 O
and O
140 O
kDa O
) O
were O
also O
detected O
. O

We O
found O
that O
NFATx1 B
DNA O
binding O
activity O
and O
interaction O
with O
AP O
- O
1 O
polypeptides O
were O
dependent O
on O
its O
central B
Rel I
similarity I
region I
and O
that O
transcriptional O
activation O
was O
reduced O
by O
deletions O
of O
either O
its O
N B
- I
terminal I
domain I
or O
its O
C B
- I
terminal I
domain I
, O
suggesting O
the O
presence O
of O
intrinsic B
transcriptional I
activation I
motifs I
in O
both O
regions O
. O

NO O
is O
produced O
from O
at O
least O
three O
different O
NO B
synthase I
( I
NOS I
) I
isoforms I
: O
neuronal B
NOS I
( O
nNOS B
) O
, O
endothelial B
NOS I
, O
and O
immunologic B
NOS I
( O
iNOS B
) O
. O

In O
astrocytes O
PDTC O
also O
dramatically O
induces O
the O
NF B
kappaB I
- I
dependent I
enzyme I
, O
iNOS B
, O
supporting O
the O
physiologic O
relevance O
of O
endogenous O
NO O
regulation O
of O
NF B
kappaB I
. O

EGF O
treatment O
induced O
IgM B
production O
in O
cells O
transfected O
with O
an O
intact O
gp130 B
cytoplasmic I
tail I
, O
but O
not O
in O
untransfected O
cells O
or O
cells O
transfected O
with O
a O
cytoplasmic B
tail I
lacking O
all O
four O
signal B
transducers I
and I
activators I
of I
transcription I
( I
Stat I
) I
binding I
sites I
. O

Moreover O
, O
EGF O
treatment O
induced O
Stat3 B
phosphorylation O
in O
cells O
transfected O
with O
the O
intact O
chimeric B
EGF I
- I
gp130 I
receptor I
along O
with O
induction O
of O
DNA O
- O
mobility O
shift O
of O
a O
classical B
interferon I
- I
gamma I
- I
activated I
site I
. O

This O
cis B
element I
binds O
a O
protein O
complex O
referred O
to O
as O
HRF B
( O
heme B
- I
responsive I
factor I
) O
, O
which O
is O
greatly O
enhanced O
both O
in O
heme O
- O
treated O
FLCs O
and O
during O
monocyte O
- O
to O
- O
macrophage O
differentiation O
. O

One O
of O
the O
latter O
elements O
, O
the O
IgH B
3 I
' I
enhancer I
, O
is O
of O
particular O
interest O
: O
( O
1 O
) O
it O
is O
B O
cell O
- O
specific O
and O
active O
only O
in O
late O
B O
cell O
development O
; O
( O
2 O
) O
in O
rodent O
plasmacytomas O
and O
in O
some O
human O
Burkitt O
' O
s O
lymphomas O
it O
is O
part O
of O
a O
locus B
control I
region I
( O
LCR B
) O
that O
is O
involved O
in O
deregulation O
of O
the O
c B
- I
myc I
oncogene I
as O
a O
result O
of O
translocation O
into O
the O
IgH B
locus I
; O
and O
( O
3 O
) O
it O
has O
been O
implicated O
in O
the O
mechanisms O
that O
control O
Ig B
gene I
class I
switch O
recombination O

Rap1 B
is O
a O
small O
, O
Ras B
- I
like I
GTPase I
whose O
function O
and O
regulation O
are O
still O
largely O
unknown O
. O

The O
transcriptional B
regulatory I
elements I
of O
many O
inducible B
T I
- I
cell I
genes I
contain O
adjacent O
or O
overlapping B
binding I
sites I
for O
the O
Ets B
and I
NF I
- I
kappaB I
/ I
NFAT I
families I
of O
transcription B
factors I
. O

The O
expression O
and O
binding O
activity O
of O
the O
Nfil3 B
protein I
( O
also O
called O
E4bp4 B
) O
, O
but O
not O
of O
Hlf B
, O
Dbp B
, O
or O
Tef B
, O
was O
found O
to O
be O
regulated O
by O
IL B
- I
3 I
in O
mouse O
pro O
- O
B O
cell O
lines O
( O
Baf O
- O
3 O
and O
FL5 O
. O
12 O
) O
. O

The O
E1A B
and I
hexon I
primers I
amplified O
DNA O
from O
representative O
adenoviral O
serotypes O
in O
all O
six O
adenoviral O
groups O
( O
A O
- O
F O
) O
. O

Stimulation O
with O
either O
PAF B
or O
FMLP B
resulted O
in O
equivalent O
phosphorylation O
and O
activation O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPk I
) I
homologue I
38 B
- I
kD I
murine I
MAP I
kinase I
homologous O
to O
HOG B
- I
1 I
( I
p38 I
) I
MAPk I
. O

Chicken B
NF I
- I
M I
transcription I
factor I
, O
in O
cooperation O
with O
either O
c B
- I
Myb I
or O
v B
- I
Myb I
, O
is O
active O
in O
the O
combinatorial O
activation O
of O
myeloid B
- I
cell I
- I
specific I
genes I
in O
heterologous O
cell O
types O
, O
such O
as O
embryonic O
fibroblasts O
. O

Co O
- O
ligation O
of O
the O
A6H B
antigen O
and O
the O
CD3 B
complex I
induced O
expression O
of O
the O
transcription B
factor I
AP B
- I
1 I
in O
CD4 O
+ O
T O
cells O
, O
whereas O
no O
increase O
in O
NF B
- I
kappa I
B I
and O
octamer B
- I
binding I
( I
Oct I
) I
proteins I
was O
seen O
compared O
to O
T O
cells O
stimulated O
with O
anti B
- I
CD3 I
alone O
. O

Molecular O
differences O
of O
the O
A6H B
molecule I
or O
distinct O
regulation O
of O
the O
A6H B
transduced O
AP B
- I
1 I
activation O
pathway O
may O
exist O
in O
CD4 O
+ O
and O
CD8 O
+ O
T O
cell O
subpopulations O
. O

The O
DNA B
- I
binding I
domain I
( O
amino B
acids I
421 I
- I
486 I
) O
is O
completely O
conserved O
among O
human B
, I
squirrel I
monkey I
, I
owl I
monkey I
, I
and I
cotton I
- I
top I
tamarin I
receptors I
. O

Expressions O
of O
human O
and O
squirrel O
monkey O
glucocorticoid B
receptors I
and O
a O
squirrel B
monkey I
receptor I
in O
which O
Phe774 O
was O
mutated O
to O
Leu O
( O
F774L O
) O
were O
similar O
. O

Shared O
gamma B
( I
c I
) I
subunit I
within O
the O
human B
interleukin I
- I
7 I
receptor I
complex I
. O

The O
gamma B
( I
c I
) I
subunit I
can O
be O
employed O
in O
receptor B
complexes I
for O
IL B
- I
2 I
, I
- I
4 I
, I
- I
7 I
, I
- I
9 I
, I
and I
- I
15 I
, O
and O
the O
multiple O
signaling O
defects O
that O
would O
result O
from O
a O
defective O
gamma B
( I
c I
) I
chain I
in O
these O
receptors O
are O
proposed O
to O
cause O
the O
severe O
phenotype O
of O
X O
- O
SCID O
patients O
. O

Elf B
- I
2 I
, O
a O
rhombotin B
- I
2 I
binding I
ets I
transcription I
factor I
: O
discovery O
and O
potential O
role O
in O
T O
cell O
leukemia O
. O

By O
screening O
a O
T O
cell O
cDNA B
library I
, O
we O
identified O
a O
novel B
ets I
transcription I
factor I
that O
binds O
RBTN B
- I
2 I
. O

Thymocytes O
expressed O
four O
- O
to O
10 O
- O
fold O
greater O
amounts O
of O
the O
3 B
. I
5 I
kb I
transcript I
than O
other O
tissues O
. O

In O
the O
rare O
hybrids O
that O
continue O
to O
express O
Ig O
, O
all O
other O
tested O
B B
lymphocyte I
- I
specific I
genes I
also O
remain O
active O
. O

The O
low O
frequency O
with O
which O
these O
Ig O
- O
expressing O
hybrids O
are O
recovered O
, O
along O
with O
the O
fact O
that O
cell O
fusions O
can O
lead O
to O
chromosome O
loss O
, O
led O
us O
to O
propose O
that O
this O
rare O
phenotype O
was O
due O
to O
loss O
of O
a O
T B
- I
cell I
- I
derived I
chromosome I
encoding I
a I
factor I
or O
factors O
with O
gene O
silencing O
activity O
. O

3BP2 B
was O
selectively O
expressed O
in O
hematopoietic O
/ O
lymphoid O
tissues O
and O
bound O
via O
its O
SH2 B
domain I
activated I
Syk I
- I
family I
kinases I
in O
mammalian O
cells O
, O
including O
in O
antigen O
receptor O
- O
stimulated O
T O
cells O
. O

In O
this O
study O
, O
a O
series O
of O
Burkitt O
' O
s O
lymphoma O
( O
BL O
) O
cell O
lines O
were O
assayed O
for O
their O
expression O
of O
tissue B
inhibitor I
of I
metalloproteinases I
( I
TIMP I
) I
- I
1 I
. O

Furthermore O
, O
recombinant O
TIMP B
- I
1 I
, O
but O
not O
TIMP B
- I
2 I
or O
a O
synthetic O
metalloproteinase O
inhibitor O
( O
BB O
- O
94 O
) O
, O
confers O
resistance O
to O
apoptosis O
induced O
by O
both O
CD95 O
- O
dependent O
and O
- O
independent O
( O
cold O
shock O
, O
serum O
deprivation O
, O
and O
gamma O
- O
radiation O
) O
pathways O
in O
TIMP O
- O
1 O
- O
negative O
BL O
lines O
. O

To O
investigate O
in O
vivo O
regulatory O
mechanisms O
that O
control O
the O
population O
of O
type O
2 O
T O
cells O
and O
disease O
susceptibility O
, O
we O
have O
created O
lines O
of O
transgenic O
mice O
in O
which O
expression O
of O
a O
chimeric B
cytokine I
receptor I
( O
the O
mouse B
interleukin I
2 I
receptor I
beta I
chain I
[ I
IL I
- I
2Rbeta I
] I
extracellular I
domain I
fused O
to O
the O
cytoplasmic B
tail I
of O
IL B
- I
4Ralpha I
) O
is O
targeted O
to O
the O
T O
lymphoid O
lineage O
using O
the O
proximal B
lck I
promoter I
. O

We O
have O
recently O
cloned O
the O
carboxylesterase B
upstream I
sequence I
and O
showed O
its O
basal B
promoter I
activity O
in O
CHO O
cells O
. O

Deregulated O
TCR B
- O
mediated O
responses O
and O
the O
fast O
kinetics O
of O
tumor O
development O
in O
these O
mutant O
thymocytes O
implicate O
Ikaros O
as O
a O
central B
tumor I
suppressor I
gene I
for O
the O
T O
cell O
lineage O
. O

The O
role O
of O
Aiolos B
, O
a O
lymphoid B
- I
restricted I
and I
structurally I
related I
gene I
, O
in O
lymphoid O
differentiation O
is O
discussed O
. O

STAT1 B
pathway O
is O
involved O
in O
activation O
of O
caprine O
arthritis B
- I
encephalitis I
virus I
long I
terminal I
repeat I
in O
monocytes O
. O

These O
data O
are O
well O
in O
line O
with O
the O
long O
- O
standing O
notion O
that O
interindividual O
differences O
in O
platelet B
monoamine I
oxidase I
may O
represent O
differences O
in O
expression O
of O
the O
enzyme O
rather O
than O
genotypic O
variation O
. O

In O
particular O
, O
TRAF6 B
interacted O
with O
membrane B
- I
proximal I
determinants I
distinct O
from O
those O
binding O
TRAFs B
1 I
, I
2 I
, I
3 I
, I
and I
5 I
. O

The O
molecular O
mechanisms O
by O
which O
IL B
- I
4 I
induces O
expression O
of O
the O
IL B
- I
4 I
gene I
are O
not O
known O
, O
although O
the O
IL B
- I
4 I
- I
activated I
transcription I
factor I
signal I
transducer I
and I
activator I
of I
transcription I
6 I
( O
Stat6 B
) O
is O
required O
for O
this O
effect O
. O

The O
triptolide O
- O
induced O
apoptosis O
is O
accompanied O
by O
increase O
of O
DEVD O
- O
cleavable O
caspases B
activity O
and O
degradation O
of O
caspase B
substrate I
poly I
( I
ADP I
- I
ribose I
) I
polymerase I
( O
PARP B
) O
. O

A O
novel O
transcription B
factor I
regulates O
expression O
of O
the O
vacuolar B
H I
+ I
- I
ATPase I
B2 I
subunit I
through O
AP B
- I
2 I
sites I
during O
monocytic O
differentiation O
. O

In O
mobility O
shift O
assays O
, O
a O
nuclear B
factor I
from O
THP O
- O
1 O
and O
U O
- O
937 O
cells O
was O
identified O
that O
binds O
to O
several O
AP B
- I
2 I
response I
elements I
within O
the O
B2 B
promoter I
, O
but O
does O
not O
react O
with O
AP B
- I
2 I
antibodies I
, O
and O
has O
a O
DNA B
sequence I
binding O
affinity O
profile O
that O
differs O
from O
AP B
- I
2 I
. O

These O
findings O
suggest O
that O
a O
novel O
AP B
- I
2 I
- I
like I
transcription I
factor I
is O
responsible O
for O
V B
- I
ATPase I
B I
subunit I
amplification O
during O
monocyte O
differentiation O
. O

The O
upstream O
regions O
UAS3 B
( O
- B
1168 I
to I
- I
440 I
) O
and O
UAS2 B
( O
- B
352 I
to I
- I
264 I
) O
both O
functioned O
in O
a O
cell O
lineage O
- O
independent O
manner O
and O
were O
together O
responsible O
for O
the O
bulk O
of O
Wp O
activity O
in O
non O
- O
B O
cells O
; O
mutational O
analysis O
indicated O
the O
importance O
of O
a O
YY1 B
binding I
site I
in O
UAS2 B
in O
that O
context O
. O

By O
contrast O
, O
UAS1 B
( O
- B
140 I
to I
- I
87 I
) O
was O
B O
cell O
specific O
and O
was O
the O
key O
determinant O
of O
the O
promoter O
' O
s O
increased O
activity O
in O
B O
cell O
lines O
. O

When O
mutations O
that O
abolished O
factor O
binding O
in O
bandshift O
assays O
were O
introduced O
into O
a O
Wp B
reporter I
construct I
, O
the O
loss O
of O
any O
one O
of O
the O
three O
UAS1 B
binding I
sites I
was O
sufficient O
to O
reduce O
promoter O
activity O
by O
10 O
- O
to O
30 O
- O
fold O
in O
B O
cells O
. O

Both O
BZLF1 B
and I
BRLF1 I
immediate I
- I
early I
transcripts I
, O
but O
not O
BMLF1 B
transcript I
, O
could O
be O
detected O
in O
individual O
CD4 O
+ O
and O
CD8 O
+ O
T O
cells O
infected O
with O
EBV O
. O

The O
first O
step O
in O
the O
nuclear O
import O
process O
is O
recognition O
of O
a O
nuclear B
localization I
sequence I
( O
NLS B
) O
within O
the O
karyophilic B
protein I
by O
a O
cytoplasmic B
receptor I
such O
as O
the O
importin B
( I
karyopherin I
) I
- I
alpha I
subunit I
. O

Further O
, O
we O
show O
that O
inhibitory O
NLS B
peptide O
interacts O
in O
vitro O
with O
a O
cytoplasmic B
NLS I
receptor I
complex I
comprised O
of O
the O
Rch1 B
/ I
importin I
( I
karyopherin I
) I
- I
beta I
heterodimer I
expressed O
in O
Jurkat O
T O
cells O
. O

The O
discrepancy O
in O
the O
degree O
of O
inhibition O
by O
membrane O
extracts O
and O
NK O
cells O
with O
mutant B
TNFRI I
suggests O
that O
additional O
pathways O
are O
utilized O
by O
NK O
cells O
to O
activate O
EC O

Blood O
monocytes O
spontaneously O
activate O
endothelial O
cells O
in O
culture O
, O
leading O
to O
adhesion O
of O
monocytic O
cells O
onto O
the O
endothelial O
surface O
and O
overproduction O
of O
endothelial O
proteins O
such O
as O
von B
Willebrand I
factor I
( O
vWf B
) O
and O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
. O

These O
data O
indicate O
specific O
modulation O
of O
the O
CREB B
/ I
ATF I
- I
1 I
family I
of O
transcription B
factors I
by O
the O
CD2 B
signalling O
pathway O
and O
suggest O
CD2 B
receptor O
modulation O
of O
CRE B
- O
mediated O
transcription O
following O
ligand O
engagement O
( O
e O
. O
g O
. O
cell O
- O
to O
- O
cell O
contact O
) O
. O

Restoration O
of O
the O
CCAAT B
box I
at O
- B
70 I
bp I
, O
or O
insertion O
of O
an O
EKLF B
binding I
site I
at O
- B
85 I
bp I
or O
- B
95 I
bp I
in O
the O
promoter B
significantly O
increased O
delta O
globin O
gene O
expression O
in O
hAEC O
. O

A O
novel O
member O
of O
the O
tumor B
necrosis I
factor I
( I
TNF I
) I
receptor I
family I
, O
designated O
TRAMP B
, O
has O
been O
identified O
. O

These O
results O
indicate O
that O
dexamethasone O
is O
able O
to O
abrogate O
the O
transcriptional O
activity O
of O
the O
human B
granzyme I
B I
gene I
promoter I
by O
inhibiting O
the O
binding O
of O
nuclear B
factors I
at O
the O
AP B
- I
1 I
and I
Ikaros I
sites I
. O

Therefore O
in O
this O
study O
, O
we O
have O
examined O
the O
role O
of O
glucocorticoid B
receptor I
/ I
s I
( O
GR B
) O
characteristics O
in O
the O
developing O
of O
these O
abnormalities O
in O
patients O
with O
PCOS O
. O

BASH B
, O
a O
novel B
signaling I
molecule I
preferentially O
expressed O
in O
B O
cells O
of O
the O
bursa O
of O
Fabricius O
. O

The O
gene O
encodes O
an O
85 B
- I
kDa I
protein I
, O
designated O
BASH B
( O
B B
cell I
adaptor I
containing I
SH2 I
domain I
) O
, O
that O
contains O
N B
- I
terminal I
acidic I
domains I
with O
SH2 B
domain I
- I
binding I
phosphotyrosine I
- I
based I
motifs I
, O
a O
proline B
- I
rich I
domain I
, O
and O
a O
C B
- I
terminal I
SH2 I
domain I
. O

These O
studies O
revealed O
that O
the O
major B
protein I
in O
extracts O
of O
PMN O
activated O
by O
G B
- I
CSF I
to O
bind O
the O
high B
- I
affinity I
serum I
- I
inducible I
element I
( O
hSIE B
) O
is O
a O
72 B
- I
kDa I
protein I
that O
cross O
- O
reacts O
with O
Stat3 B
monoclonal I
antibody I
, O
which O
we O
have O
designated O
Stat3gamma B
. O

In O
order O
to O
investigate O
the O
factors O
that O
influence O
the O
induction O
of O
ICAM B
- I
1 I
molecules O
, O
Northern O
blot O
analysis O
to O
measure O
the O
expression O
level O
of O
ICAM B
- I
1 I
mRNAs I
and O
Southern O
blot O
hybridization O
to O
analyze O
the O
integration O
of O
human O
T O
- O
cell O
- O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
provirus O
were O
done O
. O

These O
sequences O
were O
chosen O
for O
study O
because O
mass O
- O
spectrometric O
analysis O
( O
MS O
) O
of O
a O
CTL O
active O
HPLC O
peptide O
fraction O
eluted O
from O
immunoaffinity B
precipitated I
HLA I
- I
A2 I
molecule I
, O
revealed O
: O
( O
a O
) O
the O
presence O
of O
an O
ion O
with O
a O
mass O
- O
to O
- O
charge O
ratio O
( O
m O
/ O
z O
) O
of O
793 O
which O
was O
more O
abundant O
than O
other O
ions O
of O
similar O
masses O
; O
( O
b O
) O
the O
tentatively O
reconstituted O
sequence O
of O
the O
ion O
793 O
matched O
the O
sequence O
of O
peptide O
G76 O
. O

These O
concentrations O
are O
lower O
than O
concentrations O
reported O
to O
activate O
effector O
function O
of O
CTL O
recognizing O
other O
epithelial B
tumor I
Ag I
. O

Furthermore O
, O
analysis O
with O
cloned O
CD8 O
+ O
T O
cells O
indicated O
that O
G75 O
and O
G76 O
were O
not O
cross O
- O
reactive O
specificities O
, O
suggesting O
a O
key O
role O
for O
the O
N B
- I
terminal I
residues I
of O
the O
variant O
peptide O
in O
dictating O
specificities O
. O

Since O
the O
AES B
proteins I
are O
part O
of O
a O
set O
of O
transcriptional O
repressors O
encoded O
by O
the O
Enhancer B
of I
split I
[ I
E I
( I
spl I
) I
] I
genes I
, O
and O
since O
these O
repressors O
are O
activated O
to O
suppress O
cell O
differentiation O
in O
response O
to O
Notch B
receptors I
signalling O
, O
the O
AES O
peptides O
may O
represent O
a O
novel O
class O
of O
self B
- I
antigens I
that O
deserve O
further O
consideration O
as O
tumor B
Ag I
in O
epithelial O
cancers O
. O

Interleukin B
- I
10 I
( O
IL B
- I
10 I
) O
and O
transforming B
growth I
factor I
beta I
( O
TGF B
- I
beta I
) O
are O
inhibitory O
for O
B O
and O
T O
cells O
, O
IgE B
production O
, O
and O
mast O
cell O
proliferation O
, O
and O
they O
induce O
apoptosis O
in O
eosinophils O
. O

The O
IL B
- I
10 I
gene O
polymorphism O
was O
a O
C O
- O
to O
- O
A O
exchange O
571 B
base I
pairs I
upstream I
from O
the O
translation B
start I
site I
and O
was O
present O
between O
consensus B
binding I
sequences I
for O
Sp1 B
and O
elevated O
total O
serum O
. O

This O
polymorphism O
was O
associated O
with O
elevated O
total B
serum I
IgE I
in O
subjects O
heterozygotic O
or O
homozygotic O
for O
this O
base O
exchange O
( O
p O
< O
0 O
. O
009 O
) O
. O

This O
polymorphism O
represented O
a O
C O
- O
to O
- O
T O
base O
exchange O
which O
induced O
a O
YY1 B
consensus I
sequence I
and O
is O
present O
in O
a O
region O
of O
the O
promoter O
associated O
with O
negative O
transcription O
regulation O
. O

However O
, O
it O
was O
only O
the O
IL B
- I
2 I
promoter I
whose O
activation O
by O
Tpl B
- I
2 I
was O
fully O
blocked O
by O
the O
dominant B
negative I
mutant I
MEK1S218 I
/ I
222A I
and O
the O
MEK1 O
/ O
MEK2 O
inhibitor O
PD098059 O
. O

We O
investigated O
the O
function O
of O
the O
evolutionary O
conserved O
X2 B
box I
in O
the O
promoter B
of O
the O
HLA B
- I
DRA I
gene I
from O
the O
human B
major I
histocompatibility I
complex I
( O
MHC B
) O
in O
resting O
and O
activated O
B O
cells O
. O

The O
action O
of O
adenoviral B
E1A I
oncoprotein I
on O
host B
immune I
- I
response I
genes I
has O
been O
attributed O
to O
interaction O
with O
p300 B
/ I
CBP I
- I
type I
transcriptional I
coactivators I
in O
competition O
with O
endogenous B
transcription I
factors I
such O
as O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
proteins I
. O

Here O
we O
evaluated O
whether O
xenogeneic O
serum O
, O
as O
a O
source O
of O
xenoreactive B
natural I
antibodies I
and O
complement O
, O
induced O
endothelial O
cell O
activation O
with O
consequent O
leukocyte O
adhesion O
under O
flow O
conditions O
. O

In O
order O
to O
elucidate O
possible O
mechanisms O
underlying O
endothelial O
cell O
activation O
by O
xenogeneic O
serum O
, O
we O
focussed O
on O
transcription B
factor I
NF I
- I
kappa I
B I
, O
a O
central O
regulator O
for O
the O
induction O
of O
different O
genes O
, O
including O
adhesive B
molecules I
and O
chemoattractants B
. O

Plasma O
TPO B
levels O
are O
regulated O
by O
the O
platelet O
and O
megakaryocyte O
mass O
through O
Mpl B
receptor I
binding O
, O
internalization O
and O
degradation O
. O

The O
Mpl B
receptor I
is O
a O
member O
of O
the O
hematopoietin B
receptor I
superfamily I
lacking O
intrinsic O
kinase O
activity O
. O

Promoter O
analysis O
revealed O
that O
a O
GATA B
site I
in O
a O
cryptic B
promoter I
in O
the O
second B
intron I
was O
essential O
and O
sufficient O
for O
the O
TAL1 O
- O
and O
LMO O
- O
dependent O
transcriptional O
activation O
, O
and O
GATA3 B
binds O
to O
this O
site O
. O

Since O
one O
of O
the O
two O
X B
chromosomes I
is O
randomly O
inactivated O
at O
an O
early O
stage O
of O
female O
embryonic O
development O
, O
X B
- I
linked I
markers I
have O
been O
used O
to O
study O
the O
origin O
and O
development O
of O
various O
neoplastic O
disorders O
in O
affected O
heterozygous O
women O
; O
clonality O
assays O
have O
provided O
a O
useful O
tool O
to O
the O
understanding O
of O
the O
mechanisms O
underlying O
the O
development O
of O
neoplasia O
. O

Recently O
, O
a O
technique O
of O
clonal O
analysis O
has O
been O
devised O
that O
takes O
advantage O
of O
a O
highly O
polymorphic O
short B
tandem I
repeat I
within O
the O
X B
- I
linked I
human I
androgen I
receptor I
( I
AR I
) I
gene I
, O
resulting O
in O
a O
heterozygosity O
rate O
approaching O
90 O
% O
. O

We O
have O
generated O
antibodies O
that O
specifically O
immunoprecipitated O
the O
in B
- I
vitro I
- I
translated I
20 I
- I
kDa I
protein I
. O

Further O
characterization O
of O
FKHRL1 B
and O
its O
related O
family O
members O
should O
shed O
light O
on O
the O
transcriptional O
mechanisms O
of O
this O
fork B
head I
gene I
subfamily I
and O
their O
role O
in O
T O
helper O
cell O
differentiation O
and O
regulation O
of O
cell O
growth O
. O

These O
motifs O
are O
regulatory B
sequences I
within O
the O
so O
- O
called O
AU B
- I
rich I
elements I
( O
AREs B
) O
often O
found O
in O
3 B
' I
untranslated I
regions I
of O
genes O
such O
as O
cytokines B
, O
proto B
- I
oncogenes I
, O
and O
transcription B
factors I
. O

The O
nuclear B
factor I
- I
kappa I
B I
( I
NF I
- I
kappaB I
) I
family I
of O
transcription B
factors I
regulates O
genes O
involved O
in O
inflammation O
, O
cell O
proliferation O
, O
and O
cell O
differentiation O
. O

At O
the O
same O
time O
there O
was O
no O
change O
in O
the O
level O
of O
expression O
of O
the O
cell B
surface I
antigenes I
CD33 B
, O
CD34 B
, O
CD45 B
, O
CD71 B
and O
glycophorin B
A I
. O

Electrophoretic O
mobility O
shift O
assays O
( O
EMSAs O
) O
demonstrated O
that O
the O
- O
300 O
region O
of O
the O
IL B
- I
1beta I
promoter O
, O
which O
contains O
a O
nuclear B
factor I
- I
kappaB I
( I
NF I
- I
kappaB I
) I
binding I
site I
, O
contained O
a O
functional B
RBP I
binding I
site I
. O

CD27 B
/ O
CD70 O
interaction O
enhanced O
B O
cell O
proliferation O
in O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
4 I
plus O
anti B
- I
CD40 I
. O

Recent O
studies O
, O
however O
, O
demonstrate O
that O
the O
transcribed O
5 B
' I
- I
untranslated I
leader I
region I
( O
5 B
' I
- I
UTR I
) O
also O
contains O
important O
transcriptional B
elements I
. O

In O
turn O
, O
assembly O
of O
this O
complex O
mediates O
the O
enzymatic O
activation O
of O
the O
p21 B
- I
activated I
protein I
kinase I
1 I
and O
facilitates O
actin B
polymerization O
. O

LOX B
- I
1 I
is O
an O
endothelial B
receptor I
for O
oxidized B
low I
- I
density I
lipoprotein I
that O
plays O
essential O
roles O
in O
atherogenesis O
. O

In O
the O
present O
study O
, O
we O
cloned O
and O
characterized O
the O
human B
LOX I
- I
1 I
gene I
( O
HGMW B
- I
approved I
symbol I
OLR1 I
) O
. O

In O
addition O
, O
Ras B
( I
G12V I
) I
complemented O
signaling O
by O
an O
erythropoietin B
receptor I
mutant I
defective O
in O
Ras B
activation O
and O
augmented O
the O
activation O
of O
the O
beta B
- I
casein I
promoter I
by O
the O
mutant B
erythropoietin I
receptor I
signaling O
, O
suggesting O
a O
possible O
role O
of O
Ras B
in O
Stat5 B
- O
mediated O
gene O
expression O
. O

An O
81 O
% O
increment O
in O
promoter O
activity O
was O
obtained O
when O
a O
mutation O
was O
introduced O
in O
the O
GATA B
- I
3 I
binding I
site I
of O
the O
bp B
- I
267 I
to I
+ I
12 I
construct I
, O
which O
is O
comparable O
to O
that O
of O
the O
bp B
- I
245 I
to I
+ I
12 I
construct I
. O

Ligation O
of O
CD3 B
also O
induces O
the O
tyrosine O
phosphorylation O
of O
HS1 B
, O
a O
75 B
- I
kDa I
hematopoietic I
cell I
- I
specific I
intracellular I
signaling I
protein I
of O
unknown O
function O
. O

In O
addition O
, O
Northern O
blot O
analysis O
of O
cord O
and O
adult O
samples O
revealed O
similar O
maximal O
increases O
in O
c B
- I
fos I
( O
99 O
+ O
/ O
- O
15 O
and O
126 O
+ O
/ O
- O
11 O
% O
, O
p O
= O
0 O
. O
0126 O
) O
and O
c B
- I
jun I
( I
123 I
+ I
/ I
- I
9 I
and I
185 I
+ I
/ I
- I
38 I
% I
, I
p I
= I
0 I
. I
0291 I
) I
mRNA I
expression O
, O
respectively O
, O
as O
early O
as O
15 O
min O
post O
- O
alphaCD3 B
stimulation O
. O

Receptors O
for O
the O
Fc B
portion I
of O
immunoglobulin B
molecules I
( O
FcR B
) O
present O
on O
leukocyte O
cell O
membranes O
mediate O
a O
large O
number O
of O
cellular O
responses O
that O
are O
very O
important O
in O
host O
defense O
, O
including O
phagocytosis O
, O
cell O
cytotoxicity O
, O
production O
and O
secretion O
of O
inflammatory B
mediators I
, O
and O
modulation O
of O
the O
immune O
response O
. O

Thirty O
percent O
of O
GC O
B O
cells O
, O
but O
not O
naive O
B O
cells O
, O
displayed O
mutations O
in O
the O
742 B
bp I
region I
analyzed O
within O
the O
first O
intron O
of O
BCL B
- I
6 I
( O
overall O
frequency O
: O
5 O
x O
10 O
( O
- O
4 O
) O
/ O
bp O
) O
. O

Neither O
the O
E12 B
nor O
the O
E47 B
product O
of O
the O
E2A B
gene I
nor O
the O
wild B
- I
type I
HLF I
protein I
was O
able O
to O
protect O
the O
cells O
from O
apoptosis O
induced O
by O
IL B
- I
3 I
deprivation O
. O

Surprisingly O
, O
different O
combinations O
of O
disabling O
mutations O
within O
the O
HLF B
bZIP I
domain I
had O
little O
effect O
on O
the O
antiapoptotic O
property O
of O
the O
chimeric B
protein I
, O
so O
long O
as O
the O
amino O
- O
terminal O
portion O
of O
E2A B
remained O
intact O
. O

A O
regulatory B
element I
in O
the O
CD95 B
( I
APO I
- I
1 I
/ I
Fas I
) I
ligand I
promoter I
is O
essential O
for O
responsiveness O
to O
TCR B
- O
mediated O
activation O
. O

The O
DNA O
sequence O
at O
- B
120 I
also O
contains O
two O
DNA B
motifs I
homologous O
to O
the O
binding O
site O
for O
NF B
- I
AT I
. O

Progesterone O
effectively O
blocked O
a O
broad O
spectrum O
of O
K B
+ I
channels I
, O
reducing O
both O
Kv1 B
. I
3 I
and O
charybdotoxin B
- I
resistant I
components I
of O
KV B
current O
and O
KCa B
current O
in O
T O
cells O
, O
as O
well O
as O
blocking O
several O
cloned B
KV I
channels I
expressed O
in O
cell O
lines O
. O

Activation O
of O
the O
CD4 B
promoter I
occurs O
in O
the O
presence O
of O
the O
viral O
DNA O
polymerase O
inhibitor O
phosphonoformic O
acid O
, O
which O
limits O
expression O
to O
the O
immediate B
- I
early I
and I
early I
classes I
of I
viral I
genes I
. O

Both O
Tax B
- O
mediated O
apoptosis O
and O
oxidative O
stress O
can O
be O
potently O
suppressed O
by O
antioxidants O
, O
as O
is O
seen O
with O
the O
administration O
of O
recombinant B
thioredoxin I
( O
adult B
T I
cell I
leukemia I
- I
derived I
factor I
) O
or O
pyrrolidine O
dithiocarbamate O
. O

Dexamethasone O
treatment O
completely O
blocked O
12 O
- O
O O
- O
tetradecanoylphorbol O
13 O
- O
acetate O
induction O
of O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
activity O
and O
elicited O
an O
increase O
in O
the O
amount O
of O
immunoreactive B
IkappaB I
alpha I
in O
sensitive O
6TG1 O
. O
1 O
cells O
but O
not O
in O
resistant O
ICR27TK O
. O
3 O
cells O
. O

We O
determined O
whether O
Hsp70 B
induction O
by O
TS O
was O
mediated O
by O
the O
activation O
of O
the O
HS B
transcription I
factor I
, O
HSF B
. O

Replication O
of O
human O
immunodeficiency O
virus O
type O
- O
1 O
( O
HIV O
- O
1 O
) O
is O
highly O
dependent O
on O
the O
state O
of O
activation O
of O
the O
infected O
cells O
and O
is O
modulated O
by O
interactions O
between O
viral B
and I
host I
cellular I
factors I
. O

Switching O
is O
hampered O
by O
CD30 B
coengagement O
, O
possibly O
through O
interference O
with O
the O
CD40 B
- O
mediated O
NF B
- I
kappaB I
- O
dependent O
transcriptional O
activation O
of O
downstream B
C I
( I
H I
) I
genes I
. O

Are O
there O
effects O
of O
CyA O
and O
FK O
506 O
all O
attributable O
to O
CN O
inhibition O
, O
and O
how O
much O
of O
them O
are O
mediated O
through O
the O
NFATC B
family I
of O
transcription B
factors I
? O

Simultaneous O
analysis O
of O
close O
to O
600 B
genes I
indicated O
highest O
increase O
in O
the O
expression O
of O
certain O
transcription B
, I
differentiation I
and I
proliferation I
factors I
. O

It O
is O
unknown O
which O
Stat3 B
isoform I
( O
s O
) O
is O
activated O
in O
response O
to O
interleukin B
( I
IL I
) I
- I
2 I
and O
IL B
- I
15 I
. O

It O
is O
shown O
here O
that O
during O
monocyte O
to O
macrophage O
differentiation O
, O
the O
expression O
of O
LAL B
- I
mRNA I
is O
induced O
. O

Our O
results O
suggest O
that O
the O
TNFalpha B
gene I
could O
be O
one O
of O
the O
targets O
of O
NF B
- I
kappaB I
in O
EBV O
infected O
cells O
and O
that O
NF O
- O
kappaB O
protects O
EBV O
- O
infected O
cells O
from O
apoptosis O
induced O
by O
TNFalpha B
, O
which O
may O
favour O
the O
proliferative O
effect O
of O
this O
cytokine B
. O

This O
study O
shows O
that O
expression O
of O
LMP1 B
activates O
transcription O
from O
p50 B
/ I
p65 I
- I
and I
c I
- I
Rel I
- I
responsive I
promoters I
, O
and O
that O
this O
activity O
can O
be O
completely O
inhibited O
by O
expression O
of O
a O
dominant O
inhibitory B
IkappaB I
mutant I
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil B
- I
associated I
granule I
proteins I
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil B
- I
derived I
neurotoxin I
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major B
basic I
protein I
( O
MBP B
) O
, O
and O
for O
the O
Charcot B
- I
Leyden I
crystal I
( I
CLC I
) I
protein I
. O

The O
MHC B
class I
II I
transactivator I
( O
CIITA B
) O
requires O
conserved O
leucine B
charged I
domains I
for O
interactions O
with O
the O
conserved O
W B
box I
promoter I
element I
. O

The O
ability O
of O
mutants O
to O
activate O
a O
reporter O
gene O
under O
the O
control O
of O
MHC B
class I
II I
conserved O
W B
- I
X I
- I
Y I
or I
X I
- I
Y I
regulatory I
elements I
was O
determined O
. O

Two O
mutants O
displayed O
differential O
activity O
between O
the O
two O
promoters B
, O
activating O
transcription O
with O
the O
W B
- I
X I
- I
Y I
but I
not I
the I
X I
- I
Y I
elements I
. O

The O
characterization O
of O
CIITA B
mutants I
that O
are O
able O
to O
discriminate O
between O
promoters O
with O
or O
without O
the O
W B
box I
strongly O
suggests O
that O
CIITA B
requires O
such O
interactions O
for O
function O
. O

Recently O
, O
it O
was O
suggested O
that O
activation O
of O
the O
alpha B
isoform I
of O
PPAR B
by O
the O
potent O
proinflammatory O
mediator O
leukotriene O
B4 O
( O
LTB4 O
) O
enhanced O
degradation O
of O
this O
eicosanoid O
, O
offersuggesting O
a O
new O
aspect O
of O
down O
- O
regulation O
of O
inflammation O
. O

In O
the O
majority O
of O
patients O
with O
advanced O
RCC O
, O
peripheral O
blood O
T O
cells O
express O
TCRzeta B
and O
p56 B
( I
lck I
) I
, O
and O
in O
a O
subset O
, O
reduced O
levels O
of O
these O
TCRzeta B
associated I
molecules I
are O
seen O
that O
may O
increase O
during O
cytokine B
- O
based O
therapy O
. O

The O
differential O
expression O
of O
the O
genes O
in O
the O
zinc B
finger I
and I
POU I
families I
will O
lead O
to O
a O
better O
understanding O
of O
the O
cascade O
of O
gene O
expression O
which O
occurs O
following O
ATRA O
- O
induced O
differentiation O
. O

Interleukin B
- I
4 I
and I
- I
13 I
induce O
upregulation O
of O
the O
murine O
macrophage O
12 B
/ I
15 I
- I
lipoxygenase I
activity I
: O
evidence O
for O
the O
involvement O
of O
transcription B
factor I
STAT6 B
. O

The O
cytokine B
- O
dependent O
upregulation O
of O
the O
murine B
macrophage I
12 I
- I
lipoxygenase I
and O
its O
induction O
during O
experimental O
anemia O
suggests O
its O
close O
relatedness O
with O
the O
human B
reticulocyte I
- I
type I
15 I
- I
lipoxygenase I
despite O
their O
differences O
in O
the O
positional O
specificity O
of O
arachidonic O
acid O
oxygenation O
. O

Interferon B
- I
gamma I
- I
induced I
factor I
binding O
to O
the O
interleukin B
- I
4 I
- I
responsive I
element I
of O
CD23b B
promoter I
in O
human O
tonsillar O
mononuclear O
cells O
: O
role O
in O
transient O
up O
- O
regulation O
of O
the O
interleukin B
- I
4 I
- I
induced I
CD23b I
mRNA I
. O

Activation O
of O
E2F B
- O
mediated O
transcription O
by O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
Tax I
protein I
in O
a O
p16 O
( O
INK4A O
) O
- O
negative O
T O
- O
cell O
line O
. O

In O
addition O
, O
Tax B
also O
stimulates O
the O
transcription O
of O
the O
E2F B
- I
1 I
gene I
itself O
. O

p21ras B
initiates O
Rac B
- I
1 I
but O
not O
phosphatidyl B
inositol I
3 I
kinase I
/ I
PKB I
, O
mediated O
signaling O
pathways O
in O
T O
lymphocytes O
. O

The O
present O
data O
thus O
highlight O
that O
PtdIns B
3 I
- I
kinase I
and O
Akt B
/ I
PKB I
are O
not O
universal O
Ras B
effector I
molecules I
. O

Differential O
responsiveness O
of O
the O
IL B
- I
5 I
and I
IL I
- I
4 I
genes I
to O
transcription B
factor I
GATA I
- I
3 I
. O

Antibodies B
to O
Duffy B
antigens I
are O
responsible O
for O
some O
cases O
of O
transfusion O
incompatibility O
and O
newborn O
hemolytic O
disease O
. O

The O
Duffy B
protein I
is O
a O
receptor O
for O
the O
Plasmodium B
vivax I
erythrocyte I
- I
binding I
protein I
and O
is O
also O
a O
receptor O
for O
various O
chemokines B
( O
thus O
renamed O
Duffy B
Antigen I
Receptor I
for I
Chemokines I
[ O
DARC B
] O
) O
. O

The O
Fy O
( O
a O
- O
b O
- O
) O
phenotype O
has O
been O
associated O
with O
a O
mutation O
in O
the O
FY B
* I
B I
promoter I
at O
the O
GATA B
box I
that O
abolishes O
the O
expression O
of O
erythrocyte B
Duffy I
protein I
. O

Expression O
of O
the O
IL B
- I
2 I
gene I
requires O
activation O
of O
T O
cells O
through O
stimulation O
of O
the O
TCR B
and O
costimulation O
through O
accessory B
receptors I
. O

The O
transcription B
factors I
active O
at O
the O
IL B
- I
2 I
promoter I
were O
differentially O
influenced O
: O
upon O
down O
- O
modulation O
of O
okadaic B
acid I
- I
sensitive I
phosphatases I
, O
transactivation O
by O
octamer O
, O
NF B
- I
kappa I
B I
, O
and O
NF B
of I
activated I
T I
cells I
proteins I
was O
abrogated O
, O
while O
transactivation O
by O
AP B
- I
1 I
proteins I
was I
even I
enhanced I
. I

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
bis O
[ O
4 O
- O
[ O
2 O
, O
4 O
- O
dioxo O
- O
5 O
- O
thiazolidinyl O
) O
methyl O
] O
phenyl O
] O
methane O
( O
YM O
- O
268 O
) O
, O
a O
thiazolidinedione O
derivative O
, O
on O
glucose O
uptake O
, O
adipocyte O
differentiation O
through O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
, O
and O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
activity O
in O
cultured O
cells O
. O

Molecular O
and O
cellular O
analysis O
of O
human O
immunodeficiency O
virus O
- O
induced O
apoptosis O
in O
lymphoblastoid B
T I
- I
cell I
- I
line I
- I
expressing I
wild I
- I
type I
and I
mutated I
CD4 I
receptors I
. O

We O
have O
determined O
how O
the O
phosphorylation O
of O
the O
retinoblastoma B
family I
( O
pRb B
, O
p107 B
, O
and O
p130 B
) O
is O
governed O
in O
individual O
cell O
cycle O
phases O
of O
Daudi O
B O
- O
cells O
during O
cell O
cycle O
exit O
triggered O
by O
alpha B
- I
interferon I
( O
alpha B
- I
IFN I
) O
. O

alpha B
- I
IFN I
causes O
dephosphorylation O
of O
pRb B
and O
loss O
of O
p130 B
phosphorylated I
Form I
3 I
. O

However O
, O
the O
change O
in O
p130 B
phosphorylation O
in O
response O
to O
alpha B
- I
IFN I
occurs O
before O
dephosphorylation O
of O
pRb B
is O
complete O
because O
loss O
of O
p130 B
Form I
3 I
occurs O
throughout O
the O
cell O
cycle O
prior O
to O
complete O
arrest O
in O
G1 O
, O
whereas O
pRb B
is O
dephosphorylated O
only O
in O
G1 O
. O

p130 B
, O
predominantly O
in O
Form O
1 O
, O
and O
hypophosphorylated B
pRb I
bind O
an O
E2F B
DNA I
binding I
site I
; O
p130 B
complexes O
E2F B
- I
4 I
, O
whereas O
pRb B
binds O
both O
E2F O
- O
4 O
and O
E2F B
- I
1 I
. O

The O
phosphorylated O
forms O
of O
E2F B
- I
4 I
that O
bind O
to O
the O
E2F B
DNA I
site I
are O
different O
from O
hyperphosphorylated O
E2F B
- I
4 I
, O
which O
predominates O
in O
primary O
hemopoietic O
cells O
in O
G0 O
. O

In O
contrast O
to O
the O
differential O
signaling O
of O
BW B
828 I
and O
9 B
. I
3 I
in O
resting O
T O
cells O
, O
the O
two O
mAbs O
exhibited O
a O
similar O
pattern O
of O
early O
signaling O
events O
in O
activated O
T O
cells O
and O
Jurkat O
cells O
( O
p56 B
( I
lck I
) I
activation O
, O
association O
of O
phosphatidylinositol B
3 I
- I
kinase I
with O
CD28 B
) O
, O
indicating O
that O
the O
signaling O
capacity O
of O
CD28 B
changes O
with O
activation O
. O

IL B
- I
12 I
is O
a O
75 B
- I
kDa I
heterodimeric I
cytokine I
composed O
of O
two O
covalently O
linked O
p35 B
and I
p40 I
chains I
. O

This O
was O
associated O
with O
the O
down O
- O
regulation O
of O
IL B
- I
12p40 I
mRNA I
expression O
. O

Metabolic O
labeling O
combined O
with O
pulse O
- O
chase O
experiments O
and O
biochemical O
analysis O
showed O
that O
the O
majority O
of O
class B
II I
molecules I
in O
infected O
cells O
became O
resistant O
to O
endoglycosidase B
H I
, O
consistent O
with O
normal O
Golgi O
processing O
. O

Thus O
, O
compared O
with O
findings O
in O
control O
cells O
, O
class B
II I
molecules I
in O
infected O
cells O
colocalized O
to O
a O
minimal O
extent O
with O
a O
lysosomal B
- I
associated I
membrane I
protein I
- I
1 I
+ O
endosomal O
compartment O
. O

Analyzed O
DNA B
sequences I
included O
delta B
and I
beta I
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
500 I
to I
+ I
50bp I
( O
promoter B
regions I
) O
, O
truncated O
delta O
and O
beta B
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
250 I
to I
+ I
50 I
bp I
, O
and O
chimeric B
promoter I
constructions I
, O
which O
consisted O
of O
a O
distal O
delta B
or I
beta I
fragment I
fused O
to O
a O
proximal B
beta I
or I
delta I
sequence I
. O

In O
CAT B
reporter I
constructions I
no O
appreciable O
level O
of O
CAT B
activity O
was O
supported O
by O
the O
beta B
globin I
promoter I
, O
and O
only O
low O
level O
activity O
by O
the O
delta B
promoter I
. O

Fusion O
of O
the O
upstream B
portion I
of O
the O
delta B
promoter I
to O
the O
truncated O
beta B
globin I
promoter I
yielded O
a O
modest O
increase O
in O
promoter O
strength O
relative O
to O
the O
truncated B
beta I
gene I
promoter I
, O
indicating O
the O
presence O
of O
a O
positive B
transcriptional I
element I
( O
s O
) O
in O
the O
upstream B
delta I
globin I
regulatory I
region I
. O

The O
induction O
of O
IgE B
by O
IL B
- I
4 I
and O
IL B
- I
13 I
occurs O
through O
the O
activation O
of O
the O
intracellular B
signal I
- I
transducing I
protein I
Stat6 I
, O
whereas O
the O
inhibition O
of O
IgE B
class O
switching O
by O
interferon B
- I
y I
( O
IFN B
- I
gamma I
) O
occurs O
through O
the O
activation O
of O
Statl B
. O

NFAT B
regulates O
transcription O
of O
a O
number O
of O
cytokine O
and O
other O
immunoregulatory B
genes I
. O

We O
also O
report O
three O
additional O
isoforms O
of O
NFATx B
, O
designated O
NFATx2 B
, O
NFATx3 B
, O
and O
NFATx4 B
. O

This O
transactivation O
sequence O
is O
altered O
by O
tissue O
- O
specific O
alternative O
splicing O
in O
newly O
isolated O
NFATx B
isoforms I
, O
resulting O
in O
lower O
transactivation O
activity O
in O
Jurkat O
T O
cells O
. O

The O
transition O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
from O
latency O
into O
the O
lytic O
cycle O
is O
associated O
with O
the O
expression O
of O
two O
immediate B
- I
early I
viral I
genes I
, O
BZLF1 B
and O
BRLF1 B
. O

Expression O
of O
either O
BZLF1 B
or O
BRLF1 B
triggers O
expression O
of O
the O
other O
immediate B
- I
early I
factor I
, O
and O
together O
these O
activators O
act O
individually O
or O
in O
synergy O
on O
downstream B
targets I
to O
activate O
the O
viral O
lytic O
cycle O
. O

We O
first O
demonstrate O
, O
in O
human O
and O
mouse O
intraspecies O
hybrids O
, O
the O
coordinate O
suppression O
of O
MHC B
class I
II I
, O
Ii B
( O
invariant B
chain I
) O
and O
HLA B
- I
DM I
gene I
transcription O
, O
and O
the O
release O
of O
the O
silencing O
by O
the O
addition O
of O
interferon B
gamma I
. O

Transient O
transfection O
analysis O
with O
target B
plasmids I
containing O
either O
DRA B
promoter I
( O
wild O
- O
type O
or O
mutated O
) O
or O
TPA B
response I
elements I
demonstrated O
that O
pretreatment O
with O
the O
selective O
PKC B
inhibitor O
GF O
109203X O
repressed O
TPA O
- O
mediated O
activation O
. O

Multiple O
cellular B
DNA I
- I
binding I
transcription I
factors I
are O
required O
by O
HIV O
type O
1 O
for O
RNA O
synthesis O
. O

Previously O
, O
we O
demonstrated O
that O
granulocyte B
colony I
- I
stimulating I
factor I
( I
G I
- I
CSF I
) I
receptor I
mRNA I
was O
undetectable O
and O
granulocyte O
maturation O
blocked O
in O
CCAAT B
enhancer I
binding I
protein I
alpha I
( O
C B
/ I
EBPalpha I
) O
- O
deficient O
mice O
. O

Since O
the O
inhibition O
of O
Ca2 O
+ O
redistribution O
by O
an O
inhibitor O
of O
intracellular O
Ca2 O
+ O
mobilization O
, O
8 O
- O
( O
diethylamino O
) O
- O
octyl O
- O
3 O
, O
4 O
, O
5 O
- O
trimethoxybenzoate O
hydrochloride O
, O
inhibited O
TCR B
- I
induced I
FasL I
but O
not O
Fas B
, O
the O
expression O
of O
Fas B
appears O
to O
be O
independent O
of O
Ca2 O
+ O
mobilization O
. O

To O
differentiate O
whether O
the O
RA O
effect O
was O
mediated O
by O
RA B
receptors I
alpha I
, I
beta I
, I
and I
gamma I
, O
the O
expression O
of O
the O
retinoic B
acid I
receptors I
( O
RAR B
) O
was O
examined O
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
. O

Functional O
analysis O
of O
the O
promoter O
by O
transient O
transfection O
assays O
indicated O
that O
synergistic O
action O
between O
an O
SP B
- I
1 I
- I
like I
element I
at O
- O
21 O
/ O
- O
12 O
, O
a O
GATA B
site I
at O
- O
59 O
/ O
- O
54 O
, O
and O
a O
novel B
regulatory I
element I
, O
CPRE B
( O
- O
GGACTACAG B
- O
) O
at O
- O
49 O
/ O
- O
41 O
, O
is O
essential O
for O
the O
promoter O
activity O
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
. O

Administration O
of O
the O
cytokine B
interleukin I
- I
2 I
( O
IL B
- I
2 I
) O
can O
result O
in O
therapeutic O
benefits O
for O
individuals O
with O
renal O
cell O
carcinoma O
and O
melanoma O
. O

Here O
we O
investigated O
the O
impact O
of O
retinoid B
X I
receptor I
( O
RXR B
) O
, O
retinoic B
acid I
receptor I
( O
RAR B
) O
, O
and O
of O
the O
c B
- I
erbA I
/ I
thyroid I
hormone I
( I
T3 I
) I
receptor I
( O
c B
- I
erbA I
/ I
TR I
) O
on O
growth O
and O
differentiation O
of O
erythroid O
cells O
using O
an O
in O
vitro O
culture O
system O
of O
stem O
cell O
factor O
- O
dependent O
erythroid O
progenitors O
. O

In O
marked O
contrast O
, O
expression O
of O
the O
dominant B
interfering I
deltaDNA I
- I
binding I
domain I
RXR B
, O
containing O
a O
deletion O
of O
the O
entire B
DNA I
- I
binding I
domain I
, O
was O
incompatible O
with O
erythroid O
cell O
growth O
in O
vitro O
, O
suggesting O
a O
pivotal O
role O
of O
RXR B
for O
erythroid O
cell O
development O
. O

This O
observation O
was O
made O
despite O
normal O
cytoplasmic O
levels O
of O
the O
Rel B
- I
A I
protein I
. O

T O
lymphocytes O
from O
6 O
of O
the O
14 O
patients O
also O
exhibited O
an O
increased O
expression O
of O
the O
dual O
specificity B
phosphatase I
, O
map B
kinase I
phosphatase I
- I
1 I
( O
MKP B
- I
1 I
) O
. O

The O
small B
GTP I
- I
binding I
protein I
Rho I
potentiates O
AP B
- I
1 I
transcription O
in O
T O
cells O
. O

The O
effect O
of O
Rho B
on O
AP B
- I
1 I
is O
independent O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
pathway O
, O
as O
a O
dominant B
- I
negative I
MEK I
and O
a O
MEK B
inhibitor O
( O
PD98059 O
) O
did O
not O
affect O
Rho B
- O
induced O
AP B
- I
1 I
activity O
. O

To O
evaluate O
a O
potential O
mechanism O
for O
these O
differences O
in O
function O
, O
we O
evaluated O
expression O
of O
protein B
kinase I
C I
( I
PKC I
) I
isoforms I
. O

The O
activation O
of O
NF B
- I
kappaB I
has O
been O
recognized O
to O
regulate O
a O
number O
of O
genes O
necessary O
for O
normal O
T O
cell O
responses O
including O
IL B
- I
2 I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
and O
several O
T B
cell I
surface I
receptors I
. O

Uncoupling O
of O
nonreceptor O
tyrosine B
kinases I
from O
PLC B
- I
gamma1 I
in O
an O
SLP O
- O
76 O
- O
deficient O
T O
cell O
. O

SLP B
- I
76 I
was O
not O
required O
for O
TCR B
- O
induced O
tyrosine O
phosphorylation O
of O
most O
proteins O
, O
but O
was O
required O
for O
optimal O
tyrosine O
phosphorylation O
and O
activation O
of O
phospholipase B
C I
- I
gamma1 I
( O
PLC B
- I
gamma1 I
) O
, O
as O
well O
as O
Ras B
pathway O
activation O
. O

Thus O
, O
coupling O
of O
TCR B
- I
regulated I
PTKs I
to O
downstream O
signaling O
pathways O
requires O
SLP B
- I
76 I
. O

Data O
obtained O
by O
electrophoretic O
mobility O
shift O
assay O
suggested O
that O
the O
activated B
Stat I
- I
3 I
protein I
associates O
with O
the O
human B
serum I
- I
inducible I
element I
( I
hSIE I
) I
DNA I
- I
probe I
derived O
from O
the O
interferon B
- I
gamma I
activated I
site I
( O
GAS B
) O
in O
the O
c B
- I
fos I
promoter I
, O
a O
common O
DNA O
sequence O
for O
Stat B
protein I
binding O
. O

Using O
deletion B
constructs I
, O
we O
have O
defined O
an O
active B
promoter I
region I
of O
1056 O
bp O
. O

Ex O
vivo O
activation O
of O
tumor O
- O
draining O
lymph O
node O
T O
cells O
reverses O
defects O
in O
signal B
transduction I
molecules I
. O

BACKGROUND O
: O
The O
class B
II I
transactivator I
( O
CIITA B
) O
is O
a O
bi B
- I
or I
multifunctional I
domain I
protein I
that O
acts O
as O
a O
transcriptional B
activator I
and O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

Porcine B
MHC I
class I
II I
antigens I
are O
potent O
stimulators O
of O
direct O
T O
- O
cell O
recognition O
by O
human O
CD4 O
+ O
T O
cells O
and O
are O
, O
therefore O
, O
likely O
to O
play O
an O
important O
role O
in O
the O
rejection O
responses O
to O
transgenic O
pig O
donors O
in O
clinical O
xenotransplantation O
. O

Macrophages O
in O
human O
atheroma O
contain O
PPARgamma B
: O
differentiation B
- I
dependent I
peroxisomal I
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
expression O
and O
reduction O
of O
MMP B
- I
9 I
activity O
through O
PPARgamma B
activation O
in O
mononuclear O
phagocytes O
in O
vitro O
. O

Mononuclear O
phagocytes O
play O
an O
important O
role O
in O
atherosclerosis O
and O
its O
sequela O
plaque O
rupture O
in O
part O
by O
their O
secretion O
of O
matrix B
metalloproteinases I
( O
MMPs B
) O
, O
including O
MMP B
- I
9 I
. O

A O
recent O
study O
showed O
a O
MLL B
/ I
AF10 I
fusion I
in O
all O
cases O
of O
AML O
with O
t B
( I
10 I
; I
11 I
) I
and O
various O
breakpoints O
on O
chromosome B
11 I
ranging O
from O
q13 B
to O
q23 B
. O

We O
recently O
cloned O
CALM B
( O
Clathrin B
Assembly I
Lymphoid I
Myeloid I
leukemia I
gene I
) O
, O
the O
fusion O
partner O
of O
AF10 B
at O
11q14 B
in O
the O
monocytic O
cell O
line O
U937 O
. O

We O
conclude O
that O
the O
t B
( I
10 I
; I
11 I
) I
( I
p13 I
; I
q14 I
) I
indicates O
CALM B
and I
MLL I
rearrangements I
in O
morphologically O
distinct O
subsets O
of O
acute O
leukemia O
and O
may O
be O
associated O
with O
a O
poor O
prognosis O
. O

MyD88 B
, O
originally O
isolated O
as O
a O
myeloid O
differentiation O
primary B
response I
gene I
, O
is O
shown O
to O
act O
as O
an O
adaptor O
in O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
signaling O
by O
interacting O
with O
both O
the O
IL B
- I
1 I
receptor I
complex I
and O
IL B
- I
1 I
receptor I
- I
associated I
kinase I
( O
IRAK B
) O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
MyD88 B
is O
a O
critical O
component O
in O
the O
signaling O
cascade O
that O
is O
mediated O
by O
IL B
- I
1 I
receptor I
as O
well O
as O
IL B
- I
18 I
receptor I
. O

In O
addition O
, O
transcriptional O
activity O
of O
IL B
- I
2 I
and O
metallothionein B
enhancer I
and I
promoter I
regions I
and O
transcription B
factors I
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
NF B
- I
AT I
were O
analyzed O
by O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
and O
electrophoretic O
mobility O
shift O
assays O
, O
respectively O
. O

The O
concentration O
of O
c B
- I
fos I
, I
c I
- I
jun I
, I
c I
- I
myc I
, I
junB I
, I
and I
fra I
- I
1 I
mRNAs I
was O
increased O
in O
activated O
peripheral O
blood O
lymphocytes O
incubated O
with O
ciprofloxacin O
compared O
to O
that O
in O
untreated O
controls O
. O

Thrombopoietin B
supports O
in O
vitro O
erythroid O
differentiation O
via O
its O
specific O
receptor O
c B
- I
Mpl I
in O
a O
human O
leukemia O
cell O
line O
. O

We O
observed O
that O
Abs O
directed O
against O
unique O
domains O
of O
STAT6 B
have O
differential O
effects O
on O
complexes O
in O
T O
cells O
but O
not O
in O
NK O
cells O
, O
suggesting O
different O
STAT6 B
isoforms I
. O

We O
conclude O
that O
contact O
with O
fibrinogen B
- I
derived I
proteins I
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b B
/ I
CD18 I
, O
resulting O
in O
selective O
activation O
of O
transcriptional B
regulatory I
factors I
, O
including O
NF B
- I
kappa I
B I
. O

OBJECTIVE O
: O
To O
identify O
and O
characterize O
estrogen B
receptor I
( I
ER I
) I
transcripts I
expressed O
in O
immune O
cells O
of O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
and O
healthy O
donors O
. O

There O
were O
no O
notable O
differences O
in O
the O
ER B
transcripts I
between O
patients O
and O
healthy O
controls O
. O

These O
stimuli O
also O
induced O
the O
stress O
- O
activated O
kinase O
pathway O
( O
SAPK B
/ B
JNK I
) O
, O
which O
was O
required O
for O
the O
maximal O
induction O
of O
apoptosis O
. O

The O
implication O
of O
protein B
tyrosine I
kinase I
( I
s I
) I
, O
protein B
kinase I
A I
and O
/ O
or O
protein B
kinase I
C I
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV B
- I
1 I
LTR I
- I
driven I
gene I
expression O
using O
herbimycin O
A O
and O
H7 O
. O

These O
insights O
in O
the O
molecular O
events O
that O
are O
involved O
in O
TCF B
/ I
LEF I
function O
in O
these O
organisms O
may O
eventually O
lead O
to O
the O
understanding O
of O
the O
function O
of O
these O
HMG B
box I
proteins I
in O
lymphoid O
development O

Molecular O
genetic O
characterization O
of O
the O
variant B
allele I
can O
serve O
as O
a O
primary O
tool O
for O
diagnosis O
and O
subsequent O
therapy O
, O
and O
can O
provide O
a O
basis O
for O
distinguishing O
heterozygous O
carriers O
in O
familial O
androgen O
resistance O
. O

Elf B
- I
1 I
binds O
exclusively O
to O
the O
underphosphorylated O
form O
of O
Rb B
and O
fails O
to O
bind O
to O
Rb B
mutants I
derived O
from O
patients O
with O
retinoblastoma O
. O

In O
this O
study O
we O
analyzed O
the O
T B
cell I
receptor I
( I
TcR I
) I
delta I
transcripts I
expressed O
by O
CD3 O
- O
CD16 O
+ O
cells O
and O
we O
investigated O
whether O
these O
cells O
expressed O
the O
hGATA B
- I
3 I
T I
cell I
transcription I
factor I
and O
the O
recombination B
- I
activating I
gene I
( I
RAG I
) I
- I
1 I
. O

However O
, O
only O
that O
located O
at O
the O
3 O
' O
end O
appeared O
to O
be O
utilized O
in O
the O
2 B
. I
3 I
- I
kb I
cDNA I
. O

All O
NK O
clones O
and O
cell O
lines O
studied O
were O
found O
to O
express O
hGATA B
- I
3 I
- I
specific I
mRNA I
, O
suggesting O
that O
hGATA B
- I
3 I
may O
be O
involved O
in O
the O
regulation O
of O
the O
unrearranged O
TcR B
delta I
gene I
expression O
in O
NK O
cells O
. O

Jurkat O
cells O
were O
transfected O
with O
plasmids B
containing O
either O
the O
intact O
IL B
- I
2 I
promoter I
or O
its O
AP B
- I
1 I
, I
NF I
- I
AT I
, I
and I
NF I
- I
kB I
motifs I
. O

We O
further O
characterize O
which O
AP1 B
family I
members I
can O
assume O
this O
role O
. O

Antisera O
to O
Fos B
inhibits O
NF B
- I
AT I
DNA O
binding O
as O
does O
an O
oligonucleotide O
containing O
a O
binding B
site I
for I
AP1 I
. O

Activation O
of O
the O
HIV O
- O
1 O
provirus O
correlated O
with O
the O
activation O
of O
binding O
of O
55 B
- I
and I
85 I
- I
kDa I
proteins I
to O
the O
kappa B
B I
enhancer I
and O
binding O
of O
the O
50 B
- I
kDa I
HLP I
- I
1 I
protein I
to O
the O
LBP B
- I
1 I
sequences I
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
. O

Transcriptional O
activation O
of O
the O
macrophage B
colony I
- I
stimulating I
factor I
gene I
by O
IL B
- I
2 I
is O
associated O
with O
secretion O
of O
bioactive O
macrophage B
colony I
- I
stimulating I
factor I
protein I
by O
monocytes O
and O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
. O

We O
localized O
the O
LAM O
- O
, O
lipopolysaccharide O
( O
LPS O
) O
- O
, O
and O
TNF B
- I
alpha I
- B
inducible I
promoter I
activity O
to O
a O
- O
131 O
/ O
+ O
15 O
( O
positions O
- O
131 O
to O
+ O
15 O
) O
DNA O
fragment O
of O
the O
IL B
- I
1 I
beta I
gene I
by O
deletion O
analysis O
and O
chloramphenicol B
acetyltransferase I
assay O
. O

Site O
- O
directed O
mutagenesis O
demonstrated O
that O
the O
two O
NF B
- I
IL I
- I
6 I
motifs I
could O
be O
independently O
activated O
by O
LAM O
, O
LPS O
, O
or O
TNF B
- I
alpha I
and O
that O
they O
acted O
in O
an O
orientation O
- O
independent O
manner O
. O

Additionally O
, O
Nef O
expressing O
cells O
were O
transiently O
transfected O
with O
a O
plasmid O
in O
which O
HIV B
- I
1 I
AP I
- I
1 I
DNA I
recognition I
sequences I
were O
cloned O
downstream O
of O
the O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
gene O
. O

A O
serum B
response I
element I
and O
a O
binding B
site I
for I
NF I
- I
Y I
mediate O
the O
serum O
response O
of O
the O
human B
thrombospondin I
1 I
gene I
. O

Cell O
- O
type O
- O
specific O
transactivation O
of O
the O
parathyroid B
hormone I
- I
related I
protein I
gene I
promoter I
by O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
tax I
and O
HTLV B
- I
II I
tax I
proteins I
. O

The O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
and I
HTLV I
- I
II I
Tax I
proteins I
are O
potent O
transactivators B
of O
viral O
and O
cellular O
gene O
expression O
. O

A O
carboxy B
terminal I
Tax I
deletion I
mutant I
was O
deficient O
in O
transactivation O
of O
both O
the O
PTHrP B
and I
IL2R I
alpha I
promoters I
but O
not O
the O
HTLV B
- I
I I
long I
terminal I
repeat I
( O
LTR B
) O
. O

Here O
we O
have O
investigated O
the O
transcriptional O
regulation O
of O
the O
gamma B
chain I
gene O
by O
analyzing O
the O
2 B
. I
5 I
- I
kilobase I
sequence I
upstream O
of O
the O
transcription O
start O
site O
. O

The O
promoter O
activity O
from O
HIV B
long I
terminal I
repeat I
was O
greatly O
augmented O
by O
co O
- O
transfecting O
the O
Trx B
- I
expressing I
plasmid I
, O
whose O
effect O
was O
dependent O
on O
the O
NF B
kappa I
B I
- O
binding O
sites O
. O

Northern O
analysis O
demonstrated O
coordinate O
downregulation O
of O
alpha B
globin I
and O
gamma B
globin I
in O
addition O
to O
the O
two O
lineage O
- O
restricted O
transcription B
factors I
, O
SCL B
and O
GATA B
- I
1 I
. O

Activation O
of O
primary O
human O
T O
- O
lymphocytes O
through O
CD2 B
plus I
CD28 I
adhesion I
molecules I
induces O
long O
- O
term O
nuclear O
expression O
of O
NF B
- I
kappa I
B I
. O

Long O
- O
lasting O
IL B
- I
2 I
receptivity O
is O
associated O
with O
high O
- O
level O
expression O
of O
the O
inducible O
IL B
- I
2 I
receptor I
alpha I
chain I
( I
IL I
- I
2R I
alpha I
) I
gene I
that O
is O
regulated O
at O
both O
transcriptional O
and O
posttranscriptional O
levels O
. O

Resting O
T O
- O
cell O
nuclear O
extracts O
contained O
KBF1 B
/ I
p50 I
homodimer I
. O

In O
contrast O
, O
the O
binding O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
to O
its O
response O
element O
in O
the O
IL2 B
enhancer I
and O
to O
an O
NF B
- I
AT I
- I
like I
response I
element I
present O
in O
the O
IL4 B
enhancer I
was O
abnormal O
. O

Instead O
, O
they O
form O
tight O
complexes O
with O
two O
different O
classes O
of O
abundant O
cytosolic B
receptors I
called O
immunophilins B
upon O
entering O
the O
cell O
, O
and O
consequently O
inhibit O
their O
peptidyl B
prolyl I
cis I
- I
trans I
isomerase I
activities O
. O

p105 B
and O
p98 B
precursor B
proteins I
play O
an O
active O
role O
in O
NF B
- I
kappa I
B I
- O
mediated O
signal O
transduction O
. O

Transfection O
studies O
indicate O
that O
the O
I B
kappa I
B I
alpha I
gene I
is O
specifically O
induced O
by O
the O
65 B
- I
kilodalton I
transactivating I
subunit I
of O
NF B
- I
kappa I
B I
. O

A O
cell B
- I
type I
- I
independent I
lipopolysaccharide I
( I
LPS I
) I
- I
responsive I
enhancer I
element I
located O
between O
- B
3757 I
and I
- I
2729 I
bp I
upstream I
from O
the O
transcription B
start I
site I
( O
cap B
site I
) O
consisted O
of O
at O
least O
six O
discrete O
subregions O
which O
were O
essential O
to O
the O
maximal O
induction O
by O
LPS O
in O
transfected O
monocytes O
. O

The O
3H O
- O
thymidine O
uptake O
procedure O
was O
employed O
, O
incorporating O
multiple O
microbiological B
antigens I
. O

Few O
known O
genes B
( O
IL B
- I
2 I
, O
members O
of O
the O
IL B
- I
8 I
family I
, O
interferon B
- I
gamma I
) O
are O
induced O
in O
T O
cells O
only O
through O
the O
combined O
effect O
of O
phorbol O
myristic O
acetate O
( O
PMA O
) O
and O
a O
Ca O
( O
2 O
+ O
) O
- O
ionophore O
, O
and O
expression O
of O
only O
these O
genes B
can O
be O
fully O
suppressed O
by O
Cyclosporin O
A O
( O
CyA O
) O
. O

The O
PILOT B
protein O
has O
a O
calculated O
M O
( O
r O
) O
of O
42 O
. O
6 O
kDa O
and O
contains O
three O
zinc B
fingers I
of O
the O
C2H2 B
- I
type I
at O
the O
carboxyl B
- I
terminus I
which O
are O
highly O
homologous O
to O
the O
zinc B
finger I
regions I
of O
the O
transcription B
factors I
EGR1 B
, O
EGR2 B
, O
and O
pAT B
133 I
. O

NF B
- I
kappa I
B I
is O
a O
pleiotropic B
regulator I
of O
a O
variety O
of O
genes O
implicated O
in O
the O
cellular O
response O
to O
injury O
. O

Overexpression O
of O
p65 B
increases O
endogenous O
I B
kappa I
B I
protein O
in O
both O
carcinoma O
and O
lymphoid O
cells O
by O
two O
mechanisms O
: O
protein O
stabilization O
and O
increased O
transcription O
of O
I B
kappa I
B I
mRNA I
. O

Dimerization O
of O
NF B
- I
KB2 I
with O
RelA B
( I
p65 I
) I
regulates O
DNA O
binding O
, O
transcriptional O
activation O
, O
and O
inhibition O
by O
an O
I B
kappa I
B I
- I
alpha I
( O
MAD B
- I
3 I
) O
. O

We O
have O
previously O
found O
that O
NFKB2 B
( I
p49 I
/ I
p52 I
) I
acts O
in O
concert O
with O
RelA B
( I
p65 I
) I
to O
stimulate O
the O
HIV B
enhancer I
in O
Jurkat O
T O
- O
leukemia O
cells O
. O

The O
c B
- I
rel I
protooncogene I
product I
represses O
NF B
- I
kappa I
B I
p65 B
- O
mediated O
transcriptional O
activation O
of O
the O
long O
terminal O
repeat O
of O
type O
1 O
human O
immunodeficiency O
virus O
. O

Somewhat O
unexpectedly O
, O
the O
constitutive O
p21ras B
activity O
did O
not O
cause O
an O
increased O
DNA O
binding O
of O
transcription B
factors I
PEA1 B
( O
AP1 B
) O
, O
PEA3 B
, O
Oct B
- I
2 I
or O
NF B
- I
kB I

Competition O
with O
an O
AP B
- I
1 I
motif I
or O
with O
anti B
- I
Jun I
and O
anti B
- I
Fos I
antibodies I
abolished O
binding O
to O
the O
NFAT B
motif I
in O
both O
T O
and O
B O
cells O
, O
indicating O
that O
Jun O
and O
Fos O
are O
critical O
for O
NFAT B
complex I
formation O
in O
both O
cell O
types O
. O

However O
, O
when O
combined O
with O
unstimulated O
B O
or O
T O
cell O
extracts O
, O
full O
- O
length O
, O
but O
not O
truncated O
, O
Jun O
/ O
Fos O
heterodimers O
were O
able O
to O
form O
an O
NFAT B
complex I
, O
indicating O
the O
presence O
of O
a O
constitutively B
expressed I
nuclear I
factor I
( O
s O
) O
in O
B O
and O
T O
cells O
necessary O
for O
the O
formation O
of O
the O
NFAT B
complex I
in O
both O
cell O
types O
. O

In O
contrast O
to O
the O
decrease O
in O
GR B
mRNA I
seen O
in O
IM O
- O
9 O
cells O
after O
treatment O
with O
1 O
microM O
dexamethasone O
for O
16 O
- O
18 O
h O
, O
treatment O
of O
6TG1 O
. O
1 O
cells O
resulted O
in O
an O
8 O
- O
fold O
increase O
in O
GR B
mRNA I
, O
as O
determined O
by O
Northern O
blot O
and O
RNase B
protection O
analysis O
, O
with O
a O
corresponding O
3 O
- O
to O
4 O
- O
fold O
increase O
in O
GR B
protein I
. O

IFN B
- O
MCP O
was O
not O
inhibited O
by O
infection O
with O
dl343 O
, O
despite O
the O
production O
of O
large O
amounts O
of O
both O
early O
( O
E1B B
, O
p55 B
) O
and O
late O
( O
hexon B
) O
Ad B
proteins I
. O

We O
find O
that O
a O
short O
enhancer O
element O
containing O
the O
NF B
- I
kappa I
B I
binding I
site I
from O
the O
interleukin B
- I
2 I
receptor I
alpha I
- I
chain I
gene I
( O
IL B
- I
2R I
alpha I
) O
is O
preferentially O
activated O
in O
T O
cells O
. O

Groups O
1 O
and O
2 O
have O
a O
serine B
- I
rich I
region I
and O
an O
` O
` O
arginine B
element I
` O
` O
( O
RRLPIF B
) O
at O
the O
carboxyl B
terminus I
. O

All O
groups O
contain O
cysteine B
- I
and I
histidine I
- I
rich I
putative I
zinc I
finger I
domains I
and O
a O
serine B
- I
phenylalanine I
` I
` I
SFS I
' I
' I
domain I
similar O
to O
part O
of O
the O
large O
subunit O
of O
eukaryotic B
RNA I
polymerase I
II I
. O

Comparison O
of O
group O
1 O
human B
and I
mouse I
genomic I
sequences I
shows O
high O
conservation O
in O
the O
5 B
' I
flank I
and O
exons B
. O

A O
microB B
binding I
protein I
is O
encoded O
by O
the O
PU B
. I
1 I
/ I
Spi I
- I
1 I
proto I
- I
oncogene I
. O

One O
enigmatic O
aspect O
of O
GATA B
factor I
expression O
is O
that O
several O
GATA B
proteins I
, O
which O
ostensibly O
share O
the O
same O
DNA B
- I
binding I
site I
specificity O
, O
are O
coexpressed O
in O
erythroid O
cells O
. O

Site O
- O
directed O
mutagenesis O
further O
demonstrated O
that O
the O
enhancer B
function O
of O
one O
of O
the O
two O
NF O
- O
E2 O
/ O
AP1 O
motifs O
of O
HS B
- I
40 I
is O
mediated O
through O
its O
binding O
to O
NF B
- I
E2 I
but O
not O
AP1 B
transcription I
factor I
. O

We O
report O
the O
characterization O
of O
the O
cis B
- I
and I
trans I
- I
acting I
elements I
involved O
in O
the O
tissue O
- O
specific O
activity O
of O
the O
L B
gene I
erythroid I
promoter I
. O

Mutations O
and O
deletions O
of O
both O
sites O
indicate O
that O
only O
the O
association O
of O
CCACC B
/ I
Sp1 I
and O
GATA B
binding I
sites I
can O
drive O
efficient O
and O
tissue O
- O
specific O
expression O
of O
this O
R B
- I
PK I
minimal B
promoter I
. O

Protease O
treatment O
of O
nuclear O
extracts O
distinguishes O
between O
class B
II I
MHC I
X1 I
box I
DNA I
- I
binding I
proteins I
in O
wild O
- O
type O
and O
class O
II O
- O
deficient O
B O
cells O
. O

To O
further O
evaluate O
the O
role O
of O
X B
box I
DNA I
- I
binding I
proteins I
in O
class B
II I
gene I
expression O
, O
the O
role O
of O
the O
X B
box I
region I
was O
examined O
in O
both O
class O
II O
- O
positive O
and O
- O
negative O
lymphoid O
cells O
. O

To O
determine O
whether O
these O
different O
X1 O
box O
activities O
represented O
distinct O
DNA B
binding I
proteins I
or O
multimeric O
forms O
of O
the O
same O
factor O
( O
s O
) O
, O
protease B
treatment O
of O
the O
crude O
nuclear O
extracts O
followed O
by O
DNA O
- O
binding O
assays O
were O
carried O
out O
and O
demonstrated O
that O
B O
cell O
extracts O
contain O
at O
least O
two O
X1 B
- I
specific I
factors I
. O

Viruses O
containing O
the O
human B
cytomegalovirus I
immediate I
- I
early I
enhancer I
exhibited O
infectious O
kinetics O
similar O
to O
that O
of O
wild O
- O
type O
HIV O
in O
activated O
human O
peripheral O
blood O
lymphocytes O
and O
AA2 O
cells O
but O
replicated O
less O
efficiently O
in O
H9 O
and O
CEM O
cells O
. O

The O
E1A B
and I
hexon I
primers I
amplified O
DNA O
from O
representative O
adenoviral O
serotypes O
in O
all O
six O
adenoviral O
groups O
( O
A O
- O
F O
) O
. O

RESULTS O
: O
In O
the O
OM O
- O
10 O
. O
1 O
promyelocytic O
model O
of O
chronic O
infection O
, O
TNF O
- O
alpha O
- O
induced O
HIV O
- O
1 O
expression O
also O
resulted O
in O
a O
substantial O
increase O
in O
75 B
kd I
TNF I
receptor I
( O
TR75 B
) O
expression O
although O
55 B
kD I
TNF I
receptor I
( O
TR55 B
) O
levels O
were O
not O
dramatically O
altered O
. O

Surprisingly O
, O
this O
was O
the O
case O
even O
when O
an O
antagonistic B
anti I
- I
TR55 I
antibody I
was O
used O
. O

Anti B
- I
TR55 I
antibody I
cross O
- O
linking O
in O
chronically O
infected O
U1 O
promonocytic O
cultures O
could O
only O
partially O
substitute O
for O
TNF O
- O
alpha O
- O
induced O
HIV O
- O
1 O
expression O
. O

A O
reporter B
gene I
under O
the O
control O
of O
a O
T B
- I
cell I
antigen I
receptor I
element I
was O
activated O
in O
Jurkat O
cells O
by O
antigen O
receptor O
triggering O
or O
by O
a O
combination O
of O
phorbol O
myristate O
acetate O
, O
which O
activates O
protein B
kinase I
C I
, O
and O
a O
calcium O
ionophore O
. O

By O
Northern O
analysis O
, O
UT O
- O
7 O
cells O
expressed O
detectable O
levels O
of O
beta B
- I
and I
gamma I
- I
globin I
but O
not O
alpha B
- I
globin I
. O

Globin B
chains I
( O
alpha B
, O
beta B
and O
gamma B
) O
were O
clearly O
detectable O
by O
affinity O
chromatography O
in O
UT B
- I
7 I
Epo I
but O
not O
in O
UT O
- O
7 O
cells O
. O

The O
myeloid B
integrin I
CD11b I
is O
expressed O
selectively O
on O
the O
surface O
of O
mature O
macrophages O
, O
monocytes O
, O
neutrophils O
, O
and O
natural O
killer O
cells O
. O

Recent O
isolation O
of O
the O
CD11b B
promoter I
shows O
that O
92 O
base O
pairs O
( O
bp O
) O
of O
5 B
' I
- I
flanking I
DNA I
are O
sufficient O
to O
direct O
myeloid O
- O
specific O
expression O
of O
a O
reporter B
gene I
. O

Target O
antigens O
defined O
by O
autoantibodies B
in O
IDDM O
include O
insulin O
, O
a O
putative O
glycolipid O
that O
reacts O
with O
islet B
cell I
antibodies I
, O
and O
a O
64 B
, I
000 I
- I
M I
( I
r I
) I
protein I
recently O
identified O
as O
glutamic B
acid I
decarboxylase I
. O

R7 O
- O
57 O
reporter O
cells O
, O
on O
the O
other O
hand O
, O
signaled O
induced O
activity O
of O
the O
lytic B
origin I
of I
EBV I
replication I
( O
ori B
Lyt I
) O
. O

Different O
modes O
, O
like O
chemical O
induction O
, O
lytic O
superinfection O
with O
EBV O
and O
single O
gene O
trans O
- O
activation O
converted O
the O
recombinant B
ori I
Lyt I
element I
in O
R7 O
- O
57 O
reporter O
cells O
. O

The O
observation O
that O
a O
mutated B
LT I
- I
kappa I
B I
construct I
( O
M1 B
- I
CAT I
) O
was O
inactive O
in O
C81 O
- O
66 O
- O
45 O
, O
confirmed O
the O
importance O
of O
NF B
- I
kappa I
B I
in O
LT B
gene O
expression O
. O

In O
JM O
T O
cells O
, O
tax B
induced O
LT B
- I
293 I
activity O
by O
two O
- O
to O
four O
- O
fold O
, O
though O
there O
was O
no O
induction O
of O
M1 B
- I
CAT I
. O

This O
indicates O
an O
increase O
in O
either O
episomal B
DNA I
or O
concatameric B
linear I
DNA I
. O

This O
paper O
describes O
how O
the O
expression O
of O
the O
monocyte B
- I
macrophage I
Ag I
, O
CD14 B
, O
and O
the O
low O
affinity B
Fc I
receptor I
for O
IgE B
, O
CD23 B
, O
were O
inversely O
regulated O
during O
VitD3 O
- O
and O
RA O
- O
induced O
monocytic O
differentiation O
of O
human O
U O
- O
937 O
monoblasts O
. O

Cell O
- O
specific O
bifunctional O
role O
of O
Jun B
oncogene I
family I
members I
on O
glucocorticoid B
receptor I
- O
dependent O
transcription O
. O

Increased O
c B
- I
jun I
, O
jun B
- I
B I
, O
and O
jun B
- I
D I
expression O
above O
basal O
levels O
and O
increased O
transcriptional O
activity O
of O
AP B
- I
1 I
/ I
TPA I
responsive I
elements I
fused O
to O
chloramphenicol B
acetyl I
- I
transferase I
vectors I
were O
observed O
in O
T O
cells O
treated O
with O
TPA O
alone O
or O
in O
combination O
with O
dexamethasone O
. O

Studies O
with O
5 B
' I
deletion I
CD20 I
promoter I
- I
CAT I
constructs I
have O
previously O
revealed O
two O
regions O
of O
the O
promoter B
between O
bases O
- O
186 O
and O
- O
280 O
and O
between O
bases O
- O
280 O
and O
- O
454 O
which O
contained O
positive B
regulatory I
elements I
. O

Despite O
this O
lower O
affinity O
, O
a O
trimer O
of O
the O
BAT B
box I
sequence I
was O
as O
efficiently O
transactivated O
by O
an O
Oct B
- I
2 I
expression I
vector I
as O
was O
a O
trimer O
of O
the O
octamer B
sequence I
in O
HeLa O
cells O
. O

Control O
peptides O
corresponding O
to O
the O
normal O
pml B
and O
RAR B
alpha I
proteins I
were O
not O
recognized O
. O

HL O
- O
60 O
cells O
constitutively O
expressing O
an O
Egr B
- I
1 I
transgene I
( O
HL B
- I
60Egr I
- I
1 I
) O
could O
be O
induced O
for O
macrophage O
, O
but O
not O
granulocyte O
, O
differentiation O
. O

Electrophoretic O
mobility O
shift O
assays O
revealed O
three O
specific O
protein B
- I
DNA I
complexes I
formed O
with O
sequences O
of O
the O
EBNA2 B
responsive I
element I
. O

Cotransfection O
of O
an O
hGATA B
- I
3 I
expression I
plasmid I
with O
a O
reporter B
plasmid I
whose O
transcription O
is O
directed O
by O
the O
HIV B
- I
1 I
LTR I
resulted O
in O
6 O
- O
to O
10 O
- O
fold O
stimulation O
of O
LTR B
- O
mediated O
transcription O
, O
whereas O
site O
specific O
mutation O
of O
these O
GATA B
sites I
resulted O
in O
virtual O
abrogation O
of O
the O
activation O
by O
hGATA B
- I
3 I
. O

Early B
B I
- I
cell I
factor I
( O
EBF B
) O
was O
identified O
previously O
as O
a O
tissue O
- O
specific O
and O
differentiation O
stage O
- O
specific O
DNA B
- I
binding I
protein I
that O
participates O
in O
the O
regulation O
of O
the O
pre B
- I
B I
and I
B I
lymphocyte I
- I
specific I
mb I
- I
1 I
gene I
. O

Deletions O
delineated O
a O
carboxy B
- I
terminal I
dimerization I
region I
containing O
two O
repeats O
of O
15 O
amino O
acids O
that O
show O
similarity O
with O
the O
dimerization B
domains I
of O
basic B
- I
helix I
- I
loop I
- I
helix I
proteins I
. O

The O
detection O
of O
this O
protein O
selectively O
in O
extracts O
of O
lymphoid O
cells O
correlates O
with O
the O
presence O
of O
the O
E B
box I
- O
binding O
activity O
LEF1 B
/ I
BCF1 I
in O
these O
cells O
; O
this O
binding O
activity O
was O
previously O
shown O
to O
be O
efficiently O
recognized O
by O
antiserum O
directed O
against O
E2A B
gene I
products I
. O

The O
inhibition O
of O
c B
- I
fos I
and O
c O
- O
jun O
expression O
by O
IL B
- I
4 I
in O
LPS O
- O
treated O
cells O
was O
shown O
to O
be O
due O
to O
a O
lower O
transcription O
rate O
of O
the O
c B
- I
fos I
and I
c I
- I
jun I
genes I
. O

Human B
immunodeficiency I
virus I
type I
1 I
Nef I
protein I
inhibits O
NF B
- I
kappa I
B I
induction O
in O
human O
T O
cells O
. O

These O
results O
indicate O
that O
defective O
recruitment O
of O
NF B
- I
kappa I
B I
may O
underlie O
Nef B
' O
s O
negative O
transcriptional O
effects O
on O
the O
HIV B
- I
1 I
and I
interleukin I
2 I
promoters I
. O

The O
expression O
of O
c B
- I
fos I
, I
c I
- I
jun I
and I
jun I
B I
proto I
- I
oncogenes I
was O
studied O
in O
phytohemagglutinin O
( O
PHA O
) O
activated O
peripheral O
blood O
lymphocytes O
( O
PBL O
) O
from O
young O
and O
aged O
humans O
. O

The O
CD19 B
protein I
is O
expressed O
on O
the O
surface O
of O
all O
B O
- O
lymphoid O
cells O
with O
the O
exception O
of O
terminally O
differentiated O
plasma O
cells O
and O
has O
been O
implicated O
as O
a O
signal O
- O
transducing O
receptor O
in O
the O
control O
of O
proliferation O
and O
differentiation O
. O

This O
high B
- I
affinity I
site I
has O
been O
conserved O
in O
the O
promoters B
of O
both O
human B
and I
mouse I
CD19 I
genes I
and O
was O
furthermore O
shown O
to O
confer O
B O
- O
cell O
specificity O
to O
a O
beta O
- O
globin O
reporter O
gene O
in O
transient O
transfection O
experiments O
. O

This O
variation O
was O
the O
result O
of O
a O
duplication O
of O
a O
short B
DNA I
sequence I
( O
CTG B
- I
motif I
) O
. O

No O
positive O
effect O
of O
the O
duplicated O
CTG B
- I
motif I
could O
be O
detected O
. O

Based O
on O
these O
results O
we O
estimate O
a O
5 O
- O
10 O
% O
difference O
in O
virus O
production O
of O
the O
LTR B
variants I
when O
compared O
to O
that O
of O
wild O
- O
type O
. O

The O
helix B
- I
loop I
- I
helix I
( I
HLH I
) I
proteins I
are O
a O
family O
of O
transcription B
factors I
that O
include O
proteins O
critical O
to O
differentiation O
and O
development O
in O
species O
ranging O
from O
plants O
to O
mammals O
. O

Pulse O
exposure O
of O
HL60 O
to O
radiolabeled O
hormone O
for O
3 O
h O
followed O
by O
culture O
in O
medium O
without O
serum O
and O
calcitriol O
lead O
to O
nuclear O
retention O
of O
approximately O
1600 B
radiolabeled I
VDR I
by O
8 O
h O
and O
approximately O
1000 O
VDR B
by O
24 O
h O
. O

Radiolabeled B
hormone I
/ I
receptor I
complexes I
of O
nuclei O
isolated O
from O
cells O
exposed O
for O
3 O
h O
to O
radiolabeled O
hormone O
- O
- O
in O
contrast O
to O
identical O
experiments O
with O
intact O
cells O
- O
- O
did O
not O
disappear O
from O
the O
nuclear O
compartment O
upon O
incubation O
of O
nuclei O
with O
identical O
concentrations O
of O
the O
unlabeled O
compound O
. O

We O
conclude O
that O
a O
specific O
nuclear O
translocation O
mechanism O
exists O
for O
calcitriol O
in O
both O
cell O
types O
examined O
, O
most O
likely O
due O
to O
translocation O
of O
receptor B
proteins I
after O
hormone O
binding O
. O

Enhanced O
activity O
of O
topoisomerases B
in O
nuclear O
extracts O
upon O
translocation O
of O
VDR B
might O
reflect O
interaction O
of O
both O
within O
the O
nuclear O
compartment O
, O
thus O
initiating O
DNA O
- O
unwinding O
, O
a O
prerequisite O
of O
transcription O
initiation O
. O

Regulation O
of O
replicative O
functions O
in O
the O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
genome I
is O
mediated O
through O
activation O
of O
a O
virally B
encoded I
transcription I
factor I
, O
Z B
( O
BZLF1 B
) O
. O

The O
long B
terminal I
repeat I
( I
LTR I
) I
region I
of O
HIV B
proviral I
DNA I
contains O
binding O
sites O
for O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
and O
this O
transcriptional B
activator I
appears O
to O
regulate O
HIV O
activation O
. O

REV B
LTRs I
work O
efficiently O
in O
human O
lymphoid O
cells O
, O
and O
are O
viable O
alternatives O
to O
promoters B
commonly O
used O
for O
expression O
of O
cloned B
genes I
. O

Thus O
, O
Elf B
- I
1 I
is O
a O
novel B
transcription I
factor I
that O
appears O
to O
be O
required O
for O
the O
T O
- O
cell O
- O
receptor O
- O
mediated O
trans O
activation O
of O
HIV O
- O
2 O
gene O
expression O
. O

A O
novel B
T I
cell I
- I
specific I
negative I
regulatory I
element I
( O
NRE B
) O
composed O
of O
two O
protein O
- O
binding O
sites O
were O
mapped O
in O
the O
5 O
' O
flanking O
region O
of O
the O
IL B
- I
4 I
gene I
: O
- O
311CTCCCTTCT O
- O
303 O
( O
NRE B
- I
I I
) O
and O
- O
288CTTTTTGCTT O
- O
TGC O
- O
300 O
( O
NRE B
- I
II I
) O
. O

A O
T B
cell I
- I
specific I
protein I
Neg B
- I
1 I
and O
a O
ubiquitous B
protein I
Neg B
- I
2 I
binding O
to O
NRE B
- I
I I
and O
NRE B
- I
II I
, O
respectively O
, O
were O
identified O
. O

In O
this O
article O
, O
transcriptional O
regulation O
of O
the O
archetypal B
T I
- I
cell I
- I
specific I
gene I
, O
alpha B
TCR I
, O
is O
discussed O
. O

Differential O
binding O
affinities O
were O
also O
obtained O
with O
p50 B
- I
and I
c I
- I
Rel I
- I
selected I
sequences I
. O

These O
findings O
demonstrate O
that O
interaction O
of O
both O
subunits O
of O
the O
heterodimeric B
NF I
- I
kappa I
B I
complex I
with O
DNA O
is O
required O
for O
DNA O
binding O
and O
transcriptional O
activation O
and O
suggest O
that O
transcriptional O
activation O
mediated O
by O
the O
individual O
rel B
- I
related I
proteins I
will O
differ O
dramatically O
, O
depending O
on O
the O
specific O
kappa O
B O
motifs O
present O
. O

Blockade O
of O
the O
DNA B
- I
binding I
complexes I
with O
an O
anti B
- I
Fos I
mAb I
demonstrated O
a O
direct O
participation O
of O
c B
- I
Fos I
in O
the O
AP B
- I
1 I
complexes I
induced O
by O
anti B
- I
AIM I
mAb I
. O

Immunoglobulin B
molecules I
on O
the O
surface O
of O
a O
B O
lymphocyte O
are O
the O
endogenous O
` O
` O
receptors O
' O
' O
to O
which O
specific O
antigens O
bind O
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- B
95 I
and I
- I
36 I
bp I
relative O
to O
the O
transcription B
start I
site I
. O

Within O
this O
region O
, O
single O
AP B
- I
2 I
- I
and I
AP I
- I
1 I
- I
like I
consensus I
sequences I
were O
noted O
. O

Expression O
of O
M10 B
did O
not O
affect O
induction O
of O
HIV O
transcription O
mediated O
by O
the O
kappa B
B I
regulatory I
element I
or O
Tat B
. O

The O
present O
work O
has O
examined O
the O
effects O
of O
okadaic O
acid O
, O
an O
inhibitor O
of O
type B
1 I
and I
2A I
protein I
phosphatases I
, O
on O
the O
regulation O
of O
c B
- I
jun I
expression O
during O
monocytic O
differentiation O
of O
U O
- O
937 O
leukemia O
cells O
. O

Pit B
- I
1 I
is O
a O
pituitary B
- I
specific I
transcription I
factor I
that O
binds O
to O
and O
transactivates O
promoters B
of O
growth B
hormone I
and I
prolactin I
genes I
. O

The O
former O
two O
substances O
interact O
with O
T O
cells O
via O
the O
glucocorticoid B
and I
beta I
- I
adrenergic I
receptors I
respectively O
. O

In O
vivo O
footprint O
analysis O
of O
the O
HLA B
- I
DRA I
gene I
promoter I
: O
cell O
- O
specific O
interaction O
at O
the O
octamer B
site I
and O
up O
- O
regulation O
of O
X O
box O
binding O
by O
interferon B
gamma I
. O

CsA O
was O
found O
not O
to O
inhibit O
lck B
gene O
expression O
, O
nor O
the O
activity O
of O
the O
lck B
gene I
product O
. O

Mice O
transgenic O
for O
the O
human B
T I
cell I
leukemia I
virus I
( I
HTLV I
- I
I I
) I
Tax I
gene I
develop O
fibroblastic O
tumors O
that O
express O
NF B
- I
kappa I
B I
- I
inducible I
early I
genes I
. O

Leukotriene O
B4 O
transcriptionally O
activates O
interleukin B
- I
6 I
expression O
involving O
NK B
- I
chi I
B I
and O
NF B
- I
IL6 I
. O

[ O
Age O
- O
related O
changes O
in O
glucocorticoid B
and I
mineralocorticoid I
receptors I
in O
lymphocytes O
of O
healthy O
persons O
and O
patients O
with O
hypertension O
] O

Here O
, O
Stuart O
Schreiber O
and O
Gerald O
Crabtree O
review O
recent O
findings O
that O
indicate O
CsA O
and O
FK506 O
operate O
as O
prodrugs O
: O
they O
bind O
endogenous B
intracellular I
receptors I
, O
the O
immunophilins B
, O
and O
the O
resulting O
complex O
targets O
the O
protein B
phosphatase I
, I
calcineurin B
, O
to O
exert O
the O
immunosuppressive O
effect O
. O

Mutations O
affecting O
the O
5 B
' I
guanine I
residues I
of O
the O
kappa B
B I
site I
were O
unable O
to O
compete O
for O
these O
NF B
- I
kappa I
B I
- I
related I
proteins I
. O

Inducibility O
of O
endogenous O
IFN B
- I
beta I
and I
IFN I
- I
alpha I
RNA I
was O
also O
increased O
in O
PLB O
- O
IIIB O
cells O
. O

Second O
is O
a O
controlled O
phase O
of O
TCR B
gene I
rearrangement O
. O

It O
seems O
that O
the O
rearrangement O
of O
the O
TCR B
gamma I
loci I
in O
the O
gamma O
delta O
lineage O
may O
not O
always O
take O
place O
at O
a O
developmental O
stage O
strictly O
equivalent O
to O
the O
rearrangement O
of O
TCR B
beta I
in O
the O
alpha O
beta O
lineage O
, O
and O
it O
is O
not O
clear O
just O
how O
early O
the O
two O
lineages O
diverge O
. O

We O
have O
biochemically O
and O
functionally O
characterized O
a O
new O
transcription B
factor I
, O
NP B
- I
TCII I
, O
which O
is O
present O
in O
nuclei O
from O
unstimulated O
T O
and O
B O
lymphocytes O
but O
is O
not O
found O
in O
nonhematopoietic O
cells O
. O

Chloramphenicol B
acetyl I
transferase I
( O
CAT B
) O
assays O
using O
the O
HIV B
- I
1 I
( I
- I
139 I
) I
long I
terminal I
repeat I
- I
CAT I
construct I
showed O
no O
PMA O
induction O
of O
CAT B
activity O
in O
these O
subclones O
( O
unlike O
the O
parental O
line O
and O
other O
subclones O
) O
. O

Although O
it O
has O
been O
previously O
shown O
that O
the O
IL B
- I
6 I
kappa I
B I
motif I
functions O
as O
a O
potent O
IL B
- I
1 I
/ I
tumor I
necrosis I
factor I
- I
responsive I
element I
in O
nonlymphoid O
cells O
, O
its O
activity O
was O
found O
to O
be O
repressed O
in O
lymphoid O
cells O
such O
as O
a O
Jurkat O
T O
- O
cell O
line O
. O

After O
the O
DNA B
fragment I
containing O
the O
CAG B
repeats I
is O
amplified O
by O
the O
polymerase O
chain O
reaction O
, O
a O
primer O
extension O
is O
carried O
out O
; O
the O
extension O
of O
the O
end B
- I
labelled I
reverse I
primer I
adjacent O
to O
3 B
' I
end I
of O
CAG B
repeats I
stops O
at O
the O
first O
T O
after O
CAG B
repeats I
with O
the O
incorporation O
of O
dideoxy O
ATP O
in O
the O
reaction O
mixture O
. O

It O
is O
evident O
that O
assembly O
of O
the O
surface B
domain I
of O
TF B
with O
VIIa B
to O
form O
the O
binary O
TF B
. I
VIIa I
complex I
induces O
a O
significant O
increase O
in O
the O
Kcat O
of O
the O
catalytic B
domain I
of O
VIIa B
for O
small O
peptidyl O
substrates O
and O
more O
profoundly O
for O
protein B
substrate I
. O

It O
is O
also O
evident O
that O
association O
of O
X B
with O
charged O
phospholipid O
surfaces O
enhances O
the O
proteolytic O
activation O
of O
this O
zymogen B
by O
increasing O
recognition O
and O
susceptibility O
of O
the O
sessile O
peptide O
bond O
deduced O
from O
the O
markedly O
decreased O
Km O
and O
increased O
Kcat O
. O

In O
THP O
- O
1 O
cells O
, O
TPA O
also O
induced O
a O
new O
, O
faster B
- I
migrating I
NF I
kappa I
B I
species I
not O
induced O
in O
monocytes O
. O

The O
endothelium O
plays O
a O
critical O
role O
in O
inflammation O
by O
directing O
circulating O
leukocytes O
into O
extravascular O
tissues O
by O
expressing O
adhesive B
molecules I
for O
leukocytes O
[ O
e O
. O
g O
. O
, O
endothelial B
- I
leukocyte I
adhesion I
molecule I
1 I
( O
ELAM B
- I
1 I
) O
and O
intercellular B
adhesion I
molecule I
1 I
( O
ICAM B
- I
1 I
) O
] O
. O

Biochemical O
purification O
and O
cDNA O
cloning O
has O
now O
revealed O
that O
BSAP B
belongs O
to O
the O
family O
of O
paired B
domain I
proteins I
. O

We O
have O
found O
that O
the O
p49 B
( I
100 I
) I
DNA I
binding I
subunit I
, O
together O
with O
p65 B
, O
can O
act O
in O
concert O
with O
Tat B
- I
I I
to O
stimulate O
the O
expression O
of O
HIV B
- I
CAT I
plasmid I
. O

Little O
effect O
was O
observed O
with O
50 B
- I
kDa I
forms I
of O
p105 B
NF B
- I
kappa I
B I
or O
rel B
, O
in O
combination O
with O
p65 B
or O
full B
- I
length I
c I
- I
rel I
, O
which O
do O
not O
stimulate O
the O
HIV B
enhancer I
in O
these O
cells O
. O

Stable O
expression O
of O
HB24 B
, O
a O
diverged B
human I
homeobox I
gene I
, O
in O
T O
lymphocytes O
induces O
genes O
involved O
in O
T O
cell O
activation O
and O
growth O
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
identified O
two O
potential O
Ets B
binding I
sites I
, O
EBS1 O
and O
EBS2 B
, O
which O
are O
conserved O
in O
both O
the O
human B
and I
murine I
interleukin I
- I
2 I
enhancers I
. O

Possible O
mechanisms O
by O
which O
these O
proteins O
may O
regulate O
transcription O
of O
the O
epsilon B
- I
globin I
- I
encoding I
gene I
in O
erythroid O
and O
non O
- O
erythroid O
cells O
are O
discussed O
. O

This O
protein O
is O
distinct O
from O
other O
members O
of O
the O
steroid B
/ I
thyroid I
hormone I
receptor I
family I
including O
the O
COUP B
protein I
which O
has O
a O
closely O
related O
DNA O
binding O
specificity O
. O

Further O
, O
we O
observe O
that O
TAR B
- I
deleted I
mutants I
of O
HIV O
- O
1 O
demonstrate O
normal O
late O
gene O
expression O
in O
glial O
cells O
as O
evidenced O
by O
syncytia O
formation O
and O
production O
of O
viral B
p24 I
antigen I
. O

At O
least O
two O
21 B
bp I
repeats I
were O
required O
for O
high O
levels O
of O
AP B
- I
2 I
activation O
and O
mutagenesis O
of O
the O
AP B
- I
2 I
consensus I
binding I
sequences I
in O
the O
21 B
bp I
repeats I
eliminate O
this O
activation O
. O

The O
promoter O
of O
the O
major B
histocompatibility I
class I
II I
gene I
DRA B
contains O
an O
octamer B
element I
( O
ATTTGCAT O
) O
that O
is O
required O
for O
efficient O
DRA B
expression O
in O
B O
cells O
. O

Recombinant B
OTF I
- I
2 I
protein I
produced O
by O
in O
vitro O
transcription O
/ O
translation O
could O
also O
enhance O
DRA B
gene I
transcription O
in O
vitro O
. O

Furthermore O
, O
an O
antiserum O
against O
KBF1 B
( O
identical O
to O
50 B
kDa I
NF I
- I
kappa I
B I
protein I
) O
reacted O
with O
the O
p50 B
of O
NF B
- I
GM2 I
, O
indicating O
that O
the O
NF B
- I
GM2 I
polypeptide I
can O
not O
be O
immunologically O
differentiated O
from O
the O
50 B
kDa I
subunit I
of O
NF B
- I
kappa I
B I
. O

This O
suggests O
that O
the O
activation O
mechanism O
of O
the O
GM B
- I
CSF I
gene I
through O
the O
GM2 B
/ I
GC I
- I
box I
sequence I
is O
different O
from O
that O
of O
genes O
carrying O
the O
kappa B
B I
enhancer I
alone O
. O

The O
C B
- I
terminus I
has O
a O
putative O
protein B
kinase I
C I
phosphorylation I
site I
. O

A O
DNA B
probe I
that O
spanned O
a O
domain O
conserved O
among O
the O
proto B
- I
oncogene I
c I
- I
rel I
, O
the O
Drosophila B
morphogen I
dorsal I
, O
and O
the O
p50 B
DNA I
binding I
subunit I
of O
NF B
- I
kappa I
B I
was O
generated O
from O
Jurkat B
T I
cell I
complementary I
DNA I
with O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
degenerate O
oligonucleotides O
. O

This O
probe O
was O
used O
to O
identify O
a O
rel B
- I
related I
complementary I
DNA I
that O
hybridized O
to O
a O
2 B
. I
6 I
- I
kilobase I
messenger I
RNA I
present O
in O
human O
T O
and O
B O
lymphocytes O
. O

In O
vitro O
transcription O
and O
translation O
of O
the O
complementary B
DNA I
resulted O
in O
the O
synthesis O
of O
a O
protein O
with O
an O
apparent O
molecular O
size O
of O
65 B
kilodaltons I
( O
kD O
) O
. O

This O
protein B
- I
DNA I
complex I
comigrated O
with O
the O
complex O
obtained O
with O
the O
purified B
human I
p65 I
NF I
- I
kappa I
B I
subunit I
and O
binding O
was O
inhibited O
by O
I B
kappa I
B I
- I
alpha I
and O
- O
beta O
proteins O
. O

v B
- I
erbA I
overexpression O
is O
required O
to O
extinguish O
c B
- I
erbA I
function O
in O
erythroid O
cell O
differentiation O
and O
regulation O
of O
the O
erbA B
target I
gene I
CAII B
. O

The O
v B
- I
erbA I
oncoprotein I
represents O
a O
retrovirus O
- O
transduced O
oncogenic O
version O
of O
the O
thyroid B
hormone I
( I
T3 I
/ I
T4 I
) I
receptor I
c B
- I
erbA I
( I
type I
alpha I
) I
. O

This O
erbA B
- I
binding I
site I
confers O
thyroid O
hormone O
responsiveness O
to O
a O
heterologous B
promoter I
in O
transient O
expression O
experiments O
and O
is O
a O
target O
for O
efficient O
down O
- O
regulation O
of O
CAII B
transcription O
by O
the O
v B
- I
erbA I
oncoprotein I
. O

The O
CD2 B
T I
lymphocyte I
glycoprotein I
surface I
molecule I
mediates O
both O
cell O
to O
cell O
adhesion O
and O
T O
cell O
activation O
, O
two O
processes O
that O
are O
involved O
in O
the O
spread O
of O
HIV O
infection O
. O

The O
effect O
is O
mediated O
by O
the O
NF B
- I
kappa I
B I
transcription B
factor I
which O
is O
potently O
and O
rapidly O
activated O
by O
an O
H2O2 O
treatment O
of O
cells O
from O
its O
inactive B
cytoplasmic I
form I
. O

One O
gene O
of O
interest O
is O
the O
glycoprotein B
IIb I
( I
GPIIb I
) I
gene I
; O
GPIIb B
, O
the O
alpha B
subunit I
of O
the O
platelet B
cytoadhesin I
GPIIb I
- I
IIIa I
, O
is O
produced O
in O
megakaryocytes O
at O
an O
early O
stage O
of O
the O
differentiation O
, O
whereas O
the O
other O
subunit O
of O
this O
complex O
, O
GPIIIa B
, O
is O
expressed O
in O
other O
cells O
. O

The O
conversion O
of O
the O
TCEd B
to O
a O
' B
perfect I
' I
NF I
- I
kB I
binding I
site I
leads O
to O
a O
tighter O
binding O
of O
NF B
- I
kB I
to O
TCEd B
DNA I
and O
, O
as O
a O
functional O
consequence O
, O
to O
the O
activity O
of O
the O
' B
converted I
' I
TCEd I
motifs I
in O
HeLa O
cells O
. O

Previously O
, O
transcription O
of O
the O
c B
- I
fos I
gene I
has O
been O
reported O
to O
be O
transactivated O
by O
the O
viral B
transcription I
factor I
, O
Tax1 B
. O

In O
lymphocytes O
activated O
either O
by O
PHA B
or O
OKT3 B
( O
but O
not O
in O
resting O
cells O
) O
, O
a O
50 B
- I
kDa I
species I
cross O
- O
reacting O
with O
a O
monoclonal B
antibody I
against O
the O
intestinal B
vitamin I
D I
receptor I
was O
detected O
. O

Finally O
, O
RNA O
from O
activated O
lymphocytes O
was O
amplified O
by O
polymerase O
chain O
reaction O
using O
oligonucleotide O
primers O
flanking O
the O
196 B
base I
pair I
long I
region I
encoding O
the O
DNA B
- I
binding I
domain I
of O
the O
human B
intestinal I
receptor I
. O

These O
findings O
suggest O
that O
expression O
of O
the O
1 B
, I
25 I
- I
( I
OH I
) I
2D3 I
receptor I
in O
lymphocytes O
is O
triggered O
by O
distinct O
and O
contingent O
signals O
, O
and O
that O
the O
protein O
and O
the O
mRNA B
encoding O
it O
are O
identical O
to O
the O
classical B
vitamin I
D I
receptor I
. O

We O
have O
investigated O
the O
constitutive O
and O
inducible O
transcriptional O
activity O
mediated O
by O
five O
kappa B
B I
- I
related I
sequence I
elements I
in O
two O
different O
cell O
types O
. O

Previously O
, O
a O
nuclear B
factor I
, O
IRF B
- I
1 I
( O
interferon B
regulatory I
factor I
1 I
) O
, O
which O
binds O
to O
type B
I I
IFN I
and O
some O
IFN B
- I
inducible I
gene I
promoters I
, O
was O
identified O
and O
cloned O
. O

A O
dimerization B
cofactor I
of O
HNF B
- I
1 I
alpha I
( O
DCoH B
) O
was O
identified O
that O
displayed O
a O
restricted O
tissue O
distribution O
and O
did O
not O
bind O
to O
DNA O
, O
but O
, O
rather O
, O
selectively O
stabilized O
HNF B
- I
1 I
alpha I
dimers I
. O

Previous O
studies O
have O
shown O
that O
treatment O
of O
human O
myeloid O
leukemia O
cells O
with O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
is O
associated O
with O
induction O
of O
monocytic O
differentiation O
and O
expression O
of O
the O
c B
- I
jun I
and I
c I
- I
fos I
early I
response I
genes I
. O

Although O
absent O
in O
nonexpressing O
erythroleukemia O
cell O
lines O
, O
the O
DNase B
I I
site I
is O
present O
in O
uninduced O
myelomonocytic O
cell O
lines O
and O
is O
not O
changed O
after O
PMA O
induction O
. O

The O
nuclear O
extracts O
from O
resting O
and O
induced O
ML O
- O
1 O
cells O
contain O
proteins O
binding O
specifically O
to O
the O
AP B
- I
1 I
, I
AP I
- I
2 I
, I
and I
NF I
kappa I
B I
sequence I
located O
within O
the O
TNF B
promoter I
. O

Transforming B
growth I
factor I
- I
beta I
suppresses O
human B
B I
lymphocyte I
Ig I
production O
by O
inhibiting O
synthesis O
and O
the O
switch O
from O
the O
membrane B
form I
to O
the O
secreted B
form I
of O
Ig B
mRNA I
. O

One O
of O
the O
members O
of O
this O
multigene O
family O
, O
cGATA B
- I
3 I
, O
is O
most O
abundantly O
expressed O
in O
the O
T O
- O
lymphocyte O
cell O
lineage O
. O

The O
murine B
and I
human I
factors I
are O
abundantly O
expressed O
in O
a O
variety O
of O
human O
and O
murine O
T O
- O
cell O
lines O
and O
can O
activate O
transcription O
through O
a O
tissue B
- I
specific I
GATA I
- I
binding I
site I
identified O
within O
the O
human B
T I
- I
cell I
receptor I
delta I
gene I
enhancer I
. O

Expression O
of O
c B
- I
jun I
, I
jun I
B I
and I
jun I
D I
proto I
- I
oncogenes I
in O
human O
peripheral O
- O
blood O
granulocytes O
. O

We O
have O
found O
that O
purified O
human O
peripheral O
- O
blood O
granulocytes O
express O
constitutively O
significant O
levels O
of O
proto B
- I
oncogenes I
c B
- I
jun I
, I
jun I
B I
and I
jun I
D I
mRNA I
. O

The O
29 B
- I
kDa I
proteins I
phosphorylated O
in O
thrombin O
- O
activated O
human O
platelets O
are O
forms O
of O
the O
estrogen B
receptor I
- I
related I
27 I
- I
kDa I
heat I
shock I
protein I
. O

We O
have O
isolated O
a O
human B
cDNA I
clone I
encoding O
a O
zinc B
finger I
protein I
( O
NF B
- I
E1 I
) O
that O
binds O
to O
the O
negative B
- I
acting I
segment I
of O
the O
kappa B
E3 I
' I
enhancer I
. O

This O
protein O
also O
binds O
to O
the O
immunoglobulin B
heavy I
- I
chain I
enhancer I
mu I
E1 I
site I
. O

NF B
- I
E1 I
is O
also O
the O
human B
homologue I
of O
the O
mouse B
delta I
protein I
, O
which O
binds O
to O
ribosomal B
protein I
gene I
promoters I
. O

An O
upstream B
segment I
contains O
tandem B
dinucleotide I
repeats I
( B
CT I
) I
19 I
/ I
( I
CA I
) I
16 I
. O

There O
is O
a O
suitably O
located O
TATA B
box I
, O
but O
potential O
sites O
for O
CCAAT B
- I
box I
binding I
factors I
are O
far O
upstream O
, O
embedded O
in O
a O
42 B
- I
nucleotide I
repeat I
element I
. O

A O
thymus B
- I
specific I
member I
of O
the O
HMG B
protein I
family I
regulates O
the O
human B
T I
cell I
receptor I
C I
alpha I
enhancer I
. O

The O
human B
T I
cell I
- I
specific I
transcription I
factor I
TCF B
- I
1 I
alpha I
plays O
a O
key O
role O
in O
the O
tissue O
- O
specific O
activation O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
C O
alpha O
enhancer O
and O
binds O
to O
pyrimidine B
- I
rich I
elements I
( O
5 O
' O
- O
PyCTTTG O
- O
3 O
' O
) O
present O
in O
a O
variety O
of O
other O
T B
cell I
- I
specific I
control I
regions I
. O

TCF B
- I
1 I
alpha I
is O
currently O
unique O
among O
the O
newly O
emerging O
family O
of O
DNA B
- I
binding I
regulatory I
proteins I
that O
share O
the O
HMG B
motif I
in O
that O
it O
is O
a O
highly B
tissue I
- I
specific I
RNA I
polymerase I
II I
transcription B
factor I
. O

Ectopic O
expression O
of O
cloned B
Oct2 I
cDNA I
was O
shown O
to O
be O
sufficient O
to O
reconstitute O
at O
least O
some O
aspects O
of O
this O
regulation O
in O
non O
- O
lymphoid O
cells O
. O

We O
describe O
the O
isolation O
and O
characterization O
of O
multiple B
cDNAs I
encoding O
mouse B
Oct2 I
from O
a O
mature O
B O
- O
cell O
line O
and O
we O
show O
that O
a O
variety O
of O
isoforms O
of O
this O
transcription B
factor I
is O
generated O
from O
a O
single O
gene O
by O
an O
alternative O
splicing O
mechanism O
. O

Thus O
, O
both O
NF B
- I
kappa I
B I
- I
binding I
complexes I
are O
needed O
for O
optimal O
viral O
transcription O
. O

Binding O
of O
the O
65 B
- I
kDa I
plus O
50 B
- I
kDa I
heterodimer I
to O
the O
HIV B
- I
1 I
enhancer I
can O
be O
negatively O
regulated O
in O
monocytes O
, O
providing O
one O
mechanism O
restricting O
HIV B
- I
1 I
gene I
expression O
. O

Formation O
of O
the O
protein B
- I
DNA I
complex I
with O
the O
C26 B
subfragment I
was O
positively O
affected O
by O
p40tax B
. O

Moreover O
, O
kappa B
1 I
- I
kappa I
3 I
can O
each O
be O
deleted O
from O
the O
TNF B
- I
alpha I
promoter I
with O
little O
effect O
on O
the O
gene O
' O
s O
inducibility O
by O
PMA O
. O

We O
have O
generated O
a O
monoclonal B
antibody I
, O
BZ1 B
, O
to O
BZLF1 B
which O
reacts O
in O
immunohistology O
, O
immunoblotting O
, O
and O
immunoprecipitation O
and O
which O
recognizes O
both O
the O
active B
, I
dimeric I
form I
and O
the O
inactive B
, I
monomeric I
form I
of O
the O
protein O
. O

NF B
- I
kB I
is O
a O
eukaryotic B
transcription I
regulatory I
factor I
. O

Low O
levels O
of O
c B
- I
jun I
transcripts I
were O
detectable O
in O
resting O
human O
peripheral O
blood O
monocytes O
. O

Moreover O
, O
M B
- I
CSF I
- O
induced O
expression O
of O
the O
fos B
- I
related I
gene I
, O
fra B
- I
1 I
, O
was O
delayed O
compared O
to O
that O
for O
both O
c B
- I
fos I
and O
fos B
- I
B I
. O

Over O
the O
past O
decade O
it O
has O
become O
clear O
that O
glucocorticosteroid B
receptors I
play O
a O
significant O
role O
in O
the O
mechanism O
of O
glucocorticosteroid O
action O
. O

Glucocorticosteroid B
receptors I
on O
leukocytes O
of O
patients O
with O
SLE O
were O
significantly O
higher O
than O
in O
healthy O
controls O
( O
4419 O
+ O
/ O
- O
306 O
vs O
3369 O
+ O
/ O
- O
196 O
, O
p O
less O
than O
0 O
. O
005 O
) O
. O

HIV1 O
infection O
of O
human O
monocytes O
and O
macrophages O
promotes O
induction O
or O
translocation O
of O
NF B
- I
KB I
- I
related I
factors I
. O

Levels O
of O
c B
- I
fos I
and I
c I
- I
jun I
transcripts I
remained O
elevated O
during O
periods O
of O
PKC B
activation O
and O
also O
returned O
to O
levels O
observed O
in O
control O
cells O
by O
30 O
- O
36 O
days O
, O
when O
the O
cells O
entered O
retrodifferentiation O
. O

DNA O
binding O
by O
all O
four O
of O
these O
Rel B
- I
related I
factors I
is O
blocked O
by O
selective O
chemical O
modification O
of O
lysine O
and O
arginine O
residues O
, O
suggesting O
that O
both O
of O
these O
basic O
amino O
acids O
are O
required O
for O
binding O
to O
the O
kappa B
B I
element I
. O

In O
contrast O
, O
mild O
oxidation O
with O
glucose B
oxidase I
selectively O
inhibits O
p75 B
and O
p85 B
binding O
while O
not O
blocking O
p50 B
and O
p55 B
interactions O
. O

In O
addition O
, O
cell B
- I
free I
synthesized I
hGR I
was O
capable O
of O
specific O
binding O
to O
glucocorticoid B
response I
element I
( I
GRE I
) I
- I
containing I
DNA I
fragments I
. O

DNA O
binding O
by O
in B
vitro I
synthesized I
GR I
was O
blocked O
by O
the O
addition O
of O
sodium O
molybdate O
to O
the O
receptor O
preparations O
before O
steroid O
addition O
and O
thermal O
activation O
. O

Oligonucleotides O
containing O
the O
consensus B
GRE I
were O
the O
most O
efficient O
competitors O
, O
and O
fragments O
containing O
regulatory B
sequences I
from O
glucocorticoid B
- I
repressible I
genes I
were O
somewhat O
competitive O
, O
whereas O
single O
stranded O
oligonucleotides O
were O
unable O
to O
compete O
for O
mouse B
mammary I
tumor I
virus I
- I
long I
terminal I
repeat I
DNA O
binding O
, O
except O
when O
competitor O
was O
present O
at O
extremely O
high O
concentrations O
. O

These O
studies O
have O
been O
extended O
to O
show O
that O
( O
i O
) O
a O
mutant O
EBV O
strain O
lacking O
the O
gene O
encoding O
EBNA B
2 I
fails O
to O
switch O
from O
Wp O
to O
Cp B
usage O
in O
primary O
B O
lymphocytes O
, O
although O
the O
virus O
contains O
a O
functional O
Cp B
; O
( O
ii O
) O
a O
region O
from O
- B
429 I
to I
- I
245 I
base I
pairs I
upstream O
of O
Cp B
is O
essential O
for O
Cp B
activity O
in O
B O
lymphocytes O
, O
but O
only O
in O
the O
context O
of O
upstream B
and I
downstream I
sequences I
; O
( O
iii O
) O
this O
region O
contains O
an O
EBNA B
2 I
- I
dependent I
enhancer I
; O
and O
( O
iv O
) O
DNase B
I I
protection O
employing O
nuclear O
extracts O
from O
B O
and O

T O
lymphocytes O
revealed O
a O
B B
- I
cell I
- I
specific I
footprint I
in O
the O
region O
of O
the O
EBNA B
2 I
- I
dependent I
enhancer I
. O

Immune O
response O
of O
peripheral O
blood O
mononuclear O
cells O
to O
HBx B
- I
antigen I
of O
hepatitis O
B O
virus O
. O

Five O
T O
- O
cell O
clones O
specific O
for O
a O
T B
- I
cell I
epitope I
located O
at O
the O
carboxyterminal B
region I
of O
HBxAg B
were O
established O
and O
found O
to O
belong O
to O
the O
CD2 O
/ O
CD4 O
- O
positive O
, O
CD8 O
- O
negative O
subtype O
. O

The O
NF B
kappa I
B I
independent I
cis I
- I
acting I
sequences I
in O
HIV B
- I
1 I
LTR I
responsive O
to O
T O
- O
cell O
activation O
. O

The O
rate O
of O
LTR B
- O
directed O
gene O
expression O
increased O
in O
response O
to O
treatment O
with O
either O
a O
phorbol O
ester O
or O
tumor B
necrosis I
factor I
alpha I
if O
either O
the O
NFAT B
- I
1 I
or O
NF B
kappa I
B I
binding I
sites I
were O
deleted O
, O
but O
failed O
to O
respond O
to O
these O
mitogenic O
stimuli O
if O
both O
sequences O
were O
absent O
. O

Activation O
of O
proenkephalin O
transcription O
by O
JunD B
is O
dependent O
upon O
a O
previously O
characterized O
cAMP B
- I
, I
phorbol I
ester I
- I
, I
and I
Ca I
( I
2 I
+ I
) I
- I
inducible I
enhancer I
, O
and O
JunD B
is O
shown O
to O
bind O
the O
enhancer B
as O
a O
homodimer B
. O

Furthermore O
, O
the O
ability O
of O
these O
complexes O
to O
regulate O
gene O
expression O
is O
demonstrated O
by O
increased O
transcription O
from O
an O
AP B
- I
1 I
driven I
reporter I
construct I
and O
marked O
increases O
in O
the O
expression O
of O
endogenous B
AP I
- I
1 I
regulated I
genes I
. O

TCF B
- I
1 I
belonged O
to O
a O
novel O
family O
of O
genes O
that O
contain O
the O
so O
- O
called O
high O
mobility B
group I
1 I
( I
HMG I
) I
box I
. O

Third O
, O
TCF B
- I
1 I
bound O
specifically O
to O
a O
functional O
T B
cell I
- I
specific I
element I
in O
the O
T B
cell I
receptor I
alpha I
( I
TCR I
- I
alpha I
) I
enhancer I
. O

Northern O
blot O
analysis O
of O
polyadenylated B
RNA I
purified O
from O
activated O
human O
B O
cells O
revealed O
a O
single B
mRNA I
transcript I
of O
approximately O
2 O
. O
3 O
kb O
. O

There O
is O
a O
single O
methionine B
codon I
- I
initiated I
open I
reading I
frame I
of O
1 O
, O
458 O
nt O
in O
frame O
with O
a O
homeobox B
and O
a O
CAX B
repeat I
, O
and O
the O
open B
reading I
frame I
is O
predicted O
to O
encode O
a O
protein O
of O
51 O
, O
659 O
daltons O
. O

Tandem O
copies O
of O
this O
67 B
- I
bp I
MnlI I
- I
AluI I
fragment I
, O
when O
fused O
to O
the O
chloramphenicol B
acetyltransferase I
gene I
driven O
by O
the O
conalbumin B
promoter I
, O
stimulated O
transcription O
in O
B O
cells O
but O
not O
in O
Jurkat O
T O
cells O
or O
HeLa O
cells O
. O

Footprinting O
analysis O
revealed O
that O
the O
identical O
sequence O
CCGAAACTGAAAAGG O
, O
designated O
E6 B
, O
was O
protected O
by O
nuclear O
extracts O
from O
B O
cells O
, O
T O
cells O
, O
or O
HeLa O
cells O
. O

Gel O
mobility O
shift O
assays O
using O
a O
synthetic B
E6 I
motif I
detected O
a O
B B
- I
cell I
- I
specific I
complex I
in O
addition O
to O
a O
ubiquitous O
band O
found O
also O
in O
T O
cells O
and O
HeLa O
cells O
. O

In O
agreement O
with O
the O
results O
of O
gel O
retardation O
assays O
, O
tandem O
copies O
of O
the O
E6 B
motif I
stimulated O
transcription O
in O
ARH77 O
and O
Raji O
cells O
but O
not O
in O
Jurkat O
or O
HeLa O
cells O
. O

Interestingly O
, O
the O
MnlI B
- I
AluI I
fragment I
could O
suppress O
the O
basal O
- O
level O
activity O
of O
the O
conalbumin B
promoter I
in O
both O
Jurkat O
and O
HeLa O
cells O
. O

Thus O
, O
the O
novel O
enhancer O
element O
identified O
in O
this O
study O
is O
probably O
a O
target O
site O
for O
both O
positive B
and I
negative I
factors I
. O

However O
, O
blockade O
of O
the O
Ca B
( I
2 I
+ I
) I
- I
activated I
K I
+ I
channel I
is O
not O
associated O
with O
changes O
in O
cell O
- O
cycle O
gene O
activation O
, O
IL B
- I
2 I
production O
, O
IL B
- I
2R I
expression O
or O
B O
and O
T O
cell O
mitogenesis O
. O

From O
information O
available O
in O
the O
literature O
on O
the O
substrate O
specificity O
of O
the O
three O
enzymes B
, O
it O
is O
clear O
that O
a O
cysteine O
is O
not O
accepted O
in O
any O
of O
the O
S2 B
, I
S1 I
, I
S1 I
' I
, I
and I
S2 I
' I
subsites I
of O
cathepsin B
B I
and I
L I
, O
and O
not O
in O
the O
S1 B
and O
S1 B
' I
subsites O
of O
cathepsin B
D I
. O

Starting O
with O
a O
replication O
- O
incompetent O
molecular O
clone O
of O
human O
immunodeficiency O
virus O
type O
1 O
, O
lacking O
all O
the O
NF B
- I
kappa I
B I
and I
Sp1 I
binding I
sites I
present O
in O
the O
native B
long I
terminal I
repeat I
( O
LTR B
) O
, O
proviruses O
containing O
reconstructed B
LTRs I
with O
individual O
or O
combinations O
of O
NF B
- I
kappa I
B I
and I
Sp1 I
elements I
were O
generated O
and O
evaluated O
for O
their O
capacity O
to O
produce O
virus O
progeny O
following O
transfection O
- O
cocultivation O
. O

The O
human B
interferon I
beta I
( I
IFN I
- I
beta I
) I
regulatory I
element I
consists O
of O
multiple O
enhanson B
domains I
which O
are O
targets O
for O
transcription B
factors I
involved O
in O
inducible O
expression O
of O
the O
promoter B
. O

A O
2 O
- O
4 O
- O
fold O
increase O
in O
IFN B
- I
beta I
promoter I
transcription O
was O
observed O
in O
Sendai O
virus O
induced O
extracts O
, O
and O
deletion O
of O
PRDI B
and O
PRDII B
elements I
decreased O
this O
induced O
level O
of O
transcription O
. O

When O
purified O
PRDII B
and I
tetrahexamer I
binding I
proteins I
were O
added O
to O
the O
induced O
extract O
, O
a O
4 O
- O
fold O
increase O
in O
transcription O
was O
observed O
. O

Human B
and I
mouse I
Rhom I
- I
2 I
are O
highly O
conserved O
and O
, O
like O
rhombotin B
, O
encode O
two O
tandem B
cysteine I
- I
rich I
LIM I
domains I
. O

The O
purified O
homodimer B
( O
two O
p50s B
) O
of O
the O
DNA B
- I
binding I
subunit I
of O
NF B
- I
kappa I
B I
binds O
the O
B2 B
site O
of O
proenkephalin O
relatively O
better O
than O
does O
the O
heterotetramer B
( O
two O
p65s B
plus O
two O
p50s B
) O
form O
of O
the O
factor O
. O

Disruption O
of O
the O
human B
SCL I
locus I
by O
` O
` O
illegitimate O
' O
' O
V O
- O
( O
D O
) O
- O
J O
recombinase O
activity O
. O

The O
fusion B
cDNA I
results O
from O
an O
interstitial O
deletion O
between O
a O
previously O
unknown B
locus I
, O
SIL B
( O
SCL B
interrupting I
locus I
) O
, O
and O
the O
5 B
' I
untranslated I
region I
of O
SCL B
. O

Thus O
, O
in O
lymphocytes O
, O
growth B
- I
affecting I
genes I
other O
than O
immune B
receptors I
risk O
rearrangements O
. O

This O
was O
compared O
with O
the O
TREp B
binding O
of O
reticulocyte B
lysate I
- I
synthesized I
TRs I
. O

Incubation O
of O
each O
of O
the O
TRs B
with O
NE O
from O
COS O
- O
7 O
cells O
, O
which O
do O
not O
possess O
sufficient O
endogenous O
TRs B
to O
mediate O
T3 O
- O
responses O
, O
resulted O
in O
formation O
of O
a O
new O
, O
more O
greatly B
shifted I
complex I
. O

Cell O
- O
specific O
differences O
in O
activation O
of O
NF B
- I
kappa I
B I
regulatory I
elements I
of O
human B
immunodeficiency I
virus I
and I
beta I
interferon I
promoters I
by O
tumor B
necrosis I
factor I
. O

Tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
mRNA I
production O
was O
analyzed O
by O
polymerase O
chain O
reaction O
amplification O
in O
monocytic O
U937 O
cells O
and O
in O
a O
chronically O
HIV O
infected O
U937 O
cell O
line O
( O
U9 O
- O
IIIB O
) O
. O

Functional O
analysis O
of O
cis B
- I
linked I
regulatory I
sequences I
in O
the O
HLA B
DRA I
promoter I
by O
transcription O
in O
vitro O
. O

A O
closely O
related O
( O
if O
not O
identical O
) O
protein O
is O
found O
in O
both O
a O
human O
megakaryocytic O
cell O
line O
and O
purified O
human O
megakaryocytes O
; O
it O
binds O
to O
promoter B
regions I
of O
two O
megakaryocytic B
- I
specific I
genes I
. O

Furthermore O
, O
point O
mutations O
that O
abolish O
binding O
of O
NF B
- I
E1 I
result O
in O
a O
70 O
% O
decrease O
in O
the O
transcriptional O
activity O
of O
a O
megakaryocytic B
- I
specific I
promoter I
. O

Type B
- I
II I
estrogen I
- I
binding I
sites I
( O
type B
- I
II I
EBS I
) O
have O
been O
demonstrated O
in O
the O
human O
lymphoblastoid O
cell O
line O
IM O
- O
9 O
using O
a O
whole O
- O
cell O
assay O
with O
( O
6 O
, O
7 O
- O
3H O
) O
estradiol O
( O
3H O
- O
E2 O
) O
as O
tracer O
. O

We O
have O
carried O
out O
experiments O
to O
define O
the O
nature O
of O
the O
higher B
affinity I
CVZ I
binding I
site I
. O

Retroviral O
mediated O
transfer O
and O
expression O
of O
exogenous B
genes I
in O
primary O
lymphoid O
cells O
: O
assaying O
for O
a O
viral O
transactivator B
activity O
in O
normal O
and O
malignant O
cells O
. O

ER B
content O
in O
lymphocytes O
of O
each O
sample O
was O
expressed O
by O
both O
fmol O
/ O
mg O
of O
lymphocyte B
cytosolic I
protein I
and O
fmol O
/ O
micrograms O
of O
lymphocyte B
DNA I
. O

We O
show O
that O
ES O
- O
derived O
embryoid O
bodies O
express O
the O
full O
complement O
of O
mouse B
embryonic I
globin I
genes I
in O
the O
correct O
temporal O
order O
and O
that O
on O
further O
differentiation O
, O
a O
switch O
occurs O
to O
the O
fetal B
/ I
adult I
genes I
. O

When O
the O
human B
epsilon I
- I
or I
beta I
- I
globin I
genes I
driven O
by O
the O
dominant B
control I
region I
( O
DCR B
) O
are O
introduced O
into O
this O
system O
, O
the O
human B
epsilon I
- I
globin I
gene I
, O
in O
contrast O
to O
the O
beta B
- I
globin I
gene I
, O
is O
not O
deregulated O
by O
the O
presence O
of O
the O
DCR B
and O
is O
expressed O
strictly O
as O
an O
embryonic B
gene I
. O

ZRE B
- I
B I
is O
therefore O
not O
part O
of O
the O
R B
- I
inducible I
enhancer I
. O

However O
, O
one O
palindrome B
, O
either O
alone O
or O
duplicated O
, O
or O
the O
overlapping B
palindromes I
did O
not O
respond O
to O
R O
. O

In O
a O
fourth O
cell O
line O
, O
A1 O
- O
VDR O
, O
the O
receptor O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
had O
a O
low O
binding O
capacity O
and O
25 B
( I
OH I
) I
D3 I
- I
24 I
- I
hydroxylase I
activity O
was O
not O
detectable O
. O

These O
studies O
detected O
two O
novel B
domains I
referred O
to O
as O
L1 B
and O
L2 B
with O
a O
variety O
of O
lymphoid O
but O
not O
HeLa O
extracts O
. O

Characterization O
of O
defensin B
resistance O
phenotypes O
associated O
with O
mutations O
in O
the O
phoP B
virulence I
regulon I
of O
Salmonella O
typhimurium O
. O

The O
defensin B
sensitivities O
of O
Salmonella O
typhimurium O
strains O
with O
mutations O
in O
the O
phoP B
/ I
phoQ I
two I
- I
component I
virulence I
regulon I
were O
tested O
by O
using O
purified B
defensins I
NP B
- I
1 I
and O
NP B
- I
2 I
. O

The O
predicted O
periplasmic B
domain I
of O
the O
PhoQ B
protein I
contained O
a O
markedly O
anionic O
domain O
that O
could O
interact O
with O
cationic B
proteins I
and O
that O
could O
be O
responsible O
for O
resistance O
to O
defensin B
. O

This O
implied O
that O
a O
pag B
( I
phoP I
- I
activated I
gene I
) I
product I
is O
responsible O
for O
defensin B
resistance O
. O

The O
two O
proteins O
differ O
by O
a O
14 B
- I
amino I
acid I
serine I
- I
rich I
insertion I
present O
in O
one O
of O
the O
CREB B
isoforms I
. O

Competition O
experiments O
did O
not O
reveal O
any O
high B
- I
affinity I
binding I
site I
for O
BSAP B
in O
known O
regulatory B
regions I
of O
immunoglobulin B
and I
class I
II I
major I
histocompatibility I
( I
MHC I
) I
genes I
, O
suggesting O
that O
BSAP B
is O
a O
regulator O
of O
a O
different O
set O
of O
B B
- I
lymphoid I
- I
specific I
genes I
. O

The O
expression O
of O
the O
antibody B
- I
encoding I
genes I
, O
the O
immunoglobulin B
( I
Ig I
) I
genes I
, O
is O
also O
restricted O
to O
B O
cells O
. O

It O
appears O
that O
the O
B O
cell O
- O
specific O
expression O
of O
Ig B
genes I
is O
mediated O
at O
least O
in O
part O
by O
cell O
type B
- I
specific I
Oct I
factors I
, O
and O
that O
there O
are O
both O
quantitative O
and O
qualitative O
differences O
between O
Oct B
- I
1 I
and O
Oct B
- I
2 I
factors I
. O

Recently O
, O
a O
number O
of O
other O
octamer B
factor I
variants I
were O
identified O
. O

Many O
of O
these O
may O
be O
created O
by O
alternative O
splicing O
of O
a O
primary B
transcript I
of O
one O
Oct O
factor O
gene O
and O
may O
serve O
a O
specific O
function O
in O
the O
fine O
tuning O
of O
gene O
expression O
. O

We O
find O
that O
the O
factor O
that O
binds O
to O
the O
E3 B
enhancer I
motif I
, O
CATGTGGC O
, O
is O
a O
ubiquitous B
transcription I
factor I
. O

However O
, O
despite O
its O
ability O
to O
activate O
transcription O
of O
a O
transfected B
reporter I
gene I
, O
the O
factor O
is O
apparently O
unable O
to O
bind O
to O
the O
endogenous B
Ig I
heavy I
chain I
enhancer I
in O
non O
- O
lymphoid O
cells O
: O
In O
previous O
experiments O
by O
others O
, O
the O
characteristic O
in O
vivo O
footprint O
of O
this O
factor O
, O
designated O
NF B
- I
muE3 I
, O
was O
detected O
in O
B O
cells O
but O
not O
in O
non O
- O
B O
cells O
. O

Multiple B
regulatory I
elements I
in O
the O
human B
immunodeficiency I
virus I
long I
terminal I
repeat I
( O
HIV B
LTR I
) O
are O
required O
for O
activation O
of O
HIV O
gene O
expression O
. O

Results O
in O
all O
cell O
lines O
indicated O
that O
mutations O
of O
the O
SP1 B
, O
TATA B
and O
the O
TAR O
loop O
and O
stem O
secondary O
structure O
resulted O
in O
marked O
decreases O
in O
gene O
expression O
while O
mutations O
of O
the O
enhancer B
motif I
or O
TAR B
primary I
sequence I
resulted O
in O
only O
slight O
decreases O
. O

The O
clinical O
course O
and O
the O
laboratory O
data O
suggest O
that O
the O
tachycardia O
crises O
are O
the O
consequence O
of O
a O
hypersensitivity O
of O
the O
heart O
to O
thyroid O
hormones O
, O
associated O
with O
an O
increased O
number O
of O
T3 B
nuclear I
receptor I
sites O
in O
lymphocytes O
. O

We O
have O
purified O
a O
new O
T B
- I
cell I
- I
specific I
factor I
, O
TCF B
- I
1 I
alpha I
, O
that O
is O
implicated O
in O
the O
activation O
of O
genes O
encoding O
a O
major O
component O
of O
the O
human B
T I
- I
cell I
receptor I
( O
TCR B
) O
. O

A O
powerful O
enhancer O
has O
been O
mapped O
to O
an O
18 B
- I
bp I
DNA I
segment I
located O
11 O
kb O
5 O
' O
to O
the O
human B
epsilon I
- I
globin I
gene I
within O
the O
dominant B
control I
or O
locus B
- I
activating I
region I
. O

DNA O
- O
protein O
binding O
assays O
with O
nuclear O
extracts O
from O
induced O
cells O
demonstrate O
a O
high B
molecular I
weight I
complex I
on O
the O
enhancer B
. O

The O
tissue O
- O
specific O
expression O
of O
the O
MOPC B
141 I
immunoglobulin I
heavy I
- I
chain I
gene I
was O
studied O
by O
using O
in O
vitro O
transcription O
. O

Purified O
OTF1 B
from O
HeLa O
cells O
and O
OTF1 B
and O
OTF2 B
from O
B O
cells O
bound O
to O
identical O
sequences O
within O
the O
heavy B
- I
chain I
promoter I
. O

The O
same O
agents O
induce O
transcription O
from O
the O
interleukin B
- I
2 I
receptor I
alpha I
- I
chain I
and I
interleukin I
- I
2 I
genes I
, O
depending O
on O
promoter B
elements I
that O
bind O
the O
inducible B
transcription I
factor I
NF B
- I
kappa I
B I
( O
or O
an O
NF B
- I
kappa I
B I
- I
like I
factor I
) O
. O

Two O
kappa B
B I
- I
like I
motifs I
at O
positions B
- I
98 I
to I
- I
108 I
of O
the O
GM B
- I
CSF I
promoter I
were O
also O
recognized O
but O
with O
much O
lower O
affinities O
. O

In O
lymphoid O
cells O
, O
only O
the O
upstream B
sequences I
are O
required O
for O
transactivation O
by O
the O
Z B
/ I
R I
combination O
, O
and O
the O
AP B
- I
1 I
site I
is O
dispensable O
. O

This O
effect O
was O
comparable O
to O
or O
even O
stronger O
than O
the O
effect O
of O
a O
mutation O
in O
the O
OCTA B
site I
. O

DNase O
footprinting O
analysis O
corroborated O
the O
functional O
data O
showing O
that O
a O
lymphoid B
- I
specific I
protein I
binds O
to O
the O
microB B
DNA I
motif I
. O

This O
inducer O
can O
act O
in O
concert O
with O
the O
HIV B
- I
2 I
tat I
gene I
and O
T O
- O
cell O
activation O
in O
enhancing O
gene O
expression O
in O
human O
CD4 O
+ O
lymphocytes O
. O

Both O
HIV O
- O
2 O
and O
CMV B
transactivators I
enhance O
HIV O
- O
2 O
gene O
expression O
by O
transcriptional O
activation O
involving O
transcript O
initiation O
as O
well O
as O
elongation O
, O
with O
CMV B
transactivator I
affecting O
elongation O
more O
than O
the O
initiation O
. O

In O
this O
study O
we O
present O
evidence O
for O
reactivity O
of O
pregnancy O
lymphocytes O
, O
but O
not O
nonpregnancy O
lymphocytes O
, O
with O
the O
progesterone B
receptor I
- I
specific I
monoclonal I
antibody I
mPRI B
. O

Interaction O
of O
fibronectin B
with O
VLA B
- I
5 I
receptor I
on O
CD4 O
cells O
induces O
the O
AP B
- I
1 I
transcription I
factor I
. O

Int B
- I
2 I
was O
amplified O
in O
13 O
. O
1 O
% O
and O
c B
- I
myc I
was O
amplified O
in O
10 O
. O
3 O
% O
. O

Suppression O
of O
signals O
required O
for O
activation O
of O
transcription B
factor I
NF I
- I
kappa I
B I
in O
cells O
constitutively O
expressing O
the O
HTLV B
- I
I I
Tax I
protein I
. O

Transcription B
factor I
IID I
( O
TFIID B
) O
binds O
to O
the O
TATA B
box I
promoter I
element I
and O
regulates O
the O
expression O
of O
most O
eukaryotic B
genes I
transcribed O
by O
RNA B
polymerase I
II I
. O

Second O
, O
TRE B
- I
DNA I
binding I
proteins I
sedimented O
through O
a O
glycerol O
density O
gradient O
at O
rates O
corresponding O
to O
proteins O
of O
native O
molecular O
weights O
of O
35 O
to O
50 O
kD O
and O
110 O
kD O
. O

Third O
, O
only O
the O
50 B
kD I
protein I
was O
retained O
on O
a O
biotinylated O
DNA O
- O
streptavidin O
matrix O
when O
the O
DNA O
fragment O
contained O
the O
TRE B
- I
DNA I
. O

Fourth O
, O
extensive O
purification O
by O
several O
cycles O
of O
TRE B
- O
DNA O
affinity O
chromatography O
resulted O
in O
the O
32 B
, I
36 I
to I
42 I
and I
110 I
kD I
proteins I
and O
to O
less O
extent O
the O
50 B
kD I
factor I
. O

The O
cAMP B
- I
response I
element I
CRE B
, O
TGACGTCA O
, O
present O
in O
the O
21 B
base I
- I
pair I
sequence I
, O
appears O
to O
be O
essential O
for O
specific O
protein O
- O
TRE B
- O
DNA O
interactions O
because O
mutation O
of O
the O
two O
G O
' O
s O
destroys O
this O
complex O
. O

Activity O
of O
the O
immunoglobulin B
heavy I
and I
kappa I
light I
chain I
gene I
enhancers I
depends O
on O
a O
complex O
interplay O
of O
ubiquitous B
and I
developmentally I
regulated I
proteins I
. O

The O
internal O
methionine O
codons O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
II I
rex I
gene I
are O
not O
required O
for O
p24rex B
production O
or O
virus O
replication O
and O
transformation O
. O

Human O
T O
- O
cell O
leukemia O
virus O
types O
I O
( O
HTLV O
- O
I O
) O
and O
II O
( O
HTLV O
- O
II O
) O
have O
two O
nonstructural B
trans I
- I
acting I
regulatory I
genes I
, O
tax B
and O
rex B
, O
located O
in O
the O
3 B
' I
region I
of O
the O
viral B
genome I
. O

Rex B
acts O
posttranscriptionall O
to O
facilitate O
accumulation O
of O
full O
- O
length O
gag B
/ I
pol I
and O
singly O
spliced O
env B
mRNA I
in O
the O
cytoplasm O
of O
HTLV O
- O
infected O
cells O
. O

The O
' B
octamer I
' I
sequence I
, O
ATGCAAAT O
or O
its O
complement O
ATTTGCAT O
, O
is O
a O
key O
element O
for O
the O
transcriptional O
regulation O
of O
immunoglobulin B
genes I
in O
B O
- O
lymphocytes O
as O
well O
as O
a O
number O
of O
housekeeping B
genes I
in O
all O
cell O
types O
. O

In O
lymphocytes O
, O
the O
octamer B
- I
binding I
protein I
Oct B
- I
2A I
and O
variants O
thereof O
are O
thought O
to O
contribute O
to O
the O
B B
- I
cell I
specific I
gene I
expression O
, O
while O
the O
ubiquitous O
protein O
Oct O
- O
1 O
seems O
to O
control O
general O
octamer B
site I
- O
dependent O
transcription O
. O

All O
immunoglobulin B
genes I
contain O
a O
conserved O
octanucleotide B
promoter I
element I
, O
ATGCAAAT O
, O
which O
has O
been O
shown O
to O
be O
required O
for O
their O
normal O
B O
- O
cell O
- O
specific O
transcription O
. O

Mapping O
of O
B B
- I
cell I
epitopes I
of O
the O
human B
hepatitis I
B I
virus I
X I
protein I
. O

In O
the O
STLV O
- O
I O
- O
bearing O
T O
cell O
lines O
, O
tax1 B
- I
related I
antigen I
molecules I
detected O
by O
Lt B
- I
4 I
were O
heterogeneous O
, O
having O
molecular O
weights O
in O
the O
range O
of O
36 O
- O
41 O
kd O
. O

The O
corresponding O
region O
in O
the O
second O
AIDS O
retrovirus O
, O
HIV O
- O
2 O
, O
contains O
a O
conserved O
and O
a O
divergent O
NF B
kappa I
B I
binding I
site I
. O

Instead O
of O
NF B
kappa I
B I
, O
the O
activator B
protein I
3 I
binds O
to O
the O
divergent O
site O
in O
HIV O
- O
2 O
. O

When O
tested O
in O
a O
radioreceptor O
assay O
in O
human O
mononuclear O
leukocytes O
the O
synthesized O
compounds O
showed O
only O
low O
relative O
binding O
affinities O
( O
RBA O
) O
to O
type B
1 I
receptor I
, O
the O
highest O
being O
0 O
. O
72 O
% O
for O
13 O
( O
aldosterone O
= O
100 O
% O
) O
. O

This O
similarity O
in O
expression O
and O
the O
fact O
that O
NFAT B
- I
1 I
has O
been O
shown O
to O
bind O
functional B
sequences I
in O
HIV B
- I
LTR I
suggest O
a O
role O
for O
NFAT B
- I
1 I
in O
dermal O
activation O
of O
the O
HIV B
- I
LTR I
. O

A O
novel O
T B
- I
cell I
protein I
recognized O
the O
palindromic B
sequence I
within O
site B
B I
and O
also O
bound O
estrogen B
- I
or I
thyroid I
hormone I
- I
response I
elements I
with O
lower O
affinity O
. O

It O
has O
previously O
been O
shown O
that O
9S B
, O
untransformed B
progestin I
, I
estrogen I
, I
androgen I
, I
and I
glucocorticoid I
receptor I
complexes I
in O
rabbit O
uterine O
and O
liver O
cytosols O
contain O
a O
59 B
- I
kDa I
protein I
[ O
Tai O
, O
P O
. O
K O
. O
, O
Maeda O
, O
Y O
. O
, O
Nakao O
, O
K O
. O
, O
Wakim O
, O
N O
. O
G O
. O
, O
Duhring O
, O
J O
. O
L O
. O
, O
& O
Faber O
, O
L O
. O
E O
. O
( O
1986 O
) O
Biochemistry O
25 O
, O
5269 O
- O
5275 O
] O
. O

Sequence O
- O
specific O
DNA O
binding O
of O
the O
proto B
- I
oncoprotein I
ets B
- I
1 I
defines O
a O
transcriptional B
activator I
sequence I
within O
the O
long B
terminal I
repeat I
of O
the O
Moloney O
murine O
sarcoma O
virus O
. O

A O
mutant B
LTR I
containing O
four O
base O
pair O
substitutions O
in O
the O
ets B
- I
1 I
binding I
site I
was O
constructed O
and O
was O
shown O
to O
have O
reduced O
binding O
in O
vitro O
. O

We O
propose O
that O
ets B
- I
1 I
functions O
as O
a O
transcriptional O
activator O
of O
mammalian O
type O
- O
C O
retroviruses O
and O
speculate O
that O
ets B
- I
related I
genes I
constitute O
a O
new O
group O
of O
eukaryotic B
DNA I
- I
binding I
proteins I
. O

We O
have O
previously O
reported O
that O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
contain O
type O
II B
estrogen I
binding I
sites I
( O
type B
II I
EBS I
) O
. O

Proteins O
exist O
in O
leukocytes O
able O
to O
modify O
GTP B
- I
binding I
protein I
function O
in O
this O
manner O
, O
and O
their O
activity O
may O
be O
regulated O
by O
signals O
generated O
on O
phagocyte O
stimulation O
. O

Proteins O
of O
the O
Ras B
superfamily I
are O
likely O
to O
be O
involved O
in O
a O
variety O
of O
normal O
phagocyte O
functions O
through O
their O
ability O
to O
modulate O
the O
assembly O
of O
actin B
filaments I
, O
direct O
vesicle O
trafficking O
and O
fusion O
, O
and O
so O
forth O
. O

Over O
a O
72 O
- O
hr O
period O
of O
activation O
, O
the O
expression O
of O
the O
50 B
- I
kDa I
NF I
- I
kappa I
B I
, O
p50 B
, O
and O
its O
precursor O
, O
p105 B
, O
was O
increased O
progressively O
. O

Further O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
inhibited O
the O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
in O
Jurkat O
cells O
transiently O
transfected O
with O
a O
construct B
containing O
four O
tandem B
repeats I
of O
the O
NF B
- I
kappa I
B I
binding I
sequence I
of O
the O
immunoglobulin B
kappa I
light I
chain I
gene I
linked O
to O
the O
chloramphenicol B
acetyltransferase I
reporter I
gene I
. O

We O
previously O
identified O
the O
DNA B
consensus I
binding I
site I
recognized O
by O
the O
two O
DNA B
binding I
domains I
. O

The O
expression O
vector O
was O
cotransfected O
with O
the O
chloramphenicol B
acetyl I
transferase I
( I
CAT I
) I
reporter I
gene I
regulated O
by O
the O
thymidine B
kinase I
promoter I
containing O
GAL4 B
DNA I
binding I
sites I
into O
NIH O
3T3 O
, O
293 O
, O
K562 O
, O
and O
Jurkat O
cell O
lines O
. O

Analysis O
of O
the O
biochemical O
and O
cell O
biological O
properties O
of O
these O
HSFs B
reveals O
that O
HSF3 B
has O
properties O
in O
common O
with O
both O
HSF1 B
and O
HSF2 B
and O
yet O
has O
features O
which O
are O
distinct O
from O
both O
. O

The O
results O
of O
supershift O
assays O
using O
NFATp B
- I
and I
NFATc I
- I
specific I
antibodies I
indicate O
that O
NK O
cell O
activation O
early O
after O
CD16 B
ligand O
binding O
involves O
primarily O
, O
if O
not O
exclusively O
, O
NFATp B
, O
and O
Western O
blot O
analysis O
shows O
that O
this O
has O
the O
same O
electrophoretic O
mobility O
( O
approximately O
120 O
kD O
) O
as O
that O
of O
T O
lymphocytes O
. O

Exposure O
of O
activated O
human O
T O
lymphocytes O
or O
of O
a O
natural O
killer O
cell O
line O
( O
NKL O
) O
to O
IL B
- I
2 I
leads O
to O
the O
phosphorylation O
of O
Stat1 B
alpha I
, O
Stat1 O
beta O
, O
and O
Stat3 B
, O
as O
well O
as O
of O
two O
Stat B
- I
related I
proteins I
, O
p94 B
and O
p95 B
. O

These O
Stat B
proteins I
were O
found O
to O
translocate O
to O
the O
nucleus O
and O
to O
bind O
to O
a O
specific B
DNA I
sequence I
. O

Results O
indicated O
that O
( O
i O
) O
constitutive O
c B
- I
fos I
transcript I
levels O
are O
significantly O
higher O
in O
patients O
subsequently O
responding O
to O
IFN B
- I
alpha I
therapy O
( O
p O
< O
0 O
. O
01 O
) O
and O
positively O
correlated O
with O
the O
proportion O
of O
lymphocytes O
( O
r O
= O
0 O
. O
6895 O
, O
p O
< O
0 O
. O
01 O
) O
and O
negatively O
with O
the O
proportion O
of O
immature O
cells O
( O
r O
= O
- O
0 O
. O
568 O
, O
p O
< O
0 O
. O
01 O
) O
contained O
in O
the O
pbmc O
preparations O
tested O
, O
( O
ii O
) O
constitutive B
mRNA I
levels O
of O
the O
hybrid B
bcr I
/ I
abl I
, O
c B
- I
myc I
and O
p53 B
are O

In O
contrast O
to O
hematopoietic O
cells O
, O
I O
kappa O
B O
alpha O
- O
/ O
- O
embryonic O
fibroblasts O
show O
minimal O
constitutive B
NF I
- I
kappa I
B I
, O
as O
well O
as O
normal O
signal O
- O
dependent O
NF B
- I
kappa I
B I
activation O
that O
is O
concomitant O
with O
I B
kappa I
B I
beta I
degradation O
. O

Moreover O
, O
the O
induction O
of O
both O
Jak B
1 I
and I
3 I
, O
and O
STAT B
5 I
activity O
strongly O
correlated O
with O
the O
growth O
- O
promoting O
effects O
of O
IL B
- I
7 I
, O
suggesting O
that O
this O
signal O
transduction O
mechanism O
may O
play O
a O
key O
role O
in O
IL B
- I
7 I
- O
induced O
proliferation O
. O

Interestingly O
, O
microtubule B
disruption O
also O
decreased O
monocyte O
1 O
, O
25 O
( O
OH O
) O
2D3 O
synthesis O
, O
not O
by O
decreasing O
the O
Vmax O
of O
monocyte B
mitochondrial I
1 I
alpha I
- I
hydroxylase I
but O
through O
an O
increase O
in O
the O
Km O
for O
25 O
( O
OH O
) O
2D3 O
. O

Here O
we O
show O
DNA O
damage O
- O
induced O
apoptosis O
in O
these O
T O
lymphocytes O
is O
dependent O
on O
the O
antioncogenic B
transcription I
factor I
interferon I
regulatory I
factor I
( B
IRF I
) I
- I
1 I
. O

Results O
from O
site O
- O
directed O
mutations O
and O
electrophoretic O
mobility O
shift O
assays O
strongly O
suggest O
that O
this O
sequence O
mediates O
the O
ionomycin O
- O
induced O
activation O
of O
the O
TCRG B
enhancer I
. O

Our O
studies O
provide O
an O
explanation O
for O
a O
previous O
observation O
that O
TCRG B
mRNA I
levels O
, O
but O
not O
mRNA O
levels O
for O
T B
cell I
receptor I
alpha I
and I
- I
beta I
, O
are O
increased O
by O
ionomycin O
treatment O
. O

Deoxycholate O
treatment O
of O
the O
cytoplasmic O
extract O
prepared O
from O
cells O
stimulated O
by O
TNF B
- I
alpha I
in O
the O
presence O
of O
Cu2 O
+ O
resulted O
in O
the O
release O
of O
NF B
kappa I
B I
from O
I B
kappa I
B I
alpha I
, O
indicating O
that O
Cu2 O
+ O
interferes O
with O
the O
dissociation O
of O
the O
NF B
kappa I
B I
- I
I I
kappa I
B I
complex I
. O

Nonetheless O
, O
a O
membrane B
- I
proximal I
region I
of O
human O
IL B
- I
2R I
beta I
( O
Asn240 B
- I
Leu335 I
) O
was O
critical O
for O
JAK3 B
activation O
, O
and O
the O
amount O
of O
JAK3 B
present O
in O
activated O
IL B
- I
2 I
receptor I
complexes I
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B
binding O
to O
the O
receptor B
complex I
relies O
on O
both O
IL B
- I
2R I
beta I
and O
IL B
- I
2R I
gamma I
. O

This O
novel O
enzyme O
is O
distinct O
from O
E6 B
- I
AP I
, O
the O
p53 B
- I
conjugating I
ligase I
, O
and O
from O
E3 B
alpha I
, O
the O
` B
` I
N I
- I
end I
rule I
' I
' I
ligase I
. O

To O
identify O
osteoblast B
- I
specific I
cis I
- I
acting I
elements I
and O
trans B
- I
acting I
factors I
, O
we O
initiated O
an O
analysis O
of O
the O
promoter B
of O
a O
mouse B
osteocalcin I
gene I
, O
an O
osteoblast B
- I
specific I
gene I
. O

IBR B
is O
a O
503 B
- I
amino I
- I
acid I
- I
long I
acidic I
protein I
which O
is O
99 O
. O
0 O
% O
identical O
to O
the O
recently O
reported O
human B
NRF I
- I
1 I
/ I
alpha I
- I
Pal I
factor I
and O
highly O
related O
to O
the O
invertebrate O
transcription B
factors I
P3A2 B
and O
erected B
wing I
gene I
product I
( O
EWG B
) O
. O

Evidence O
for O
normal O
vitamin B
D I
receptor I
messenger I
ribonucleic I
acid I
and O
genotype O
in O
absorptive O
hypercalciuria O
. O

Sequence O
analysis O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
CD69 B
gene I
revealed O
the O
presence O
of O
a O
potential O
TATA B
element I
30 B
base I
pairs I
upstream I
of O
the O
major O
transcription B
initiation I
site I
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription B
factors I
( O
NF B
- I
kappa I
B I
, O
Egr B
- I
1 I
, O
AP B
- I
1 I
) O
, O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

The O
exon B
- I
intron I
structure I
of O
the O
5 B
' I
portion I
of O
the O
thromboxane B
receptor I
gene I
was O
determined O
initially O
by O
comparing O
the O
nucleotide B
sequence I
of O
the O
5 B
' I
flanking I
genomic I
clone I
with O
that O
of O
a O
novel B
human I
uterine I
thromboxane I
receptor I
cDNA I
that O
extended O
the O
mRNA B
141 B
bp I
further I
upstream I
than O
the O
previously B
identified I
human I
placental I
cDNA I
. O

Promoter O
function O
of O
the O
5 B
' I
flanking I
region I
of O
the O
thromboxane B
receptor I
gene I
was O
evaluated O
by O
transfection O
of O
thromboxane B
receptor I
gene I
promoter I
/ I
chloramphenicol I
acetyltransferase I
( I
CAT I
) I
chimera I
plasmids I
into O
platelet O
- O
like O
K562 O
cells O
. O

These O
studies O
are O
the O
first O
to O
determine O
the O
structure O
and O
organization O
of O
the O
5 O
' O
end O
of O
the O
thromboxane B
receptor I
gene I
and O
demonstrate O
that O
thromboxane B
receptor I
gene I
expression O
can O
be O
regulated O
by O
activation O
of O
protein B
kinase I
C I
via O
induction O
of O
an O
AP B
- I
2 I
- I
like I
nuclear I
factor I
binding O
to O
upstream B
promoter I
elements I
. O

Proteins O
in O
the O
first O
group O
contain O
multiple O
HMG B
boxes I
, O
are O
non O
- O
sequence O
- O
specific O
, O
and O
recognize O
structural O
features O
as O
found O
in O
cruciform B
DNA I
and O
cross B
- I
over I
DNA I
. O

The O
abundant O
chromosomal B
protein I
HMG B
- I
1 I
belongs O
to O
this O
subgroup O
. O

As O
in O
HMG1B B
, O
the O
overall O
structure O
of O
the O
Sox B
- I
4 I
HMG B
box I
is O
L O
- O
shaped O
and O
is O
maintained O
by O
a O
cluster O
of O
conserved O
, O
mainly O
aromatic O
residues O
. O

This O
death O
- O
promoting O
activity O
of O
Bik B
can O
be O
suppressed O
by O
coexpression O
of O
Bcl B
- I
2 I
, O
Bcl B
- I
XL I
, O
EBV B
- I
BHRF1 I
and O
E1B B
- I
19 I
kDa I
proteins O
suggesting O
that O
Bik B
may O
be O
a O
common O
target O
for O
both O
cellular B
and I
viral I
anti I
- I
apoptotic I
proteins I
. O

We O
have O
analyzed O
the O
expression O
of O
TCL1 B
mRNA I
and O
protein B
in O
peripheral O
blood O
lymphocytes O
( O
PBLs O
) O
from O
four O
AT O
cases O
and O
from O
healthy O
controls O
. O

Fluorescence O
in O
situ O
hybridization O
of O
the O
TCL1 B
genomic I
locus I
to O
lymphocyte O
metaphases O
from O
the O
AT O
patient O
with O
the O
T O
- O
cell O
clonal O
expansion O
showed O
that O
the O
breakpoint O
of O
the O
t O
( O
14 O
; O
14 O
) O
translocation O
lies O
within O
the O
TCL1 B
locus I
and O
is O
accompanied O
by O
an O
inverted O
duplication O
of O
the O
distal B
part I
of O
chromosome B
14 I
. O

Inhibition O
of O
endogenous B
C I
/ I
EBP I
proteins I
, O
using O
either O
an O
excess O
of O
C B
/ I
EBP I
binding I
sites I
or O
a O
trans B
- I
dominant I
negative I
inhibitor I
, O
demonstrated O
that O
C B
/ I
EBP I
proteins I
are O
required O
for O
basal O
and O
activated O
levels O
of O
HIV B
- I
1 I
LTR I
transcription O
in O
the O
promonocytic O
cell O
line O
U937 O
. O

Northern O
( O
RNA O
) O
blots O
and O
binding O
assays O
showed O
that O
NF B
- I
IL6 I
is O
the O
only O
known O
C B
/ I
EBP I
family I
member I
which O
is O
increased O
when O
U937 O
cells O
are O
activated O
. O

However O
, O
transcription O
from O
crippled B
HIV I
- I
1 I
LTRs I
lacking O
C B
/ I
EBP I
sites I
can O
still O
be O
induced O
following O
activation O
of O
U937 O
cells O
. O

We O
report O
here O
that O
both O
NF B
- I
M I
- I
dependent I
promoter I
constructs I
and O
resident O
genes O
could O
be O
activated O
by O
addition O
of O
beta O
- O
estradiol O
to O
the O
NF O
- O
M O
- O
estrogen O
receptor O
expressing O
progenitors O
. O

Functional O
specificity O
for O
repression O
matches O
the O
DNA O
binding O
specificity O
of O
complex B
3 I
; O
both O
repressor O
activity O
and O
complex B
3 I
binding O
require O
the O
consensus B
sequence I
CTCACNTNC O
. O

PU B
. I
1 I
is O
a O
hematopoietic B
transcription I
factor I
belonging O
to O
the O
Ets B
- I
family I
. O

It O
binds O
the O
so O
- O
called O
Pu B
box I
, O
an O
important O
tissue B
- I
specific I
regulatory I
DNA I
element I
present O
in O
a O
number O
of O
genes O
expressed O
in O
these O
cell O
lineages O
. O

The O
effects O
of O
CsA O
on O
endothelial O
cells O
were O
also O
detected O
at O
the O
chromatin B
structure O
level O
, O
as O
DNasel B
hypersensitive I
sites I
within O
both O
the O
GM B
- I
CSF I
enhancer O
and O
the O
E B
- I
selectin I
promoter I
were O
suppressed O
by O
CsA O
. O

Increased O
intracellular O
stores O
of O
latent B
NF I
- I
kappa I
B I
may O
also O
result O
in O
rapid O
inducibility O
of O
NF B
- I
kappa I
B I
- O
dependent O
cytokine B
gene O
expression O
. O

The O
DNA B
binding I
region I
specifying O
high O
affinity O
for O
GRE B
sites I
is O
required O
. O

Our O
data O
support O
the O
view O
that O
steroid O
- O
mediated O
cell O
death O
occurs O
by O
a O
process O
requiring O
direct O
interaction O
of O
steroid B
- I
receptor I
complexes I
with O
the O
genome O
. O

Full O
- O
length O
cDNAs B
and O
genomic B
clones I
were O
isolated O
, O
and O
the O
gene O
structure O
was O
determined O
. O
Comparison O
of O
the O
deduced O
amino O
acids O
shows O
88 O
% O
sequence O
identity O
between O
mouse B
and I
human I
BOB I
. I
1 I
/ I
OBF I
. I
1 I
. O

The O
NH2 B
- I
terminal I
126 I
amino I
acids I
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
are O
both O
essential O
and O
sufficient O
for O
interaction O
with O
the O
POU B
domains I
of O
either O
Oct1 B
or O
Oct2 B
. O

As O
this O
phosphorylation O
was O
independent O
of O
protein B
kinase I
C I
activity O
, O
we O
tested O
whether O
a O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( O
CaM B
kinase I
) O
might O
phosphorylate O
the O
Ets B
- I
1 I
protein I
after O
elevation O
of O
intracellular O
free O
calcium O
concentrations O
. O

CD30 B
is O
a O
recently O
described O
member O
of O
the O
tumor B
necrosis I
factor I
/ I
nerve I
growth I
factor I
receptor I
superfamily I
. O

In O
all O
cell O
lines O
investigated O
, O
the O
NF B
- I
kappa I
B I
complexes I
induced O
following O
CD30 B
engagement O
were O
shown O
to O
contain O
p50 B
NF I
- I
kappa I
B1 I
, O
p65 B
RelA I
, O
and O
possibly O
other O
transcription B
factors I
. O

The O
expression O
of O
MHC B
class I
II I
genes I
in O
mouse O
T O
cells O
can O
be O
reconstituted O
upon O
transfection O
with O
the O
human B
CIITA I
cDNA I
. O

Because O
HLA B
class I
II I
molecules I
present O
antigen O
to O
T B
cell I
receptors I
( O
TCRs B
) O
, O
we O
have O
searched O
for O
a O
TCR B
gene I
associated O
with O
the O
production O
of O
anti B
- I
Ro I
( I
SSA I
) I
antibodies I
. O

This O
RFLP B
pair I
occurs O
in O
76 O
% O
of O
patients O
with O
Ro B
( I
SSA I
) I
precipitins O
, O
84 O
% O
of O
anti O
- O
Ro B
( I
SSA I
) I
- O
positive O
patients O
lacking O
La B
( I
SSB I
) I
precipitins B
, O
but O
only O
41 O
% O
of O
the O
patients O
lacking O
both O
precipitins B
( O
P O
= O
0 O
. O
0004 O
) O
. O

The O
majority O
of O
patients O
who O
have O
these O
RFLPs B
and O
HLA B
class I
II I
antigens I
previously O
associated O
with O
the O
anti O
- O
Ro B
( I
SSA I
) I
response O
make O
this O
antibody O
, O
suggesting O
that O
interactions O
between O
products O
of O
these O
loci B
occur I
in O
response O
to O
Ro B
( I
SSA I
) I
. O

However O
, O
while O
IL2 B
expression O
requires O
the O
contribution O
of O
Ca O
( O
2 O
+ O
) O
- O
and O
protein B
kinase I
C I
- O
dependent O
signals O
, O
we O
report O
that O
activation O
of O
human B
IL4 I
transcription O
through O
the O
Ca O
( O
2 O
+ O
) O
- O
dependent O
pathway O
is O
diminished O
by O
protein B
kinase I
C I
stimulation O
in O
Jurkat O
T O
cells O
. O

Human B
IL4 I
promoter I
- O
mediated O
transcription O
is O
downregulated O
in O
Jurkat O
cells O
stimulated O
with O
the O
NF B
- I
kappa I
B I
- I
activating I
cytokine I
tumor B
necrosis I
factor I
alpha I
and O
suppressed O
in O
RelA O
- O
overexpressing O
cells O
. O

Many O
cytokines B
activate O
signal B
transducer I
and I
activation I
of I
transcription I
( I
STAT I
) I
transcription I
factors I
, O
which O
, O
in O
turn O
, O
activate O
transcription O
of O
inflammatory O
effector O
genes O
. O

Monocytic O
cell O
lines O
and O
normal O
peripheral O
blood O
monocytes O
were O
infected O
with O
HIV O
- O
1 O
in O
vitro O
and O
cultured O
in O
the O
presence O
or O
absence O
of O
F B
( I
ab I
' I
) I
2 I
fragments I
of O
monoclonal B
anti I
- I
CR1 I
or O
anti B
- I
CR3 I
Abs I
or O
with O
C3 B
fragments I
. O

Mutually O
exclusive O
interaction O
of O
a O
novel O
matrix B
attachment I
region I
binding I
protein I
and O
the O
NF B
- I
muNR I
enhancer I
repressor I
. O

To O
understand O
the O
role O
of O
MARs B
in O
IgH B
enhancer I
regulation O
, O
we O
have O
identified O
a O
novel O
MAR B
- I
binding I
protein I
, O
MAR B
- I
BP1 I
, O
from O
soluble O
nuclear O
matrix O
preparations O
based O
on O
its O
ability O
to O
bind O
to O
the O
MARs B
associated O
with O
the O
IgH B
enhancer I
. O

Purified O
MAR B
- I
BP1 I
migrates O
as O
a O
33 B
- I
kDa I
protein I
, O
and O
it O
can O
be O
found O
in O
nuclear O
matrix O
preparations O
from O
a O
number O
of O
different O
types O
of O
lymphoid O
cell O
lines O
. O

C B
/ I
EBP I
alpha I
is O
the O
major O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
( O
C B
/ I
EBP I
) O
form O
binding O
to O
this O
site O
in O
nuclear O
extracts O
of O
U937 O
cells O
. O

Because O
NF B
- I
kappa I
B I
activates O
many O
immunoregulatory B
genes I
in O
response O
to O
pro O
- O
inflammatory O
stimuli O
, O
the O
inhibition O
of O
its O
activity O
can O
be O
a O
major O
component O
of O
the O
anti O
- O
inflammatory O
activity O
of O
glucocorticoids O
. O

Transcriptional O
repression O
of O
the O
interleukin B
- I
2 I
gene I
by O
vitamin O
D3 O
: O
direct O
inhibition O
of O
NFATp B
/ I
AP I
- I
1 I
complex I
formation O
by O
a O
nuclear B
hormone I
receptor I
. O

We O
therefore O
examined O
vitamin O
D3 O
- O
mediated O
repression O
of O
activated O
IL B
- I
2 I
expression O
by O
cotransfecting O
Jurkat O
cells O
with O
IL B
- I
2 I
promoter I
/ I
reporter I
constructs I
and O
a O
VDR B
overexpression I
vector I
and O
by O
DNA O
binding O
. O

We O
examined O
by O
northern O
hybridization O
the O
expression O
of O
Id2 B
and I
Id3 I
mRNA I
in O
human O
leukemia O
/ O
lymphoma O
lines O
and O
patient O
samples O
, O
as O
well O
as O
resting O
and O
activated O
normal O
human O
lymphocytes O
from O
peripheral O
blood O
( O
PBL O
) O
. O

As O
neutralizing B
anti I
- I
IL I
- I
6 I
Abs I
effectively O
down O
- O
regulated O
the O
early O
induction O
of O
STAT B
proteins I
and O
as O
exogenously O
added O
IL B
- I
6 I
rapidly O
activated O
DNA O
binding O
similar O
to O
TCR B
- O
mediated O
bindings O
, O
it O
can O
be O
concluded O
that O
IL B
- I
6 I
is O
the O
factor O
responsible O
for O
the O
activation O
of O
STAT B
proteins I
in O
a O
primary O
T O
cell O
response O
. O

A O
central O
role O
for O
a O
single B
c I
- I
Myb I
binding I
site I
in O
a O
thymic B
locus I
control I
region I
. O

We O
now O
show O
that O
the O
core O
contains O
a O
single O
critical O
c B
- I
Myb I
binding I
site I
. O

Lymphoid B
enhancer I
- I
binding I
factor I
1 I
( O
LEF B
- I
1 I
) O
is O
a O
regulatory B
high I
mobility I
group I
( I
HMG I
) I
protein I
that O
activates O
the O
T B
cell I
receptor I
alpha I
( I
TCR I
alpha I
) I
enhancer I
in O
a O
context O
- O
restricted O
manner O
in O
T O
cells O
. O

HIV B
- I
1 I
envelope I
glycoproteins I
induce O
activation O
of O
activated O
protein B
- I
1 I
in O
CD4 O
+ O
T O
cells O
[ O
published O
erratum O
appears O
in O
J O
Biol O
Chem O
1995 O
Dec O
1 O
; O
270 O
( O
48 O
) O
: O
29038 O
] O

